

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number: WO 99/47540 (43) International Publication Date: 23 September 1999 (23.09.99)
C07H 21/04, C07K 1/00, 16/00, C12N 15/00, 1/20, C12P 21/06, A61K 38/00, C12Q 1/68, G01N 33/53, 33/566			
(21) International Application Number: PCT/US99/05804		(US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). YU, Guo-Liang [CN/US]; 242 Gravett Drive, Berkeley, CA 94705 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, MD 22020 (US). WEI, Ying-Fei [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). DUAN, Roxanne, D. [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). KYAW, Hla [MM/US]; 520 Sugarbush Circle, Frederick, MD 21703 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). SHI, Yanggu [CN/US]; 437 West Side Drive #102, Gaithersburg, MD 20878 (US). MOORE, Paul, A. [US/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US).	
(22) International Filing Date: 18 March 1999 (18.03.99)		(30) Priority Data: 60/078,566 19 March 1998 (19.03.98) US 60/078,576 19 March 1998 (19.03.98) US 60/078,573 19 March 1998 (19.03.98) US 60/078,574 19 March 1998 (19.03.98) US 60/078,579 19 March 1998 (19.03.98) US 60/078,578 19 March 1998 (19.03.98) US 60/078,581 19 March 1998 (19.03.98) US 60/078,577 19 March 1998 (19.03.98) US 60/078,563 19 March 1998 (19.03.98) US 60/080,314 1 April 1998 (01.04.98) US 60/080,312 1 April 1998 (01.04.98) US 60/080,313 1 April 1998 (01.04.98) US	
(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).		(74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).	
(72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
Published <i>With international search report.</i>			
(54) Title: 95 HUMAN SECRETED PROTEINS			
(57) Abstract			
<p>The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finnland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

95 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and 5 polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or 10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic 15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in 25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes 30 encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human

growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent 5 medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, 10 antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

15

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

20 In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of 25 matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released 30 into the extracellular space, the secreted protein can undergo extracellular processing

to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of the coding sequence, but do not comprise all or a portion of any intron. In another embodiment, the nucleic acid comprising the coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an

overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

5 Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or
10 temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent
15 hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTO, heparin, denatured salmon sperm DNA, and
20 commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a
25 complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any
30 polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of

single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single-
5 and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of
10 modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
15 The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched,
20 and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol,
25 cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation,
30

gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

5 (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

10 "SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

15 "A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not 20 more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

This gene is expressed primarily in anergic T cells and merkel cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a 30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders and inflammatory diseases. Similarly, polypeptides

and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 108 as residues: Ala-55 to Gln-64.

The tissue distribution in T-cells and merkel cells indicates that the protein products of this gene are useful for the diagnosis and/or treatment of immune system diseases. Furthermore,

15 Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by 20 boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune 25 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a 30 tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2329 of SEQ ID NO:11, b is an integer of 15 to 2343, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: IPENRRPASXCTWSMWTTSRTTTRPPWGRFSSVSSASV SSTRKTRWRTRSTSCCRSSRRRVAAPFCTPSASTEPSARMEAPPLELPVVHTFSFL TFVFTYRCGAGDSITQINCA YEMGEEMPKRQMKAIFLLFHFL (SEQ ID NO:205), IPENRRPASXCTWSMWTTSRTTTRPPWGRFSSVSSASVSST (SEQ ID NO:206), RKTWRTRSTSCCRSSRRRVAAPFCTPSASTEPSARMEAPPLELP (SEQ ID NO:207), and/or VVHTFSFLTFVFTYRCGAGDSITQINCA YEMGEEMPKRQ MKAIFLLFHFL (SEQ ID NO:208). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in placental, brain and breast tissues, and to a lesser extent in T cells and tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative and/or endocrine disorders and neoplasias, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurodegenerative, developing, endocrine and

immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, endocrine, immune, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 109 as residues: Ala-55 to Asn-60, Lys-65 to Met-71; Leu-75 to Asn-86, Asp-93 to 10 Asp-110, Leu-130 to Cys-138, Gln-149 to Glu-154, Thr-172 to Ile-179, Glu-185 to Arg-192.

The tissue distribution in breast and brain tissues indicates that the protein products of this gene are useful for the diagnosis and/or treatment of endocrine disorders, neurodegenerative disorders, developmental disorders, immune system 15 diseases and neoplasias. The tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be 20 produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus.

Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in 25 vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Likewise,

30 Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be

involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1163 of SEQ ID NO:12, b is an

integer of 15 to 1177, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

5 The translation product of this gene shares sequence homology with bovine beta-mannosidase, which is thought to be important in lysosomal catabolism of glycoproteins. See, for example, J. Biol. Chem. 270, 3841-3848 (1995), incorporated herein by reference in its entirety. Based on the sequence similarity between these proteins the translation product of this gene will sometimes hereinafter be referred to
10 as human beta-mannosidase. Human beta-mannosidase is expected to share certain biological activities, particularly enzymatic activities, with bovine beta-mannosidase. Such activities may be assayed by methods known in the art, described in J. Biol. Chem. 270, 3841-3848 (1995), and/or disclosed elsewhere herein.

15 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: HPSIIWSGNNEALMMNWYHISFTDRPIYIKDYVTL YVKNIRELVLAGDKSRPFITSSPTNGAETVAEAWVSQNPNSNYFGDVHFYDYI SDCWNWKVFPKARFASEYGYQSWPSFSTLEKVSSTEDWSFNSKFLHRQHH EGGNKQMLYQAGLHFKLPQSTDPLRTFKDTIYLTTQVMQAQCVKTETEFYRRS RSEIVDQQGHTMGALYWQLNDIWQAPSW (SEQ ID NO:209), and/or

20 VRVHTWS
 SLEPVCSRVTTERFVMKGGEAVCLYEEPVSELLRRCGNCTRESCVVSYLSAD HELLSPTNYHFLSSPKEAVGLCKAQITAIISQQGdifVFDETSAVAPFVWLDV GSIPGRFSDNGFLMTEKTRTILFYPWEPTSKNELEQSFHVTSLTDIY (SEQ ID NO:210). Polynucleotides encoding these polypeptides are also encompassed by the
25 invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

 This gene is expressed primarily in colon tissue, and to a lesser extent in thymus stromal cells and chondrosarcoma tissue.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chondroma and mannosidosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of 5 the above tissues or cells, particularly of the chondro and immune system. The expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, metabolic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such 10 a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to bovine beta-mannosidase indicates that the protein products of this gene are useful for the diagnosis and/or treatment of chondroma and mannosidosis. Human beta-mannosidosis is an autosomal recessive, 15 lysosomal storage disease caused by a deficiency of the enzyme beta-mannosidase. Furthermore, the homology of the translation product of this gene to beta-mannosidase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as lysosomal storage deficiencies, Tay-Sachs disease, 20 phenylketonuria, galactosemia, hyperlipidemias, porphyrias, and Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 25 related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2093 of SEQ ID NO:13, b is an

integer of 15 to 2107, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: PRLTPRMKWPTAALASRLLGWTVLRPPYPRVPSLPQVT LHPTDGLMAVLYTGGEGRRTLGEQHFFHETFVTRWLLGPVPVRFGACSPSFL APRRGQGAPAGXFCACPRPASRQLCPWPALPGTPYSNSAPLCTGMGHSNTPQ GPPSPQYALSPTEPTSLSGNSHLPAILVL (SEQ ID NO:211),
10 PRLTPRMKWPTAAL ASRLLGWTVLRPPYPRVPSLPQVTLHP (SEQ ID NO:212), TDGLMAVLYTGGE GRRTLGEQHFFHETFVTRWLLGPVPVRFG (SEQ ID NO:213), ACSPLSFLAPRRGQGAPAGXFCACPRPAS RQLCPWPALPGTP (SEQ ID NO:214), and/or
15 YSNSAPLCTGMGHSNTPQGPPSPQYALSPTEPTSLGNS HLPAILVL (SEQ ID NO:215). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human lung (adult and fetal), and to a lesser extent in liver and brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary disorders and hemostasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the lung and liver tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 111 as residues: Arg-28 to Gln-36.

The tissue distribution in lung and liver tissues indicates that the protein products of this gene are useful for the diagnosis and/or treatment of pulmonary disorders and hematopoietic disorders. The tissue distribution in adult and fetal lung tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene may be involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Alternatively,

Expression of this gene product in liver tissue indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:14, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: HLLEVTPCRLPVPEFPGRTPRGSRTPD (SEQ ID NO:216). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in rapidly dividing liver tissue, (e.g., hepatoma, hepatocellular carcinoma, and fetal liver tissue), and to a lesser extent in normal liver tissue, and other tumors such as colon cancer and uterine cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, particularly hepatomas, colon cancer, and uterine cancer.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, colon and uterus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., liver, colon, uterus, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 112 as residues: Trp-35 to Trp-45, Pro-52 to Asp-57, Thr-73 to Arg-82, Pro-105 to Leu-112, Pro-115 to Arg-127, Pro-140 to Gln-151.

The tissue distribution in liver tissues and cancers thereof, as well as other 5 cancerous tissues, indicates that the protein products of this gene are useful for the diagnosis and/or treatment of cancers, particularly, hepatoma, colon cancer and uterine cancer, as well as cancers of other tissues where expression has been observed. Furthermore, expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, 10 and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is 20 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 745 of SEQ ID NO:15, b is an integer of 15 to 759, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in hepatocellular tumors. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a 30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatomas. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., liver,

5 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 113 as residues: Pro-32 to Gly-40.

The tissue distribution in hepatocellular tumors indicates that the protein products of this gene are useful for the diagnosis and/or treatment of hepatomas, as well as cancers of other tissues where expression has been observed. Furthermore, 15 expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein 20 may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of 25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1796 of SEQ ID NO:16, b is an 30 integer of 15 to 1810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

This gene is expressed primarily in human rhabdomyosarcoma tissue, as well as in placental tissue.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, malignant neoplasms and reproductive disorders. Similarly, 10 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, 15 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 20 114 as residues: Arg-23 to Trp-28, Phe-93 to Lys-98, Arg-199 to Trp-206, Gly-208 to Met-213.

The tissue distribution in placental tissue and human rhabdomyosarcoma tissue indicates that the protein products of this gene are useful for the diagnosis and/or treatment of skeletal and reproductive disorders. Furthermore, the tissue 25 distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then 30 transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus.

Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature 5 and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is 15 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:17, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

This gene is expressed primarily in fetal liver/spleen and fetal skin tissues, and to a lesser extent in breast cancer tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as 25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders and neoplasias. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of 30 disorders of the above tissues or cells, particularly of the fetal tissue and adult immune system, expression of this gene at significantly higher or lower levels may be

routinely detected in certain tissues or cell types (e.g., developing, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression 5 level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal liver/spleen and skin tissues indicates that the protein products of this gene are useful for the diagnosis and/or treatment of developmental disorders and malignant neoplasias. Likewise, expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this 10 protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, fetal development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.

15 Alternatively, the tissue distribution in fetal skin tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, 20 erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or 25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1116 of SEQ ID NO:18, b is an integer of 15 to 1130, where both a and b correspond to the positions of nucleotide

10 residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

The translation product of this gene shares sequence homology with the bacterial gufA gene, as well as a C. elegans protein of unknown function.

15 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: MIPGSDSQTALNFGSTLMKKKSDPEGPALLFPESELSIRI
GRAGLLSDKSENGEAYQRKAAATGLPEGPAVPVPSRGNLAQPGGSSWRRI
ALLLILAITIHNVPEGLAGVGVGFGAIEKTAATFESARNLAIGIGIQNFPEGLAVS
LPLRGAGFSTWRAFWYGQLSGMVEPLAGVFGAFAVVLAEPILPYALAFAAAG

20 AMVYVVMDDIPIEAQISGNGKLASWASILGFVVMMMSLDVGLG (SEQ ID NO:217), MIPGSDSQTALNFGSTLMKKKSDPEGPALLFPESELSIRIGRA (SEQ ID NO:218), GLLSDKSENGEAYQRKAAATGLPEGPAVPVPSRGNLAQPG
(S E Q I D N O : 2 1 9) ,
GSSWRRIALLLILAITIHNVPEGLAGVGVGFGAIEKTAATFESAR (SEQ ID
25 NO:220), NLAIGIGIQNFPEGLAVSLPLRGAGFSTWRAFWYGQLS GMVEP
(SEQ ID NO:221), LAGVFGAFAVVLAEPILPYALAFAAAGAMVYVV
DDIIPEAQIS (SEQ ID NO:222), and/or GNGKLASWASILGFVVMMMSLDVGLG
(SEQ ID NO:223). Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 This gene is expressed primarily in cells of the immune system, particularly macrophage.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system, such as AIDS, as well as

5 inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

10 types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in immune cells such as macrophage indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages,

20 including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker

25 and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

30 various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in macrophage also strongly indicates a role

for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or 10 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 869 of SEQ ID NO:19, b is an integer of 15 to 883, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 10

This gene is expressed primarily in the spleen metastatic melanoma tissue as well as in embryonic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a 20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the spleen or immune system, developmental disorders, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above 25 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., spleen, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene 30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 117 as residues: Asn-37 to Lys-44, Ser-73 to Glu-78, Ala-103 to Ser-111.

The tissue distribution in spleen metastatic melanoma and embryonic tissues indicates that the protein products of this gene are useful for the diagnosis and/or treatment of disorders affecting the spleen, including cancers of the spleen, as well as cancers of other tissues where expression has been observed. Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 975 of SEQ ID NO:20, b is an integer of 15 to 989, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

It has been discovered that this gene is expressed primarily in cells of the immune system, including monocytes and neutrophils.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders affecting the immune

system, such as AIDS. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or 5 lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 118 as residues: Ser-12 to Asp-20, Gly-22 to Gly-32, Ala-49 to Thr-57.

The tissue distribution in monocytes and neutrophils indicates that the protein products of this clone are useful for the diagnosis and/or treatment of immune system disorders, including AIDS. Furthermore, expression of this gene product in 15 monocytes and neutrophils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune 20 responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune 25 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in monocytes and neutrophils also strongly 30 suggests a role for this protein in immune function and immune surveillance. Protein,

as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 481 of SEQ ID NO:21, b is an integer of 15 to 495, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

It has been discovered that this gene is expressed primarily in cells of the immune system, including monocytes.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 20 diagnosis of the following diseases and conditions: disorders affecting the immune system. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels 25 may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

30 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 119 as residues: Glu-35 to Trp-42.

The tissue distribution suggests that the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in monocytes suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all 5 hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as 10 well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have 15 commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in monocytes also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or 20 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2303 of SEQ ID NO:22, b is an integer of 15 to 2317, where both a and b correspond to the positions of 30 nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

It has been discovered that this gene is expressed primarily in cells of the immune system, including monocytes.

5 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders of the immune system. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell 10 type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene 15 expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in monocytes indicates that the protein products of this clone are useful for the diagnosis and/or treatment of disorders of the immune system. Expression of this gene product in monocytes suggests a role in the regulation of the 20 proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

25 Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory 30 bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in monocytes also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or 5 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1712 of SEQ ID NO:23, b is an integer of 15 to 1726, where both a and b correspond to the positions of 15 nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The translation product of this gene shares sequence homology with a gene 20 from *C. elegans* of unknown function.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: TRPITYVLLAG (SEQ ID NO:224). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, 25 polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

It has been discovered that this gene is expressed primarily in fetal lung, liver, spleen and heart tissues, as well as adult liver, bladder, endometrial stromal cells, synovium, colon cancer, smooth muscle, keratinocytes, and the bone marrow derived 30 cell line RS4;11.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders of the musculo-skeletal system, and cancers of the immune system. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculo-skeletal and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in tissues of the immune system indicates that the protein products of this clone are useful for treating proliferative disorders of immune system precursor cells. Alternatively, the tissue distribution in smooth muscle and heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 515 of SEQ ID NO:24, b is an integer of 15 to 529, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: GTSLTAPLLEFLLALYFLFADAMQLNDKWQGLCW^P (SEQ ID NO:225). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in T-cells, fetal 10 spleen and infant brain tissues, and to a lesser extent in many other tissues including melanocytes, lung cancer, macrophages, dendritic cells, stromal cells, adrenal gland and others.

Therefore, nucleic acids of the invention are useful as reagents for differential 15 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: inflammation and autoimmunity, developing tissues. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developing system, expression of this gene at 20 significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 122 as residues: Ser-46 to Gly-51.

The tissue distribution in T-cells and other immune cells indicates that the 30 protein products of this clone are useful for treating diseases involving the activation of T-cells, including inflammation and autoimmune diseases. Alternatively, the tissue distribution in a wide range of fetal tissues suggests that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and

treatment of cancer and other proliferative disorders. Similarly, fetal development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as,
5 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1741 of SEQ ID NO:25, b
15 is an integer of 15 to 1755, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: LANFZCSDCAQTVLFVLZFZILVFTYEIPF (SEQ ID NO:226). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 13. Accordingly, polynucleotides related to this invention are useful as a
25 marker in linkage analysis for chromosome 13. Recently another group published this gene, referring to it as CLN5 (See Genbank Accession No.: 3342386).

It has been discovered that this gene is expressed primarily in placental tissue, 12 week embryos, and tumors including testes, tongue and pharynx, and to a lesser extent in adipose tissue, tonsils, melanocytes, fetal spleen, macrophages, T-cells,
30 amniotic cells, and brain tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: tumors, particularly of the tongue and throat, and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and digestive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., tongue, throat, brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 123 as residues: Pro-44 to Ala-60, Val-187 to Thr-193, Lys-203 to Ala-210, Thr-212 to Cys-219.

The tissue distribution in tongue and pharynx carcinoma tissue indicates that the protein products of this clone are useful for diagnosing and/or treating oral cancers, including tumors of the throat and tongue. Furthermore, the tissue distribution in brain tissue suggests that the protein product of this clone is useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as neuronal ceroid lipofuscinoses (NCLs), Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1737 of SEQ ID NO:26, b is an integer of 15 to 1751, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences:

QAWHEVGGGVRRCWVLGERRAGSLLSASYGTFAMPG

15 MVLFGRRWAIASDDLVFPGFFELVVRVLWWIGILTLYL (SEQ ID NO:227),
and/or PGMVLFGRRWAIASDDLVFPGFFELVVRVLWWIGILTLYLMHRGKLD
CAGGALLSSYLVLMILLAVVICTVSAIMCVSMRGTCNPGPRKSMSKLLYIRL
ALFFPEMVWASLGAAWVADGVQCD (SEQ ID NO:228). Polynucleotides
encoding these polypeptides are also encompassed by the invention.

20 It has been discovered that this gene is expressed in activated neutrophils,
infant brain tissue and primary dendritic cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders of the immune system,
25 and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell
30 types (e.g., immune, brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual

having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 124 as residues: Pro-47 to Met-53, Ser-130 to Ser-138.

5 The tissue distribution in neutrophils and primary dendritic cells indicates that the protein products of this clone are useful for diagnosing and/or treating immune system disorders. Expression of this gene product in neutrophils and primary dendritic cells suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem 10 cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker 15 and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of 20 various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils and primary dendritic cells also strongly suggests a role for this protein in immune function and immune surveillance.

Alternatively, the tissue distribution in brain tissue suggests that the protein product of this clone is useful for the detection/treatment of neurodegenerative 25 disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play 30 a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 1198 of SEQ ID NO:27, b is an integer of 15 to 1212, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

It has been discovered that this gene is expressed primarily in neutrophils, and to a lesser extent in other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 20 diagnosis of the following diseases and conditions: immune and inflammatory disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels 25 may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

30 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 125 as residues: Gln-17 to Ser-24.

The tissue distribution in neutrophils indicates that the protein products of this clone are useful for the diagnosis and/or treatment of immune and inflammatory disorders. Expression of this gene product in neutrophils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of 5 potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as 10 well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have 15 commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or 20 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:28, b is an integer of 15 to 1112, where both a and b correspond to the positions of 30 nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: HERNCFPMWLNHSAPPPV (SEQ ID NO:229).

5 Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in neutrophils, and to a lesser extent in other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

10 diagnosis of the following diseases and conditions: immune and inflammatory disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels
15 may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

20 The tissue distribution in neutrophils indicates that the protein products of this clone are useful for the diagnosis and/or treatment of immune and inflammatory disorders. Expression of this gene product in neutrophils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene
25 product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker
30 and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune

deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 734 of SEQ ID NO:29, b is an integer of 15 to 748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: GWTRENDHRALSKAGIGSAEIQPSNLRVGSAKDLGKPW AGKLLLLSSCLLFFSLGVLYRGQMLAPPLQEDWKGGVKDSLDLIDDSSASPIPP SYLEYKAALYPFSEHKSVRNATDSLTFVLVTDHFLDNQDSQ (SEQ ID NO:230), GWTRENDHRALSKAGIGSAEIQPSNLRVGSAKDLGKPWAGKLLLL (SEQ ID NO:231), SSCLLFFSLGVLYRGQMLAPPLQEDWKGGVKDSLDLIDDSSASPIPP (SEQ ID NO:232), and/or SYLEYKAALYPFSEHKSVRNATDSLTFVLVTDHFL DNQDSQ (SEQ ID NO:233). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in ovarian cancer tissue, and to a lesser extent in other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for
5 diagnosis of the following diseases and conditions: ovarian cancer. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ovaries, expression of this gene at significantly higher or lower levels may be detected in
10 certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 127 as residues: Thr-20 to Gly-27, Gly-32 to Phe-41.

The tissue distribution in ovarian cancer tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of ovarian cancer, as well as cancers of other tissues where expression has been observed. Protein, as
20 well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 764 of SEQ ID NO:30, b
30 is an integer of 15 to 778, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

5 When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent other cells, through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The
10 Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following
15 amino acid sequences: LKFHQESLSGD (SEQ ID NO:234). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in fast-growing tissues such as immune/hematopoietic tissues, early developmental stage human tissues, and tumor tissues, and to a lesser extent in some other tissues.

20 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: growth disorders, immune and inflammatory diseases, and tumorigenesis. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for
25 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune/hematopoietic system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an
30 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 128 as residues: Glu-60 to Arg-65.

The tissue distribution in immune tissues, in conjunction with the biological activity data, indicates that the protein products of this clone are useful for the

5 diagnosis and/or treatment of growth disorders, immune and inflammatory diseases, and tumorigenesis. Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells suggests that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic

10 development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:31, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a

25 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: EAKSRPVTQAGVQWHDLGSLQPLPP (SEQ ID NO:235).

30 Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in ovarian cancer tissue, and to a lesser extent in fetal liver/spleen and retinal tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: ovarian cancer, immune disorders, and retinal disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ovaries, immune and ocular systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, ovaries, retina, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in ovarian cancer tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of ovarian cancer, as well as cancers of other tissues where expression has been observed. The tissue distribution also suggests that the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in fetal liver/spleen suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have

commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in retinal tissue suggests that the protein product of this clone is useful for the treatment and/or detection of eye disorders

5 including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma, retinochoroiditis, retinopathy and retinoschisis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 725 of SEQ ID NO:32, b is an integer of 15 to 739, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a

20 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene shares sequence homology with a C. elegans protein of unknown function (See Genbank Accession No.: gnllPIDle1348017). When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and

25 proliferation. The gene encoding the disclosed cDNA is thought to reside on

30

chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: EAKSRPVTQAGVQWHDL GSLQPLPP (SEQ ID NO:236),

5 and/or ALVLVCRQR YCRPRDLLQRYDSKPIVDLIGAMETQSEPSELEDDVVIT
NPHEAILENEDWIEDASGLMSHCIAILKICHTLTEKLVAMTMGSGAKMKTSA
SVSDIIVVAKRISPRVDDVVKS MYPPLDPKLLDAR (SEQ ID NO:237).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in fast growing
10 tissues such as early development stage human tissues, immune/hematopoietic
tissues, melanocytes, and tumor tissues, and to a lesser extent in some other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: growth disorders, immune and
15 inflammatory disorders, skin and connective tissue disorders, and tumorigenesis.

Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fast growing tissues such as early development stage human tissues,
20 immune/hematopoietic tissues, skin and connective tissue, and tumor tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., musculo-skeletal, skin, immune, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder,
25 relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 130 as residues: Pro-34 to Ser-43, Glu-54 to Ser-60.

The tissue distribution suggests that the protein product of this clone is useful
30 for the diagnosis and/or treatment of growth disorders, immune and inflammatory disorders, and tumorigenesis. Alternatively, the tissue distribution in melanocytes, in

conjunction with the observed biological activity data, suggests that the protein product of this clone is useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. 5 keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune 10 disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma.

Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, 15 and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 20 related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 25 general formula of a-b, where a is any integer between 1 to 1448 of SEQ ID NO:33, b is an integer of 15 to 1462, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent other cells, through the Jak-STAT signal

5 transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate
10 proteins involved in the proliferation and differentiation of cells

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences:

D V E S R G P S A R C L P V V P G S L L P G L E P A T K L M P G G L A P G H G
A P V R E L L L P L L S Q P T L G S L W D S L R H C S L L C N P L S C V P A L E A P P S L V S L G C S G G C
15 P R L S L A G S A S P F P F L T A L L S L L N T L A Q I H K G L C G Q L A A I L A A P G L Q N Y F L Q C V A
P G A A P H L T P F S A W A L R H E Y H L Q Y L A L A L A Q K A A A L Q P L P A T H A A L Y H G M A L
A L L S R L L P G S E Y L T H E L L S C V F R L E F L P E R T S G G P E A A D F S D Q L S L G S S R V P R
C G Q G T L L A Q A C Q D L P S I R N C Y L T H C S P A R A S L L A S Q A L H R G E L Q R V P T L L P
M P T E P L L P T D W P F L H (SEQ ID NO:238),
20 D V E S R G P S A R C L P V V P G S L L P G L E P A T K L M P G G L A P G H G A P V R E (SEQ ID NO:239), L L L P L L S Q P T L G S L W D S L R H C S L L C N P L S C V P A L E A P P S L V S L G C (SEQ ID NO:240), S G G C P R L S L A G S A S P F P F L T A L L S L L N T L A Q I H K G L C G Q L A A I L A (SEQ ID NO:241), A P G L Q N Y F L Q C V A P G A A P H L T P F S A W A L R H E Y H L Q Y L A L A L A Q K (SEQ ID NO:242), A A A L Q P L P A T H A A
25 L Y H G M A L A L L S R L L P G S E Y L T H E L L S C V F R (SEQ ID NO:243), L E F L P E R T S G G P E A A D F S D Q L S L G S S R V P R C G Q G T L L A Q A C Q D L (SEQ ID NO:244), and/or P S I R N C Y L T H C S P A R A S L L A S Q A L H R G E L Q R V P T L L P M P T E P L L P T D W P F L H (SEQ ID NO:245). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in hematopoietic tissues and fetal heart tissue, and to a lesser extent in brain and gall bladder tissues, and some other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and inflammatory disorders, cardiovascular disorders, and growth disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and vascular systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., vascular, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 131 as residues: Tyr-88 to Trp-102, Asp-105 to Ser-110.

The tissue distribution in hematopoietic tissues, in conjunction with the observed biological activity data, indicates that the protein products of this clone are useful for the diagnosis and/or treatment of immune and inflammatory disorders and growth disorders. Alternatively, the tissue distribution in fetal heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2801 of SEQ ID NO:34, b
5 is an integer of 15 to 2815, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

10 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: VGSVLGAFLTFPGLRLAQTHRDALT (SEQ ID NO:246). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in
15 linkage analysis for chromosome 19.

It has been discovered that this gene is expressed primarily in human pituitary tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for
20 diagnosis of the following diseases and conditions: hyperpituitarism and hypopituitarism. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or
25 lower levels may be detected in certain tissues or cell types (e.g., endocrine, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. This gene is found on the short arm
30 of chromosome 19 and, therefore, is useful as a chromosome marker.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 132 as residues: Met-1 to Pro-6, Gln-89 to Ala-94, Pro-161 to Cys-173.

The tissue distribution in pituitary tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of pituitary disorders. More 5 generally, the tissue distribution in pituitary tissue suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, 10 hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 15 related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 20 general formula of a-b, where a is any integer between 1 to 1064 of SEQ ID NO:35, b is an integer of 15 to 1078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 26

It has been discovered that this gene is expressed highly and specifically in placental and bone marrow cDNA libraries, and to a lesser extent in T-cells.

Therefore, nucleic acids of the invention are useful as reagents for differential 30 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune, developmental and reproductive disorders. Similarly, polypeptides and antibodies directed to those

polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developing systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types

5 (e.g., immune, developmental, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

10 The tissue distribution in bone marrow and placental tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of immune and reproductive disorders. The tissue distribution in bone marrow suggests that the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia,

15 thrombocytopenia or leukemia. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in
20 the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the tissue distribution in placental tissue suggests that the protein product of this clone is useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta suggests that this gene
25 product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus.

Expression of this gene product in a vascular-rich tissue such as the placenta
30 also suggests that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in

vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, 5 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of 10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1203 of SEQ ID NO:36, b 15 is an integer of 15 to 1217, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequences:

LECTDTIMVHCSLKLLSPSDXSHSASQVAKTRGVHHXTQ

LIFKVFFVXMGSHSTKYXSIRPGLLP (SEQ ID NO:247). Polynucleotides encoding these polypeptides are also encompassed by the invention.

25 It has been discovered that this gene is expressed primarily in human prostate and smooth muscle tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders in the prostate gland, 30 vascular and connective tissues. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential

identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive and urinary system and vascular system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, vascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in prostate and smooth muscle tissues indicates that the protein products of this clone are useful for the diagnosis and/or treatment of prostate gland, vascular and connective tissue disorders. The tissue distribution in smooth muscle tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. The expression in the prostate tissue may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1268 of SEQ ID NO:37, b is an integer of 15 to 1282, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a
+ 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: ESSFVPPAAHSSL (SEQ ID NO:248). Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 It has been discovered that this gene is expressed primarily in human pituitary tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: hyperpituitarism and
10 hypopituitarism. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., endocrine,
15 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in pituitary tissue indicates that the protein products of
20 this clone are useful for the diagnosis and/or treatment of pituitary gland disorders such as hypopituitarism and hyperpituitarism. More generally, the tissue distribution in pituitary tissue suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of
25 the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 545 of SEQ ID NO:38, b is an integer of 15 to 559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

In specific embodiments, polypeptides of the invention comprise the following
a m i n o a c i d s e q u e n c e s :
LLPGQQEATQCVEAGAGEGALTPMCPCCRQEKFVVDLYKEF
15 EPSLVNSTVYIMAMAIQMAPFAINYKVRPGPCXNIHCLPTQPHPMKPSVPHPH
RARPSWRACPRTSPWCGVWFHSWPSLACSSAPRPTSTASLASWTSWLSSS
WSLPRSCSWTSAWRSWPTASCSSWGPRS (SEQ ID NO:249),
LLPGQQEATQCV EAGAGEGALTPMCPCCRQEKFVVDLYKEFEPVLN (SEQ ID
NO:250), STVYIMAMAIQMAPFAINYKVRPGPCXNIHCLPTQPHPMKPSVP
20 (S E Q I D N O : 2 5 1) ,
HPRARPSWRACPRTSPWCGVWFHSWPSLACSSAPRPTSTA (SEQ ID
NO:252), and/or SLASWTSWLSSWSLPRSCSWTSAWRSWPTASCSSWG PRS
(SEQ ID NO:253). Polynucleotides encoding these polypeptides are also
encompassed by the invention.
25 It has been discovered that this gene is expressed primarily in human pituitary
and breast tissues, and to a lesser extent in endometrial and ovarian cancer tissues.
Therefore, nucleic acids of the invention are useful as reagents for differential
identification of the tissue(s) or cell type(s) present in a biological sample and for
diagnosis of the following diseases and conditions: hyperpituitarism and
30 hypopituitarism, and cancers of the female reproductive system. Similarly,
polypeptides and antibodies directed to those polypeptides are useful to provide

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., endocrine, reproductive, 5 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 10 136 as residues: Ser-3 to Lys-8.

The tissue distribution in pituitary tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of disorders in the pituitary gland. More generally, the tissue distribution in pituitary tissue suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention 15 of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, the tissue distribution in breast tissue and cancerous tissues of 20 the endometrium and ovaries suggests that the translation product of this gene is useful for the detection and/or treatment of disorders and cancers of the female reproductive system, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence 30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 789 of SEQ ID NO:39, b is an integer of 15 to 803, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: TRNILSFIKCVIHNFWIPKESNEITIIINPYRETVCFSVEP VKKIFNY (SEQ ID NO:254). Polynucleotides encoding these polypeptides are also 10 encompassed by the invention.

It has been discovered that this gene is expressed primarily in human synovial sarcoma tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, 15 polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., skeletal, connective, cancerous and wounded tissues) 20 or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 25 137 as residues: Thr-29 to Pro-34.

The tissue distribution in synovial sarcoma tissue indicates that the protein products of this clone are useful for the diagnosis and/or treatment of diseases of the synovium. In addition, the

Expression of this gene product in synovium suggests a role in the detection 30 and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma,

tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia

5 congenita, familial arthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

10 related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

15 general formula of a-b, where a is any integer between 1 to 1496 of SEQ ID NO:40, b is an integer of 15 to 1510, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: LVVLFASSNSRYLKYFFLVPLILGSAW (SEQ ID NO:255). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in human

25 rhabdomyosarcoma and fetal liver/spleen tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: malignant neoplasms and hematopoiesis. Similarly, polypeptides and antibodies directed to those polypeptides

30 are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,

particularly of the skeletal and immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., musculo-skeletal, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an 5 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 138 as residues: Gly-29 to Thr-35.

The tissue distribution in rhabdomyosarcoma and fetal liver/spleen tissues 10 indicates that the protein products of this clone are useful for diagnosis and treatment of skeletal and immune disorders. The expression in rhabdomyosarcoma tissue suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various muscle disorders, such as muscular dystrophy, cardiomyopathy, fibroids, myomas, and rhabdomyosarcomas. Alternatively,

15 Expression of this gene product in fetal liver/spleen tissue suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of 20 cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune 25 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a 30 tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1081 of SEQ ID NO:41, b is an integer of 15 to 1095, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

It has been discovered that this gene is expressed primarily in fibrosarcoma tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: fibrosarcoma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissue system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 139 as residues: Ser-34 to Gln-40, Gly-42 to Glu-48, Tyr-56 to Leu-62.

The tissue distribution in only fibrosarcoma tissue suggests that the protein product of this clone is useful for the treatment, diagnosis and/or prognosis of

fibrosarcoma's or other disorders related with fibrous tissue including fibroma, fibromatosis, fibromyoma, fibromyositis, fibrosis and fibrositis. Likewise, the expression in fibrosarcoma tissue suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various muscle disorders, 5 such as muscular dystrophy, cardiomyopathy, myomas, and rhabdomyosarcomas. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 10 related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 15 general formula of a-b, where a is any integer between 1 to 1148 of SEQ ID NO:42, b is an integer of 15 to 1162, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

It has been discovered that this gene is expressed primarily in Hodgkins lymphoma and breast cancer tissues, and to a lesser extent in stromal cells and brain tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential 25 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: lymphoma, breast cancer, and neurological disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, 30 particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types

(e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 140 as residues: Pro-22 to Lys-29.

The tissue distribution in Hodgkins lymphoma, brain and breast cancer tissues suggests a role in the treatment, diagnosis and/or prognosis of breast cancer, immune and hematopoietic disorders including arthritis, asthma, immunodeficiency diseases, 10 leukemia and Hodgkin's lymphoma and neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed 15 tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 643 of SEQ ID NO:43, b is an integer of 15 to 657, where both a and b correspond to the positions of 25 nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

In specific embodiments, polypeptides of the invention comprise the following 30 amino acid sequences: HEWKCKQKYSEGGSGNTRIGN (SEQ ID NO:256). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in chronic synovitis tissue, and to a lesser extent in fetal kidney and testes tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: synovitis, renal disorders and male infertility. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissue system, the renal system, and the male reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., skeletal, renal, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 141 as residues: Met-33 to Pro-39, Ser-74 to Trp-79.

The tissue distribution of this gene in chronic synovitis, testes, and kidneys suggests a role in the treatment, diagnosis and prognosis of synovial membrane disorders including synovitis, renal disorders including kidney failure, renal colic, renal diabetes, hypertension, osteodystrophy, tubular acidosis and kidney stones; and male infertility. Furthermore, the tissue distribution in testes tissue indicates that the protein product of this clone is useful for the treatment and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific

tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. In addition, the

Expression of this gene product in synovium suggests a role in the detection
5 and/or treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and
10 specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial arthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1141 of SEQ ID NO:44, b is an integer of 15 to 1155, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a
25 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: LLPLCFLGPRQVLEEFPSIV (SEQ ID NO:257).

30 Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in brain tissue, and to a lesser extent in osteoclastoma and testes tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

5 diagnosis of the following diseases and conditions: neurological disorders and male reproductive disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system and the male reproductive system, expression of
10 this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

15 The tissue distribution of this gene in brain tissue suggests a role in the diagnosis, prognosis and/or treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition, the gene or gene product may also play a role in the
20 treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
30 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:45, b

is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 36

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: PTRPSKHQEAGS (SEQ ID NO:258). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 3. Accordingly, 10 polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

It has been discovered that this gene is expressed primarily in adult and fetal heart tissue, and to a lesser extent in fetal lung and fetal liver/spleen tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential 15 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: cardiovascular and immune disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of 20 the vascular and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., vascular, immune, pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in 25 healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 143 as residues: Val-2 to Ser-14.

The tissue distribution in heart, fetal liver and fetal spleen tissues suggests a role in the treatment and/or diagnosis of cardiovascular disorders including 30 myocardial infarction, congestive heart failure, coronary failure, as well as immune disorders including autoimmune diseases, such as lupus, transplant rejection, allergic

reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS. Furthermore, the tissue distribution in adult and fetal heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, 5 atherosclerosis, stroke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 10 related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 15 general formula of a-b, where a is any integer between 1 to 4009 of SEQ ID NO:46, b is an integer of 15 to 4023, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 37

It has been discovered that this gene is expressed primarily in testes tissues. Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: male infertility and reproductive 25 disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, cancerous 30 and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in testes tissues suggests a role in the treatment and/or diagnosis of male infertility, and testicular disorders including cancer. Furthermore, 5 the tissue distribution in testes tissue indicates that the protein product of this clone is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such 10 agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related 15 functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 528 of SEQ ID NO:47, b is an integer of 15 to 542, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

It has been discovered that this gene is expressed primarily in apoptotic T-cells, and to a lesser extent in brain tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and neurological disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 145 as residues: Glu-33 to Tyr-42.

The tissue distribution in apoptotic T-cells suggests potential roles in the treatment and/or diagnosis of immune disorders including of immune and autoimmune diseases, such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS. Alternatively, expression in brain tissue suggests a role in the treatment and/or diagnosis of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Furthermore, the tissue distribution in apoptotic T-cells indicates that the translation product of this gene may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1481 of SEQ ID NO:48, b is an integer of 15 to 1495, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

The translation product of this gene shares sequence homology with phosphomannomutase, which is thought to be important in mannose metabolism.

15 It has been discovered that this gene is expressed primarily in meningioma and testis tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: meningioma related diseases.

20 Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels 25 may be detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 146 as residues: Ser-33 to Lys-43.

30 The tissue distribution in meningioma, and the homology to phosphomannomutase, suggests that the protein product of this clone is useful for the

diagnosis and/or intervention of meningioma related diseases. For example, the gene product can be used for preventing microbial infection of the meninges, for imaging conjugates, or as a secretory factor as a endocrine with systemic, central or peripheral nerve functions. Protein, as well as, antibodies directed against the protein may show 5 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 804 of SEQ ID NO:49, b is an integer of 15 to 818, where both a and b correspond to the positions of 15 nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

It has been discovered that this gene is expressed primarily in tonsils, 20 osteoclastoma and retinoic acid treated teratocarcinoma cells, and to a lesser extent in macrophages, female bladder, adipose tissue, myeloid progenitor cells, prostate tissue, and number of other tissues and organs.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 25 diagnosis of the following diseases and conditions: tonsils and osteoclast related diseases. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and bone systems, expression of this gene at significantly higher or lower 30 levels may be detected in certain tissues or cell types (e.g., immune, skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,

synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.

5 147 as residues: Glu-55 to Arg-61, Gln-84 to Ser-92, Ser-99 to Ser-104.

The tissue distribution in tonsils and osteoclastoma suggests that the protein product of this clone is useful for the diagnosis and/or intervention of diseases related to tonsils or osteoclasts. For example, tonsillitis, adenoids, peritonsilar abscess, neoplasms, or bone related disorders like rickets, abnormalities of bone growth and 10 modelling, facture, osteonecrosis, and osteoporosis etc. Expression of this gene product in osteoclastoma suggests that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis.

Alternatively, the expression of this gene product in tonsils suggests a role in 15 the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

20 Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory 25 bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1697 of SEQ ID NO:50, b is an integer of 15 to 1711, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

It has been discovered that this gene is expressed primarily in resting T-cells. Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 15 diagnosis of the following diseases and conditions: T-cell related disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in 20 certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in resting T-cells suggests that the protein product of 25 this clone is useful for the diagnosis and/or intervention of T-cell related disorders, such as infection, inflammation, allergy, tissue/organ transplantation, immune deficiency etc. Furthermore, the expression of this gene product in T cells also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor 30 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 735 of SEQ ID NO:51, b is an integer of 15 to 749, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The translation product of this gene shares weak sequence homology with Human metastasis suppressor KiSS-1 fragment, which is thought to be important in the diagnosis, prevention, staging and/or treatment of cancers, such as melanoma (See Accession No. W15789).

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: GQGPAGRWVRRLPCSRRAGGERGPHGVWAGPQM SCGLXFGP (SEQ ID NO:259), WRTQGPMVLLVVVTCPATMLTEPQNPHLIGF VAYSGPSHTTQPHKYWLLLDGQADPAAAEGPVKRKAASVWWPQALRHLS LLVHCWEESYEMNIGCQSLWAGGLASSGNGWDLGVAFRRTDCMSSSLHW KEFKYAPGSLHYFALSFVLILTEICLVSSGMGFPQEGKHFSVLGSPDCSLWGR D E H V P R E F A (S E Q I D N O : 2 6 0) ,
25 WRTQGPMVLLVVVTCPATMLTEPQNPHLIGFVAY SGPSHTTQ (SEQ ID NO:261), PHKYWLLDGQADPAAAEGPVKRKAASVWW PQALRHLSLL (SEQ ID NO:262), VHCWEESYEMNIGCQSLWAGGLASSGNGW DLGVAFRRTDCM (S E Q I D N O : 2 6 3) ,
SSSSLHWKEFKYAPGSLHYFALSFVLILT EICLVSSGMGFPQEG (SEQ ID
30 NO:264), and/or KHFSVLGSPDCSLWGRDEHV PREFA (SEQ ID NO:265). Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

It has been discovered that this gene is expressed primarily in tonsils,
5 osteoclastoma and teratocarcinoma tissues, and to a lesser extent in female bladder,
adipose tissue, myeloid progenitor, prostate tissue, and number of other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: diseases related to tonsils and
10 osteoclasts. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and bone system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, skeletal,
15 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in tonsils and osteoclastoma tissues suggests that the
20 protein product of this clone is useful for the diagnosis and/or treatment of diseases related to tonsils and osteoclasts. For example, tonsillitis, adenoids, peritonsilar abscess, neoplasms, or abnormal growth and modelling of the bone, osteonecrosis, osteoporosis, osteodystrophy, osteoclastoma etc. Expression of this gene product in osteoclastoma suggests that it may play a role in the survival, proliferation, and/or
25 growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis.

Moreover, the expression of this gene product in tonsils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene
30 product may be involved in the regulation of cytokine production, antigen

presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1077 of SEQ ID NO:52, b is an integer of 15 to 1091, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The translation product of this gene shares sequence homology with the Drosophila gene "maleless", which is one of four known regulatory loci required for increased transcription (dosage compensation) of X-linked genes (See Genbank Accession No.: gil157906).

It has been discovered that this gene is expressed primarily in normal prostate tissue, testes tissue, whole 6-week old embryonic tissue, human colon carcinoma

(HCC) cell line, and cerebellum tissue, and to a lesser extent in primary breast cancer, activated T-cells, and many other tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: diseases of the prostate or colon, or male reproductive disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate or colon carcinoma, and male reproductive disorders, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., colon, prostate, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 150 as residues: Val-39 to Ala-45.

The tissue distribution in colon and prostate tissues suggests that the protein product of this clone is useful for the diagnosis and/or treatment of prostate disorders such as prostatitis, prostatic hyperplasia, prostate cancers, or human colon carcinoma, as well as cancers of other tissues where expression has been observed. Alternatively, the tissue distribution in testes tissue, in conjunction with the homology to the *Drosophila maleless* gene, suggests that the translation product of this gene is useful for the detection and/or treatment of disorders involving the testes or the transcription of X-linked genes. Furthermore, the tissue distribution indicates that the protein product of this clone is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence.

This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the

protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related

5 functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2240 of SEQ ID NO:53, b is an integer of 15 to 2254, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The translation product of this gene shares weak sequence homology with *Eimeria* antigen Eam45 M3, which is thought to be important in uses as a vaccine for protecting chickens against coccidiosis.

25 It has been discovered that this gene is expressed primarily in adrenal gland tissue, and to a lesser extent in activated T-cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: adrenal cortical insufficiency, 30 adrenal cortical hyperfunction, neoplasia. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., endocrine, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,

5 plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in adrenal gland tissue suggests that the protein product of this clone is useful for the diagnosis and/or intervention of disorders caused by

10 adrenal gland abnormalities, such as adrenal cortical insufficiency, adrenal cortical hyperfunction, and neoplasia. More generally, the tissue distribution suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus),
15 adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 472 of SEQ ID NO:54, b is an integer of 15 to 486, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

The translation product of this gene shares sequence homology with neural thread protein, tumor necrosis factor related gene product, human alpha-1C2 adrenalin receptor, which is thought to be important for diagnosing the presence of Alzheimer's disease, neuroectodermal tumours and a malignant astrocytoma, or

5 diagnosis of hepatocellular carcinomas and preneoplastic or pathological conditions of the liver, and tumor immunity.

It has been discovered that this gene is expressed primarily in activated T-cells and endothelial cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: Alzheimer's disease, neuroectodermal tumours and a malignant astrocytoma, hepatocellular carcinomas and tumors of various origins. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and endothelial cells, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, endothelial, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual

10 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

15

20

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 152 as residues: Arg-38 to Arg-47.

The tissue distribution in immune and endothelial tissues, and the homology to neural thread protein, tumor necrosis factor related gene product, human alpha-1C2 adrenalin receptor, or Smaller hepatocellular oncoprotein (hhcm) gene product suggests that the protein product of this clone is useful for the diagnosis and/or treatment of tumors of various origins, including neuroectodermal tumours and a malignant astrocytoma, hepatocellular carcinomas, as well as syndromes inflicted by

25

30

these cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1256 of SEQ ID NO:55, b is an integer of 15 to 1270, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

It has been discovered that this gene is expressed primarily in tumor tissues such as hepatocellular tumor, hemangiopericytoma, chronic lymphocytic leukemia, and activated T-cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: tumors of various origins. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatocellular tumor, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., liver, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in hepatocellular tumors suggests that the protein product of this clone is useful for the diagnosis and/or targeting of hepatocellular carcinomas, preneoplastic or pathological conditions of the liver, Alzheimer's disease,

neuroectodermal tumours and malignant astrocytoma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:56, b is an integer of 15 to 2059, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

It has been discovered that this gene is expressed primarily in glioblastoma, ulcerative colitis, and hemangiopericytoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: glioblastoma, hemangiopericytoma and their inflicted disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 154 as residues: Pro-31 to Ala-37.

The tissue distribution suggests that the protein product of this clone would be useful for the diagnosis, targeting and/or treatment of tumors in the brain, such as 5 glioblastoma and hemangiopericytoma. Additionally, the gene products can be useful agent for the diagnosis and treatment of ulcerative colitis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 854 of SEQ ID NO:57, b is an integer of 15 to 868, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

It has been discovered that this gene is expressed primarily in bone marrow. Therefore, nucleic acids of the invention are useful as reagents for differential 25 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of 30 the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types

(e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 155 as residues: Thr-47 to Val-53.

The tissue distribution in bone marrow suggests that the protein product of this clone is useful for the diagnosis and/or treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-10 suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Furthermore, the tissue distribution in bone marrow suggests that the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, 15 thrombocytopenia or leukemia.

The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, 20 immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence 30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 972 of SEQ ID NO:58, b is an integer of 15 to 986, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

It has been discovered that this gene is expressed primarily in bone marrow.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

10 diagnosis of the following diseases and conditions: immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of
15 the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in
20 healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 156 as residues: Leu-40 to Cys-47.

The bone marrow tissue distribution suggests that the protein product of this clone would be useful for the diagnosis and treatment of immune disorders including:
25 leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Furthermore, the tissue distribution in bone marrow suggests that the protein product of this clone is useful for the treatment and diagnosis of
30 hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia.

The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy,

5 immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 681 of SEQ ID NO:59, b is an integer of 15 to 695, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a

20 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IAQGTVPLTKRGVQSSGPDYPEGTLTPLPRG (SEQ ID NO:266 and 267). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in dendritic cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 30 diagnosis of the following diseases and conditions: immune disorders and related conditions such as leukemias, lymphomas, inflammation, hematopoietic dysfunction,

arthritis and asthma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of dendritic cells. For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels
5 may be detected in certain tissues or cell types (e.g., dendritic cells, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 157 as residues: Ser-25 to Phe-31, Lys-55 to Arg-61.

15 The tissue distribution in dendritic cells suggests that the protein product of this clone is useful for the diagnosis and/or treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer.

20 Moreover, the expression of this gene product in dendritic cells also strongly suggests a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 300 of SEQ ID NO:60, b
30 is an integer of 15 to 314, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DCLYLALSFPWHCHCHHHPPSGSLLYPF (SEQ ID NO:268). Polynucleotides encoding these polypeptides are also encompassed by the invention. The translation product of this gene shares sequence homology with a C. elegans protein of unknown function (See Genbank Accession No.: gil1947142 10 (AF000264)).

It has been discovered that this gene is expressed primarily in healing abdominal wound tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 15 diagnosis of the following diseases and conditions: tissue necrosis, wound healing, ulceration, neoplasms or cancer. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of injured tissue, expression of this gene at significantly 20 higher or lower levels may be detected in certain tissues or cell types (e.g., vascular, endothelial, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 158 as residues: Pro-34 to Tyr-43, Gln-73 to Cys-86, Pro-98 to Leu-103.

The tissue distribution in healing abdominal wound tissue suggests that the protein product of this clone is useful for the treatment and/or diagnosis of conditions involving tissue repair and wound healing. Tissue repair may be indicated in cases of 30 injury to the skin or internal organs, ulceration, cellular necrosis or other conditions involving healing of both diseased or non-diseased, traumatized tissue. In addition,

because of the implications of tissue regeneration, remodeling and growth regulation, the protein product of this gene may have indications in the diagnosis and treatment of neoplasms and cancer.

More generally, the tissue distribution in endothelial tissue indicates that the

5 protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. Likewise, the tissue distribution further suggests that the protein product of this clone is useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital

10 disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema,

15 photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis,

20 erysipelas, impetigo, tinea, athletes foot, and ringworm). Moreover, the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint

25 abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 720 of SEQ ID NO:61, b is an integer of 15 to 734, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

The translation product of this gene shares sequence homology with FAR-17A, which is an androgen induced protein, absent in castrated hamsters (See Genbank Accession No.: gil191315), as well as a male hormone-dependent gene 15 product (See GenSeq Accession No.: R10612). The gene encoding the disclosed cDNA is thought to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequences: ASLPPSRPLANMALVPCQVLRMAILLSYCSILCNYKA 20 IE MPH QTYGGSWKFLTFIDLVIQAVFFGICVLTDLSSLTRGSGNQEQLK KLISLRDW (SEQ ID NO:269). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in fetal liver and spleen tissue, and to a lesser extent in a variety of other fetal tissues and brain tissues.

25 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune disorders including leukemias, lymphomas; reproductive and endocrine disorders, including testicular cancer; and liver disorders (e.g. hepatoblastoma, metabolic diseases and conditions 30 that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 10 159 as residues; Thr-59 to Gly-70, Tyr-132 to Glu-150.

The tissue distribution and homology to FAR-17A suggests that the protein product of this clone is useful for the treatment and/or diagnosis of androgen related conditions and disorders. Male reproductive and endocrine disorders would be potential area of application (e.g. endocrine function, sperm maturation). It may also 15 prove to be valuable in the diagnosis and treatment of testicular cancer.

More generally, the protein product of this clone may be useful for the treatment and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is 20 also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other 25 specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1396 of SEQ ID NO:62, b is an integer of 15 to 1410, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 to calcium. Thus it is likely that the product of this gene is involved in a signal transduction
15 pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of monocytes, and to a lesser extent, in immune or hematopoietic cells and tissues. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes.

In specific embodiments, polypeptides of the invention comprise the following
20 amino acid sequence: MSRSSRISGLSCPWLL (SEQ ID NO:270). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

25 It has been discovered that this gene is expressed primarily in T-cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and hematopoietic diseases and/or disorders. Similarly, polypeptides and antibodies directed to those
30 polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,

particularly of the immune and haemopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an 5 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 160 as residues: Pro-42 to Cys-50, Leu-61 to Ala-66.

The tissue distribution in T-cells, combined with the detected calcium flux

10 activity in monocytes suggests that the protein product of this clone would be useful for the treatment and diagnosis of immune and hematopoietic disorders. Moreover, the expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine 15 production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency

20 diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue 25 injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the 30 expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1217 of SEQ ID NO:63, b is an integer of 15 to 1231, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 54

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DHWPAGFLPPAPGLKFPVALEVFRKVLPACVPTDCSGS AGKERNS (SEQ ID NO:271). Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 It has been discovered that this gene is expressed primarily in liver. Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: metabolic diseases and liver conditions. Similarly, polypeptides and antibodies directed to those polypeptides are 25 useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., hepatic, liver, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, 30 urine, synovial fluid or spinal fluid) taken from an individual having such a disorder,

relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 161 as residues: Ser-31 to Gln-41.

5 The tissue distribution in liver suggests that the protein product of this clone would be useful for treatment and diagnosis of disorders of the metabolic system and liver disorders. Moreover, the protein product of this clone is useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of
10 hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
15 related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
20 general formula of a-b, where a is any integer between 1 to 598 of SEQ ID NO:64, b is an integer of 15 to 612, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 55**

When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates sensory neuron cells, and to a lesser extent in other neural cells and tissues, through the EGR1 signal transduction
30 pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes

containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

It has been discovered that this gene is expressed primarily in T-cells and monocytes, and to a lesser extent in cancerous tissues, including cancerous colon tissue and placenta.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and haemopoietic disorders and cancer such as colon cancer, but also such cancers as breast cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, adenoma, and the like. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and haemopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 162 as residues: Glu-63 to Trp-72.

The tissue distribution in T-cells and monocytes, combined with the detected EGR1 biological activity suggests that the protein product of this clone would be useful for treatment and diagnosis of disorders of the immune and haemopoietic systems and colon and other cancers. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an

agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,

inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis,

hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to

5 transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Moreover, the protein may represent a secreted factor that influences the
10 differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression cellular sources marked by proliferating cells suggests this protein may play a role in the
15 regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell
20 death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA).

Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate
25 apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 5 general formula of a-b, where a is any integer between 1 to 2256 of SEQ ID NO:65, b is an integer of 15 to 2270, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene has homology with several human keratin genes at the nucleotide level (see, for example, Troyanovsky, et al., Eur. J. Cell Biol. 59:127-137 (1992) which is hereby incorporated by reference herein). Based on the sequence similarity, the translation product of this clone is expected to share 15 biological activities with keratin and growth factor proteins. Such activities are known in the art, and some of which are described elsewhere herein.

It has been discovered that this gene is expressed primarily in neutrophils.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 20 diagnosis of the following diseases and conditions: immune and haemopoietic disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and haemopoietic system, expression of this gene at significantly higher 25 or lower levels may be detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

30 The tissue distribution in neutrophils suggests that the protein product of this clone would be useful for treatment and diagnosis of disorders of the immune and

haemopoietic system. Furthermore, sequence homology of the polynucleotides and polypeptides of the present invention with a number of human cytokeratin molecules, such as CK-8, CK-15, and CK-17, indicate that molecules of the present invention can be used diagnostically as markers of basal cell differentiation in complex epithelia
5 and therefore indicative of a certain type of epithelial stem cells, as well as markers of the differentiation of other cell types such as neutrophils or other immune cells.
Molecules of the present invention, or agonists or antagonists thereof, can also be used therapeutically to treat differentiation disorders of epithelial, neutrophil or other immune cell differentiation or activation. Protein, as well as, antibodies directed
10 against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1269 of SEQ ID NO:66, b
20 is an integer of 15 to 1283, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

25 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: EEIATSIEPIRDFLAIVFFASIGLHVFPFTVAYELTVLVF
LTLSVVV (SEQ ID NO:272). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in synovium,
30 placenta, and stromal cells, and to a lesser extent in several other tissues and organs,

including, among others, bone marrow, palate, pituitary gland, and in tissue derived from osteosarcoma and chondrosarcoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: developmental disorders, as well as disorders of the musculoskeletal and haematopoietic systems, and cancers including especially osteosarcoma and chondrosarcoma, but also other cancers including breast cancer, colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, adenoma, and the like. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic and musculoskeletal systems, as well as developmental disorders, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., synovium, placenta, stromal, immune, hematopoietic, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 164 as residues: Pro-81 to Ser-88.

The tissue distribution in placenta suggests that the protein product of this clone would be useful for treatment and diagnosis of developmental disorders. Polynucleotides and polypeptides of the present invention can be used diagnostically and therapeutically to detect and treat many cancers, particularly osteosarcoma and chondrosarcoma. In addition, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and

inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial

5 osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).

Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein,

10 as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of 15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1249 of SEQ ID NO:67, b 20 is an integer of 15 to 1263, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

25 Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of renal mesangial cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of renal and developing cells and tissues. Thus, 30 polynucleotides and polypeptides have uses which include, but are not limited to, activating renal and developing cells and tissues.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: YCNLQCR (SEQ ID NO:273). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in the whole
5 developing embryo, as well as in ovarian cancer and placenta.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: developmental or reproductive diseases and/or disorders, in addition to the following and ovarian cancer, as well as
10 other cancers including breast cancer, colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, and the like.
Similarly, polypeptides and antibodies directed to those polypeptides are useful to
15 provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing and fetal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph,
20 amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in embryonic and ovarian tissue, combined with the detected calcium flux activity, suggests that the protein product of this clone would be
25 useful for treatment and diagnosis of developmental disorders as well as ovarian and other cancers. Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving
30 cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of

some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA).

Therefore, the polynucleotides and polypeptides of the present invention are
5 useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

Alternatively, the protein is useful in the detection, treatment, and/or prevention of
10 vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1603 of SEQ ID NO:68, b is an integer of 15 to 1617, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SALIGNPKGCFGCFSPVVLREWSVESWKSRLPFFQAICK LKTNFR (SEQ ID NO:274). Polynucleotides encoding these polypeptides are also
30 encompassed by the invention.

It has been discovered that this gene is expressed primarily in hypothalamus and anergic T cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: neurological and inflammatory defects, diseases, and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 166 as residues: His-33 to Trp-38.

The tissue distribution in hypothalamus and T-cells suggests that the protein product of this clone would be useful for study and treatment of immune and nervous system disorders. The protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal

differentiation or survival. Moreover, the expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1375 of SEQ ID NO:69, b

is an integer of 15 to 1389, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 60

The translation product of this gene shares nucleotide sequence homology with the human PKD1 gene which is thought to be important in polycystic kidney disease.

This gene is expressed widely with a predominant expression exhibited in
10 liver, pediatric kidney, and in the whole 8 week old developing human embryo.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: cancer, growth, renal, and metabolic defects, diseases, and/or disorders. Similarly, polypeptides and antibodies
15 directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine, digestive and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., renal, metabolic, hepatic, developmental,
20 and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, bile, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in pediatric kidney suggests that the protein product of
25 this clone would be useful for study and treatment of renal and general neoplasias and growth and development disorders. The protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and
30 kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome.

Moreover, the expression within embryonic tissue suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders, particularly of the liver and other organs. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1882 of SEQ ID NO:70, b is an integer of 15 to 1896, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HEAALRGP (SEQ ID NO:275). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in human striatum depression.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: stroke, in addition to other, neurologically-related diseases and/or defects. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., neural, musculoskeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 168 as residues: Glu-50 to Glu-61.

The tissue distribution in human striatum depression suggests that the protein product of this clone would be useful for study and treatment of central nervous system orders, such as seizures and other neurological conditions. The protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal

differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 294 of SEQ ID NO:71, b is an integer of 15 to 308, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This clone has homology to a cystine rich granulin peptide(s) from leucocyte(s) which has been termed Granulin E. Granulins inhibit keratinocytes and is useful topically for wound healing. The gene encoding the disclosed cDNA is

20 believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

It has been discovered that this gene is expressed primarily in infant brain.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

25 diagnosis of the following diseases and conditions: neurological, developmental, and growth defects. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetus and the nervous system, expression of this gene at

30 significantly higher or lower levels may be detected in certain tissues (e.g., neural, developmental, growth, and cancerous and wounded tissues) or bodily fluids (e.g.,

lymph, amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. Based on the strong conservation of cysteine residues, the polypeptide of the present 5 invention can be used to inhibit keratinocytes and promote wound healing.

The tissue distribution in infant brain suggests that the protein product of this clone would be useful for study and treatment of nervous system, neurodegenerative and developmental disorders. The protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, 10 behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive 15 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse 20 formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The homology to granulin proteins suggest the protein product of this clone is useful for the treatment, diagnosis, and/or prevention of various skin disorders 25 including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, 30 uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus),

keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm). Moreover,

5 the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e.

10 spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1674 of SEQ ID NO:72, b is an integer of 15 to 1688, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SNAAGNVVRAFLYINHLKL GCKVGLA (SEQ ID NO:276). Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 It has been discovered that this gene is expressed primarily in prostate cancer and dendritic cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: reproductive, immune, and hematopoietic diseases, defects and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, seminal fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 15 170 as residues: Trp-47 to Thr-54.

The tissue distribution in prostate cells and tissues indicates that the protein products of this clone are useful for study, diagnosis and treatment of neoplasias, esp. of the prostate, and hormonal and metabolic disorders. Moreover, the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1124 of SEQ ID NO:73, b is an integer of 15 to 1138, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NWAVLNMLLSKGKITIFLGPLEC GS (SEQ ID NO:277). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in B cell lymphoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and hematopoietic diseases, disorders, and/or defects, particularly cancers. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hemopoietic and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in B cell lymphoma suggests that the protein product of this clone would be useful for study and treatment of blood and immune disorders and neoplasias, esp. of the lymphatic system. The protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, 5 pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as 10 infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed 15 tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 763 of SEQ ID NO:74, b is an integer of 15 to 777, where both a and b correspond to the positions of 25 nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

It has been discovered that this gene is expressed primarily in B cell 30 lymphoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune and hematopoietic diseases, disorders, and/or defects, particularly cancer. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hemopoietic and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in B cell lymphoma suggests that the protein product of this clone would be useful for study and treatment of neoplasias, esp. of lymphatic organs, and immune disorders. The protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1046 of SEQ ID NO:75, b is an integer of 15 to 1060, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 66

The translation product of this gene shares sequence homology with a rat protein phosphatase, in addition to, a human heterogeneous nuclear ribonucleoprotein R (See Genbank Accession No.gil2697103 (AF000364)). When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates sensory neuron cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. This gene also showed activity in sensory neurons using the EGR assay described in the Example section.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PSHQTRKGKSAKLLDRPPEALRMKIITTLAHLQLLEV
G V V V G G E V D (S E Q I D N O : 278),
FQASSANNQQNWGSQPIAQQPLQQGGDYSG
25 NYGYNNNDNQE FY QDTY GQQWK (SEQ ID NO : 279), WXPLLXTSGSPGLXGFG
TRMNGKEIEGEEIEIVLAKPPDKKRKERQAARQASRSTA YEDYYHPPPRMPP
PIRG RGRGGGRGGYGYPPDYYGYEDYYDDYYGYDYHDYRGGYEDPYGYD
DGYAVRGRGGGRGGRGA PPPRGRGAPPRGRAGYSQRGAPLGPPRGSRG
RGGPAQQQRGRGSRGSRGNRGNVGGKRKADGYNQPSKRRQPTTNRTGV
30 PNPSLSSRFSKVVTILVTMVTIMTTRNFIRILMGN GSRQVRA (SEQ ID
NO : 280), RMNGKEIEGEEIEIVLAKPPDKKRKER (SEQ ID NO : 281), YYHPPP

RMPP PIRGRGRGGGRGGY (SEQ ID NO:282), DYRGGYEDPYGYDDGYAV RGRGGGR (SEQ ID NO:283), PPPRGRAGYSQRGAPLGPPRGSRGGRGG (SEQ ID NO:284), and/or ADGYNQPDSK RRQPTTNRTGVPNPSLSSRFSKVVT (SEQ ID NO:285). Polynucleotides encoding these polypeptides are also encompassed by
5 the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

It has been discovered that this gene is expressed primarily in human primary breast cancer, lung, and leukocytes.

10 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: reproductive, immune, or pulmonary diseases and/or disorders, particularly breast cancer. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide
15 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune and respiratory systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, immune, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g.,
20 lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in breast cancer cells and tissues, in addition to immune cells, combined with the homology to a protein phosphatase suggests that the protein
25 product of this clone would be useful for diagnosis and treatment of breast cancer and abnormalities of the lung and the immune system. Moreover, the expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen
30 presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,

5 inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia,

10 rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in

15 the differentiation and/or proliferation of various cell types. The protein is useful in modulating the immune response to aberrant cells and cell types, particularly proliferative cells (e.g. protein may increase the immunogenicity of tumor antigens either directly or indirectly, or may activate apoptosis). The protein is useful in treating, detecting, and/or preventing various pulmonary disorders, which include, but

20 are not limited to, ARDS, emphysema, and cystic fibrosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

30 general formula of a-b, where a is any integer between 1 to 1489 of SEQ ID NO:76, b is an integer of 15 to 1503, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LQIPPSSQSLGLKNADSSI (SEQ ID NO:286), GGPESAPW LPAVLRAPVLT SRCASSDSEGPVWFCQPGSGPSSTEMSCHCILGPGSSCLCVL RGSMWTPSVPGVWPQPAKETGASSCSVFSANNGSCPLPLHNHQRQASLDTGL SLEHVPGESYFYSPVG (SEQ ID NO:287), SSDSEGPVWFCQPGSGPSSTEMSC
10 HCILGPGSSC (SEQ ID NO:288), WTPSVPGVWPQPAKETGASSCSVFSANNG (SEQ ID NO:289), and/or QRQASLDTGL SLEHVPGESYF (SEQ ID NO:290). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in human B cell lymphoma.

15 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune or hematopoietic diseases and/or disorders, particularly B cell lymphoma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes
20 for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an
25 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in B-cell lymphoma suggests that the protein product of this clone would be useful for diagnosis and treatment of immune or hematopoietic diseases and/or disorders, particularly proliferative conditions. Moreover, the
30 expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including

blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 858 of SEQ ID NO:77, b is an integer of 15 to 872, where both a and b correspond to the positions of 5 nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

In specific embodiments, polypeptides of the invention comprise the following 10 amino acid sequence: SSSLVLTIRSQLFLASFHSTSIFCALN (SEQ ID NO:291). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in osteoarthritic cartilage.

Therefore, nucleic acids of the invention are useful as reagents for differential 15 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: osteoarthritis and other bone/cartilage disorders, particularly degenerative conditions. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of these tissue(s) or cell type(s). For a number of 20 disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., skeletal, joint, autoimmune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression 25 level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in osteoarthritic cartilage suggests that the protein product of this clone would be useful for the diagnosis, treatment, and/or prevention of osteoarthritis. Moreover, the gene product is useful in the detection and treatment 30 of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma,

tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia
5 congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 559 of SEQ ID NO:78, b is an integer of 15 to 573, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.
20

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

25 It has been discovered that this gene is expressed primarily in fetal brain, pharynx carcinoma, and Hodgkin's lymphoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: developmental and/or proliferative
30 diseases and disorders, particularly pharynx carcinoma, and Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to

provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental,

5 proliferative cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.

10 176 as residues: Tyr-30 to Ser-40.

The tissue distribution in pharynx carcinoma and Hodgkin's lymphoma suggests that the protein product of this clone would be useful for diagnosis and treatment of immune and proliferative conditions. Moreover, expression within fetal tissue and other cellular sources marked by proliferating cells suggests this protein

15 may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure 20 to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein 25 may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

Alternatively, the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to

30 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,

trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep

5 patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein

10 may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of

15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1495 of SEQ ID NO:79, b
20 is an integer of 15 to 1509, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

25 The translation product of this gene shares sequence homology with insulin-like growth factor binding protein. Moreover, the protein has homology to the human Slit-1 protein (See Genbank Accession No. gnl|PID|d1036170 (AB017167)), which is thought to play an integral role in neural development. In Drosophila embryogenesis, the slit gene has been shown to play a critical role in CNS midline formation. Each
30 Slit gene encodes a putative secreted protein, which contains conserved protein-protein interaction domains including leucine-rich repeats (LRR) and epidermal

growth factor (EGF)-like motifs, like that of the Drosophila protein. The Slit genes form an evolutionary conserved group in vertebrates and invertebrates, and the mammalian Slit proteins may participate in the formation and maintenance of the nervous and endocrine systems by protein-protein interactions.

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: the EGF-like domain: CCCRLGLSGPKC (SEQ ID NO:292); in addition to the following: RAFWGLGALQLLDLSANQLEAL (SEQ ID NO:293), HASGRRTGSADDGLQGRTGSGPPTAGAGGGGAAP (SEQ ID NO:294), VSAAAGARLAPRAPGAPAGCRPMRGCAARAARKSLVPVLPAGWRSGPAA
10 AARPGPRRLAHAPSAARSRAGPGAVARPLPRLHAAAHGRGCGPAAARAGA GSGPGARRAARVPTAGRPPGTHVHTSGQSGAPRDPEGEALADTWATQGQD SSSNSSSSGRGRDQEGRPMGAAPPPPAPAVGGPLPVWPSPSSAEPVLRPDAW
(S E Q I D N O : 2 9 5) , TRPAAERAPRTTGSRDAQAAGLPPRVPAGGLPPCGALPGR
15 GLGRCCCCCCCCRLGLSGPKCRPGPRPRGPWAPRTAPRCARACREACQLSAL SLPAVPPGLSLRLRALLLDHNRVRALPPGAFAGAGALQRLLDRENGLHSVHV RAFWGLGALQLLDLSANQLEALAPGTFAPLRALRNLSLAGNRLARLEPAALG ALPLLRSLSLQDNELAALAPGLLGRLPALDALHLRGNPWGCGCALRPLCAWL RRHPLPASEAETVLCVWPGRLTLSPLTAFSDAAFSHCAQPLALRDLARGLHA
20 RAGLLPRQPGFLPGAGLWAHRLPCAPPPPHRRPPAETVQTRTPITPTAVPR P R T R G A P S A A A Q A (S E Q I D N O : 2 9 6) , GCRPMRGCAARAARKSLVPVLPAGWRSGP AAAARPGPRRLAHAPSA (SEQ ID NO:297), PGAVARPLPRLHAAAHGRGCG PAAARAGA (SEQ ID NO:298), SGQSGAPRDPEGEALADTWATQGQ (S E Q I D N O : 2 9 9) ,
25 PPAPAVGGPLPVWPSPSSAEPV (SEQ ID NO:300), APRTTGSRD AQAAAGLPPRVPAGGLP (SEQ ID NO:301), GPRPRGPWAPRTAPRCARACRE (SEQ ID NO:302), AVPPGLSLRLRALLLDHNRVRALPPGAFAGA (SEQ ID NO:303), LGALQLLDLSANQLEALAPGTFA (SEQ ID NO:304), PPGAFAGAG ALQRLLDRENGLHSVHVRAFWGLGALQ (SEQ ID NO:305), RNLSLAGNRLA
30 RLEPAALGALPLLRSLS (SEQ ID NO:306), LPALDALHLRGNPWGCGCALRP LCAW (SEQ ID NO:307), TVLCVWPGRLTLSPLTAFSDAAFSHCAQPLALRD

(SEQ ID NO:308), LHARAGLLPRQPGFLPGAGLWAHR (SEQ ID NO:309), and/or TVQTRTPPIPTPTAVPRPRTRGAPS (SEQ ID NO:310). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in a breast cancer
5 cell line, MDA36.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: neural, reproductive, and proliferative diseases and/or disorders, particularly breast cancer and degenerative
10 conditions. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, reproductive, and
15 proliferative cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
20 177 as residues: Met-1 to Arg-10, Arg-64 to Ala-71, Gly-124 to Gly-131, Pro-189 to Arg-194, Val-223 to Gly-228.

The tissue distribution in a breast cancer cells and tissues and homology to insulin-like growth factor binding protein suggests that the protein product of this clone would be useful for diagnosis and treatment of breast cancer, and other forms of
25 cancer. Moreover, the homology to the conserved human slit-1 protein suggests that the protein is useful in the treatment, diagnosis, and/or prevention of neural disorders, particularly developmental and degenerative conditions. Similarly, the protein is useful for the treatment and/or diagnosis of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to
30 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,

trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep 5 patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein 10 may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of 15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1095 of SEQ ID NO:80, b 20 is an integer of 15 to 1109, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 71

25 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HASGRPD RSSA PIGNSGLPCPDLEPLGGLQSKCRLCAPTE ARGLWSRSLCSDRCDTWRS (SEQ ID NO:311), and/or GLPCPDLEPLGGLQSK CRLCAPTEARGLW (SEQ ID NO:312). Polynucleotides encoding these 30 polypeptides are also encompassed by the invention. This gene also maps to chromosome 1, and therefore can be used in linkage analysis as a marker for chromosome 1.

It has been discovered that this gene is expressed primarily in salivary gland and colon carcinoma.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: colon carcinoma and other digestive system or gastrointestinal diseases and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., digestive system, gastrointestinal, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, chyme, bile, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 178 as residues: Val-34 to Leu-39, Ser-64 to Cys-74, Ser-86 to Ser-95, Arg-128 to Ala-136.

The tissue distribution in salivary gland and colon carcinoma suggests that the protein product of this clone would be useful for the treatment and diagnosis colon cancer and other digestive system diseases and/or disorders, such as ulcers, and other proliferative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 793 of SEQ ID NO:81, b is an integer of 15 to 807, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QEWESELGERRKPLQA (SEQ ID NO:313). Polynucleotides encoding these polypeptides are also encompassed by the invention.

10 It has been discovered that this gene is expressed primarily in 6 week old human embryos.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: embryological defects; aberrant 15 development; aberrant cellular proliferation (e.g. cancers), and other developmentally related or proliferative diseases and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing human embryo, expression 20 of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not 25 having the disorder.

The tissue distribution in 6 week old human embryos suggests that the protein product of this clone would be useful for the diagnosis and/or treatment of defects in embryonic development. Elevated expression of this gene product in early 6 week human embryos suggests that this gene product plays a critical role in normal human 30 development. Alternatively, this gene product may be involved in the pattern of cellular proliferation that accompanies early embryogenesis. Thus, aberrant

Expression of this gene product in tissues - particularly adult tissues - may correlate with patterns of abnormal cellular proliferation, such as found in various cancers. Moreover, this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1029 of SEQ ID NO:82, b is an integer of 15 to 1043, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: CQSSNLIFFQFVNILFNLMMMDILVDFSITKMPINSIFSLYF

CYEII (SEQ ID NO:314). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in 6 week old human embryo.

5 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: abnormal embryonic development; abnormal cellular proliferation; developmental defects, and other developmentally related or proliferative diseases and/or conditions. Similarly,
10 polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing human embryo, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, and cancerous and
15 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in 6 week old human embryo suggests that the protein product of this clone would be useful for the diagnosis and treatment of disorders of human embryonic development. Expression of this clone in developing embryos suggests that it plays a critical role in early human development. Alternatively, it may be involved in key cellular proliferation events that occur during embryogenesis. Therefore misexpression of this gene in adult tissues may lead to abnormal patterns of
25 cellular proliferation and cancer. Moreover, expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.
30 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell

death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types 5 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence 15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1159 of SEQ ID NO:83, b is an integer of 15 to 1173, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a 20 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GPVWLFCFLTLCKPSQLFSQENSCMDVAGGVTTCLPP 25 WFSRGAPAQMSQWPPSSDHGAVRAGRDSRVGPVQPSHLTCEGGKEEREKNK KAEVNPPPTGMGLANRIPRDDITLKLRNQGKLRTKENRTQSAKRHP (SEQ ID NO:315), VACKPENRTKTHFASSPACDGHALGGQVGFAICFLSCLFPPM (SEQ ID NO:316), and/or SHMPMPNTPKQQLLFSEDNELLVSLRTGRKPTLQAALRVTG (SEQ ID NO:317). Polynucleotides encoding these polypeptides are also 30 encompassed by the invention.

It has been discovered that this gene is expressed primarily in pleural cancer and endometrial tumors, and, to a lesser extent, in bone marrow & apoptotic T cells.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

- 5 diagnosis of the following diseases and conditions: pleural cancer; endometrial tumors; hematopoietic disorders; immune dysfunction. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the lungs and immune system, expression
- 10 of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not
- 15 having the disorder.

The tissue distribution in pleural cancer and endometrial tumors indicates that the protein products of this clone are useful for the diagnosis and treatment of various reproductive cancers, including pleural cancer and endometrial tumors. In addition,

- 20 Expression of this gene product within T cells & bone marrow suggests that it may play a role in normal hematopoiesis. Therefore, this gene product may also be useful in the diagnosis and/or treatment of a variety of hematopoietic disorders, including defects in immune surveillance, inflammation, impaired immune function, and T cell lymphomas. Use of this gene product may be appropriate in situations designed to affect the proliferation, survival, and/or differentiation of various
- 25 hematopoietic cell lineages, including blood stem cells.

- Moreover, this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in
- 30

acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein
5 may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1547 of SEQ ID NO:84, b is an integer of 15 to 1561, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares low sequence homology with *dreg-2*, a gene product originally identified in *Drosophila* that shows an oscillating pattern of expression tied into a circadian clock rhythm.

25 In specific embodiments, polypeptides of the invention comprise the following
a m i n o a c i d s e q u e n c e :
AHRLQIRLLTWDVKDTLLRLRHLGEAYATKARAHGLEV
EPSALEQGFRQAYRAQSHSFPNYGLSHGLTSRQWWLDVVLQTFHLAGVQDA
QAVAPIAEQLYKDFSHPCTWQVLDGAEDTLRECRTRGLRLAVISNFDRRLEGI
30 LXGLGLREHFDFVLTSEAAAGWPKPDPRFQEALRLAHMEPVVAAHVGDNYL
CDYQGPRAVGMHSFLVVGPQALDPVVRDSVPKEHILPSLAHLLPALDCLEGS

T P G L (S E Q I D N O :319),

EGDPRGRPRPRPLGPPQLTLPTALXDILRQVRAPGLRLSRA

LEVGRKGSPIFKIQIYL (SEQ ID NO:318), IRLLTWDVKDTLLRLRHLGEAYA

TKA (SEQ ID NO:320), LEQGFRQAYRAQSHSFNPYGLSHG (SEQ ID NO:321),

5 HLAGVQDAQAVAPIAEQLYKDFSHPC (SEQ ID NO:322), VLDGAEDTLRECR
TRGLRLAVIS (SEQ ID NO:323), REHFDVFVLTSEAAGWPKPDPRIFQEA (SEQ
ID NO:324), EPVVAAHVGDNLCDYQGPRAVGMHSFL (SEQ ID NO:325),
and/or VVRDSVPKEHILPSLAHLLPALD (SEQ ID NO:326). Polynucleotides
encoding these polypeptides are also encompassed by the invention.

10 It has been discovered that this gene is expressed primarily in tumors of the
pancreas & thymus and to a lesser extent in a variety of fetal tissues, including fetal
brain, liver, spleen, and kidney.

Therefore, nucleic acids of the invention are useful as reagents for differential
identification of the tissue(s) or cell type(s) present in a biological sample and for
15 diagnosis of the following diseases and conditions: pancreatic cancer; thymic cancer;
disorders of fetal development; abnormal cellular proliferation; hematopoietic
disorders. Similarly, polypeptides and antibodies directed to those polypeptides are
useful to provide immunological probes for differential identification of the tissue(s)
or cell type(s). For a number of disorders of the above tissues or cells, particularly of
20 the pancreas and immune system, expression of this gene at significantly higher or
lower levels may be detected in certain tissues or cell types (e.g., developmental,
metabolic, immune, hematopoietic, and cancerous and wounded tissues) or bodily
fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid or spinal fluid)
taken from an individual having such a disorder, relative to the standard gene
25 expression level, i.e., the expression level in healthy tissue from an individual not
having the disorder.

The tissue distribution in proliferative and developmental cells and tissues
indicates that the protein products of this clone are useful for the diagnosis and
treatment of cancers, particularly pancreatic and thymic cancer. Expression of this
30 gene product within various fetal tissues also indicates that it is useful in the diagnosis
and/or treatment of human developmental disorders. Taken together, the observation

that this gene product is expressed in cancers and in fetal tissues indicates that it plays a role in proliferation and/or differentiation events that are associated with early development. Misexpression of this gene product in adult tissues, therefore, may directly contribute to abnormal cellular proliferation and/or dedifferentiation that 5 accompanies cancer. Finally,

Moreover, the expression of this gene product in fetal liver/spleen also suggests that it plays a role in hematopoiesis, and is useful in the diagnosis and/or treatment of a variety of disorders of the immune system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or 10 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1419 of SEQ ID NO:85, b is an integer of 15 to 1433, where both a and b correspond to the positions of 20 nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

In specific embodiments, polypeptides of the invention comprise the following 25 amino acid sequence: IRKLGPGGLAPCSCRSGQVFPRV (SEQ ID NO:327).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in frontal cortex, particularly derived from epileptic patients.

Therefore, nucleic acids of the invention are useful as reagents for differential 30 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: epilepsy; neurodegenerative

diseases and disorders, particularly learning disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, CNS, and/or PNS, expression of
5 this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

10 The tissue distribution in frontal cortex tissue suggests that the protein product of this clone would be useful for the diagnosis and/or treatment of disorders of the brain and nervous system, particularly epilepsy. Moreover, the expression of this gene product suggests that it may play a role in various critical processes of the nervous system, including nerve survival, pathfinding, signal conductance, and/or synapse
15 formation. It may have effects on various processes including homeostasis, learning, motor function, language, etc. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed
20 tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1363 of SEQ ID NO:86, b is an integer of 15 to 1377, where both a and b correspond to the positions of
30 nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

In specific embodiments, polypeptides of the invention comprise the following

a m i n o a c i d s e q u e n c e :

5 KPLRMARPGGPEHNEYALVSAWHSSGSYLDSEGLRHQDD
FDVSLLVCHCAAPFEEQGEAERHVLRLQFFVVLTSQRELFPRLTADMRRFRK
PPRLPPEAPEPGSSAGSPGEASGLILAPGPAPLFPPPLAAEVGMARARLAQLVRL
AGGHCCRDTLWKRLFLEPPGPDRRLGGRLALAEELLEAVHAKSIGDIDP
QLDCFLSMTVSWYQSLIKVLLSRFPRAVAISKAQTWELSTWLR (SEQ ID
10 NO:328), ARGTLELPTPLIAAHQLYNVADHASSYHM (SEQ ID NO:329),
SHCEWPGQG AQNTTSMPWCRHGTVLAPTWTLDIFDTR (SEQ ID NO:330),
PLTTVSHLCPL
SLRVFTSHLDITAGHSHRDDTWVPIPALPLKHLRPPSSPFALGPWVSHPLMRW
VQKLSHLHSNPGTGFMSMGKSAEKLKC (SEQ ID NO:331), STAARGAPGPGR
15 AGGTPRSSPCQIHWRPPAGLLPIHDGLLVPEPDQSSPKLPQSCRHFQSPDL
GTQYLVALNQKFTDCSALVFWTPLRKDVSEVVFREALPVQPQDTRSPPAQLV
STYHHLESVINTACFTLLDPPLKGVDWITECHCSLNHGPTRLPARGRTDQPF
W A P G Q A R H (S E Q I D N O : 3 3 2) ,
HQRLCNVLRVCCPSLAAGTALPKHPQPLTHPGL
20 QRVRSTPRTPWALLGYSFRPPW (S E Q I D N O : 3 3 3) ,
PGGPEHNEYALVSAWHSS GSYLDSEGLR (S E Q I D N O : 3 3 4) ,
DVSSLVCHCAAPFEEQGEAERHVLR (S E Q I D N O : 3 3 5) ,
RLTADMRRFRKPPRLLPPEAPEPGSSAGS (SEQ ID NO:336), GEASGLI
25 LAPGPAPLFPPPLAAEVGM (S E Q I D N O : 3 3 7) ,
TLWKRLFLEPPGPDRRLGGRL (SEQ ID NO:338), and/or
LAEELLEAVHAKSIGDIDPQLDCFLS (SEQ ID NO:339). Polynucleotides
encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in fetal liver/spleen and leukocytes, and to a lesser extent in a colon adenocarcinoma cell line.

30 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for

diagnosis of the following diseases and conditions: hematopoietic disorders; immune dysfunction; colon cancer; colorectal adenocarcinoma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders
5 of the above tissues or cells, particularly of the immune system and colon, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., hematopoietic, immune, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard
10 gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 184 as residues: Leu-16 to Ser-23, Ser-38 to Pro-43, Gly-53 to Leu-60.

The tissue distribution in colon adenocarcinoma suggests that the protein
15 product of this clone would be useful for the diagnosis and/or treatment of gastrointestinal diseases and/or disorders, particularly proliferative conditions. Expression of this gene product in fetal and proliferative cells and tissues suggests that it may be a marker cancers, and that its misregulated expression may in fact contribute to the development or progression of the types of cancers dictated by its
20 expression.

Similarly, the expression of this gene product in fetal liver/spleen - a primary site of early hematopoiesis - taken together with its expression in peripheral blood leukocytes suggests that this gene product may play a role in a variety of hematopoietic processes, including the survival, proliferation, activation, and/or
25 differentiation of all blood cell lineages, including the totipotent hematopoietic stem cell. Such a gene product may therefore play a role in a variety of hematopoietic disorders including inflammation; immune dysfunction; defects in immune surveillance; and hematopoietic cancers and lymphomas. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
30 formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA).

Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1701 of SEQ ID NO:87, b is an integer of 15 to 1715, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

The gene encoding the disclosed cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 20.

It has been discovered that this gene is expressed primarily in brain.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s)

or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. This gene is believed to reside on chromosome 20, D20S111-D20S195. Polynucleotides corresponding to this gene are useful, therefore, as chromosome markers.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 185 as residues: Met-1 to Tyr-6, Thr-38 to Ala-44.

The tissue distribution in brain tissue indicates that the protein products of this clone are useful for diagnosis and treatment of disorders of the central nervous system. Moreover, the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 403 of SEQ ID NO:88, b is an integer of 15 to 417, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, 15 other immune and hematopoietic cells or cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS 20 element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FQLYFNPELIFKHFQIWRLITNFLFFGPVGFNFNMIFLY RYCRMLEEGSFRGRTADFVFVFMFLFGGFLMTLFGLFVSLVFLGQAFTIMLVYV 25 WSRXNPYVRMNFFGLLNFQAPFLPWVLMGFSSLGNSIVDLLGIAVGHIYFF LEDVFPNQPGGIRILKTPSILKAIFDTPDEDPNYNPLPEERPGGFAWGEGQ SEQ I D N O : 3 4 0) , GVGQATVGKMAYQLRLEYLQIPPVSRAYTTACVLTTAAVQLELITPF QLYFNPELIFKHFQIWRLITNFLFFGPVGFNFNMIFLYRYCRMLEEGSFRGR 30 TADFVF (SEQ ID NO:341), LIFKHFQIWRLITNFLFFGPVGF (SEQ ID NO:342), FLYRYCRMLEEGSFRGRTADFVFMF (SEQ ID NO:343), LVFLGQAFTIMLVYV

WSRXNPYV (SEQ ID NO:344), VLMGFSLLGNSIIVDLLGIA (SEQ ID NO:345), NQPGGIRILKTPSILKAIFDTPDED (SEQ ID NO:346), RLEYLQIPPVSRAYTTAC VLTTAAVQLE (SEQ ID NO:347), and/or RLITNFLFFGPVGFNFLFNMIFLYRYC RMLE (SEQ ID NO:348). Polynucleotides encoding these polypeptides are also 5 encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

It has been discovered that this gene is expressed primarily in smooth muscle, fetal brain, fetal liver and to a lesser extent in activated macrophage, colon cancer.

10 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: developmental diseases, immune-related diseases, neural disorders, and vascular diseases and conditions. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide 15 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, vascular, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, 20 plasma, amniotic fluid, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in fetal liver, macrophage, and fetal brain indicates that 25 the protein products of this clone are useful for treating and diagnosis of immune system-related diseases and CNS diseases. Moreover, the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow 30 reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as

infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the protein is useful in the detection, treatment, 5 and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism.

Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells, combined with the GAS biological activity, suggests this 10 protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure 15 to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein 20 may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, 25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 30 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1153 of SEQ ID NO:89, b is an integer of 15 to 1167, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a
5 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

The translation product of this gene shares sequence homology with proacrosin binding proteins (sp32) from non-human mammalian species. The binding 10 of sp32 to proacrosin may be involved in packaging the acrosin zymogen into the acrosomal matrix. See, for example, J Biol Chem. 1994 Apr 1; 269(13): 10133-10140, incorporated herein by reference. Accordingly, the inventors have termed the translation product of this gene human sp32 or "h-sp32". Contact of cells with supernatant expressing the product of this gene has been shown to increase the 15 permeability of the plasma membrane of PMN to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both neutrophils, and to a lesser extent in other immune and hematopoietic cells. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, 20 activating

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HASAGPDGSSPA (SEQ ID NO:349), ELLLEKPKPWQPPAAAPHRALLVLCYSIVENTCIITPTAKAWKYMEEEILGFG KSVCDSLGRHMSTCALCDFCSLKLEQCHSEASLQRQQCDTSHKTPFAAPCL
25 P P R A C P S A T R (S E Q I D N O : 3 5 0) , LPGWGFPTKICDTDYIQYPNYCSFKSQQCLMR NRNRKVSRMRCLQNETYSALSPGKSEDVVLRWSQEFTLTLGQFG (SEQ ID NO:351), SPVLLPAFPPLPVPLLALPVASPLPACVLVSAPACAPLLAPACAL ALAPGFPGTRRIVGALPRCC (SEQ ID NO:352), LLVLCYSIVENTCIITPTAK 30 AWKYMEEEILGFGKS (SEQ ID NO:353), and/or LKLEQCHSEASLQRQQC DTSHKTPFA (SEQ ID NO:354). Polynucleotides encoding these polypeptides are

also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

It has been discovered that this gene is expressed primarily in testis.

5 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: reproductive disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For
10 a number of disorders of the above tissues or cells, particularly of the reproductive diseases, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, testis, prostate, epidymus, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, seminal fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having
15 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. This gene is believed to map to chromosome 12 and is thought to be useful as a chromosome marker.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 20 187 as residues: Asp-27 to Ser-32, Pro-52 to Thr-58, Arg-63 to Asn-70, Gln-78 to Gly-83, Thr-107 to Asn-113, Thr-160 to Val-176, Ser-188 to Gly-241, Leu-248 to Pro-265, Tyr-302 to Gly-314.

The tissue distribution in testis, combined with the specific homology to the sp32 protein indicates that the protein products of this clone are useful for the
25 diagnosis, treating, and/or prevention of reproductive diseases and/or disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is
30 also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs 5 where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. The protein is useful in application and utility as a contraceptive, either directly or indirectly. Based upon the detected calcium flux activity, the protein may also be useful as an effect treatment for infertility (i.e. for inhibiting autoimmune 10 disorders). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of 15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1878 of SEQ ID NO:90, b 20 is an integer of 15 to 1892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

25 The translation product of this contig has consistent sequence homology with a number of previously described viral tat proteins (see, for example, Stevens, et al., J. Virol. 64:3716-3725 (1990), which is hereby incorporated by reference, herein).

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QVSQLILSLSCGMDGLALDGSPSPSPXTEKAGRCISQTS 30 (SEQ ID NO:355), QVSQLILSLSCGMDGLALDGSPSPSPXTEKAGRCISQTSPL GKWEV (SEQ ID NO:356), RASKTVPRMPPNWPAAKMPCLCHIRTVEHLGTIS

SGAPGRPTGQQAARTYHICWIHPGQKIDS LPPSSQHPRSQQLAPGTWPSTTT
KPAEETLGSSASLPISQARKSEKCTFQPSPWXVRGKESHQVPAHPSHRTETES
D HSPVRKPPSRGTRTGDFTVGDWSEAWLLELALL (SEQ ID NO:357), RMPPN
WPAKMPCLCHIRTVEHLG (SEQ ID NO:358), GRPTGQQAARTYHICWIHPG
5 QKIDS (SEQ ID NO:359), WPSTSTTKPAEETLGSSASLPISQA (SEQ ID NO:360),
KSEKCTFQPSPWXVRGKESHQVP (SEQ ID NO:361), and/or KPPSRGTRTGDF
TVGDWSEAWLLE (SEQ ID NO:362). Polynucleotides encoding these polypeptides
are also encompassed by the invention.

It has been discovered that this gene is expressed almost exclusively in
10 neutrophils.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of immune disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. In addition, molecules of the present invention can be used to regulate transcription and translation of genes in cells of the immune system, as well as in other cell types. Such transcriptional and translation regulation is useful for diagnosing and treating a number of disorders in which an altered state of transcription and translation may be a factor in the disorder. Such disorders include many viral infections, particularly of immune cells, including HIV-1, HIV-2, human T-cell lymphotropic virus (HTLV)-I, and HTLV-II, as well as other DNA and RNA viruses such as herpes simplex virus (HSV)-1, HSV-2, HSV-6, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus, adenoviruses, rhinoviruses, 20 influenza viruses, reoviruses, and the like. In addition, the ability to use molecules of the present invention to molecularly regulate the processes of transcription and

translation is useful in the diagnosis and treatment of many types of cancers, particularly those of the immune system, including ovarian cancer, breast cancer, colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, 5 neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, and the like.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 188 as residues: Gln-2 to Trp-12, Ala-30 to Glu-35, Gln-42 to Ser-51.

The tissue distribution in neutrophils, combined with the homology to viral tat 10 proteins suggests that the protein product of this clone is useful for the diagnosis and treatment of immune disorders, particularly viral infections and proliferative disorders. Further, since this clone has a high degree of sequence relatedness to factors which are involved in the regulation of transcription and translation, this clone 15 is useful as a regulator of such processes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 509 of SEQ ID NO:91, b 25 is an integer of 15 to 523, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

30 The translation product of this contig has clear sequence identity with a number of thioredoxins and endoplasmic reticulum resident proteins (see, for

example, Shorosh and Dixon, Plant J. 2:51-58 (1992), which is hereby incorporated by reference, herein).

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PCADCLSAWA (SEQ ID NO:363). Polynucleotides encoding 5 these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

It has been discovered that this gene is expressed primarily in adipocytes and 10 striatum depression, and in lower abundance in prostate, whole brain, fetal liver, and spleen.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: Prostate cancer, CNS diseases, 15 immune disorders . Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, hematopoietic, 20 immune, and cancerous and wounded tissues) or bodily fluids (e.g., seminal fluid, amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. Since the translation product of this clone has a high degree of sequence relatedness 25 to many thioredoxins, it can be used as a food additive to improve flour quality or to suppress the anti-nutritional effects of leguminous plants. Molecules of the present invention can further used to inactivate toxins, for example, bee or snake venom.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 189 as residues: Trp-43 to Ala-49, Pro-68 to Ala-74, Glu-100 to Gly-111, Glu-120 to 30 Asn-125, Pro-141 to Ala-154, Asp-157 to Lys-171, Cys-177 to Ile-182, Ser-248 to Leu-253, Thr-280 to Glu-285, Gly-353 to Val-359.

The tissue distribution in whole brain suggests that the protein product of this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease,

5 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including
10 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The secreted protein can also be used to determine

15 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating
20 human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors);
25 hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies
30 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1368 of SEQ ID NO:92, b is an integer of 15 to 1382, where both a and b correspond to the positions of 10 nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 83

When tested against TF-1 cell lines, supernatants removed from cells 15 containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, in immune and hematopoietic cells or tissues, through the JAK-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a 20 large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following 25 amino acid sequence: HASGYLCIVLL (SEQ ID NO:364). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed exclusively in Rejected Kidney.

Therefore, nucleic acids of the invention are useful as reagents for differential 30 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: kidney and other urinary tract

disorders and disorders related to, or resulting from, transplantation. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and 5 renal systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., renal, kidney, urogenital, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression 10 level in healthy tissue from an individual not having the disorder. Molecules of the present invention are particularly useful in the diagnosis and treatment of disorders related to transplantation, particularly kidney transplantation.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 190 as residues: Asn-49 to Gln-54, Glu-150 to Asp-159.

15 The tissue distribution in rejected kidney tissue suggests that the protein product of this clone would be useful for diagnosis and treatment of disorders related to or resulting from rejection of transplanted organs, particularly the kidney. Moreover, the protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, 20 proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Considering the tissue distribution and detected ISRE biological activity, the protein is useful in modulating the immune 25 response to aberrant kidney proteins, including autoantigens and aberrant proteins which are often present in degenerative and proliferative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 5 general formula of a-b, where a is any integer between 1 to 1733 of SEQ ID NO:93, b is an integer of 15 to 1747, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 84

The translation product of this gene shares sequence homology with the conserved MAL and plasmolipin protein (Magyar, et al, Gene 189:269-275 (1997); See Genbank Accession No.gnl|PIDle183885), which are thought to be important in modulating T cell function, and proper CNS function, respectively. When tested 15 against Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, immune or hematopoietic cells and tissues, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT 20 pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following 25 amino acid sequence: NSARAARAEIVLGLLVWTLIAGTEYFRVPAFGWV (SEQ ID NO:365). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in T cells. Therefore, nucleic acids of the invention are useful as reagents for differential 30 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of immune, hematopoietic, and neural diseases and/or disorders. Similarly,

polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in
5 certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. Nucleic acids of the present invention are useful as probes for
10 detecting traumatic and pathological changes in the central and peripheral nervous systems. Molecules of the present invention may be involved in regulating the growth of Schwann cells and other neural cells. Molecules of the present invention are also useful as modulators of the interaction between Schwann cells and other neural cells and the extracellular matrix and is therefore useful for the therapeutic intervention in
15 nerve damage primarily by facilitating regeneration of damaged axons and regenerating nerve cells in damaged nervous system tissues.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 191 as residues: Ser-58 to His-64.

The tissue distribution in T-cells, combined with the homology to the MAL and plasmolipin proteins and the detected GAS biological activity suggests that the protein product of this clone would be useful for the diagnosis and treatment of immune disorders including, but not limited to, AIDS and other immunodeficiencies. Moreover, the expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell
25 lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an
30 agent for immunological disorders including arthritis, asthma, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne,

neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 586 of SEQ ID NO:94, b is an integer of 15 to 600, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

The translation product of this clone has sequence identity to a protein tyrosine kinase reported by Oates and Wilks (The Worm Breeders Gazette 14:87-87 (1995), which is hereby incorporated by reference herein). The gene encoding the
15 disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

It has been discovered that this gene is expressed primarily in cerebellum, adult brain, retina, spinal cord, and kidney cortex.
20 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: neural, visual, and renal diseases and/or disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification
25 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, retina, and kidney cortex. Expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, visual, renal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual
30 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

The tissue distribution in cerebellum, adult brain, and spinal cord tissue suggests that the protein product of this clone would be useful for the diagnosis and treatment of neural diseases and disorders. The protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, 5 behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive 10 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

Expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and 20 kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 30 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 572 of SEQ ID NO:95, b

is an integer of 15 to 586, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 86

The translation product of this clone has homology to trkB, and it is thought that the protein of the present invention is a novel novel neural receptor protein-tyrosine kinase, a trkB homolog (See for example,). This protein is likely to be derived from a gene for a ligand-regulated receptor closely related to the human trk 10 oncogene. Northern (RNA) analysis showed that the trkB gene is expressed predominantly in the brain and that trkB expresses multiple mRNAs, ranging from 0.7 to 9 kb. Hybridization of cerebral mRNAs with a variety of probes indicates that there are mRNAs encoding truncated trkB receptors.

In specific embodiments, polypeptides of the invention comprise the sequence 15 PCSPPDSPPLPGAFVWRVLWVC (SEQ ID NO:366). Polynucleotides encoding this polypeptide are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in breast cancer, colon tumor, and B-cell lymphoma.

Therefore, nucleic acids of the invention are useful as reagents for differential 20 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: breast cancer, colon tumor, B-cell lymphoma. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of 25 the immune, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, gastrointestinal, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy 30 tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 193 as residues: Ser-29 to Asn-40.

The tissue distribution in proliferative cells and tissues suggests that the protein product of this clone would be useful for the treatment, detection, and/or prevention of cancer, particularly in the indicated tissues. The expression within cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

Alternatively, the homology to the trkB protein suggests the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal

differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 788 of SEQ ID NO:96, b is an integer of 15 to 802, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARACFAYNGVCSEGRCWDSHFHGSV (SEQ ID NO:367), MSNMGKIPSLSLHIPINKYICSRIPKFIQKVNKSTVLQICLKRQIILNKNKMSDH

20 SKIGKANLVQIDIHSLGIVETGCVPSKRYCTLLTEQSGFPFLSHP (SEQ ID NO:368), MAGCCLKLFGVLSLCFLCGLISIERVICNPVSADFQVSTFCQRHCLLR SKVMFXIKGXTATIEVINENCTLVAAPPIGFPIXFL (SEQ ID NO:369), MSDHS KIGKANLVQIDIHSLGIVETGCVPSKRYCTLLTEQSGFPFLSHP (SEQ ID NO:370), MAGCCLKLFGVLSLCFLCGLISIERVICNPVSADFQVSTFCQRHCL LRSK (SEQ ID NO:371), VMFXIKGXTATIEVINENCTLVAAPPIGFPIXFL (SEQ ID NO:372). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in dendritic cells,

30 and smooth muscle.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune, hematopoietic, and vascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to 5 those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., immune, hematopoietic, smooth muscle vascular, and cancerous and wounded tissues) or 10 bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 15 194 as residues: Asp-40 to Ser-52.

The tissue distribution in dendritic cells suggests that the protein product of this clone would be useful for immune disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 20 related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 25 general formula of a-b, where a is any integer between 1 to 1212 of SEQ ID NO:97, b is an integer of 15 to 1226, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 88**

The translation product of this gene shares sequence homology with androgen-dependant expressed protein from golden hamster hair follicles which is thought to be important in regulating the secretions from glands in the skin (See GenBank Accession No. gil191315).

5 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PTEGRQKVLKTFTVPRSALAMTKTSTCIYHFLVLSWYTF LNYYISQEGKDEVKPKILANGARWKY (SEQ ID NO:373), PTEGRQKVLKTF TVPRSALAMTKT (SEQ ID NO:375), PRSALAMTKTSTCIYHFLVLSWYTFLN YYISQEGK (SEQ ID NO:374), and/or FLNYYISQEGKDEVKPKILANGARWKY 10 (SEQ ID NO:376). Polynucleotides encoding these polypeptides are also encompassed by the invention.

It has been discovered that this gene is expressed primarily in lung, colon cancer, and testis.

Therefore, nucleic acids of the invention are useful as reagents for differential 15 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: disorders of secretory cells including cells in the lung, colon, testis and the skin. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders 20 of the above tissues or cells, particularly of the secretory epithelial cells in the lung, intestine, testis and skin, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., 25 the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 195 as residues: Val-21 to Asp-30, Pro-101 to Thr-109.

The tissue distribution and homology to androgen regulated protein suggests 30 that the protein product of this clone would be useful for treating disorders that involve highly secretory cells including those in the colon, testis, and skin. It may be useful for diagnosing disorders such as colon, lung, or testicular cancer and may be

used to treat pulmonary conditions in patients with compromised respiratory function. In addition, the polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, 5 this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis 10 of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, 15 inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1106 of SEQ ID NO:98, b is an integer of 15 to 1120, where both a and b correspond to the positions of 25 nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

The translation product of this gene shares sequence homology with dec-205 a 30 transmembrane protein which is thought to be important in antigen presentation in dendritic cells and T-cells.

It has been discovered that this gene is expressed primarily in macrophage, dendritic cells, lung and ulcerative colitis.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: inflammatory diseases such as ulcerative colitis. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 196 as residues: Asp-30 to Arg-36, Gln-59 to Val-65.

The distribution in macrophage, dendritic cells, lung and ulcerative colitis tissues, and homology to antigen presenting receptors suggests that the protein product of this clone would be useful for modulating the immune response in both acute and chronic inflammatory conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2582 of SEQ ID NO:99, b is an integer of 15 to 2596, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

5 This gene maps to chromosome 22 and therefore polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 22.

In specific embodiments, polypeptides of the invention comprise the sequence FKDQLVYPLLAFT (SEQ ID NO:377) and/or RQALNLPDVFGLV (SEQ ID NO:379). Polnucleotides encoding these polypeptides are also encompassed by the
10 invention.

It has been discovered that this gene is expressed primarily in fetal spleen and liver as well as cd34 positive cells and to a lesser extent in several tissues suggesting a presence in blood or blood forming tissues.

Therefore, nucleic acids of the invention are useful as reagents for differential
15 identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: developmental defects in the blood and blood forming cells. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
20 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., fetal spleen and liver as well as cd34 positive cells, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene
25 expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 197 as residues: Gln-54 to Gly-61, Asn-79 to Leu-91, Glu-99 to Thr-105, Pro-120 to Gln-126, Pro-128 to Phe-134, Arg-150 to Arg-156, Arg-160 to Arg-170.

30 The tissue distribution in fetal spleen and liver as well as cd34 positive cells suggests that the protein product of this clone would be useful for treating disorders in

the development, proliferation, or regulation of blood forming cells including diseases such as lymphomas, granulomas, leukemias, and in the preservation and or replenishment of stem cells in the blood.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1006 of SEQ ID NO:100, b is an integer of 15 to 1020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ATASHDLLLF (SEQ ID NO:379), MSINICLMQSKTQGSCQ YLLLPHPVPIILKVSTVFSLLSLFRLFLSFCPHPKKCSYLLKYYGPLEGHKTLX 20 YLRTNLGVIQPPLRMYAAEDCNGIG (SEQ ID NO:380), MSINICLMQSKTQG SCQYLLLPHPVPIILKVSTVFSLLSLFRLFL (SEQ ID NO:381), and/or SFCPHPK KCSYLLKYYGPLEGHKTLX YLRTNLGVIQPPLRMYAAEDCNGIG (SEQ ID NO:382). Polynucleotides encoding these polypeptides are also encompassed by the invention.

25 It has been discovered that this gene is expressed primarily in T cells, fetal heart and chronic lymphocytic leukemia and to a lesser extent in kidney, lung, and 16 week embryos.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for 30 diagnosis of the following diseases and conditions: disorders of the blood including abnormalities in T cell function or blood cell proliferation such as leukemia .

Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be

5 detected in certain tissues or cell types (e.g., T cells, fetal heart and chronic lymphocytic leukemia, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 198 as residues: Leu-45 to Val-50.

The tissue distribution in T cells, fetal heart and chronic lymphocytic leukemia suggests that the protein product of this clone would be useful for treating abnormalities of the blood particularly those involving T-cells and the abnormal

15 proliferation of blood cells such as lymphocytic leukemia. In addition, it suggests the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Moreover, the expression of this gene product suggests a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be

20 involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an

25 agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host

30 diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia,

rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed

5 progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The expression in fetal heart tissue would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. The tissue distribution in kidney

10 suggests the protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe

15 kidney, polycystic kidney, and Falconi's syndrome.

In addition, the tissue distribution in embryonic tissue suggests the protein product of this clone is useful for the diagnosis, detection, and/or treatment of developmental disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the

20 regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell

25 death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue

30 differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 1506 of SEQ ID NO:101, b is an integer of 15 to 1520, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The translation product of this gene shares sequence homology with ctg4 which is a glutamine repeat containing gene thought to be a candidate genetic disease locus.

In specific embodiments, polypeptides of the invention comprise the sequence 20 KEEDDDTERLPSKCEVCKLLSTE (SEQ ID NO:383 and 384) LQAELSRTGRSR EVLELGQ (SEQ ID NO:385 and 386), RQAVIVCRRRFV (SEQ ID NO:387), PPRWAHPKAPEGSPDPPSPPSALGLSVLPWSDSPWHISVSPCAQREHYSPGS AHINSLRPLPALSLKRCKARVSSSCLYPAPAPAPAPAPLEIDRCDSVPPVALCSAA YTLRICWASVLCHRPPPSTSQPKPRARPKKGKAIFPTAQVP (SEQ ID NO:388), 25 PPRWAHPKAPEGSPDPPSPPSALGLSVLPWSDSPWHISVSPCAQREHYSPGS AHINSLRPLPALSLKRCK (SEQ ID NO:389), and/or ARVSSSCLYPAPAPAPAPLEIDRCDSVPPVALCSAA YTLRICWASVLCHRPPPSTSQPKPRARPKKGKAIFPTAQVP (SEQ ID NO:390). Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 It has been discovered that this gene is expressed in several tissues including lung, heart, kidney, adrenal gland, smooth muscle, cerebellum, and embryonic tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: inherited developmental disorders possibly with a neuropsychiatric component. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 199 as residues: Lys-25 to Ser-36, Ser-53 to Glu-60, Thr-70 to Arg-75, Arg-111 to Thr-119, Glu-161 to Leu-189.

The tissue distribution and homology to glutamine repeat family member CTG4 suggests that the protein product of this clone would be useful for identifying and treating specific diseases related to nucleotide triplet expansion. The tissue distribution in embryonic tissue suggests the protein product of this clone is useful for the diagnosis, detection, and/or treatment of developmental disorders. The relatively specific expression of this gene product during embryogenesis suggests it may be a key player in the proliferation, maintenance, and/or differentiation of various cell types during development. It may also act as a morphogen to control cell and tissue type specification. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1292 of SEQ ID NO:102, b is an integer of 15 to 1306, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: EEKLFTSAPGRDFWVMGETRDGNEEN (SEQ ID NO:391). Polynucleotides encoding these polypeptides are also encompassed by the invention.

15 The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

It has been discovered that this gene is expressed primarily in cancerous and fetal tissue.

20 Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: cancer, developmental anomalies or fetal deficiencies. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification 25 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system and developing fetus, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) 30 taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 200 as residues: Met-1 to Ser-6.

5 The tissue distribution in fetal tissue suggests that the protein product of this clone would be useful for the treatment and diagnosis of developmental anomalies or fetal deficiencies. In addition to fetal tissue, expression in a variety of cancerous tissues suggests a role in the treatment and diagnosis of uncontrolled cell proliferation and/or differentiation (e.g. cancer). Moreover, the expression within embryonic tissue
10 and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can
15 result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders
20 and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 771 of SEQ ID NO:103, b is an integer of 15 to 785, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

10 This gene is expressed primarily in hypothalamus, T-cells, and adipose tissue.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immune (e.g. immunodeficiencies, autoimmunities, inflammation, leukemias & lymphomas) and neurological (e.g.

15 Alzheimer's disease, dementia, schizophrenia) disorders. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous, hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may

20 be detected in certain tissues (e.g., immune, neural, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder. The tissue distribution suggests that the protein product of this

25 clone would be useful in the intervention or detection of pathologies associated with the hematopoietic and immune systems, such as anemias (leukemias). In addition, the expression in brain (including fetal) might suggest a role in developmental brain defects, neuro-degenerative diseases or behavioral abnormalities (e.g. schizophrenia, Alzheimer's, dementia, depression, etc.).

30 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 201 as residues: Phe-64 to Gly-77, Pro-83 to Asp-99.

The tissue distribution in hypothalamus suggests the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease,

5 Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in

10 feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. This gene product may be involved in the regulation of cytokine production,

15 antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency

20 diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue

25 injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the

30 expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the protein

product of this clone is useful for the diagnosis, prevention, and/or treatment of various metabolic disorders which include, but are not limited to, Tay-Sachs disease, phenylketonuria, galactosemia, hyperlipidemias, porphyrias, and Hurler's syndrome.

The protein is useful in the treatment and/or prevention of neurodegenerative

5 conditions, particularly those which occur secondary to aberrant fatty acid metabolism (i.e. defects which affect the synthesis and integrity of the myelin sheath). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2001 of SEQ ID NO:104, b is an integer of 15 to 2015, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 95

The translation product of this gene was shown to have homology to the murine leucine-rich repeat protein (See Genbank Accession No. gil2880079), which is thought to be important in neural development.

25 In specific embodiments, the polypeptides of the invention comprise the sequence:QKPTFALGELYPPLINLWEAGKEKSTSLKVKATVIGLPTNMS (SEQ ID NO:392). Polynucleotides encoding this polypeptide are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as 30 a marker in linkage analysis for chromosome 7.

It has been discovered that this gene is expressed primarily in T-cells and brain.

Therefore, nucleic acids of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the following diseases and conditions: immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, inflammation, anemias (leukemia) and other hematopoietic disorders, neurological diseases of the brain such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia and specific brain tumors. Similarly, polypeptides and antibodies directed to those polypeptides are useful to provide immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 202 as residues: Met-24 to Gly-29, Ala-57 to Thr-63.

The tissue distribution in T-cells suggests that the protein product of this clone would be useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. The expression in brain, combined with the homology to the leucine-rich repeat protein suggests that the protein product of this clone would be useful for the treatment and diagnosis of developmental, degenerative and behavioral conditions of the brain and nervous system, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette Syndrome, mania, dementia, paranoia, addictive behavior, obsessive-compulsive disorder and

sleep disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 353 of SEQ ID NO:105, b is an integer of 15 to 367, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: NT Seq. X	NT SEQ ID NO: NT Seq. X	5' NT of Total Clone Seq. Start Codon	5' NT of AA SEQ ID NO: Sig Pep Y	First AA of Signal Pep Y	Last AA of Sig Pep Y	First AA of Secreted Portion	Last AA of ORF
1	HKGCR51	209628 02/12/98	pSport1	11 2343	1 2343 94	94 108	1 34	35	35	74
2	HPMDK28	209628 02/12/98	Uni-ZAP XR	12 1177	1 1083 58	58 109	1 27	28	28	201
3	HLDCD04	209628 02/12/98	pCMV Sport 3.0	13 2107	197 2107 397	397 110	1 32	33	33	371
3	HLDCD04	209628 02/12/98	pCMV Sport 3.0	106 1889	1 1889 193	193 203	1 32	33	33	57
4	HLDON23	209628 02/12/98	pCMV Sport 3.0	14 1262	208 1256	368 368	111 1	20	21	113
5	HLDRM43	209628 02/12/98	pCMV Sport 3.0	15 759	1 759 164	164 112	1 20	21	21	151
6	HLQAM28	209628 02/12/98	Lambda ZAP II	16 1810	1 1810 43	43 113	1 36	37	37	55
7	HLTDE74	209628 02/12/98	Uni-ZAP XR	17 1052	1 967 106	106 114	1 20	21	21	236
8	HLTFA64	209628 02/12/98	Uni-ZAP XR	18 1130	1 1130 268	268 115	1 42	43	43	43
9	HMCFY13	209628 02/12/98	Uni-ZAP XR	19 883	1 883 175	175 116	1 30	31	31	64

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: X	5' NT of Total NT Seq.	3' NT of Clone Seq.	5' NT of Start Seq.	AA SEQ First AA of ID NO: Y	Last AA of Sig Pep	First AA of Sig Pep	Last AA of Sig Secreted Portion	Last ORF
10	HMMBD35	209628 02/12/98	pSport1	20	989	169	989	237	237	117	21
11	HMQCY03	209628 02/12/98	Uni-ZAP XR	21	495	1	495	185	118	1	14
12	HMSBX84	209628 02/12/98	Uni-ZAP XR	22	2317	1	2317	57	57	119	20
13	HMSKI186	209628 02/12/98	Uni-ZAP XR	23	1726	1	1726	84	84	120	1
14	HMVBBS81	209628 02/12/98	pSport1	24	529	1	529	34	34	121	1
15	HMWEB02	209628 02/12/98	Uni-Zap XR	25	1755	1	1755	106	106	122	1
16	HMZAD77	209628 02/12/98	pSport1	26	1751	1	1451	49	49	123	1
17	HNFIY77	209628 02/12/98	pBluescript	27	1212	28	1212	228	228	124	1
18	HNHEK85	209628 02/12/98	Uni-ZAP XR	28	1112	1	1112	35	35	125	1
19	HNHEU93	209628 02/12/98	Uni-ZAP XR	29	748	1	748	57	57	126	1
20	HODAH74	209628 02/12/98	Uni-ZAP XR	30	778	1	778	163	163	127	1

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: X	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Start Codon	First SEQ ID NO: Y	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF			
21	HODCU34	209628 02/12/98	Uni-ZAP XR	31	1324	1	1324	229	128	1	25	26	65
22	HODCZ09	209628 02/12/98	Uni-ZAP XR	32	739	9	739	225	129	1	43	44	49
23	HOEDB32	209628 02/12/98	Uni-ZAP XR	33	1462	73	1462	104	130	1	21	22	226
24	HOGAG15	209628 02/12/98	pCMV Sport 2.0	34	2815	1	2815	411	131	1	17	18	117
25	HPIBO48	209628 02/12/98	Uni-ZAP XR	35	1078	1	1076	77	132	1	31	32	305
26	HPMFP40	209628 02/12/98	Uni-ZAP XR	36	1217	1	1217	37	133	1	24	25	44
27	HPRCU95	209628 02/12/98	Uni-ZAP XR	37	1282	1	1282	138	138	1	30	31	43
28	HPTTG19	209628 02/12/98	Uni-ZAP XR	38	559	1	559	215	135	1	16	17	49
29	HPTVX32	209628 02/12/98	pBluescript	39	803	215	803	318	136	1	27	28	80
30	HRDDV47	209628 02/12/98	Uni-ZAP XR	40	1510	1	1510	146	137	1	31	32	276
31	HRDEN56	209628 02/12/98	Uni-ZAP XR	41	1095	1	1095	84	138	1	26	27	56

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID X	NT Total Seq. NO: NT Seq.	5' NT of Clone Seq.	3' NT of Seq.	5' NT of AA of Start Signal Codon	NT SEQ ID of AA of Sig Pep Y	AA First of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HSFAN12	209641 02/25/98	Uni-ZAP XR	42	1162	1	1162	39	139	1	36	37
33	HSQCM10	209641 02/25/98	Uni-ZAP XR	43	657	1	654	130	140	1	19	20
34	HSVAT68	209641 02/25/98	Uni-ZAP XR	44	1155	1	1155	63	141	1	25	26
35	HSXEC75	209641 02/25/98	Uni-ZAP XR	45	1112	1	1112	295	295	1	33	34
36	HTDAI54	209641 02/25/98	pSport1	46	4023	1	4023	37	37	143	1	37
37	HTEIT45	209641 02/25/98	Uni-ZAP XR	47	542	14	542	29	29	144	1	35
38	HTGBE48	209641 02/25/98	Uni-ZAP XR	48	1495	1	1495	169	169	145	1	18
39	HTLEPS3	209641 02/25/98	Uni-ZAP XR	49	818	1	818	73	73	146	1	45
40	HTTB176	209641 02/25/98	Uni-ZAP XR	50	1711	1	1711	133	133	147	1	22
41	HTWKG71	209641 02/25/98	Lambda ZAP II	51	749	1	749	32	32	148	1	19
42	HTXDN32	209641 02/25/98	Uni-ZAP XR	52	1091	27	804	120	120	149	1	24

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: X	NT Total Seq. NT	5' NT of Clone Seq.	5' NT of AA of Start Codon	5' NT of AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
54	HLDRP33	209641 02/25/98	pCMV Sport 3.0	64	612	1	612	215	161	1	26
55	HMSJM65	209641 02/25/98	Uni-ZAP XR	65	2270	1	2231	111	162	1	27
56	HNGFE55	209641 02/25/98	Uni-ZAP XR	66	1283	1	1283	132	163	1	15
57	HNKAA41	209641 02/25/98	pSport1	67	1263	1	1123	142	164	1	19
58	HRAAJ19	209641 02/25/98	pCMV Sport 3.0	68	1617	1	1617	48	165	1	20
59	HSAWV96	209641 02/25/98	Uni-ZAP XR	69	1389	1	1389	278	278	1	21
60	HSBBT37	209641 02/25/98	pBluescript SK-	70	1896	1	1896	100	167	1	25
61	HSDZR57	209641 02/25/98	pBluescript	71	308	1	308	27	168	1	27
62	HUSIT18	209641 02/25/98	pSport1	72	1688	1	1688	343	343	1	24
63	HWBCP79	209641 02/25/98	pCMV Sport 3.0	73	1138	1	1138	233	233	1	21
64	HYAAL70	209641 02/25/98	pCMV Sport 3.0	74	777	1	777	88	88	1	41

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: NT Seq. X	5' NT of Total Clone Seq. NT Seq.	3' NT of Clone Seq. NT Seq.	S' NT of Start Signal Seq. Codon	AA SEQ ID NO: AA of Signal Seq. Codon Pep Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of Secreted Portion	First AA of ORF	Last AA of ORF
65	HYAAY86	209641 02/25/98	pCMVSPORT 3.0	75	1060	1	1060	118	172	1	26	27	46
66	HAPBS03	209651 03/04/98	Uni-ZAP XR	76	1503	45	1479	252	173	1	28	29	41
67	HBJLC01	209651 03/04/98	Uni-ZAP XR	77	872	1	872	87	174	1	34	35	46
68	HBLKD56	209651 03/04/98	pSport1	78	573	1	573	90	175	1	21	22	40
69	HCENK38	209651 03/04/98	Uni-ZAP XR	79	1509	1	1509	10	176	1	28	29	52
70	HCHMX01	209651 03/04/98	pSport1	80	1109	1	1109	104	177	1	26	27	249
71	HCHNF25	209651 03/04/98	pSport1	81	807	1	807	180	178	1	30	31	147
72	HE6GA29	209651 03/04/98	Uni-ZAP XR	82	1043	1	1043	142	179	1	15	16	47
73	HE6GE84	209651 03/04/98	Uni-ZAP XR	83	1173	1	1173	334	334	180	1	14	15
74	HETHO95	209651 03/04/98	Uni-ZAP XR	84	1561	1	1561	309	309	181	1	24	25
75	HFCFJ18	209651 03/04/98	Uni-ZAP XR	85	1433	170	1433	206	182	1	25	26	45

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Signal Seq.	AA SEQ ID NO: Y	First AA of ID NO:	Last AA of ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of Secreted Portion	First AA of ORF	Last AA of ORF	First AA of AA of AA of Secreted Portion	Last AA of AA of AA of Secreted Portion	First AA of AA of AA of Secreted Portion	Last AA of AA of AA of Secreted Portion
76	HFPBM30	209651 03/04/98	Uni-ZAP XR	86	1377	1	1377	144	144	183	1	35	36	40						
77	HFXKT05	209651 03/04/98	Lambda ZAP II	87	1715	1	1715	204	204	184	1	18	19	79						
78	HKB1E57	209651 03/04/98	pCMVSPORT 1.0	88	417	1	417	30	30	185	1	26	27	46						
79	HLWAD77	209651 03/04/98	pCMVSPORT 3.0	89	1167	304	1167	326	326	186	1	24	25	140						
80	HLWAY54	209651 03/04/98	pCMVSPORT 3.0	90	1892	1	1892	38	38	187	1	25	26	338						
81	HNGBU28	209651 03/04/98	Uni-ZAP XR	91	523	57	523	230	230	188	1	26	27	65						
82	HOUHHH51	209651 03/04/98	Uni-ZAP XR	92	1382	630	1296	57	57	189	1	35	36	360						
82	HOUHHH51	209651 03/04/98	Uni-ZAP XR	107	1201	1	815	172	172	204	1	1	2	161						
83	HRAAB15	209651 03/04/98	pCMVSPORT 3.0	93	1747	1	1747	35	35	190	1	14	15	159						
84	HSAVH65	209651 03/04/98	Uni-ZAP XR	94	600	1	600	104	104	191	1	24	25	100						
85	HSDGN55	209651 03/04/98	Uni-ZAP XR	95	586	1	586	177	177	192	1	26	27	42						

Gene No.	cdDNA Clone ID	ATCC Deposit Nr and Date	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of Secreted Portion
86	HSSXAH81	209651 03/04/98	Uni-ZAP XR	96	802	1	802	88	88	193	1	21
87	HSSXBX80	209651 03/04/98	Uni-ZAP XR	97	1226	1	1226	77	77	194	1	22
88	HTEHV08	209651 03/04/98	Uni-ZAP XR	98	1120	1	1120	382	382	195	1	17
89	HUFAK67	209651 03/04/98	pSport1	99	2596	1	2596	225	225	196	1	21
90	HUSXSS50	209651 03/04/98	pSport1	100	1020	1	1020	179	179	197	1	23
91	HAPONI17	209651 03/04/98	Uni-ZAP XR	101	1520	1	1520	266	266	198	1	23
92	HATAC53	209651 03/04/98	Uni-ZAP XR	102	1306	13	1306	99	99	199	1	21
93	HAMFK58	209641 02/25/98	pCMV Sport 3.0	103	785	1	785	279	279	200	1	31
94	HYCH68	209641 02/25/98	pSport1	104	2015	34	1571	81	81	201	1	19
95	HCUHK65	209641 02/25/98	ZAP Express	105	367	1	367	80	80	202	1	26

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly , the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further

below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and 5 diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or 10 deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or 15 deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of 20 plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can 25 also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be 30 isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed

sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from 5 the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides 10 produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains 15 secretory or leader sequences, pro-sequences, sequences which aid in purification , such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced 20 version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

25

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of 30 McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the

information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two
5 methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a
10 protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes
15 vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely
20 uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the
25 naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

30 **Polynucleotide and Polypeptide Variants**

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

5 By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the 10 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire 15 sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known 20 computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences 25 are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identiy are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 30 0.05, Window Size=500 or the lenght of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95%

"identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the the

query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by 5 results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query 10 sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N- 15 terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the 20 remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not 25 manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding 30 regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter

the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced
5 for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an
10 organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA
15 technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after
20 deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological
25 activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every
30 possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See,

Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or 5 C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular 10 polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, 15 inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

20 The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these 25 positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. 30 For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

(Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which 5 amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and 10 Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

15 Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, 20 such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

25 For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 30 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid 5 substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 10 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

15

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 20 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and 25 primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-30 450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-

1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-
1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-
2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited
clone. In this context "about" includes the particularly recited ranges, larger or
5 smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.
Preferably, these fragments encode a polypeptide which has biological activity. More
preferably, these polynucleotides can be used as probes or primers as discussed
herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid
10 sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the
deposited clone. Protein fragments may be "free-standing," or comprised within a
larger polypeptide of which the fragment forms a part or region, most preferably as a
single continuous region. Representative examples of polypeptide fragments of the
invention, include, for example, fragments from about amino acid number 1-20, 21-
15 40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding
region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90,
100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about"
includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1)
amino acids, at either extreme or at both extremes.

20 Preferred polypeptide fragments include the secreted protein as well as the
mature form. Further preferred polypeptide fragments include the secreted protein or
the mature form having a continuous series of deleted residues from the amino or the
carboxy terminus, or both. For example, any number of amino acids, ranging from 1-
60, can be deleted from the amino terminus of either the secreted polypeptide or the
25 mature form. Similarly, any number of amino acids, ranging from 1-30, can be
deleted from the carboxy terminus of the secreted protein or mature form.
Furthermore, any combination of the above amino and carboxy terminus deletions are
preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments
are also preferred.

30 Also preferred are polypeptide and polynucleotide fragments characterized by
structural or functional domains, such as fragments that comprise alpha-helix and

alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

5 Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to 10 an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

15 In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In 20 contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) 25 further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson 30 et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow, M. et al., *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle, F. J. et al., *J. Gen. Virol.* 66:2347-2354 (1985).) A preferred immunogenic epitope includes 5 the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes 10 in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear 15 more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

20

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the 25 polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present 30 invention include not only heterologous signal sequences, but also other heterologous

functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See,

D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide.

5 In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein.

10 Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

15

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The

expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or 5 UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples 10 of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture media and conditions for the above-described host cells are known in the art.

15 Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 20 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods 25 are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from 30 recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,

phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

5 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, 10 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine 15 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

20 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide 25 sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 30 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al.,

Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

5

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

10 The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

15 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids
20 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides
25 can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved
30 using fluorescence *in situ* hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however,

polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to 5 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, 10 the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated 15 with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or 20 translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide 25 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using

30 polynucleotides of the present invention. Any of these alterations (altered expression,

chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J.

10 Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can
15 be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.

25 In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA
30 markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using 5 this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification 10 techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. 15 (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

20 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by 25 organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences 30 in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA

antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

5 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M.,
10 et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such
15 as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo
20 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for
25 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or
30 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety

needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.

5 In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which
10 involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

15 Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to
20 activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can
25 also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as
30 molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also

be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules 10 may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in 15 treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or 20 disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in 25 treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes 30 include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency,

Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

5 Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet 10 disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

15 A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the 20 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic 25 anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary 30 Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

25 **Hyperproliferative Disorders**

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune 5 response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to 10 neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by 15 a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, 20 located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, 25 particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

30 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the

present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis,

opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis,

5 Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

10 Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and

15 Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these

20 symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

30 A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See,

Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, 5 reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration 10 occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used 15 prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure 20 ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a 25 polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized 30 neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or 5 site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system 10 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present 15 invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

20 A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or 25 small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural 30 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*.
5 Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

10 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

15 Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

25 All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

30 Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity , and (b) 5 determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as 10 discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be 15 used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, 20 tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat 25 content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated 30 nucleic acid molecule comprising a nucleotide sequence which is at least 95%

identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of 5 positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of 10 positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the 15 range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide 20 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

25 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X
30 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

30 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
5 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and
10 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence
15 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

20 A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
25 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological
30 sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least

one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the

5 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

15 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

20 Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in

the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence
5 at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a
10 polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
15 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group
20 consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least
25 one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence
30 selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide

comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA 5 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

10 Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted 15 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell 20 type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

25 Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least 30 one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino

acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5 In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at 10 least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number 15 shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide 20 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

30 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is

expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of
5 SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1
10 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an
15 isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

20

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.
25 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
30 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
5	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
	pCMVSport 3.0	pCMVSport 3.0
10	pCR®2.1	pCR®2.1
	Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap	
	XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos.	
	5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.	
	16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res.	
15	17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are	
	commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey	
	Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and	
	pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain	
	XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+	
20	and KS. The S and K refers to the orientation of the polylinker to the T7 and T3	
	primer sequences which flank the polylinker region ("S" is for SacI and "K" is for	
	KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to	
	the orientation of the f1 origin of replication ("ori"), such that in one orientation,	
	single stranded rescue initiated from the f1 ori generates sense strand DNA and in the	
25	other, antisense.	
	Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from	
	Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors	
	contain an ampicillin resistance gene and may be transformed into E. coli strain	
	DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et	
30	al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University,	
	NY) contains an ampicillin resistance gene and can be transformed into E. coli strain	

XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., 5 Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional 10 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample 15 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ 20 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular 25 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection 30 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with

phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction
5 leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific
10 to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

15 A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

20 Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After
25 labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H)
30 or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to

manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

5 **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is 10 repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc.). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in 15 the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^R), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified 30 fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain

M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r).

Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and

5 confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG

10 (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The

20 QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

25 The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, 30 containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250

mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further

5 includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

10 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating

15 the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

20 The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit

30 weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM

Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate 5 is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the 10 pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA 15 by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The 20 filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

25 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 30 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium

acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the
5 above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

10

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector
15 contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak
20 Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such
25 as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

30 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in

Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in

5 Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment 10 then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a 15 commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified 20 by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGoldTM 25 baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μ g of BaculoGoldTM virus DNA and 5 μ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are 30 added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded

in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

5 After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell

10 culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded

15 in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of

20 infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ³⁵S-methionine and 5 µCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation.

25 The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

30 **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a

chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo

contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

15 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

30 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These

primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

15 Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACACACATGCCACC GTGC
CCAGCACCTGAATTGAGGGTGACCGTCAGTCTCCTCTTCCCCCAAAA
CCCAAGGACACCCCTCATGATCTCCGGACTCCTGAGGTACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGG
20 ACGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCCTGCCCATCCGGATGAGCTGACCAAGAACCAAG
25 GTCAGCCTGACCTGCCTGGTCAAAGGTTCTATCCAAGCGACATGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAACTACAAGACCAAGCCT
CCCGTGCTGGACTCCGACGGCTCTTCTCCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACG CAGAAGAGCCTCTCCGTCTCCGG
30 GTAAATGAGTGCACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the 5 production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are 10 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures 15 involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 20 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are 25 selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can 30 be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is

possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody
5 whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the
10 antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic
15 chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in
20 the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulian et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

25

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in
30 Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each

5 well (note: a 12-channel pipetter may be used with tips on every other channel).

Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml
10 DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate.
15 With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45
20 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too
25 much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6
30 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of Kcl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

5 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the
10 polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

15 **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The
20 binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in
25 many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus
30 upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,

Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>			<u>STATs</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5 10 5':GCGCCTCGAGATTCCCCGAAATCTAGATTCCCCGAAATGATTCCCC
GAAATGATTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTGCAAAGCCTAGGC:3'
(SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 25 5':CTCGAGATTCCCCGAAATCTAGATTCCCCGAAATGATTCCCCGAAA
TGATTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCGCCCTAACTCCGCCAGTCCGCCATTCT
CCGCCCATGGCTGACTAATTTTTATTATGCAGAGGCCGAGGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTGAGGCCT
AGGCTTTGCAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and 5 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-10 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into 15 mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described 20 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. 30 Thus, factors that increase SEAP activity indicate the ability to activate the Jak-STAT5 signal transduction pathway. The T-cell used in this assay is Jurkat T-cells

(ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-
5 SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected.
10 Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life
15 Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25
20 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in
25 Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100
30 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred

5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed

10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source

15 of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,

20 stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate

25 myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATs signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

30 To transiently transfet U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell

Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

5 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄.7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then
10 resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example
11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon
20 gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

5 The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 10:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCGG -3' (SEQ ID NO:6)
5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes Xhol/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine

growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS
5 (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5
10 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ml of Neuronal Growth Factor (NGF). Over fifty-fold
15 induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development,
25 anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and
30 class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating diseases. For example, inhibitors of NF- κ B could be used to treat those 5 diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary 10 to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGACTTCCCGGGACTTCCGGGACTTCCGGAC
TTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
15 5':GCGGCAAGCTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following 20 sequence:

5':CTCGAGGGACTTCCGGGACTTCCGGGACTTCCGGGACTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATACTCCGCCCTAACTCCGCC
ATCCCGCCCTAACTCCGCCAGTCCGCCATTCTCCGCCATGGCTGA
25 CTAATTTTTTATTTATGCAGAGGCCGAGGCCCTCGGCCTTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTGGAGGCCTAGGCTTGTAAAAA
GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- 30 promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and

HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes Sall and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small**5 Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants

which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

5 The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

10 For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

15 A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

20 For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

25 For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

30 To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm;

and (6) Sample addition is 50 μ l. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

5 **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 μ l of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St.

Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar

5 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodynne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of
10 Loprodynne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM
15 Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well
20 catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many
25 methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include
30 PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM

5 ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

10 The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide.

15 Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

20 Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

25 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine

phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by 5 substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against 10 Erk-1

and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

15 A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

20 After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place

of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the 25 Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

10 PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTHERM Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct 15 sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

20 Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Manheim); and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe 25 is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, 30 Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv.

et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and 5 translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

10 A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

15 For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to 20 the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

25 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

30 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard

curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

5

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the 10 secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 15 $\mu\text{g}/\text{kg}/\text{day}$ to 10 $\text{mg}/\text{kg}/\text{day}$ of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 $\text{mg}/\text{kg}/\text{day}$, and most preferably for humans between about 0.01 and 1 $\text{mg}/\text{kg}/\text{day}$ for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 $\mu\text{g}/\text{kg}/\text{hour}$ to about 50 $\mu\text{g}/\text{kg}/\text{hour}$, either by 1- 20 4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention 25 are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to 30 modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No.

5 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions

10 also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and

15 EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to

5 recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as

10 polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

15 The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile.

20 Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

25 Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

30 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical

compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the 5 polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or 10 normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to 15 increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

20

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels 25 of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense 30 polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and

5 separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS,

10 penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

15 pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

20 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site.. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions

25 appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

30 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.

The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, 5 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no 10 selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or 15 after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods 20 to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter 25 or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 30 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or
5 aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present
10 invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are
15 preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies
20 have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder,
25 stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It
30 is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection

into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that 5 quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked 10 DNA.

Example 28: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, 15 guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

20 Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology 25 (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the 30 polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-

mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones 5 containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene 10 in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et 15 al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site 20 of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively 25 introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the 30 recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA

expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also
5 be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more
10 than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for
15 screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not
20 limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

25 **Example 29: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by
30 reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding

regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene 5 of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely 10 adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered 15 to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using 20 recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited 25 to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the 30 invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and 5 Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For 10 example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological 15 function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

It will be clear that the invention may be practiced otherwise than as 20 particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent 25 applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<p>A. The indications made below relate to the microorganism referred to in the description on page <u>180</u>, line <u>N/A</u></p>		
<p>B. IDENTIFICATION OF DEPOSIT</p>		<p>Further deposits are identified on an additional sheet <input type="checkbox"/></p>
<p>Name of depositary institution American Type Culture Collection</p>		
<p>Address of depositary institution (<i>including postal code and country</i>) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America</p>		
<p>Date of deposit <u>February 12, 1998</u></p>	<p>Accession Number <u>209628</u></p>	
<p>C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>)</p>		<p>This information is continued on an additional sheet <input type="checkbox"/></p>
<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>)</p>		
<p>E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>)</p> <p>The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i>)</p>		
<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p><i>C. Williams</i></p> <p>Authorized officer</p>		
<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>183</u> , line <u>N/A</u>		
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>		
Name of depositary institution American Type Culture Collection		
Address of depositary institution (<i>including postal code and country</i>) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America		
Date of deposit <u>February 25, 1998</u>	Accession Number <u>209641</u>	
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>) This information is continued on an additional sheet <input type="checkbox"/>		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>)		
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>) The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i>)		
For receiving Office use only		
<input checked="" type="checkbox"/> This sheet was received with the international application <u>C. Williams</u> Authorized officer		
For International Bureau use only		
<input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>186</u> , line <u>N/A</u>		
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input type="checkbox"/>
Name of depositary institution American Type Culture Collection		
Address of depositary institution (<i>including postal code and country</i>) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America		
Date of deposit <u>March 4, 1998</u>	Accession Number	<u>209651</u>
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>)		This information is continued on an additional sheet <input type="checkbox"/>
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>)		
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>) The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i>)		
For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application <u>C. Williams</u>		<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer		Authorized officer

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
 - 20 having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

30 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (g) a variant of SEQ ID NO:Y;
 - (h) an allelic variant of SEQ ID NO:Y; or
 - (i) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
 - (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

5 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

15

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

30

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- 5 (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc., et al.

<120> 95 Human Secreted Proteins

<130> PZ027PCT

<140> Unassigned

<141> 1999, March 18

<150> 60/078,566

<151> 1998-03-19

<150> 60/078,574

<151> 1998-03-19

<150> 60/078,576

<151> 1998-03-19

<150> 60/078,563

<151> 1998-03-19

<150> 60/078,573

<151> 1998-03-19

<150> 60/078,578

<151> 1998-03-19

<150> 60/078,579

<151> 1998-03-19

<150> 60/078,581

<151> 1998-03-19

<150> 60/078,577

<151> 1998-03-19

<150> 60/080,314

<151> 1998-04-01

<150> 60/080,312

<151> 1998-04-01

<150> 60/080,313

<151> 1998-04-01

<160> 392

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaatact	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tccccccaaa	acccaaggac	accctcatga	120
tctcccgac	tcctgagggtc	acatgcgtgg	tggtgacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtaacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacacgacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtagc	aagtgcagg	tctccaaacaa	agccctccca	accccccattcg	360
agaaaaccat	ctcccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catccccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgcggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	ggaaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agccctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> Site
<222> (3)
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2
Trp Ser Xaa Trp Ser
1 5

<210> 3
<211> 86
<212> DNA
<213> Homo sapiens

<400> 3
gcgcctcgag atttccccga aatcttagatt tccccgaaat gatttcccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4
<211> 27
<212> DNA
<213> Homo sapiens

<400> 4
gcggcaagct ttttgcaaag ccttaggc 27

<210> 5
<211> 271
<212> DNA
<213> Homo sapiens

<400> 5
ctcgagatcccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttcccg 60

aaatatctgc catctaatt agtcagcaac catagtcccg cccctaactc cgcccatccc	120
gccccctaact ccgcccagg tccggccat ggctgactaa ttttttttat	180
ttatgcagag gcccaggccg ctcggccctc tgagctattc cagaagttagt gaggaggctt	240
ttttggagc ctaggctttt gaaaaagct t	271
<210> 6	
<211> 32	
<212> DNA	
<213> Homo sapiens	
<400> 6	
gcgctcgagg gatgacagcg atagaacccc gg	32
<210> 7	
<211> 31	
<212> DNA	
<213> Homo sapiens	
<400> 7	
gcgaagcttc gcgactcccc ggatccgcct c	31
<210> 8	
<211> 12	
<212> DNA	
<213> Homo sapiens	
<400> 8	
ggggactttc cc	12
<210> 9	
<211> 73	
<212> DNA	
<213> Homo sapiens	
<400> 9	
gccccctcga ggggactttc ccggggactt tccggggact ttccggact ttccatcctg	60
ccatctcaat tag	73
<210> 10	
<211> 256	
<212> DNA	
<213> Homo sapiens	
<400> 10	
ctcgaggaga cttccccggg gactttccgg ggactttccg ggactttcca tctgccatct	60
caattagtca gcaaccatag tcccggccct aactccgccc atcccccccc taactccgccc	120
cagttccgccc cattctccgc cccatggctg actaattttt ttatattatg cagaggccga	180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggctttttt gaggcctagg	240
ctttgcaaa aagtt	256

<210> 11
<211> 2343
<212> DNA
<213> Homo sapiens

<400> 11

acgcgtccgg	tttttcaaag	gtttaactgt	ccagggcaga	tacttaagac	tatctgatca	60
tccattaaaa	acttttcaca	tagtcttgct	taaatggatc	cattatgttt	accattata	120
ttgttcttag	ctgttagttt	aagaaattta	tttcatttgt	taatacttac	tttccattac	180
cttcccctt	tctgtgacaa	tccggttgata	cttgaagacc	tctcttgat	tcatctttagg	240
gttaatattt	ttaaggccaa	acagcctaaa	ttctatggta	atcaactcca	gccttgtgt	300
atgaaatctt	ctgcataaaag	ataggtttaa	atcaaacttag	attgcagatt	ttattgaaga	360
aattgtgtt	ttaagagttg	acaaaatatata	gttgtatggc	taaaacaaaag	aaaataacttc	420
tggtgccttct	gcatttagta	gaagaaaaac	tatatatgtt	tgtgaccaaa	gtataaaaata	480
tgattcttc	cagggaggt	aaggttatgc	acaagatttt	cactagcgc	tctaaaaggc	540
taccctcaat	taattgccat	gaacatttca	tagccctaga	aggatgttag	ctcatttcag	600
tgtcatccgt	gtttatttctt	tattgttatta	ttcagcagtc	attttaacac	tatgctagac	660
acttttagaga	ttcagaagag	taacagggtt	tctgttctca	tgaagcttat	caggagacag	720
aaaacatatg	aatttagatct	aattggaggc	aaactgaaaat	atatagtgga	gttagtgtgg	780
ttatcagcac	ataaaatgagt	gatccatcaa	caaaaaggaga	aattgggagg	gttttatggg	840
ccaaaaacag	catgattaaa	tgtgatagag	tatatgtcat	gttttaggt	tgatgaacat	900
tcagttatgt	gtgacgataa	ggataattga	aaaaatatga	aaggctatga	tgccagaaag	960
tattatggga	caagatctt	aaaccagtgt	tacctaggg	gtatgaattt	aatatgggaa	1020
ttctttaact	cctttatgac	tggaagatga	gcatcagagt	gtctgcgacc	attttgcata	1080
tatgatgtac	cagttttaa	atgtttggct	tttccagg	gatgaaagcg	ggggatgagt	1140
taagaaccac	tgctgtgaag	gattcacaac	tatTTTtagg	cagttggta	aaaatgacca	1200
atTTtagttt	aagaactga	ctgtggctcc	agagtatgtt	ggagaagtga	aatggagac	1260
taggataaac	aggtggaga	ctattagtct	aattaagatg	taattataaa	tctaagctag	1320
gaacgtaaaa	tgagaatgca	aagtaagaaa	caaataatggg	gaaaattata	tgtaaaagta	1380
ataggacttg	gcatcttact	gatgtgattt	attatgagaa	aaatgaagca	tgtggaggag	1440
tccactggac	agtaggaaat	tcagcctaag	acttgggtaa	gagttctgt	gagttgtgaa	1500
ttcagaggcc	agagatgtga	tatTTTaaat	tttggttcaa	gatttcccag	gtataagaaa	1560
gcaagaggat	taaagcattt	taattaaact	ttaagcagt	catattttag	ttatagataa	1620
gataaaacaag	aaatctaggg	atcaaataagg	atTTTaaattt	gtagtgtca	ttcagtcacag	1680
tagttacgta	ctgttattca	caagagtata	taaatcaaatt	tacaaggaat	taaggatata	1740
aacgtgataa	gaaagtatgc	actgtactct	ttgaggaagt	ttgccataga	aaggaagaag	1800
aaataggatg	gtagatcaga	agtaaagcag	gaccaggatgg	ggggagggtt	tgcagtgagg	1860
cagtatgtat	aatcatttaa	aacatgggtt	tggagtccctc	tcaggttcca	tgtttgtat	1920
ggacataatg	ataataatcc	cttcatTTA	aggctgttgt	gaggattaaa	tgtgttaatg	1980
tgcaaataac	tttacacagt	gcctggata	taataaaatgc	ttgttaccta	ttaactagta	2040
tttggTTcta	aggcttaattt	aagtccata	attgatttgc	aggatttagat	caggagtata	2100
gtggacatgt	tgggatttaa	atTTTaaat	atagagatgc	tttttaggac	cattgtttaga	2160
accagaagag	atTTTtacc	aagttcacac	agaaatgttag	gtgcattggc	tgggcatgt	2220
ggctcacacc	tgcagtccca	gcaactggga	aggctgaggc	agaagaactg	cttgaggcc	2280
acatTTtag	accagcctgg	gcaacatattt	aagacccgt	ctccaccaaa	aaaaaaaaaaa	2340
aaa						2343

<210> 12
<211> 1177
<212> DNA
<213> Homo sapiens

<220>

<221> SITE
 <222> (1095)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1115)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1142)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1162)
 <223> n equals a,t,g, or c

<400> 12

agccaccatg	ccccgcctag	attaaaaatt	tgaagacata	ttctctacta	tgagccaatg	60
aaattactca	ttttgtttct	atcccatttg	ctgtcccttg	cttttggaat	tttgtgtctt	120
agtgtgactg	tgatttttc	tctccttttg	tctttcagca	aacggggatt	cagcgtccga	180
tcctttggaa	cagggactca	cgtgaagctt	ccaggaccag	ctcccgacaa	gcccaatgtt	240
tatgatttca	aaaccacata	tgaccagatg	tacaatgatc	ttcttaggaa	agacaaaagaa	300
ctctatacac	agaatgggat	tttacatatg	ctggacagaa	ataagagaat	caagccccgg	360
ccagaaaat	tccagaactg	caaagacctg	tttgatctga	tcctcacttg	cgaagagaga	420
gtgtatgacc	aggtggtgga	agatctgaat	tccagagaac	aggagacctg	ccagccygtg	480
cacgtggtca	atgtggacat	ccaggacaaac	cacgaggagg	ccaccctggg	ggcggttctc	540
atctgtgagc	tctgccagtg	tatccagcac	acggaagaca	tggagaacga	gatcgacgag	600
ctgctgcagg	agttcgagga	gaagagtggc	cgcaccccttc	tcgcacaccgt	ctgcttctac	660
tgagccccagc	gcccccatgg	agccgcctt	ggagcttctt	gttgttcata	ctttttcctt	720
cctgacattt	gttttactt	acaggtgttc	tgctggtgac	gttagcatta	cccaaataaa	780
ctgtgcata	gaaatgggag	aggagatgcc	aaaacgccag	atgaaagcaa	tcaagttct	840
tcttttccac	ttttacttat	gagcrggata	ttgattacaa	agtttttctt	ctttaaccaa	900
aaaggaaaaga	caacggtttg	tgtgcacttc	ccgacatacc	tgtgtcttgc	tgtgcctgccc	960
ttccctccct	cctccccacc	gggcccggact	gtacagagcc	ctgctgcggc	gtgttaggaa	1020
tgacctggaa	ttgtcaataa	acagatgctg	ctgtcaaaaa	aaaaaaaaaa	aaaaaaaaaa	1080
aaaaaaaaaa	raaancaaaa	aaaaaaaaaa	aaggnggggc	cgaaggttt	ttccctttgg	1140
tnggggtat	ttttggcttgc	gnattggcct	tcgtttt			1177

<210> 13
 <211> 2107
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (149)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (487)

<223> n equals a,t,g, or c

<400> 13

ttaggtatg catataaaag aaaacaaaat attaaaaaca cttaaaggag atctgacaa	60
acctaaagag aaaaaaaaata ataaaaattaa gtaaagaaaw ggtatggcag gatTTtatgt	120
ttgcctgtgc cctttatcca actgatcang gcttcctgga wtcagtgaca gcagaagtt	180
cctaccagat caagagactg aaatctcatic cttctatcat catatggagt ggcaataatg	240
aaaatggaga ggcgtgtatg atgaattggt atcatatcag tttcaactgac cggccaatct	300
acatcaagga ctatgtgaca ctctatgtga aaaacatcag agagctcgta ctggcaggag	360
acaagagtc tccttttatt acgtccagtc ctacaatgg ggctgaaact gttgcagaag	420
cctgggtctc tcaaaaaccct aatagcaatt attttgtga tgtacatTT tatgactata	480
tcagtgnatt gctggaaactg gaaagtttc cccaaagctc gatttgcatc tgaatatgg	540
tatcagtctt ggcgtcctt cagtagatcattt gaaaaggctc cgctctacaga ggactggct	600
ttcaatagca agtttactt tcatcgacaa catcacaaag gtgttaacaa acaaattgtt	660
tatcaggctg gacttcattt caaactcccc caaaggcacag atcattacg cacatTTaa	720
gataccatctt accttactca ggtatgcag gccctgttgc tcaaaacaga aactgaattc	780
tacccggcgtt gtcgcagcga gatagtggat cagcaagggc acacgtatggg ggcactttat	840
tggcagtttttga atgacatctg gcaagctcctt tcctgggtt ctctttagta cggaggaaag	900
tggaaaatgc ttcatTTTTT tgctcagaaat ttctttgtctc cactgttgcg agtaggctt	960
gagaatgaaa acaygttcta tatctatggt gtgtcagatc ttcaactcgga ttatTCatgt	1020
acactcagt tgagagtcca tacatggagc tccctggagc ccgtgtgctc tctgtgtact	1080
gaacgttttgc tgatgaaagg aggagaggct gtctgcctt atgaggagcc agtgtctgaa	1140
ttgctgagga gatgtggaa ttgcacacgg gaaagctgtg tgggttccctt ttacccccc	1200
gctgaccatg aactcctgag cccgaccaac taccatTCty tgctctcacc gaaggaggcc	1260
gtggggctct gcaaggcgc gatcaactgcc atcatctc agcaagggtga catattgtt	1320
tttgcacccgg agacccctcgc tgctgcctcc tttgtttgtt tggatgttagg aagcatccca	1380
gggagattta gtgacaatgg ttccctcatg actgagaaga cacaactat attatTTTAC	1440
ccttggggatg ccaccaccaaa gaatgagttt gagcaatTTT ttcatgtgac ctccttaaca	1500
gatattttactt gaaggaaatctt aggttgcattt ttcaactggac aatgggata aagcatttt	1560
aaaggcaccga ctggagggaga aggcaacaga gacaaggaga gaagccgaga gacatgtctg	1620
cgtgcgcac ccacatctgag cgattgtctt gtgaagagggt gtacactgaa cattttcagg	1680
ggaggctgtt taccctggca atgtcctcaa acaaggctgt gcccgggtgt cctggaaatct	1740
gtgccaggac tggatTTTTTA gcccTTTacc ttcagctttt agcaggacat gaaccaggat	1800
taacaagatg sccctgcacg tggatTTTTA aatgtgacat ggcaggatct atggaaaccaa	1860
atggaaaggat ttaggttgcgtt gtaggtctt cacagttagc tttggggat acagaataact	1920
caaataaaat gctttgttat tatttcagag ggaatggcga ttggaaatgtt acaacagaga	1980
tttcttgggt gtagcttattt gggtaaaggat atatggatat tttctgtac atgtgaaatt	2040
atataaaaat aaaaggTTATA taaaattacat tgaaaaaaaaaaaaaaa aaaaaaaaaaaaaaagg	2100
cgccgcgc	2107

<210> 14

<211> 1262

<212> DNA

<213> Homo sapiens

<400> 14

ccatGGCC cgasctgaat acttgaagga gctcaagatg agggaaatctc gctgggaagc	60
tgacaccctg gacaaagagg gactgtcgga atctgttgcgt agctcttgc cccttcagtg	120
acccttagaag aatgatttggc cagatgttagg ccatctggag cagaggggca ctaacccagg	180
ctgacgcacaa gaatgaagt gcccactgca gcccggcga gcaggcttct tggatggaca	240
gtgctgagac ccccatatcc cagatcccc agcctccctc aggttactct gcacccccaca	300
gatggtttgc tggctgtgtt gtatactggc ggggaggcga ggactctggg agaacagcac	360
ttctttcatg agaccttgcgtt tactcggtgg ttactgggtc ctgtgcctgt ccgttttgg	420
gcacgcaccc ctctatcattt tttggctccg agaagaggc aagggcccc cgcaggtarc	480

ttctgtgctt	gccctcgccc	tgccagcagg	cagctgtgcc	cctggcctgc	ccttcccg	540
accccttatt	ccaactcagc	tcctcttgc	actggaatgg	ggcaactccaa	caccctcag	600
gaccaccc	ccccacagta	tgcactcagc	cccacagaac	ccaccagtct	ttctggaa	660
tcacacctgc	ccgccatctt	ggtactttag	gttaatccct	caagcatgaa	agctggatct	720
tttggggtt	aagaagccca	agccttgtc	ctgccc	ctggagca	ctcaggaggg	780
ttccttggc	ctcatctc	ccacccgt	tccctctgg	ccccacacta	gccacagcgc	840
gggccttgt	ctggagttt	agcctggac	agggagaggg	aggcttggag	acagtctgac	900
ccagtgcct	ctaggccacc	cacttctagg	cctgccc	ccccgtggag	ccctggcaa	960
gctcttccc	ctttctggc	ctgggtctc	ccatcttc	aatggggctg	ataccttcac	1020
agcccacagc	atgggcactt	atgaggacaa	agtgaattt	acctggaaaa	gaatgtattt	1080
gagagtttct	tttaaataat	cagcgggtgt	ttgtgattt	tagcccttct	gcccttaaat	1140
gcttccttg	gcaagagctg	tctgtcctcc	ctgcaggagg	ctgagtgta	agagtatcat	1200
tcattgtt	tctattaaat	tat	tttttctgc	aaaaaaaa	aaaaaaaaat	1260
cg						1262

<210> 15
<211> 759
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (22)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (36)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (51)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (52)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (57)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (58)
<223> n equals a,t,g, or c

<400> 15

```

ggattaacaa atttncaca cnaggaaaac aggttnttga cccaaatttagg nnttttnnca 60
aaaaagctta ttttaggtt gacacttatt agaagttacg cttgcaggt taccggttcc 120
ggaattcccg ggtcgAACcc caaggggttc gcggacccc gacatgagga ggctcctcct 180
ggtcaccaggc ctgggtgtt tgctgctgtt ggaggcaggt gcagtccca caccctaagg 240
ccctatacaag atgcaagtca aacactggcc ctcagagcag gacccagaga aggccctgggg 300
cgcccggtgtt gtggagcctc cggagaaggg cgaccagctg gtgggtctgt tccctgtcca 360
gaagccgaaa ctcttgacca ccgaggagaaa gccacgaggt cagggcaggg gccccatcct 420
tccaggcacc aaggccttgg a tggagaccga ggacaccctg ggccgtgtcc tgagtccccg 480
gccccaccat gacagcctgtt accaccctcc gcctgaggag gaccaggcg aggagaggcc 540
ccgggttgtt ggatgtccaa atcaccagggt gctcctggga ccggagggaa accaagacca 600
catctaccac ccccaagttagg gctccagggg ccatactgc ccccgccctg tcccaaggcc 660
caggctgtt ggactgggac cttccctacc ctggccca gac tagacaata aaccccaaggca 720
ggccggggaaa aaaaaaaaaaa aaaaaaaaaaa ggcggccgc 759

```

<210> 16

<211> 1810

<212> DNA

<213> Homo sapiens

<400> 16

cacgagggtg tgcgtgctta ggcaggaacc cagtttact ttatgccatg tgaaaggtt
cttttccag tatcaccagt gagttcaactg tctctccact ggctctcagt gctgcttcg 60
ttacttgac acttcccacg tgtgcatttgc tctccacctg gggctcttag ggtctctatt 120
ctacactgccc tattttccctt tctgtcctaa caccatagca tttaaactcac ccgtcatcc 180
gtgttgcata gaatttccctt catagaactc atcaaagtat gattaactgt gctccctcgag 240
ggcaggaatt atgcacatcg gatcaccaggc ctctcccttg tccttagcac gccatctgca 300
aatttagcaga tactcggtaa atgtgttatttactcgaagta tattttgtgt ctctctgtg 360
cacagcactg ccctggaaag aacttaggatg aggtatttgc ttgtgttgc cacataacaa 420
accctgcacg aactccctgg atggaagtga ccaccgtgttgc tctgtggatt gtctgcagg 480
ctctgttgg gtcacggat cccacaacag agccagggttgc cggtcttcctc atggctgtca 540
gaggtttacg tattttccctt cctccacca aagtctgttgc ttgtgttatttccatcttgc 600
ctatatccac atcttttaat aatgtctaaaa tccccgtttt ctctaaagca ttggatttgc 660
ccaactgaag aaggaccacg tgtgttgcgtt ggcctgttgc ggacacaagcc gtttccgatc 720
caagtcaact gctggcttc ttagacgaag gtgtgttgggt gtctccacca cggagaggag 780
ggacagcagg tgagaccata ggccaggaag gaagggcaca gcctaagcgt gcagtggctt 840
agccagagac cctcgtgcac cagcccttcca ggtgttatttgc ggaacttgcgt tcagcccgagg 900
ccatatccaa gtgtgttgcgtt tctcggagca tatatgttgc ggcacccggaa gaggcttgc 960
cctggccctgg tggagcttgc gggccgcagg gccgcgggtt ggggtcaggaa ggttgttgc 1020
aggatcttgc tacaggctgg gcctccctgc aggctgttgc cccggagcac ggggttgc 1080
gttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1140
gttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1200
gttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1260
tggggccctgtt gggggccacaa gagatgttgcatttccatttgc accaggattt ccctggccgg 1320
agcagcccttgc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1380
aaagacttgc tcttaacgttgc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1440
agccgcaccc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1500
gttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1560
tggggccctgtt gggggccacaa gagatgttgcatttccatttgc accaggattt ccctggccgg 1620
cggtgttaacg tgccgttttcatccttgc ctttttagcccc ggtgttgcgtt ctttttttgc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1680
gagggttgcgtt ctttttagcccc ggtgttgcgtt ctttttttgc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1740
tcttcttaact gttgcgttgcgtt ctttttagcccc ggtgttgcgtt ctttttttgc tttccacca gagggttgcgtt caggaccaag ctggacagc aaccaccagg ccctggggca 1800
aaaaaaaaaaaaaaa 1810

<210> 17
<211> 1052
<212> DNA
<213> Homo sapiens

<400> 17

gcaatttct	gcatacgcatc	agcaatgagt	ctgtacaact	gtcttgctgc	actaattcat	60
aagataccat	atggacaatg	cacgattgca	tgtcgtggca	aaaacatgga	agtgagactt	120
attttcctct	ctggactgtg	catagcagta	gctgttgg	gggctgtgtt	tgcggatgaa	180
gacagggtgg	cttgatttt	acaggatattc	ttggggattt	cttctgtct	gaatttaatt	240
aaaacactga	agttggccaa	cttcaagtca	tgtgtgatac	ttcttaggcct	tctcctcctc	300
tatgatgtat	tttttgtttt	cataacacca	ttcatcacaa	agaatggta	gagttatcatg	360
gttgaactcg	cagctggacc	ttttggaaat	aatgaaaat	tgccagtagt	catcagagta	420
ccaaaaactga	tctatttctc	agtaatgagt	gtgtgcctca	tgccctgttt	aatattgggt	480
tttggagaca	ttattgtacc	aggcctgtt	attgcatact	gtagaagatt	tgtatgttcag	540
actggttctt	cttacatata	ctatgtttcg	tctacagttt	cctatgttat	tggcatgata	600
cttacattt	tttgtctgg	gctgatgaaa	aaggggcaac	ctgctctcct	ctattttagta	660
ccttgcacac	ttattactgc	ctcagttgtt	gcctggagac	gtaaggaaat	aaaaaaagttc	720
tggaaaggta	acagctatca	gatgatggac	cattttggatt	gtcaacacaa	tgaagaaaac	780
cctgtgat	ctggtaaca	gattgtccag	caataatatt	atgtggaact	gctataatgt	840
gtcattgatt	ttctacaaat	agacttcgac	tttttaaatt	gacttttgaa	ttgacaatct	900
gaaagagtct	tcaatgatat	gcttgcaaaa	atataatttt	atgagctgtt	actgacagtt	960
acatcataaa	taactaaaac	gctttgtttt	taatgtaaa	gttgtgcctt	cacattaaat	1020
aaaacatatg	gtctgtgtar	tttcaaaaaaa	aa			1052

<210> 18
<211> 1130
<212> DNA
<213> Homo sapiens

<400> 18

ggcacgaggc	catttgtata	attcttttagt	aaattgtatt	aatggggagaa	tctgttaagtt	60
atgtctgaac	tttcagggtt	tcttataatt	gtcttttcc	ttagtgcaga	tgttctatgt	120
cataagaata	aaatggttca	caccaataca	agtaacttagt	tgtggaaagg	gagagttagaa	180
gataaaaaatg	gagattttcc	tgtgctacag	gcttagtcaa	gcttatggtc	tatTTatgg	240
ttatcaaagg	caattaaata	gtgttgaatg	ttctgccttt	acctacattt	catttttcat	300
gtacttagtt	acaatttgaa	ccctcttcta	ttttttccct	gctctgttt	ctgtttcatt	360
ttagtttcc	ttttccctga	ttatcattt	ggcatgttaag	tgacacccag	tagcattgt	420
ttaattctgc	ttgggacagt	gccaaagctt	tactatactc	tttttgtt	ctgttgctt	480
tctcttgcta	atttgcttga	ctagataact	aagaatttcag	gtaagcatta	gcttttgtt	540
cactgagaat	aataacaactt	gcaagataat	taatttggat	tgttctacat	gtatTTcgtt	600
tatttcttt	taccttgc	atttattacg	acattttgaa	ttatTTacat	acccatattt	660
cttctttctt	ttatggctca	gctcaactat	cttttttta	atactggtag	cttcctcaag	720
gttggaaaac	aagatctgaa	tactatagaa	aataataact	atTTTCTGT	ggtcattat	780
aagatataat	ggctttggat	tttgggggtga	tttttctact	gtcagttaa	aaaaaaacttg	840
tctatttgc	tttgggtgtt	attacttcta	gttaagagta	tttccaaggaa	aagtttcatg	900
ttacttattt	ttttccatg	tcttttccaa	aaagaactta	ttttttat	tataataaaat	960
atcagtggaa	aagttaggtt	cgttatata	aaattaactt	taggctgggt	gcagtggtc	1020
aaggcttat	ttgggaggcc	gaggcaggag	gattgcttga	actcaggagt	tcgaaaactag	1080
cgtggcaat	gtagcgagac	ctggctctca	aaaaaaaaaa	aaaaaaaaaa		1130

<210> 19

<211> 883
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (19)
 <223> n equals a,t,g, or c

<400> 19

gtcaccgtgg	gctttaant	atgatccccc	gctcagattc	gcagactgca	ctgaacttcg	60
gctctacgtt	gatgaagaag	aagtctgate	ctgagggtcc	cgcgcgtctc	ttccctgaga	120
gtgaactttc	catccggata	ggtagagctg	ggcttcttc	agacaagagt	gagaatggtg	180
aggcatatca	gagaaaagaag	gcggcagcca	ctggccctcc	agagggtcct	gctgtccctg	240
tgccttctcg	agggaatctg	gcacagcccg	cgccgcagcag	ctggaggagg	atgcactgc	300
tcatcttggc	catcactata	cacaacgttc	cagaggtct	cgctgttgg	gttggatttg	360
gggctataga	aaagacggca	tctgctaccc	ttgagagtgc	caggaatttg	gccattggaa	420
tcgggatcca	gaatttcccc	gagggcctgg	ctgtcagcct	tcccttgcga	ggggcaggct	480
tctccaccc	gagagcttc	ttgttatgggc	agctgagcgg	catgggtggag	cccctggccg	540
gggtcttgg	tgccttgcc	gtggtgctgg	ctgagccat	cctgcccctac	gctctggcct	600
ttgctgcccgg	tgccatggc	tacgtggta	tggacgacat	catccccgaa	gcccagatca	660
gtggtaatgg	gaaactggca	tcctggccct	ccatccctggg	attttagtgc	atgtatgcac	720
tggacgttgg	cctgggctag	ggctgagacg	cttccggaccc	cgggaaaggc	catacgaaga	780
aacagcagtg	gttggcttct	atgggacaac	aagcttcttt	cttcacatta	aaacttttt	840
ccktcctctc	ttcttcaaaa	aaaaaaaaaa	aaaaaaactc	gag		883

<210> 20
 <211> 989
 <212> DNA
 <213> Homo sapiens

<400> 20

ctggcttggc	tgctataactc	ttgccttca	ctgaacctca	gtttcctca	tctgaatagt	60
tgggagactc	attccctgcct	ttctcatgtc	cctggctatt	tggtaaacc	gccagtagga	120
agacatctg	aaatgtatta	aagtggtctt	agctagacag	agtgggcatt	ccagggtcag	180
cagagattct	gaagtctaga	ccagttccct	gggtggccg	ttgtcagtcc	tagcagatgg	240
ccaggtcagc	cctcaggctg	gaaattttag	ggcagctatt	gttaggtgtc	tcctcttgct	300
gtgctgagat	acggtaaga	tcatacttag	gtcttttttg	gaagaacata	caagacgaga	360
aaaaaaaaaa	gatcatactt	aggggctccc	ggaatttgct	ctgccctagg	ttgctgagac	420
ctctagaacc	tgtcaggct	aaaggaactc	agtccgtaga	tccgagagag	gtgtcagggg	480
agaccaggag	catgtctaca	ctgcccagg	actttgcct	cctcccccaa	gccagcagga	540
tggcccaaaa	aggctccccc	agcagatcat	cttgcagct	ccttttttag	ctccagtggc	600
agcagggatg	aggaagggaa	agttctatca	ttttttcta	attaaaatg	acatttaaaa	660
tcactagctt	agtgggggcc	aggtgtggtg	gctcatgcct	tttgtccctag	cactttggga	720
ggccaagacg	agtggatcgc	ttgagcttag	gagttaaaga	ccagtctgg	caacatagcg	780
aaacggccgc	tctataaaaa	aataaaaaaa	ttagctggat	gtgggtgtc	acacctgtat	840
tcttagctgc	ttgtggggct	aaggcgaaag	gatcacttga	gcccaggagg	tcaaggctgt	900
agtgagctgt	ttgtgccact	gcactctagc	ctgggtgaca	aagaaaacc	ctgtctcaaa	960
aaaaaaaaaa	aaaaaaaaag	ggcggccgc				989

<210> 21
 <211> 495
 <212> DNA

<213> Homo sapiens

<400> 21

ggtggaatgt	agtggaaaacg	agatgctgtc	tctwagggac	taaggaagct	atcttcctc	60
ttccgacatt	tgctgactgg	tcgatgctag	atgatcttga	gaccctgtgc	tgaggactgg	120
agaactacag	gaaaggagca	gtatctctga	attatcggtgt	ggaagggtcac	ttgtcttagcc	180
cctgtatgact	gtgagcctct	tcctccctgt	tgccacctct	cagtcacaag	acggctgtcg	240
cgactcgagc	tcatgtcccc	attcaaggca	gcaagaaggc	catggagcgg	cacccgtccag	300
cagatgcccc	tgcaggccat	ctctccaggc	tcaggaacct	aaagaagaat	ctacccagat	360
gtggtgccta	cacctgtat	cccaccatt	tgggaggctg	aggcaagagg	atcacttgag	420
cccaggagtt	ggagaccaac	gtaggcaata	cagcaagact	cccatctcta	aaaaaaaaaa	480
aaaaaaaaaaac	tcgag					495

<210> 22

<211> 2317

<212> DNA

<213> Homo sapiens

<400> 22

ccctaaagag	ttgaagaact	aattggtcgg	aaaaaattgg	atattgaatt	cataagatgt	60
aaaaatggac	tggattttt	gtagtttgg	ttgctttaa	aaaaattagt	gttagcttc	120
aagtgaatta	caaccttaaa	tttgagattt	cctttgtga	accatggaaag	tttacccagt	180
ggtaaggaga	actgtatgt	tttagattt	gaataagtac	tgtgtttaa	tcacagctct	240
taattcaaag	cattgattt	attccacgt	gtctgtata	ttcagaaaca	aaaaaacaag	300
tggaaaaagt	atgaccccg	tgtcgagat	ggctatgtgt	gcatgtatat	acaaatagac	360
acgttatatgt	gcatgttacc	tttacgtaca	tgtggaaaaa	cagttctaat	taagtcaata	420
tgtgtcttgt	atttgcatt	attagagtt	gattttccta	atggtcgagg	gccttttgg	480
tggcccgag	tttgattt	tgtggatgt	tgatgaagac	ttagtgaata	gccacagttac	540
tcagttttc	cttcacaga	ttaatctgcc	agtttctccc	actgtgtatt	gtgttatatgt	600
gatagaattt	gagggggaaa	ataacacacc	agctaattgt	gaaacgaact	ggctctagtc	660
tgttaaggta	cgggaccacg	ccaatttat	aactgattga	ggcattgcca	tttttcactt	720
aactcttga	atcaagtcat	aattttattt	aataattttt	ttgaggcaga	gtttcgctct	780
tgtcgctcag	gttggagtgc	agtggcccaa	tcttgccta	ctgcaaccc	cgccctccag	840
gttcaaggga	ttctccctgcc	tcageccct	gagtggctgg	gattacaggc	acccgcacc	900
aagcctagct	attttttt	tatTTTTT	tagagacggg	gttgcaccat	gttggccggg	960
ctggctaca	actcctgact	tcaggtgatt	caccggcctc	ggcccccac	acagctggaa	1020
ttacagggt	gagccaccgt	gcccggacc	aatcaagata	tatTTTTAA	gaactgttt	1080
atgttatttta	tttatttcat	tcttcaatag	gtatttacat	gtctgtcttc	ggagatgggt	1140
tttagagttt	ttttttttt	tttgagacc	gagtcttgc	ctgttgccta	ggctggaggg	1200
cagtggcg	atctcggtc	actgcaagct	ccgcctcccg	aattcaacgc	attctctgc	1260
ctcagcctcc	tgagtggct	ggactacagg	cgcccccac	cacggccggc	taatatttt	1320
catttttagt	ataggtgggg	tttcaccgt	ttagccagga	tgggtgcgt	ctcctgaccc	1380
cgtgatcgc	ccgcctcgcc	ttcctaaagt	gctgggattt	caggcgttag	ccaccaagcc	1440
cggccggt	tagagttt	aacaagacaa	agctccttgc	aaagctaacc	ttgggagggt	1500
tggggaaaac	cacaaagagg	gtgacaagat	aatttcat	agggctaaagg	gataggaaga	1560
aaatgaagat	gggacatgtt	aagtaataat	aatagatgac	atttgaacac	tgtgccatc	1620
actctgtcga	ttgtttaca	tataccttgc	gacaacccta	agaggttaggc	accgttatta	1680
cggacattt	acaggtgaaa	cagggacaca	ggaaaaagtaa	gtAACATGCC	cagctgtga	1740
atcaaggcag	ccccggacca	gagtccactc	tctgagaaat	ggcattttgg	caggatcgag	1800
aatgaggagg	agatccagt	tggcagaggc	cctggggagg	aatgggctgg	aagtattcga	1860
gaaaccacaa	agtaagagt	gcctgagttt	cccagagagg	tgtatggag	gcaggagtca	1920
gagcgtgtct	accctcgtag	gccattggag	gcttacatgt	ggaagggaca	gtttctgatt	1980
cctgtttaaa	aagagggtct	ctgtccgggc	gcggggctc	acgcctgtag	tcccagcact	2040
ttgggaggcc	gaggcggg	gatcgcgagg	tgggagatc	gagaccatcc	tggctaaacac	2100

cccggtctcta ctaaaaatac aaaaacaaaa tttagccccgc atggtggcgg ggcgcgttgc	2160
tctcagctgc tcgggaggct gagggcggaaag aatggcgta accttggaaagg cggagcttgc	2220
agtggccgg gatttgtcca ctgcactcca gcttggcga cagagcgaga ctccatctcc	2280
aaaaaggaat tcgatatcaa gcttatcgat accgtcg	2317

<210> 23

<211> 1726

<212> DNA

<213> Homo sapiens

<400> 23

ctttttggct ctcattttga atttttcaag agtcatgtt ctttgtcttc attaaaaaaaaa	60
aaaaggttttt atatcggtt tgaatgtcat tcgggatatac tatacatataca tgcacataacc	120
tcatttttat tgcatttcac tttattgcac ttttgcataa gacatttttt acagattcaa	180
ggtttggcaa ccctatgtcc ataagtctgt cagcaccatt ttttcaacat atgtgtctcat	240
tttgcctctc tgtcacattt ttttttttc ctgagacagg gtctgtctt gtcacccagg	300
ctggaatgca gtgggttaat tatgcctcac tgcggccttg acctcttggg ctcaggat	360
cctcttgctt gcgccttgc agtagctgag actacagatg tacaccacca cacacccagc	420
taagtttaa attttttat agagatgggg tttccctatg ttgcccacgc tgctctcgaa	480
ctcctggct taagtatcc tcccacctca gctttcaaa gtgcgggat tacaggcatg	540
ayccacagca cctggctct gtgtcacgtt ataataattc tgccaatattt ccagatttcg	600
tcattattaa atctgtttagt gtgatctgtt atcagcgaaac tctgtatgtt ctgtctaatt	660
gctttggat gcagtgaacc cgtcagatgc atccatgagg gttgaatca acttcttcca	720
aaatcctgtt aatcaagatg gaacttaatc gattaatgtt gtgtatgttc tgactgtcc	780
accaatctgtt gggccctca tcactctccc ttcctcagg cctccctatt ccctgagaca	840
caataatatt gaaatttagac caattaataa ccctgcaatg tgaaggaag aagttacatg	900
tctctcactt taaaataaaaa gcttagaaattt attaagctt gtgaggaggg catttcgaaa	960
gctgagagag gctgaaagct aggccgggtt tgccaaatag ctggcaatgt tggaaatgca	1020
tagggaaaagt tcttgaagga aattttttt gttactccag tgaacacaca aatgttaagt	1080
aagcaaaaaca gccttattgc ttatggaaag aaagtctgaa tggctctgaat agaagatcac	1140
atcagccaaa acatgtcctt aagccaaagc ctaatctata atagatcagg cccttaagtct	1200
cttccattcc ttgaaggcac agagagggtt agaagggtca gaagaaaaagt tggaaagctag	1260
ccaaacccctt gttgtcgagt ttaaggaaaaa aagccatctc cataacatgg aagtgcaga	1320
tgaaggcagca ggcactatgtt gggaaagctgc agcaagttt acagaaaaatc tagctaatga	1380
tgagggtggc tacactaaaa acagattttc aatggagaca aaacacccctt ctattggaa	1440
aagatgcctt ctaaagcttt cataggtttaga gagagggtcag tgcattggct tggaaagaaca	1500
ggctgattctt cttgttagag gcacatgtt ccagtgtttaatgttgaag ccagtgttta	1560
tttatcattc tggaaatgtt agggccctta agcattatgc taaatctact ctgcctgtgc	1620
tctagaaatg gaatagcaaa gcacgtatgtt gacacatct gtttacaaca tggatgtgt	1680
aatattttaa gcctatattt gagacctact gctaaaaaaa aaaaaa	1726

<210> 24

<211> 529

<212> DNA

<213> Homo sapiens

<400> 24

acgcgtccga ttacttacgt gtcctggct gggatggcac tggcattca gaaaagggtt	60
tccccggagg tgctggcct gtgtcgaaac acagcgctgg tgggtgggtt gatggaggtt	120
ctggccctgc tcctggcctt ctacctggcc accgtgcga gtgcacccgtt cacctttcac	180
ctgctggcctt acagtggctt caaaatacgtt ggaatgtatcc tcagtgtctt cacggggctt	240
ctgttccggca gcgatggctt ctacgtggcg ctggccttggaa ctcacatggc gtcacatgtac	300
ttcattgtgc gtcattttggc gacagcgatcc ctggcccccgg acagcatggg gggcccccgtt	360

ccccggcagc gtctccagct ctacctgact ctgggagctg cagccttcca gcccctcatc	420
ataatactggc tgactttcca cctggtcccg tgacccctg gccccagatg gcactgagtt	480
tttcattcat tgaagatttga atttccttga aaaaaaaaaa aaaaaaaaaa	529

<210> 25
<211> 1755
<212> DNA
<213> Homo sapiens

<400> 25	
ggcacgagcc tcacagcgcc tctgctggag ttccctgctgg ccttgtactt cctctttgct	60
gatgccatgc agctgaatga caagtggcag ggcttgcgt ggcctatgtat ggacttcctg	120
cgtgtgtca ccggggccct catctacttt gctatctcca tcacggccat cgccaaatgtac	180
tcggatgggg cttccaaagc cgctgggggg tctgtgcctg acactcgggc tggttgcctca	240
agcagatctg aaatggggccg tgagctgggg gcagcggcct cccgggagca gggagtcagc	300
cctgtatgc atccatcca ccctgtccac aggtgtttgg cttctttgct accatcggt	360
ttgcaactgr ttcttacctg atcttaacg acgtggccaa attcctcaaa caaggggact	420
ctgcagatga gaccacagcc cacaagacag aagaagagaa ttccgactcg gactctgact	480
gaaggcctgc ggggccttg gcaacctgag ccacacaggc ctccacccct ggccttcaca	540
ggggtcgtcg gctgtggagc ggaggcctgg acttctgagt tgcaagaggg gctgcggaca	600
cagcaggccc cctacagcct cagggtctgc ctgagcccag cctaccaggc ttgccttcata	660
gctcagcact gttgaccacg ctgcgtatga gggcatctt ggtatcccac tccttcctcc	720
catttctgtc ccacaggcct tcaagccctt aacgtctctg ccaaaaacca gcacaaggag	780
acaaagcaga gcctgtctg tatctggca gcaggtgttc catgtctgtca ggtggcgggg	840
gtcggtttca ctaacaggaa caaagacaga aaccatgaca gggctgcccc	900
gccaggcccc ggtgggtttg tctgcacttg gtgcctctgc ccacaccagc cactttggtg	960
acaatgaccc ttccaagaat ctttggtca aggagcacca gtcccttctt cattctgaa	1020
gcagggagaa attgacctt gccttgcgc ccaggaagtg gggctggca cccataacta	1080
acacctccca ccctggaaa ccatgtcttcc tgggggttag atgaccattc tgggtctaag	1140
actgttcaa agaagagctc atagactgac tggccagaa gacagagggt acaacagtgg	1200
catcacagtg acagtgtcat ggggagctgg gggggccctg ccaaaaccctc ttcttcctta	1260
gagcccagcc agcaggcagg agttcctggc ccctcaggac agtgaacttc cagacctcag	1320
ggcagggtcta tggggccactg caggagatga gaccagcctt ctgtgttca ctaacgattt	1380
atactgtgtat tctgtctttt atggaatttt gtaactttt atatttttt atgcaaaaagc	1440
agcttcttaa cagatggcat tttctgtgac tctaggcttc aaaaaagagc cagagttctg	1500
gaccatgtt tggagcattt gtgccttat tctcttgcgt gtgaatctt tacccctgaaa	1560
aaaagccata atgaattaag ccagactgac cacttgcctg gagtgtgtgc ttgaaaaaac	1620
cagagcaata ctgttggta ttgtatcagg cttcagatca aactggtaac accaatgtgg	1680
atcctgacag ctgcgtttt tagcaaaaat acacgtgaaa tctgactacc atttaaaaaa	1740
aaaaaaaaaaaa aaaaaa	1755

<210> 26
<211> 1751
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1520)
<223> n equals a,t,g, or c

<220>
<221> SITE

<222> (1557)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1689)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1729)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1735)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1741)
 <223> n equals a,t,g, or c

<400> 26

gggtgcagcc tcatggcgca ggaggttagac acggcacagg gcccggat gcccggggc	60
gccccggcggg ctggggacg cgcttcgtgg tgctggccc tggcgctgct ttggctcgcg	120
gtggttccgg gctggcccg ggtctcgggc atccccccc ggcgccactg gccggtgccc	180
tacaagcgct ttgacttccg tccaaaacct gatccttatt gtcaagctaa gtatacttgc	240
tgtccaactg gtcacccat cccagttatg gagggtgatg atgacattga agttttcga	300
ttacaagccc cagtatggga atttaaatat ggagacccctc tggacactt gaaaattatg	360
catgatgcca ttggattcag aagtacatta actggcaaga actacacaat ggaatggtat	420
gaacttttcc aacttggcaa ctgtacattt ccccatctcc gacctgaaat ggatgcccct	480
ttctggtgta atcaaggcgc tgcctgctt tttgagggaa ttgatgatgt tcactggaa	540
gaaaatggga cattagttca agtagcaact atatcaggaa acatgttcaa ccaaattggca	600
aagtgggtga aacaggacaa tggaaacagga atttattatg agacatggaa tgaaaaagcc	660
agccccagaaa agggggcaga gacatggttt gattcctacg actgttccaa atttgtgtta	720
aggaccttta acaaggttgc tgaatttggaa gcagagttca agaacataga amccaactat	780
acargaatat ttcttacag tggagaacct acttatctgg gaaaatggaaac atctgtttt	840
gggccaacag gaaacaagac tcttggttt gccataaaaa gattttatta ccccttcaaa	900
ccacatttgc caactaaaga atttctgtt agtctcttc aaatttttga tgcagtgtt	960
gtgcacaac agttcttattt gtttataat ttgaatatt ggttttacc tatggaaattc	1020
ccttttatta aaataacata tgaagaaaatc ctttaccta tcagaaacaa aacactctt	1080
ggtttataaa acacccataat tctactgttc tttttctcc aatcaccacg atctgtttt	1140
caggggggtga ttttactttt gtgaatttct tagcctttt tccttggtgc ataaaagttaa	1200
aatgcacatc agcagaatttgc tgcataatc acatctcagg actcttcttct tggaaaga	1260
ctgaaatttgc tactatatttgc gccaaggatgatgatgttgcgttggatgttttgcgttggat	1320
gagcctttgt taatatggat aattatggat catatcgat atgtaggacc tttggacc	1380
gggtcctaca gatagatatg gtgtggccag atttaaaaaa taccttcaaa aaaaaaaaaat	1440
acattcagtg acattttcat ggtggggagct cttttttctg atatggcgt tacactttt	1500
cacttaatgt cttagtttgc agactaactt tacaacttctt ataaattttgc ggaaccnagt	1560
ttagtataatgt ctgattacat tccattcacc taactttagg cattcggtt agacaccata	1620
actgggrgkgr atkgkgytc cyagratgtg ggccaaatccc agtgggttaac accatatttgc	1680
tgggctggng attttgggaa ctatcttaggt aaacgggctt ggtggttcnt ttaancatac	1740
ntaaccacca c	1751

<210> 27
<211> 1212
<212> DNA
<213> Homo sapiens

<400> 27

gccaagcttg	gcacgargtt	ggtggcggcg	tccggagggtg	ctggtttgtt	ctcggtgaac	60
ggcgcgcggg	gtctctcccg	agtgcgagct	acgggacctt	cggcatgccg	ggatggtagc	120
tcttcggccg	gcgctggccc	atcgccagcg	acgacttggt	cttcccaggg	ttcttcgagc	180
tggtcgtgcg	agtgcgtgtt	tggattggca	ttctgacgtt	gtatctcatg	cacagagaa	240
agctggactg	tgctgggttga	gccttgccta	gcagttactt	gatgtcctc	atgattctcc	300
tggcagttgt	catatgtact	gtgtcagcca	tcatgtgtt	cagcatgaga	ggaacgattt	360
gttaaccctgg	accgcggaag	tctatgtcta	agctgttta	catccgcctg	gcgctgtttt	420
ttccagagat	ggtctggccc	tctctggggg	ctgcctgggt	ggcagatggt	tttcagtgcg	480
acaggacagt	tgttaaacggc	atcatcgcaa	ccgtcgtgtt	cagttggatc	atcatcgctg	540
ccacagtggt	ttccattatac	attgtctttt	acccttctgg	ggggaaaatg	gctccatatt	600
cctctgcggg	ccccagccac	ctggatagtc	atgattcaag	ccagttactt	aatggccctca	660
agacagcagc	tacaagcgtg	tggaaaccca	aatcaagct	cttgtgtgt	tgcattggaa	720
aagacgacca	tactcgggtt	gcttytctga	gtacggcaga	gcttttctca	acctactttt	780
cagacacaga	tctggtgcctt	agcgcacattt	cgccggccct	cgccctgttt	catcagcaac	840
aggacaatat	caggaacaac	caagacactgc	ccaggtggtc	tgccatgccc	cagggagctc	900
ccaggaagct	gatctggatg	cagaattaga	aaactgccc	cattacatgc	agtttgcagc	960
agcggccat	gggtggscccc	tctacatcta	cagaaaccccc	ctcacggggc	tgtcaggay	1020
tggtggtgac	tgaaatttagc	tggacatggt	tgcacacacc	tgttaatcaca	gctactcggg	1080
aggttgaggc	gggagaatcg	cttgaaccag	ggagttggag	gttcagtga	gtggagatca	1140
caccattggcc	ctgcagcccta	agcaacagag	caagattctg	tctcaaaaaaa	aaaaaaaaaa	1200
aaaaaaactcg	ag					1212

<210> 28
<211> 1112
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1105)
<223> n equals a,t,g, or c

<400> 28

ggcacgagca	aacatccagg	agtgtgcacc	ggtcatgcaa	ggtgtttgt	ttggctttgt	60
ctggcttttt	agtttttgt	ggcaggagaa	taaatctagt	gcctctccct	ccacattagc	120
caaaagtgg	agtccctgtc	cagtcagcat	tccttgatg	cctgggttat	tagtccgttt	180
tttcacactg	ctataataaa	aagaactgccc	caagactggg	taactaataa	aggaaaagg	240
tttaattgac	tcacacttct	gcatgtttgg	gaggccttag	gaaagttaca	atcaggcaga	300
aggtgaagt	cgttcgtctt	aatggcggca	ggtgagacag	tgttaggtt	aaactgtcaa	360
acacttataa	aaccatcata	gctcatgaga	cctcattcac	tgtcacgaga	acagcatggg	420
ggaaccggcc	ccatgatcta	atcacctccc	actaggtecc	tcctccacc	tgtggggatt	480
atgaggatta	caattcaaga	tgagattttg	gcaggggcac	cgagccaaac	catacacct	540
tatatgtgcc	cagtgttgac	ctaggcgttg	ggatgcagaa	acaaaacacga	catgggctgt	600
gccttgggg	gctcacactc	ttgtggaga	agcatgtga	tccctaaata	agaaatgta	660
tgtgctgtt	acagagtacc	atgaaaggca	ggatgaactc	tttgggagga	agaagcaagg	720
aaagctttag	agagttgtcg	gtttttgagg	gatggagcag	gcattttcta	catggggaaa	780
gtgttaggaaa	gagtattcca	ggcagagtgg	agagcaagag	caaaggcgg	gaagcctgtg	840

ctgcgaattc cttgccggc aggatccctg tcttactgct gtttagagat caatatatgt	900
caagtgactg gaagtgtgg ttttgtctg ggacttagtag gtagaacaga aagagttgg	960
atggagttag caaccatgg agaaatagag gctcggttc agctgataca aggcttgta	1020
taccaagctg aggagcacaa gatttggAAC ataataccaa atgctgggg gccatggag	1080
ggccatggga gctctgatag tttntctcg ag	1112

<210> 29
<211> 748
<212> DNA
<213> Homo sapiens

<400> 29	
ggcacgagcg aaactgtttt ccaatgtggc tgaaccactc tgcatTTCCA ccagtaatga	60
gaatgagagt tgctgttgc ccacggcctc accagcattt ggtgggtgtca gtgtcttgg	120
tttttagccat cctaataagt gtttagtggct atcattgttt tcatttgcaa ttctcttaca	180
tgggtkgaa catcttccc catgtttatt tgtcatctgc atatcttctt cggccagtt	240
tctgttcaga tcttttgc cttttttgtt gcttgcattgt ttgtttgtgt ttgatTTTT	300
aaagaaaagct ttttttatta ttgagttgtat atagtgttgc tatagtgtgg ataacagttc	360
tctatcagat aggttttttgc caaatatttt ccccaatctg tggactgtct tctcattttt	420
ttgataaaatgt gctttaaaat aataatctgg ccgggcgcag tggctcatgc ctgtatTTCC	480
agcactttgg gaggccaagg gcagatcatc tgaggtcggg agttcgagac cagcctgacc	540
aacatggaga aaccccatct ctactaaaaa tataaaattt gtccccgtg gaggcacatg	600
cctgtatTTCC cagctacttgc agaggcttag acaggagaat ctcttgcacc cgggagggtgg	660
aggttgcagt gagccaaat cgtccactg tattccagcc tggacaataa gagcaaaaact	720
ccatctcaaa aaaaaaaaaa aactcgag	748

<210> 30
<211> 778
<212> DNA
<213> Homo sapiens

<400> 30	
ggaactaaaa agctttgtgt tttcagggt ggggtggcagg gggatatagt gagggtggac	60
cagggagaat gaccataggg cactaagtaa ggctgggatt ggatcagcag aaatccaacc	120
ctctaacctt agggtaggga gtgctaagga tctggggaaa ccatggctg ggaagctgt	180
cttgctctcc tcgtgtctgc tgtttttttc cttgggtgtc ctatacagag gccagatgtt	240
ggcaccacctt ctccaggagg attggaaagg aggagtaaag gattctgatt tgattgtga	300
ttccagtgc tccccatcc caccatcttta cctggaaat aagctgcct tgcattttttt	360
ttctgagcac aagtctgtgc gtaatgcac tgactctttt actttttttt tagtaactga	420
tcatttccca gacaaccaag attctcaata agtcccagtc tcatacacaat tattatattt	480
tccttttccct cataccaact tgactatgtt tcactggaaac ccacaggtct tgggacagaa	540
tgaggcatta cctcattgaa ctttagctgc ctgcattgtgtt cctctgtcct caagtcttcc	600
tcagatcatt tctcaagctg gctcccagct tagggcaaag agaatctcca tgatgtgt	660
acttcttagct tgccacagac acaattctac tccaaagtca gcctggcata gtaacattga	720
tgtcaggggaa gacatatcg tttgaggcata tacaaaaaaa aaaaaaaaaa aactcgag	778

<210> 31
<211> 1324
<212> DNA
<213> Homo sapiens

<400> 31

acgagctaat gattttgt	gaagatggcc agagtaatca gagtaattaa	tttggggat	60
ggtgaaggat aaggAACCTG	atcagatATC aagggtgggg	gtactcttgc taaACTGA	120
cagttagggTC	cttgctaaaa ctggTTTTA	caagagAGAG cacAGGTAGG	180
gattcGGGAG	actgactAAA gtttcatCAA	gaatCTTGT caggAGACAT	240
atacttaAGT	ttttttttt atgcggTTT	gttttaaaca ggtaatAGC	300
gctaaaATCC	atgcattCA	tgcacacaat ggctggatCC	360
aagatGGGAA	agtatttCTC	ccaaatCTAA tcttggcta	420
aggtAAAATT	atTTTACAT ttgaaATTAT	gtttacatt gcttgcTCT atgatAGGGT	480
ttcaAAAGGT	attgtAAAGT ttcatTTGT	aaaatCTGGT ttttttttCTT	540
taaaAGTAAGC	attgattCTT	tggctgtcAG atagcactAC	600
ccccCTCAGT	gtcccCTCCC	agaATAACT gcctctCCAT	660
tagggAAACA	ccacttAAAAA	aaaaatATG ccctacaACA	720
tgacttttTA	ataaAGAGGT	gcaaggGGCA gaagtGGAAG	780
caagAGCCTG	gggttgAGAG	ggatTTTCT	840
gtaactcATT	caactAGGGA	gcaagtCTAG tattatATAG	900
cagtagTAGT	atattaACCA	aataAGAGCA	960
tcttAAAC	agatactGC	caagAGCCTG gagattAAAT	1020
ctattgttAT	cttagtCCTG	cttagttaACA	1080
acttAAATC	acttAAACCA	tttctgtgt	1140
atagGAAGAA	ttgtgaggAT	tatctataAA atggAAATTA	1200
aaatatttAA	tatAGAGTT	tgagatAGTA	1260
tataatCCTT	ttgtgaggAT	tatgtAAAGT	1320
aaaa	tttgcatttTA	tttgcatttTA	1324

<210> 32
<211> 739
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (732)
<223> n equals a,t,g, or c

<400> 32

ggcacAGGAGA	caggatCCTG	gtttgggtac	cttagttAA	tagAAACCCA	ggtgAAACC	60
tagattGAG	ggcattttgtt	tgagactatt	tagccacAGC	aggcAAAGCA	ggaAGATCA	120
gcctgtCACT	gtctactCCT	tagtattAA	actgtcaAAAC	atgggAGGTA	actgctgtATG	180
catttttCAG	ttgatAGTT	atatacttC	tctgaaggAT	cctaATGATA	gttaaccATT	240
tctcattttt	attttGCTGG	attgttttCT	gttttttGCT	tcagcattCT	tgcttttGCT	300
gtgcttactt	ttggagTTT	gattccCTGT	gtcactgttt	tcttCGCAT	acacCTCTCA	360
ggtttACACA	gtaaACAATG	tgaatgtGAT	cacAAATA	cgcacAGAAC	atctgaccGA	420
ggaggAAAAA	aagAGATATA	aaggtaatCA	ccaccACCC	cccacCTCCT	gttttGTTGT	480
tatTTTTAA	gcctAGAGGG	aactctttGT	tggctctGTT	aagtTTAGGG	ttaatgtGAT	540
tgggttGtG	taagcctaAC	cctaacttCT	wctctctc	tctctttttt	tttttttttG	600
aggcaaAGTC	tcGCCCTGTC	acccaggCTG	gagtgcAGTG	gcacGACCTT	ggctcactGC	660
aacctCTGCC	tcctgaggCA	ggagaATCAC	ttgaacctGG	caggcGGAGG	ttttggTGTAG	720
ctgaggTCGT	gnCATTGCA					739

<210> 33
<211> 1462
<212> DNA
<213> Homo sapiens

<400> 33

ggccatggc	ggggcagtcg	cgggatgcgc	ccgggagcca	cagcctgagc	tttagcccat	60
gaggaggatg	tgaccgggac	tgagtcagga	gccctctga	agcatggaga	ctgtgggtat	120
tgttgcata	ggtgtgtctgg	ccaccatctt	tctggcttcg	tttgcagcc	tgggtctgt	180
ttcaggcag	cgctactgccc	ggccgcgaga	cctgctcag	cgctatgatt	ctaagcccat	240
tgtggacccat	attgggtcca	tggagaccca	gtctgagccc	tctgagttag	aactggacga	300
tgtcgccat	accAACCCCC	acattgaggc	cattctggag	aataaagact	ggatcgaaga	360
tgcctcggtt	ctcatgtccc	actgcattgc	catcttgaag	atttgcaca	ctctgacaga	420
gaagcttgg	gccatgacaa	tgggctctgg	ggccaaagatg	aagacttcag	ccagtgtcag	480
cgacatcatt	gtggggcca	agcggatcag	ccccagggtg	gatgatgtt	tgaagtgcgt	540
gtaccctccg	ttggacccca	aactcctgga	cgcacggacg	actgcctgc	tcctgtctgt	600
cagtcacccgt	gtgctgtgt	caaggaatgc	ctgcccattgc	acgggaggcc	tggactggat	660
tgaccagtc	ctgtcggtct	ctgaggagca	tttggaaatgc	cttcgagaag	cageccctagc	720
ttctgagcca	gataaaggcc	tcccaggccc	tgaaggcttc	ctgcaggagc	agtctgcaat	780
tttagtgcct	caggccagca	gttagccat	aaggccccgt	ccgcctatccc	tggatggctc	840
agcttagct	tctactttt	cctatagagt	tagttttct	ccayggctgg	agagttcagc	900
tgtgtgtgca	tagtaaagca	ggagatcccc	gtcagtttat	gccttttttgc	cagttgc当地	960
ctgtggctgg	tgagtgccag	tctaatacta	cagttgggg	agatgcatt	cactctctgc	1020
aagaggagta	ttgaaaactg	gtggactgtc	agctttttt	agtcaccta	gtgtttcaa	1080
aaaaattggag	ccaccgtcta	agaaatcaag	aggtttcaca	ttaaaaattag	aatttctggc	1140
ctctctcgat	cggtcagaat	gtgtggcaat	tctgatctgc	atttcagaa	gaggacaatc	1200
aattgaaaact	aagttaggggt	ttcttctttt	ggcaagactt	gtactcttc	acctggccctg	1260
tttcattttat	ttgttattatc	tgccctggtcc	ctgaggccgtc	tgggtctctc	ctctcccttg	1320
caggtttggg	tttgaagctg	aggaactaca	aagttgatga	tttctttttt	atctttatgc	1380
ctgcaatttt	acctagctac	cactaggtgg	atagtaaatt	tatactttag	tttccctcaa	1440
aaaaaaaaaaa	aaaaaactcg	ag				1462

<210> 34

<211> 2815

<212> DNA

<213> Homo sapiens

<400> 34

gggtcctgga	gtgccctcggt	ctgatagaga	ctatagttcg	agagttcttg	cccaccagtt	60
ggtcctctgt	gggggcaggg	cctaccctta	gtctatacaa	agtaccctgt	gtctactgc	120
tgaaactact	tcgtgtccgt	gcctcagtcg	ggaggaat	tgctgcccgg	ctgttgagca	180
gtcttgcata	ccggagccgc	ctgtggccca	tcatagctga	ggctccccaa	gaactggcct	240
tgcctccaga	ggaagctgag	atgttgagca	ccgaggccct	ccgtctgtgg	gtgtggctg	300
cctcctatgg	ccaggccgtt	tacccatata	gggagctcta	cccagtgc	atgcgggcct	360
tgcagggtgt	cccgccggag	ctcagcaccc	accacccatca	accctgtcc	atgcagcga	420
tagcctca	gtcactctc	ctcacccaggc	taaccctggc	agccggcagt	accctgtctg	480
aaaccatca	tgattctgt	gaggccagcc	tctggccac	cccttcctta	gtcacttgg	540
cacaggtgtc	tgggctccag	ccttgcgtt	agccgtgtct	aaggcagacc	ttgaagttgc	600
tgtccagacc	tgagatgtgg	agagccgtgg	gcccaagtgc	cgttgcctgc	ctgttgc当地	660
tgggagccca	ctaccaggcc	tggagccagc	aaccaagctc	atgcccggag	gattggctcc	720
aggacatgga	gcgcctgtca	gagagctgt	gctgccactg	ctgagtcagc	ccacactgg	780
cagcctgtgg	gattccctta	ggcactgctc	ccttctctgc	aaccgcgtgt	cctgtgtgcc	840
agcccttggaa	gctcccccca	gcctcggtc	actgggtgc	tcgggaggct	gcccccgct	900
cagtctggct	ggctcagcc	cacccttccc	attcctact	gccttcctct	cttttcttaa	960
taccctggcc	cagatccaca	aggggctgt	tggccagctg	gtgcctat	tggctgccc	1020
gggactccag	aattacttcc	tccagtgtgt	ggctcctggg	gtgcctccac	acctcacacc	1080
tttctctgca	tggccctgc	gccatgagta	ccacctgcag	tacctggcac	tcgcctgc	1140
ccagaaagcg	gcagcgctc	agccactgcc	agccaccat	gtgcctct	atcatggat	1200

ggccttgcc	ctgtcgagcc	ggctgctgcc	cggaaagttag	tacctcaccc	atgagactgct	1260
gctgaggctgt	gtattccggc	tgaggatccct	ccccggaaaaga	acatcaggggg	gtccagaggc	1320
agccgacttc	tctgaccagec	tgtcgtttag	aagcagcaga	gtccctcggt	gtgggcgaaagg	1380
gactctgtc	gctcaggcct	gccaggaccc	ccccagcatc	cgcaactgtct	acctgactca	1440
ttgctcgcca	gccccgagcca	gtctgctggc	ctcccaggct	ctgcaccggag	gggagactaca	1500
gcgagtccta	accctgtac	tgccccatgcc	tacggagccg	ctgctgccc	ccgactggcc	1560
cttcctgcac	tgattcgct	ctacaccggg	cttcagacac	ccctctggga	ctctctccac	1620
agacaccatg	ggcacagcca	tgccccgttcc	gcagtgggtg	ctagttttgg	agagctggcg	1680
cccccagggct	ctctgggctg	tgccccctgc	tgccccctg	gcacggctca	tgtgtgtgtt	1740
cctgggtggac	agtgagctgt	tccggggagtc	cccagtacag	catctgggtgg	cagccctct	1800
cgccccagtc	tgtcagccctc	aagtcttgc	aaacctcaac	ctggactgccc	gactccctgg	1860
cctgacgtct	ttccctgacc	tctatgcca	cttcctggat	cattttgagg	ctgtctcttt	1920
tggggaccac	ctctttgggg	ccctgggtcc	cctggccctg	cagcgtcggt	tcagtgtcac	1980
cttgcgcctt	gccctctttg	gggaacacgt	gggagcctt	cgagctctga	gcctgcctct	2040
gaccgcgtt	cctgtgtccc	tggagtgtta	cacagtgcct	cctgaagaca	acctggccct	2100
ccttcagctc	tacttccgg	ccctgggtac	tggtgcgtc	cgcccacgtt	gggtccccgt	2160
gctataatgt	gtggctgtgg	ctcatgtcaa	tagtttcatc	ttctctcagg	acccacagag	2220
ctcagatgg	gtcaaaagctg	cccgaggag	tatgctgcag	aaaacatggc	tgctggcaga	2280
tgaggggttc	cggcagcacc	tcctgcacta	taagtttccc	aattccacgc	tcccagagg	2340
ctttgagetc	tatttctcagt	tgccccctct	gcgtcagcac	tacccctccaga	gactgacttc	2400
aacagtgtc	aaaaatgggg	tatcagagac	ctaggatagt	tgatataat	ggaaagatgg	2460
gtacgttgtc	ctgttatccag	cctttcaaca	gatgtctggc	cagacgaaga	acattgtgtc	2520
ctaattggtag	gcaggagacc	aaggagcaga	aggcttgcct	tcctgggagc	aggttggttt	2580
agctgtttt	gagcagttag	cccttaccatt	acatccgtat	atctggggct	tctgaaggc	2640
tgtgctggga	gtgaagagtg	gtttagctat	ttacccgctc	tttggggaca	gggcaaaacta	2700
aatgcatccc	ttcttaccta	actcccaacc	cctgcctgg	gctgaggcat	atgaatgtca	2760
tagttgtca	ttaaaaataaa	tgttttttat	cttcctggaaa	aaaaaaaaaa	aaaaaa	2815

<210> 35

<211> 1078

<212> DNA

<213> Homo sapiens

<400> 35

ggggggctct	gtgcgtgggt	ccttcctcac	cttcccaggc	ctgcggcgtgg	cccagaccca	60
ccgggacgca	ctgaccatgt	cgaggagacag	accatgtcg	cagtccctcc	tgcacacccag	120
cttcctgtct	ccccgttca	tcctgtggct	ctggacaaag	cccatgtcac	gggacttct	180
gcaccaggcg	cggtttgggg	agacgcgttt	ctccctgtcg	tccgattctg	cttcgactc	240
tggggcgcctc	tgggtgctgg	tggtgctgtg	cctgctgcccgg	ctggcgggtga	cccgggccca	300
cctgcaggcc	tacctgtgcc	tggccaagggc	ccggggtggag	cagctgcgaa	gggagggtcg	360
ccgcacatgaa	gccccgtaaaa	tccagcagaa	ggtgggtccga	gtctactgtct	atgtgaccgt	420
ggtgagaccc	cagtacactga	cgccgctcat	cctcaccctc	aactgcacac	ttctgctcaa	480
gacgctggga	ggctattccct	ggggcytgggg	cccagctccct	ctactatccc	cccgacccat	540
cctcagccag	cgctggccccc	atcggtctcg	gggaggacga	agtccagcag	actgcagcgc	600
ggattgcccc	ggcyctgggt	ggcgtctta	ctcccccctt	cctccgtggc	gtctctggct	660
accccrctcg	gtggacggct	gcctgccagc	tgcgtccag	ccttttcggc	ctctacttcc	720
accagcacct	ggcaggctcc	tagctgcctg	cagaccctcc	tggggccctg	aggtgtgttc	780
ctggggcagc	gggacactag	cctggccccc	ctgtttgcgc	ccccgtgtcc	ccagctgcaa	840
ggtggggccg	gactccccgg	cgttcccttc	accacagtgc	ctgaccggcg	gcccccccttg	900
gacgcccggagt	ttctgcctca	gaactgtctc	tcctggggcc	agcagcatga	gggtccccgag	960
gccattgtct	ccgaagcgta	tgtgccagggt	ttgagttggcr	agggtgtatgc	tggctgctct	1020
tctgaacaaa	taaaggagca	tgccgatttt	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1078

<210> 36
<211> 1217
<212> DNA
<213> Homo sapiens

<400> 36

cggcacgagg ttgaatgtta	gccctggagg agatccatgt	cttactcgct ctttctggcc	60
cttctgtctt ttgcctctgc	aattcttttt gtagctggca	cgatagcagg gactgggggt	120
ctatccttc atggatttgc	tacaatattt gtccttactg	gaaaatggta acatccgggt	180
ctgatttaat tggcattaca	cttacacagg gactctgagc	acccccgtca ccacaccaga	240
cagtggacca gttttcacag	ctacaaagag cttagaaatgt	gtttaacatc atccagtgca	300
tccccctaatt caaaaccatc	ctcactaattc aatcatattc	accctaaaaat attacaaaatg	360
agattgattc catctcaaga	caatttgtca aatacttaat	tttcttcttg gatgattcta	420
cttactggat attttagaaa	gagaaatgtc tgagataaaa	tccctcacat ttactcaata	480
taacaaatta ctgtttctac	tccttattctg agtagtgctt	ctgaagattg tttgctgttag	540
tgttgtctt gataaaatga	atgtcagtag tgagcccttt	agagatacca tgctcagaaa	600
tcctcttgg gatcagaaga	tacctaaaaat tctcccttt	tgcccacttg gtttagatgag	660
tgatataat tttggatect	gaaaaagaaga gattgggttc	ttttcttttc tggtggtggt	720
agtgggttta tctgtggctg	tgatgggttgc ttgttacttgc	ttttctctct ctctggctct	780
ggcttttgc ttccctgttag	tgttctttctcttccaaac	aaatagttaa attaaacgtg	840
agcttctgaa ttgtacttgc	tcatactttc aaaacataac	agattaataa aaatagatgt	900
gtcctgattt aaaaacatgcc	ccctggaaag gcatgtgtt	ttatgaaatc atgataatat	960
aactgcattt ttacatggca	gtataaaatat tagtctgttgc	aattcatttg tccaattgtt	1020
taactttgtg gagcagtgtt	ttgacctttg atacataatt	ctggagcaag tggagtggtt	1080
gcaggcagat gagacagtgt	tatatcagga ttttcaatc	aacttttagtt ggaggcctgg	1140
caattacaaa catcttcaga	tgtttctgtt accattataa	atatgaaaaa aacctttca	1200
aaaaaaaaaaa aaaaaaaaaa			1217

<210> 37
<211> 1282
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (153)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1220)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1222)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1232)
<223> n equals a,t,g, or c

<220>

<221> SITE
 <222> (1246)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1282)
 <223> n equals a,t,g, or c

<400> 37

actcgtgccg aattcggcac gagccattct gagtttggtc ccttcccaaa agtaggggtt	60
tttgttgaa aatctgagca aacctcttt gactttctg gggtgaggatg aaggagaar	120
gggctcagct aaagaacatg gggagattag ggnaacaatg ccttttattt ctgccttta	180
aagcaatttc aggagtttc ttccctttt ggctccctgc tgactccaca gagcgaaaca	240
cccaaagctg ggactttcca cctcttaat gctcagtgaa gagcgggcca ggggggtgtg	300
gaaaagaaaag ggtcctggag gagcccaaat tacgaatggc tagagactgg cattggcaag	360
cgaggaggct tcgtcacagt gtatgtttcc ggttgcggc gggtaactgtc ccaggggctg	420
gggggtrttc cgtcttctgc agatcaactc ccgcaggcta aatgtggaca tcgcggatc	480
atgcttgata aacggaccaa taatcaagtg gagattcatt agaaccacat aaccctact	540
aggttgatt ctcaagtata agscctggc tggcccag sctggagtgc actgacacca	600
tcatggttca ctgcagcctc aaactcctga gcccaagtga tycctccac tcagcctcac	660
aagtagctaa gactagaggt gtgcaccatc amaccagct aatttttaaa gtttttttg	720
tararatggg gtcccactct acaaaaatatw taagtataag gcckggctcg ttgcccargc	780
tgggsaaccct tggactaag gcaatcctcc agcctcagcc tcctaaagtg ctgggattac	840
aggcgtgagc caccgcaccc acctcttagga tctctactat tgaggaaaaaa ttggaggcat	900
caaactccaa gggaaaaaca tgaagactcg ctggccacc atggatggag gttttctc	960
ttaaaattcc cacagcaccg catggactg cctctcttgg gacctcagcg ttcccttctt	1020
tgctctaagc aatacgctct gccactggag attctgagat ggccgatttc cttttggata	1080
tttaagttt gaaatcatgc tcatttggca taggaatgtt tcacttcagt tcctttaaa	1140
caaaaaggaca cacaaccacg attgccccctc cctcccaag ggtcactggc cttcatgcat	1200
cagtaatgtt tccaaaaatn nttaagtac cnacatgcag tggccngctt ttcattttc	1260
caagtgaagc catcagaaaa an	1282

<210> 38
 <211> 559
 <212> DNA
 <213> Homo sapiens

<400> 38

gattcggcac gagctgaagc cctgggtgcc actgctggcc cagcaggag gaggttgtcg	60
ctgctcgggc tgaagtgagg tggggctcg gctggccctc cagtttccca cctggccctt	120
gattgtgagg aaggcctggc ctggctcgag aagcccgaaa gcacctgagt aggagatcc	180
ctttgcctca cctgcagctc attcaagctt gtgcattggg gttgggtcc tcaggatctt	240
gcttcctgt ttagggagg cagccccaaa gagtgctggg accagtttg agagtctaa	300
ggaatgtgg tctgcagcga ccctacttgt gctctgcgtc ctctgccaac tgcagcatgg	360
gtgaacatct gtacatctgt ccccataatg aaaatggct cagcaaataa caaaaatatt	420
accatttagc aatcaggcac ttattaaaag cctggcccaa taaacttaaa aaaaaaaaaa	480
aaaaactcga gggggggccc ggtacccaat tcgcctata gtgagtcgta ttacgcgs	540
tcamtggccg tcgtttaca	559

<210> 39
 <211> 803
 <212> DNA

<213> Homo sapiens

<400> 39

ggcagagcta	ggccaggcgag	agcctagctc	ttgccagggc	agcaggaagc	cacacagtgt	60
gttgaagccg	gagcaggaga	ggggggccctg	actccccatgt	gtcccttcgcag	gcaggaggcag	120
ttcgtggact	tgtacaagga	gtttgagcca	agcctggtca	acagcaccgt	ctacatcatg	180
gcccattggca	tccagatggc	accccttcgc	atcaattaca	aagaaggcc	tggggccctgc	240
cmaaaacattc	actgtctgcc	cacccagccc	caccccatga	agccatctgt	cccttcattccc	300
cacaggggccc	gcccttcatg	gagagcctgc	ccgagaacaa	gcccctggtg	tggagtctgg	360
cagtttcaact	cctggccatc	atggcctgc	tccttcggc	ctegccccgac	ttcaaacagcc	420
agtttggcct	cgtggacatc	cctgtggagt	tcaagcttgt	cattggccag	gtccctgcctcc	480
tggacttctg	cctggcgctc	ctggccgacc	gcgttcgtca	gttcttcctg	gggaccccccga	540
agctgaaaagt	gccttcctga	gatggcagtg	ctggtaaaaa	ctggccaccc	tggctggccgc	600
tggcgggaaa	ccccaaacagg	gccccgggag	ggaacccctgc	ccccaaacccc	ccacagcaag	660
gctgtacagt	ctcgcccttg	gaagactgag	ctgggacccc	cacagccatc	cgctggcttg	720
gccagcagaa	ccagccccaa	gccagcacct	ttggtaaaaa	aagcagcata	tgagatttt	780
aaaaaaaaaaa	aaaaaaaaactc	gag				803

<210> 40

<211> 1510

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (426)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (454)

<223> n equals a,t,g, or c

<400> 40

cacgagaaaac	attcttatctt	ttatcaaatg	tgtgattcat	aacttttgg	taccaaagg	60
atctaacgaa	ataaccataa	tcatcaatcc	atacagggag	actgtgtgt	tctctgtgg	120
gcctgtcaag	aaagatattt	actatatgtat	acatgtaat	cgaaacatca	tggatttcaa	180
actcttcctt	gtgtttgtgg	caggagtttt	tcttttcttt	tatgcaagg	ccctggagtc	240
aaagccctac	tttcttattac	tccctgggaa	ctgtgctagg	tgttctaatt	acatagtctt	300
tgtcttgctg	ttggtaaaaa	gattcatccg	aagtatacg	ccttttgggg	ctctaattgtt	360
tggttgttgg	tttgctctag	tttatattgt	atgccagg	atggaaagtc	tgaagtggct	420
gtggtnntgaa	aacagatata	atgtatcagg	ctangtctt	atagttggat	ttttcagctt	480
tgttggttgt	tacaagcatg	ggcccccctgc	acacgacagg	agcagaagtc	ttctgtatgt	540
gatgctgcga	ctccctccccc	tgttctgg	ctatgttgt	gtggctgtgc	ctcagttgc	600
ctatgcagcc	ataatccctcc	tcatgtcctc	ctggagtc	cactacccac	tgagagcatg	660
cagttatatg	aggtgaaaa	tggagcagt	gtttacatca	aaagagctgg	tggtaaaa	720
tcttacggaa	gacgagtaca	gggagcaagc	tgatgtgaa	acgaacagtg	ctctggagga	780
gctacgcccgg	gcctggcggaa	aacccgactt	tccctcatgg	ctggctgtct	ccagactcca	840
cactccttagc	aaatttgcag	attttgttct	tggaggaagc	cacttgcac	ctgaagaaat	900
cagtctgcatt	gaagagcagt	atggccttgg	gggtgccttc	ttggaaagac	agctctttaa	960
cccgagttact	gcctgacatg	cgacccctca	gttgacttca	ttctggacaa	ggaagtgggc	1020
aaagggcagg	attcttattaa	agtaggcag	aactgttcta	gtgaacggtg	gcaaaaaacat	1080
ttgctgtgaa	aaaaaacaag	tcagtctgaa	aaggaaaaacc	aaccatttt	gaagataact	1140
tagcatttt	ggtgacttct	gctacttatt	gtactgtagg	tggataccaa	aattctgtga	1200

cagccactac cacttacctt gaatgaaggg tttcatttagg aacaggggaa tggcggtt	1260
cttaaggggc tagtaagcat gaacagggtgc tttgtcgaca ccagggcaact aaatctggtc	1320
ttaatccctt gaaccgtgtc cagaagactc tgcaataactc ttcttatagt tcgtcagtat	1380
aagtccctaa agagacctga gacatgctgg accagtgttt tccaaagtac agctcacagg	1440
ctactaccaa gtgttgtca ataaaggat tctgagggtca actaagattg ataaaaaaaaa	1500
aaaaaaaaaaa	1510

<210> 41
<211> 1095
<212> DNA
<213> *Homo sapiens*

<400> 41
gcttgggtt gctatttgct tcttcaaatt ctcgttattt aaaatatttc tttcttgcac 60
cgttgattct gggatcagcc tggatgtgtc aaacactgcc tgccaggcgtt agagctcagt 120
gcatttcttc ccttttattt ctgctgtatgg gattgtctggc catgaccgggt gagaggaatc 180
aaggaaaccca ttactatgag ttctcaggat tcatcttcaa atctcaaatg atgtggtcaaa 240
ttaaacccaaa ttaaaaaacaa gctcttgcata aaagcaagtt aaaaacaagc tcttgcacctt 300
gagaagaaat gattggtatt aggaagactg ttgagctgtat actgccttc attcattctc 360
taccctgtgt cttggataca ggagcaaagt aagaaaaataa tcacagcttt attgagggct 420
ctatgagcaa ggcttgggtga ggatggaaaga gaatggagct atcagttgtat gagaacctac 480
taggtgttga gtccttacata ttcatgtgcctt attttaaaact ttctaacaac ttcatgtgtat 540
agcgttgtcc cgattttaaaa aaaaaaaaaatag atgtggaaac tgaacctggaa gaaggtgtgt 600
aattttgttcca aggttgcaca ggcaaaagggg caaaaattcag cttaaaacccc aggactgttt 660
ccacagctcc aagtyccctt tattcatggg atttgtaaaga tggagccccct gccactgttag 720
catttataac ttactttggaa gaataagatt cctgaaagta cgtttaataaa aaaaaaaaaaaaaga 780
tgtccagcta tgtacggcag ctcacgcctg taatcccagc actttgagag gcaaagggggg 840
gaggatagct tgaggtctaag agtttaagac taacctggc aacatggcaa gaccctgtct 900
ctaaaaaaaaaca aaatttagccaa gttgtgggtgg catgcacccctg tagtccaagc tactcaggag 960
gctaaagggtga gagggtcgct tgagcccagg agtttgaggc tgcaagtggc catgatggcgc 1020
ccactgcact ccagtgcaga gtgcaggcata cagaatgaga ccccatcaca aaaaaaaaaaaaaa 1080
aaaaaaaaaaac tcgag 1095

<210> 42
<211> 1162
<212> DNA
<213> *Homo sapiens*

<220>
<221> SITE
<222> (340)
<223> n equals a,t,g, or c

```

<400> 42
ggcacgagct gattcctaag gaatattcta gccaaatcat gtatctgtgg ttttagtttt 60
ctacagttagg gctgtgcgggt tgctgcctgc tttatagggc atgtggggtt atatggtata 120
tgctgttact tgggcacagc agcaccaact cattacagga tggaggggca gaacccccag 180
agcacccctg ggctcacgtg cggtagcagct gcaggagaga gctgtccccc tggttttatg 240
tttttaatta attctgtttc ctcaagattga tgattaaatt tatttttcca gcttgaccaa 300
gaaggcgctca ccataaccaga tctggggaggt ctctccctcan ctctgataga cacagagagg 360
aatctgggcc tgcttcgtggg attacacgtt tcctatttag caatgagcac accgctgtct 420
cctgtcgaga ttgaatgtgc cagtaagaaa atctttactt tttgctaaatt agcagattt 480
ttttttttgg aactgtaaatg gccattaaga gtggggagagg gccaggcaca gtggttcatg 540

```

cctgtaatcc cagcaacttgc ggagggtgtg gcacgtggat tgcttgagat caagattttg	600
agaccagcc gggcaacatg gcaaaaacccc atctctacaa aaaacacaaa aattagccag	660
gcatgttggc acgttattgt agtccccatg actcaggagg ctgaggtagg aggattgcctt	720
gagcctggga ggttggggct gcagttagtc atgatcatac cactgcactc cagcctgggt	780
gacagagcaa gactctctct ttaaaaaaagc aggagatggc caggcagtgg ctcatgcctg	840
taatcccgac actttgggag gctgaggcggt gtggatcacc tgaggtcagg agttcaagac	900
cagcctggcc aatgttgta aaccccatgt ctactaaaaa tgcaaaaatt agctgggtgt	960
ggtgacgggt gcctgtatac cttaggtactc gggacgtgtga cgtaggagaa ttgcttgaac	1020
ccaggacaca gaggttgcag tgagctgaga tcacgcact gcactccagc ctgggtgaca	1080
agagcgagac tcgggttcca aaaaaaaaaa aggagaggag gattcaacac agttgatgat	1140
gacaaaaaaaaaa aaaaaaaaaaa aa	1162

<210> 43
<211> 657
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<400> 43	
cccccccggt gntgcaggaa ttccggcacar attttacatg cttttaagtt aatgttgaa	60
aactaatcac aagcgttcc taacccaaaa aatgacatgt tgtaaaagga caataaacgt	120
tgggtcaaaa tggagcctga gtcctgggcc ctgtgcctgc ttcttttctt gggAACAGCC	180
ttgggtctacc caccactccc aaggcattct tccaaatgtg aaatccctgaa agtaagattg	240
cacccctcttc ctctccgtat caacatcggt atgatgtctc ctgtgcctc accctttgtc	300
tgcaatgtatca ctggatagga ctgggtggaaa gggagcagcc tgacagagct cccaaatgtgg	360
agaatatatggc atccctccac cstatatttga tggacgggt aaggcttaggc ctgcaggatc	420
ccttacccctg accaaagact gtgttggggc gccatttggaa aatcccgaggg ttgcaaaaga	480
atacaatctt acttgcagggt ggatattctc tatactctt tttatgtcat cttaaaaatcc	540
caaacatccc ctgggttgggt atcaattaca gttgtgtcca cttttatttt atgtactttt	600
ataaaaaaaaa aaaaactttt tggtaatata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	657

<210> 44
<211> 1155
<212> DNA
<213> Homo sapiens

<400> 44	
ggcacgagt gaaatgttaag cagaaataca gcgagggttc agaaaatact agaataggca	60
acatgctttt cctctctgtc tctatctgca catctgtttt atttcttgc ctcagcagac	120
tcaccatctc tgctccat cccgtatggt gggaaaggat gcccacccac acctccccag	180
gccatctgtt agagctccaa ccacgtggaa tgacggatc cattctgttc tctatctctg	240
ctctagtttccaa aatttctgg gggaaaatgtt cccagctcac ttcaggctcc cactcttgg	300
ccagtgggtt gcaaaatttc caagcgttagc ttctgtcaatg tcctgtctt gggtaggtg	360
aaaatgttggt gaaatattgtt gagctgttca gattcacaa gaaattatctt actattgtt	420
ggggagaatg cccaggggac agatgtttt gggtaaggaa caataacaag acactagaaa	480
ggaaaatccc aattttatcc tcctacagag tcagcatccc acacattttc cttcacagaa	540
actgacaat aatccatggg ggcagcttag cagatgggtt gaaaaaaagcg acaggctcat	600
catcagttt caacacccctt atacatcagg ctggccctt gctacctcat gcattattta	660
agcacaatgc atctccctct aattgtgtca tggctggag gagaatgtga agttctgtct	720

gtcttttagca aacatgttgc aagtactgtc tgtctgaaaa ccaaatggaa gagggtaaac	780
ttgatgatcc acttgatttt agttttagga cctggatgca taggcagatg tcagtttaca	840
aggattctgt gtactttaag gaatgttttc tgagcatgtc cagtaacaaca gacgctctgt	900
taggtagctg tagttaggt ttttgggtt taagtatgtg aagatttaaa tgtatcagct	960
cacttactca gaaaatctga ggcagtgcta gccaaaccaa atggttcaag caaatgtcat	1020
cagtatttgg cctttccag tcttttact cctctatcct ctgtgtctgc ttcaattcta	1080
cacaagctt ctctatgtgg tggctccaga ttttatatct tctagtagat atttttttaa	1140
aaaaaaaaaaaa aaaaa	1155

<210> 45
<211> 1112
<212> DNA
<213> Homo sapiens

<400> 45	
gccggaggaa gagcgtctgc aaaactgggt tcctagaagt atagacggac ttagctttw	60
gtagaattt gtgaggagca gcgcctcggt agagcagaat ggctggcggt ggccagtgtct	120
tcccgccagc acgcagctct gcggccctcca gaattccccct gttctgagct tgatgcccct	180
agccgttccc ctaccctactt cctcccccctcc tctctagccc tctcacaggg gtattgtcta	240
cctctctgtt ttcttggcc taggcaagtt ttagaggagt tcccaagcat tgttatgagg	300
ccagtggtct cgctgggctg ggccggatgg cctgggcttg tgggtggcct gagggctctc	360
ctggggcctt ctctttcccc agtcacccctt ggagccacag aagcagtgtca ctcattggat	420
gtctgttctt aacacagctt ctcttctac attaaaaaaaa atcattattt cattttggaa	480
agcagtgtctc atcaaaaagca actttttaaa cctattttat tggcccttta aatgttctct	540
cccgctgaaa ctgccttggaa gaggctatct gctgcttcc catttaccca catcaggta	600
ttctccatgt cactcagtgg agatgactcc agatgtgtt aaagmctgga caattcacct	660
atactgttta gggaaattacc tccttaatta cctggtmga ttgtcagcag acatgttcat	720
ccgatgatag tactgcagtt ttcttattat aatttgcaga ctttatcta acctgcactc	780
atgtacagat tattaaaaagt tttaaaatgt aactgatcag tattgatcaa tcattgtctt	840
gattttttt tacagcgtat atttctaattt atattttta aagccaagag aactgggttga	900
atgaatgtt attttcctga aggtatttt aagataaaagc ttccataatgg cgtgtaaact	960
ttgcataatgt atgtatgtt atacatattt tcacatttga aaatcttgc ggttgcact	1020
ggtttatac aaaatatcga atagtggaaa ttgtataatt acaatcatgt aattaaaagt	1080
attaacccaa aaaaaaaaaaaa aaaaaaytcg ag	1112

<210> 46
<211> 4023
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1049)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2758)
<223> n equals a,t,g, or c

<400> 46	
cccaacgcgtc cgtccaaaca tcaggaggca ggcagcatgg taaatgagaa agaagccagg	60
actggggatgc caaagtccctg gcttctatgt ctggctttgc tactaatcaa atatgtgact	120

ttttgc	aaac catac	tcac taaac	catt ttctt	tgagcgtgtt ggacc	180
ccccag	aa cccc	tttgc	tttgc a	aggcaagga taagt	240
aaggagg	taa aagg	atgc	atgc a	tttgc acaca	300
cagaaga	ac aagg	atct	atct a	tttgc caggacat	360
cccttg	gg tggt	gtt	gtt a	tttgc gcac	420
atctat	cacc tacc	tttgc	tttgc gcat	tttgc ccatt	480
tttctt	tttctt	tttgc	tttgc ggag	tttgc ttttgc	540
gcagtgg	gc gatc	tttgc	tttgc cact	tttgc aact	600
gcctcag	ccct cccg	tttgc	tttgc aagg	tttgc ccatt	660
tctat	tttta tttt	tttgc	tttgc tttt	tttgc atct	720
gttagag	ac ag gttt	tttgc	tttgc cacc	tttgc gatgtt	780
gtggatcc	gc ccc	tttgc	tttgc ggct	tttgc tacgg	840
cccggctac	tttgc agt	tttgc	tttgc cact	tttgc caact	900
caaccctaa	tttgc tata	tttgc	tttgc ctat	tttgc aaatt	960
ctcaagat	gtttaa aact	tttgc	tttgc gatg	tttgc gatgtt	1020
gggagaat	at tagt	tttgc	tttgc ttct	tttgc aactt	1080
tttactttc	tttgc aggccat	tttgc	tttgc gttt	tttgc aactt	1140
acttctgata	tttgc tttt	tttgc	tttgc tagt	tttgc ttttgc	1200
ctgaaatgt	tttgc gttt	tttgc	tttgc attt	tttgc atcaa	1260
attactctaa	tttgc taaa	tttgc	tttgc tttt	tttgc attt	1320
aaagttaggc	tttgc accatt	tttgc	tttgc atct	tttgc gttt	1380
attgtctattc	tttgc atcc	tttgc	tttgc aactt	tttgc tgagg	1440
tcatttagaa	tttgc tgac	tttgc	tttgc tcat	tttgc gacac	1500
aaattaagac	tttgc caact	tttgc	tttgc aact	tttgc gttt	1560
atgttttta	tttgc gtct	tttgc	tttgc gggt	tttgc aacca	1620
aggccaaact	tttgc atgc	tttgc	tttgc tggc	tttgc gaccc	1680
catccctccc	tttgc ttca	tttgc	tttgc tttt	tttgc ctata	1740
tttcttcc	tttgc acta	tttgc	tttgc tttt	tttgc ttct	1800
tttcttcc	tttgc tttt	tttgc	tttgc tttt	tttgc ttct	1860
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	1920
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	1980
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2040
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2100
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2160
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2220
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2280
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2340
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2400
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2460
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2520
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2580
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2640
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2700
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2760
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2820
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2880
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	2940
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3000
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3060
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3120
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3180
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3240
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3300
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3360
tttcttcc	tttgc attt	tttgc	tttgc tttt	tttgc ttct	3420

aaaaaaaaactg	aaaagaaccc	tttgaagtta	gacaaactgt	ccagagacat	agtgctaaaa	3480
tcctccytct	ttttcttycc	acagcttcta	gaattcctct	ccagagctac	tctcaaggta	3540
tatccaggg	acaggcccct	ttggctccaa	cccacacgcc	tgaactttaa	ggatcattgg	3600
actatcttct	ctgtggccar	cgcagctctc	ttctgttgc	acagaatggc	catgataggc	3660
atgcttttt	cccacccact	ggaaggctca	caggcaaggt	gagagaggac	acagaaggtg	3720
ccaacactgt	cgctacagta	aggacctgaa	gtgacttga	gaaattcacc	ctcacaaaacc	3780
ttccttcagg	agcaggcatt	gttagtgcag	aggcacagat	tccgtcctt	accagctgca	3840
gaatcttggg	caagttacat	agcctctgt	agcctcatcg	gtaaacagtg	ggggttatga	3900
aacccaccc	acagggttgt	tgtgaggatc	caatgagttg	atttaggtaa	gcacctagca	3960
catgccgtgg	caccaagtaa	gcactcaata	aatcactcaa	ctccttaaa	aaaaaaaaaa	4020
aaa						4023

<210> 47

<211> 542

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (389)

<223> n equals a,t,g, or c

<400> 47

agggcacgag	ttttttatg	actacataat	gtttattgcg	atctatTTTA	aggctttca	60
tggatcttt	cagctatgca	catggttagt	cataatgatt	gtcattttag	gtcagagttt	120
ctcagcctt	gcattgtga	cattttgggt	aattcttgt	tgttagggct	gtcctgtaca	180
ctgttaggggt	tttagcagca	tccctgatct	ctacctacta	aatGCCAGGA	gcaacacagt	240
acctccagct	cagtgtgac	aactactgaa	tgtctccaga	caactactga	atgtctccag	300
acattgcaga	gaaattgagt	ctgggtgaga	agtcactgtt	ttagggcata	atTTTTGGGT	360
agactgttag	attctttgt	tgcgttgtn	ctggcctgt	taactcttct	taatttatctg	420
ctactcaa	atgtttggga	tcaGCCACTG	tcttccattt	ctctttgtct	cacagatcta	480
ctccacagct	cttctccctt	caaacactgt	tcctcagcat	cttggTTTTT	gcagccaaac	540
at						542

<210> 48

<211> 1495

<212> DNA

<213> Homo sapiens

<400> 48

cgccacgagg	ctacttat	tttatgaagg	acatTTTTG	ttagatgatc	tcatcctctg	60
tgttatttt	tgttgggtt	tgtttttgc	ttgttgggtt	gtttgtttct	tccatgtaa	120
aaaaagtagt	gtaaagcagta	ggaagaaaat	gaggaagatg	tatTTGcat	gttcttcctt	180
tcaatgttct	tacacattgt	attactgat	tgtggtaata	gcttctataa	aatctgccc	240
agctgggatt	atgcagctt	gcaagaatct	actagattt	attcttaactc	atattagctt	300
gtccttatcaa	cttctggaa	tatctaatta	ttgctttaa	aagttcctg	cctttcaacg	360
tttccctgt	atgcAAAACC	tttcccagac	cttggTTTCT	taaaagaaaag	atgttgctac	420
agttcccaat	tcttcttat	tacaggctca	ggtgtacagg	ttattctggc	ttaattttat	480
ctaatgaagc	ccatTCCTT	ttgtacatga	agatgtact	taaacctatg	tttacaaaact	540
aaagagacta	atcactcaat	atgaaaacat	gaaaacattt	ttgtttaaaa	tattaagatg	600
aaaaatagtt	aatatggatt	atTTTGTCT	tttactttt	aaaaaaagtt	acatattgt	660
tgcactgtgc	tgtaccaaga	attctacatt	ttaatgaatt	ataaaattat	tctgcacat	720
atcacgtcac	agtatttctg	ctctatttat	tcatatacat	agaaatataat	atgggcttaa	780

tcatttaaaa tttgttgcag caagaactct cctacctgta ggcaatagat tgctatgtt	840
tcaacaaatt gtggcaaatt ctaaacagca attctttgt acgtaatagg acatttcata	900
ctagaaaaat aaagtaatgt ttttgacatt ggatttggc cagttctaa tgaagcaatg	960
gttgggttgt taatatgtct tctgttagtgc tttagcattgc caaattaaaa agggtaaatt	1020
ttatggaaat cctgagacca ggaagatatc aatttcatgt gtacttaatg gtataaaagt	1080
ttttacaggc tctatcacca tacaatatac taaagacatt ttatagttt atcaactata	1140
gagcttttgt ctccaaaaag taatttttga aaaacatatac ttctggcca ggtgtgggg	1200
gcccacgcctg taacccccagc actttgggg gcccggggatcac ctgaggtcag	1260
gaatttgaga ccaacactggc caacatgggt aaaccccatc tctactaaaa gtacaaaaat	1320
tagccagggc tgggtggcagg cacctgaaat cccagctact aggaggttg aggccaggaga	1380
atcaacttgc aaactggggat ggagggttgca gtgagccgt atcacgccc tgcactccag	1440
cctgggggac aagagtgaga cttcatctca aaaaaaaaaa aaaaaaaaaa aaaaa	1495

<210> 49
<211> 818
<212> DNA
<213> Homo sapiens

<400> 49	
aaaacttgag tatgttgggg gaaggaatat atatatatct gggagagaat ggatacgtt	60
tgtttttctg aaatgaaatt agaaagatgt tcagttgtct tgcattct tgcaaacctt	120
gcagtttgc gggccctgtt tctgccttgc atcattttcc actgtgtatc kgattctagg	180
agcgtgaaca gggagacaaa ggtgaagttt gtgcacaccc ctgtccatgg ggtgggtcat	240
agctttgtgc agtcgcgtttt caaggctttt gmccctgttc cycctgaggc tgccctgaa	300
cagaaagatc cggatccgtg gtttccaaaca gtgaaatacc cgaatcccgaa agaggggaaa	360
ggtgtcttgg taacctaatt tttttttaaa ttatgaaatc tgctttata ttcaaaaacta	420
ttactgtcaa gtaaaaataca tttttatgtg ttttcattgt gctgaagaaa aactaatttc	480
agcatggaaa tatgtatgtt tggctgggtg cagcgtctca tgtctgtat cccagcactt	540
tgggagacca aggcaggcag atcaacttgag gtcagggttt cgagaacagc ctggccaaaca	600
tggcaaaacc ctgtctctac taaaatatac aaaattagct ggggtgggtg gtacatgcct	660
gtaatcccaag ccacttggga ggctgaggca cttagattgt ttgaacctga gagatggagg	720
ttgcagttagtgc accactgcac tccagctgg gtgacagggt gacagagcga	780
gactctgtct aaaaaaaaaa aaaaaaaaaa aactcgag	818

<210> 50
<211> 1711
<212> DNA
<213> Homo sapiens

<400> 50	
ggcacgagcg ctccctgtcc gccactgagg gacccggta ccaaccctca ttagctcag	60
tttgcccatc tggcccggtg ctaacacacaca gttctggga gactttcccc attcccagag	120
gagtagtgcg aaatgcgtgt acctctagtc ttaagctggg cgttgtatt agttgggttt	180
tctgggtctt attagcaag tggaaagttt tggcccttc cttcaactgtg tgacctgact	240
agtccctctg gattgcattt atggaaatgtt atacgagacc tagttccat ggaggaactc	300
actgattccg cgagggagat ggggtactgg atgatggct tcagccctaa ggctatgtt	360
ccagtgtctt ctgggtgttt ccaagagcgg caagaaacacgataaaatctct gacccttc	420
aggtgcagcc agagagacac tagccccactg atggacggac agacgtgggc aagggtccgt	480
gtcactaaac cacccaccac tggccacagct gcctacaaca gacacatcg atgacactcc	540
gggcaaataa atgatttca ctgaggactt actgggtttt ataataaggc ctgggtgtaga	600
gaagtccctc aacctattgt gcaacgagtt ttgagaagcg ggtaaatgtt atgaaaaat	660
gttttggatc ataaattcat ctacaggaag accaatattt actgaatgaa gctttcattt	720
aaagagctaa aatatgtttt gtttttttat atgtggatac tactttaaac ctaacgacta	780

ttcattgtat catagcttgt gatgtattct gctcatggct tttaaggtaa attgtgccat	840
gatccactgc cattctaatt gctttaacaa gtcattacca cactactgtt acatcttaat	900
tatgcataca gacaggtaga ctgttttac atatgtgaac taactagtt tcaaagcaaa	960
tgcagatgt attctgcaag taaagtctt ttctctctga aatttcttagg gatgttctt	1020
aagtgaatt catattaaaa ctgaagattt tagttacaag aactgagtgc agattaagtc	1080
tttgcatttc aacatagtca agatacaact gtggatattt catgaaagta tgcaataaaa	1140
tgtctctacc tggaaaaatc tatcaagcag cgtcacagta ctgaatttga aaccagaaat	1200
actgggtttt tatataaatg cttcatagat ttgtttttagt ataaaaggca cataactctc	1260
ctaaacctca caccacctct tgaataggtt taataagtcc acatcaatgc tgatgcctt	1320
gctatttata aactcttaca gtatgtatgtt aagtggaaatg acaatgttcaat atcattctt	1380
ggccaacttt gaccagttt atacagaaac atgtgccaac ttttctgttt gcaaggataa	1440
tatcaaagca aacaccagaa agtttatatct ttgatgcatt ttttcaaaat catacacata	1500
atacacaaac caaagacaaaa tggatatat tacgtcagaa aatataaaatg cttccctt	1560
cttctttgc caagaaagtc caatattttc accatttttga tgacacacaat caactttt	1620
taagctggaa gttaatgtct cattgttttca attgttctaa ataaaacacct tttcccttga	1680
gtattgcctt aaaaaaaaaaaaaaaa aaaaaaaaaaaa a	1711

<210> 51

<211> 749

<212> DNA

<213> Homo sapiens

<400> 51

gccaaaccag rtaataattt cttataata catgaagtcg ttatggca tttatgttct	60
taggtggcca atgggttat ctggggggga gactttata ctccataaggg acagcttgc	120
cattaacttt caaagttctt ctaaagcagc gtcaggagat atatttgggtt gtcatgacta	180
gtggcattcc actgacatgt aatgggttaga ggctgggttag acatcctacg atgcacaaga	240
cagcctccca caataaagaa ctgtgtggcc caaaaatatc agtgatgctg agattgagaa	300
acttaaagaa attttaaaat taactctata caaaatctaa tggggatgtt ttctccatgt	360
atctgtgact gcaatgacca gaggactgtt ccataaagaa agtgctaa gttggctggg	420
tgccgtggcc tacacctgtt atcccagcac tttggggagggc caagggtgggtt ggatcacctg	480
aggtcaggag ttcgagacca gcctggccaa catggaaaa ccccatctct actaaaaat	540
acaaaaatata gctgggtgtt gtggcacgca cctgttagtca cagctactca ggagggtttag	600
gcaggagagg tgcttgaacc cggggatgg aggttgcagt gagccgagat tatgccattt	660
cactccagcc tgggtgacag agtggacaaa aaaaaaaaaaaa aaaaaactcg agggggggcc	720
cggttacccaa ttcccttat aggagtc	749

^

<210> 52

<211> 1091

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1079)

<223> n equals a,t,g, or c

<400> 52

ggccagttggc cagggtcaca gggcaaggtc ccgcggggccg ctgggtgcgg cgacttccgt	60
gctcccgccg agcggggcgg aagcggggccg cgcaactgggg agtggggctt gggccgcaga	120
tgtcatgtgg cctgtttttt ggaccgtggt tcgtacttat gctccctatg tcacatttttcc	180
tgttgccttc gtggcgggg ctgtgggtta ccacctggaa tgggtcatca gggggaaagga	240
ccccccagcccc gtggaggaggaaaagagcat ctcagagcgc cggggaggatc gcaagcttgg	300

tgagcttcta ggcaaggacc acacgcaggt ggtgagcctt aaggacaagc tagaatttc	360
cccgaaagct gtgctgaaca gaaaccgccc agagaagaat taatggagga cacagggcc	420
tatggctcta ctgtgggtgg tgacttgcctc tgctaccatg ttgacagagc cccagaacct	480
acatctaatt ggcttggtt ctattctgg cccttcccc accacacagc cacacaaaata	540
ctggctgctc cttgatggcc aggcagaccc agcagcagcc gagggggccag tgaagaggaa	600
ggccgcacatc gttgtgtggt gcccacaagc actcaggcat ctgagttac ttgtgcactg	660
ctgggaggag agttatgaga tgaacattgg ctgtcaatct ctgtgggcag ggggtttggc	720
ctctagtggg aatggctggg atttgggcgt tgcctttagg agggataacct gcatgtctag	780
ttccagtctg cactgaaaag aattcaaata tgcacctggc tcccttcaact attttgcctt	840
atcctttgtg ctcatctta ctgaaatctg tcttgcagc tcaggaatgg gattccccca	900
ggaagggaaag cactttctg ttctgggaag cccagactgt tcactttggg gcagggacga	960
acatgtgctc cgtgaatttg ctgaaaaca gtcaccatct tctaccccca tcactgtata	1020
gtaaaaaaacc tgattaaagt ggtatctgag aaccawaaaaaaa aaaaaaaaaaaa aaaaactcgng	1080
ggggggcccg g	1091

<210> 53
<211> 2254
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1182)
<223> n equals a,t,g, or c

<400> 53	
ggcacgaggc ccgctgaat gttatcatca cccaaacctcg ccgcacatctct gctgtgtctg	60
tggcacagcg ggtcagccac gaactggcc cctccctcgcc ccggaaatgtg ggcttccagg	120
tgcgggttggaa aagtaagccc ccatcccgag gccccccct gctcttctgc actgtggta	180
tcctgctgcg taastgcaga gcaaccccccag cctgggggcgt gtgagccacg tcategtggaa	240
tgagggtgcatt gaggcgggacg tgaacacaga ctttctgtc atcctgctca agggcctgc	300
cggyytcaac cccgcctgc ggctggtgct catgaktgcc acaggggaca atgagcgctt	360
ctcccgatac ttgggtggct gcccccgtcat caaggtgcct ggcttcatgt acccagtca	420
ggagcactac ctagaggaca tcctggccaa gttggggcaag caccagtacc tgcacccggca	480
ccggcaccat gagtctgagg atgaatgcgc actcgatttgc gaccttgcata ctgatctgg	540
tctgcacatc gatgctgcgc gggaaaccagg tggatcctgc tgctccctgc ctgggtggca	600
gagatcaaag gagtgcagca ggcctccag gaggccctgg gcatgcacga gagcaagtac	660
ctcatcctgc cagtgactc caacatcccc atgatggatc agaaggccat attccagcag	720
cctccagttt gggtgcgc gattgtcttgc gccaccaaca ttgctgagac ttccatcaca	780
atcaatgaca tcgtcatgt ggtggacagt gggctgcaca aggaagaacg ctatgacctg	840
aagaccaagg tgcctgcct ggagacagt tggatcaa gagccaatgt gatccagcgc	900
cggggccggg cggcccgctg ccagtccggc tttgcctacc acttgttccc tgcacccgg	960
ctggagaaaaa tggccctt ccaagtgcac gagatcctgc gcacacctct tgagaacctg	1020
gtgctcaag cgaaaatcca catgccttag aagacggcg tggagttccct gtccaaggct	1080
gtggacagtc caaacatcaa ggcaatggac gaggctgtga tcttgcctca ggagatcg	1140
gtgctggacc agcgggagta cctgactacc ctggggcagc gnctggctca catctccacc	1200
gaccccccggg tggcaaggc cattgtgttg gctgccatct tccgtgcct gcacccacta	1260
ctgggtgtcg ttccctgcct caccggggac cccttcagca gcacccctaca gaacccggca	1320
gagggtggaca aggtgaaaagc actgttgagc catgacagcg gcagtgacca cttggccctt	1380
gtgcgggctg tcgcggctg ggaggaggtg ctgcgttgc aggacccgcag ctccgggaa	1440
aattacctgg agaaaaaacct gctgtacgca cccagcctgc gcttcatcca cggactcata	1500
aagcagttct cagagaacat ttatgaggcc ttccctgg ggaagccctc ggactgcacc	1560
ctggccctccg cccagtgcaa cgactacagt gaggaggagg agctggtaa gggcgtgctg	1620
atggccggcc tctaccccaa cctcatccag gtgaggcagg gcaaggtcac ccggcagggg	1680

aagttcaagg ccaacacggt cacatataagg accaaatcg gcaacatcct gctgcacaag	1740
tcgaccatta acaggaggc cacacggta cggagccat ggctgacgta tttcatggca	1800
gtcaagtcca atggcagcgt ctgcgtccgg gactccctc aggtgcaccc gctagctgt	1860
ctgctgctga ccgacgggga cgtgcacatc cgtgatgacg ggcgccggc caccatctca	1920
ctgagcgcaca gtgacctgct gcggctggag ggtgactcgc gtaccgtgcg gctgctgaag	1980
gagctgcggc gggccctggg ccgcattggg gaggcggagcc tgccagcga gctggctgca	2040
cttcccccca gcgtacagga ggagcacggg cagctgcttg cgctactggc agagctgctg	2100
cgaggaccct gtggcagctt tgatgtgcgc aagacagctg acgactgagc cctgcttctg	2160
ctggggctgt gtacagatg caaatgttta tttaaaaataa agttcttattt atcccttctg	2220
aaaaaaaaaaaa aaaaaaaaaaa aaaaaaaaaact cgag	2254

<210> 54
<211> 486
<212> DNA
<213> Homo sapiens

<400> 54	
cacactgaca tctcccaac aggtgaggc agggagagct ccagacaggg agaggccttc	60
agagaacagg aaggaagctc cttccctctt ctgcatttt cagcctgttag ctcacgtgcc	120
tttatgccc cacatctcat tctgtctggg gactccatac gtagtggctg tctaccttcc	180
cgcggtggatt gtaatgttt tgctaccagg ggtcaggcca tactcatcac tgccaggccct	240
gaagcatcca tcattttccct cgagctcagt atgtgcctcg tacatgttagc acagtggaaa	300
aacttgagct ttgctggcaa agacagacag aatgagctt aatctcagcc cagctatggc	360
tttcttagtc ctgtggcttag aaaatgactt agccttttgg actttggta acccatctgc	420
aaaacagggg tggcacccac ctcttagaaa gttacagtgg tcaaaaaaaaaaaaaaaaaa	480
ctcgag	486

<210> 55
<211> 1270
<212> DNA
<213> Homo sapiens

<400> 55	
gaaaccatcc aagataagag acatgggagt gaaattcaca cccactctgg ctttcataacc	60
atgggtctga acattagccc atgggttttcc ttggccatac tgacctgtgc catttcagct	120
gcattcatct cagttgggtgt tgcgtcttgc tgatccca caggagcagt	180
aagaacctga ggaagagtag ggtcagagga gtctgggaga atgaggaaat atgagagccc	240
caggaactga aaaggcctgt gagagactct gagcttctgg gaaacaggtt taggttcttt	300
ttatttcaat aataacagaa acaactgtca aaaccatgtg cctgtactat ttggagtgt	360
gtccttgcag aatctcatta taagaacctt aggaaatagg cacatcatct cctggataga	420
atccttagaa atgggcacta taatgggcac tttatccat ttataaaca tggaaattga	480
ggcacagaga gattaagtagc ttcccagg tcatacagct agtgatggag gagctagcat	540
ttgaacccsg gagtttttag tctattgagt ttaaccgaca gatcatactg tggggatgtt	600
gggaggragg gtgaagcaag caartgaaca aatgartctg ggatttarga cttgccagac	660
aaacaaggcc caagaggcaa gtgtcagggt ggggttagtt gggagtcagc agagttgggt	720
tggaaattcaa gctttccac ctgtggcta taaaccttgg ttgggtaaatg aacccaaggt	780
aaatgagatc atctctgtaa aactcttgc cttgtggctg gcacatagta aatgcttaat	840
aagggttccac tggtagtatt actgttactg ataacatata aatagattgt attaatggac	900
cataattgca actgtataaa acaaattcca tgggtggcca ggcgcagtgg ctcaaggctg	960
taatcccatc acttcgggag gccgagggtgg gcagatcagc aggtcaggag atcaagacca	1020
tcctggctaa cacagtgaaa cccatctct actaaaaata caaaaaaaaaatt agccaggcat	1080
ggtggcgggt gcctgttattc ccagctactt gggaggctga ggcaggagaa tggcgcgaac	1140
ccagggggcg gagcttgcag tggcttgcact gcactccagc ctggggcaca	1200

gagcgagact ccgtcycaa aaaaaaaaaaaa aaaaaaactcg agggggggcc cgaacccaat	1260
cgccctata	1270

<210> 56
<211> 2059
<212> DNA
<213> Homo sapiens

<400> 56	
ggcacgagcc tcactggta aacacaagct ctggcagg aacaagctct cgccaggaa	60
tgcacagaga agcactaagt caaagtcatc tccgtgttgt cattaaaatt ccagtgaatg	120
aaaaagttt aggaaacatt aactgttaat ggcttatgtt ttagctgttc tctgttttaa	180
aaggcctttgg gcactttca aacctaaca acaactgatt gaatttctat tgatggtcaa	240
agtggtaaaa atacctttt gtatctaag acaacttta ggtggcatttta agaccccgg	300
ggtcttagggg cctccaggtg tacggcttg aagtaaggc aagaagcatg ggtgccct	360
aggagcactg ggaggacag tggaggaaga ggccccggg ggggccact gctgaggcag	420
ctcttagggc cctgcactt actttgtca gagcaaagg tgccgtcage tgggtccatc	480
ccccgcctgt gcccgtggat ctgggctgctg tcagcacccg gaccggcccc agcagcacat	540
ctgtcaaaagc ggaaaacagt tcaacacacca gagectcatg tggaaagagttt ccaggcgctc	600
agacttttctt ccttcatgac cctcatctt getctggc ctcagccgc ctgtcgtaact	660
gcaggaaaatt ttgttctgt cttgtcttca aagacttcaag ggcttagaaac ggaccataga	720
aagatatgaa ccgagagccg tggcagctgtt ccagtttca ggctgatatt tttgttagatg	780
ccatgcagat aacacagcag ggtccaggcc cttccctctg gaactcacac tccggctgtat	840
tttggagga accgctggc aggttctgca caggaacagt taactctgca gaggacagttt	900
tccacatctg ggctgagtttcccaaaagaaac tgcccttaaac aacgtcttgc ggaaggcgg	960
tggcgtcaag agaagtaaaag ttttccatgtt ccagtttgc gcaatgtttaat actagctatt	1020
ttaataggaa agattttttttttccatgtt ttggttttta tttttagaaat catgaaatag	1080
caagttggct ctgctgaatgtt agaaaatggt ggcggggagt cggccactgac catcgctgtc	1140
gcagagcacc ttccctgtca cccacagctgtt gggccggc tgtaacgcagg tccctgtgt	1200
gcgggtgccc aagaggcgtt agggctgcgtt ctggccatgtt gtctccaccc tggacaccat	1260
gaatcatgat aggttcttagt ggtctccatcc cacaggctt ctgtgtctt cctggacac	1320
tcgggacttag ttgttcttagt gttttctttaa aattctgttagt taattgcattt gtagagcatc	1380
cctaattccca acttcagaaa tccaaaatgc tccagtgtt atttcatttgc agcatcatgt	1440
cagtgtctcag atatggtcag accctggagc actttgcattt ctgaatgtt ggtgtctcag	1500
cctgcgtctg acagaagctc cagagaagttt gctgcgtt cagggcaaga ggctccctggc	1560
tttggggcttccatgtt gggccatgtt gggccatgtt gacccatgtt ccctctgttgc	1620
ataggaatgt gctcgggcag ggaacccggc gacccatgtt ctggcccccctt cttttcccccgg	1680
ctctgcgtccg ttttcgggtt cctgtgggtt tggctgtgtt cagccctgtt gcccgtggac	1740
tatagtgtct tgggtccctg caggcttggc ttttccatgtt cccatgtt ggtggcaagt	1800
gcctgtgttccatgtt gggccatgtt gggccatgtt gacccatgtt ccctctgttgc	1860
gagggttgcag tgagccgaga ttgcgcattt tcaactccatgtt ctggcagca agagcgagac	1920
tttgcgtccatgtt gggccatgtt gggccatgtt gacccatgtt ccctctgttgc	1980
gcccagaatgt tctgttgcag ttttccatgtt ctggcagca agatccatgtt acccaaaaat	2040
aaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa	2059

<210> 57
<211> 868
<212> DNA
<213> Homo sapiens

<400> 57	
gactgactat agggaaagct ggtacgcctg caggtaccgg tccgaaattt cgggtcgacc	60
cacgcgtccg ctgttttttccatgtt gggccatgtt gacccatgtt ccctctgttgc	120

agatggatgg tggcccaggt gcattttcca gggctgggt tctccagatc ccgtggcttc	180
tgtttagtgtt aggcaacttt gctctgtgtg aacctcgccc ctgtccctct gccgggcacc	240
cctggcagga agcaggactc ccacccctcac cctgacttag actgtccctct gagtcagctc	300
ctctccaaga caggagtggg cagccctggg cagttctg gccccttgc aaagtgaggg	360
scaggaagct ggggctgccc tccagaaaagc cggggtaggr actctgaaaa ataccccttc	420
taaacggaaag cagggytctc cagttccact tggcgcccccc tccacacaagg cccttcctcc	480
ctgaggaccc cacccttcta ccccttcccc agcagccctt ggaccctcac ctctctccgg	540
tgtccgtggg tcctcagccc agggtgagct gcagtcaggg gggatgggac gggcaggcca	600
gaggtcagcc agctcttagc agagaagagc cagccagacc ccaaccctgt ctctgtcca	660
tgccctttgt gatttcagtc ttggtagact tgtatggaa gtttttgct tcaaagttt	720
tgtttttgtt tgttttgtt ttgttttgag ggggtggggg gggatacaga gcagctgatc	780
aatttgtatt tatttttttta aacattttac taaataaaagc caaataaaagc ctcaaaaaaaaaa	840
aaaaaaaaaaaa aaaaaaaaaaggc gggccgc	868

<210> 58

<211> 986

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (592)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (669)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (767)

<223> n equals a,t,g, or c

<400> 58

gaaaattaatgtttagata aaaatatgcc attcttatct gttttgggtttt ttaatcttgg	60
cttaatattt ggggttgagt cattttgtttt gagagctgtc ctgttttattt caggggtgtc	120
agcaacatcc cagatggaaag cagcatcccc ctacccagct gtgacaaaaaa gaaaaaaaaa	180
tgtctccaka cactgccaaa tatcttctgg ggggtggccctt gggtgagaac cactgcttta	240
gtggataaac tttaggcagg agggaaatga tcgcagttgg atagttggag gaatgtggag	300
caagggaaac aataaactgt gaccataaaa acatagaaaag atggctata tgtggatttt	360
tttttaaagc acgtagaatt gcttaaaaatg gacaacagca gcatataaaat cagtggcaga	420
gttgggtggct gaatttagag catcttaagt ctatgttctc ctggAACAGA gtgcagataa	480
ttcagtttac agcttggcta ggtgcattttt gaaagtattt gtcacacacaca aacagttaat	540
gtatggggaa gataacttct atactagtag gagagaaaatg gaacaagaat wntaaataca	600
ctatcaaaaat atgcaagaat ggcagmrgga aaaggccagaa caagctgcaa aacmcacaca	660
caatttagana taaatatttt gggacacaaat aaatgtgaat ggattaaaac ctctgttaat	720
gacaaaagtgc tccagttaaa ggaaggcAAA tagtggattt aggaatngat tactatatga	780
tgattttttttt ctcagttcaa caggaagatg attgatggaa ctttccatca tttgtacac	840
agtcttagaa gatattaaag caaacattca agaagaaaatt gatcacctac taccatagtg	900
tatTTTATTG aattttgtaca ttcaataaa gtgtcataag gcacgggtga aggaaaaaaaaa	960
aaaaaaaaaaaa aaaaaaaggc gggccgc	986

<210> 59
<211> 695
<212> DNA
<213> Homo sapiens

<400> 59

ttttttttct	tgaaataaaa	tggggagta	atggaaata	attttttga	gcccttcgt	60
ttctaaaaat	gtttgcattg	tgccatcgt	tttgacagtt	cagttccagg	ttgaaaatta	120
tttttcttgc	gaatgttaac	agctgcctc	tatccatgt	tttatctaa	ttgtgtgaa	180
gagaatctt	ctgattctta	ttctttttt	ggtgcacgt	ttaattttt	tgtcttctt	240
tttttcccc	tggaaagttt	taggcctcc	cttttatctt	tgttagtctga	gatctgacaa	300
tgatgggtgt	gtctagttt	ccccaggata	cttttcatt	tgtccctggc	agcactagta	360
gatccttca	gtttgtgtac	ttctgttttct	cttgctctgg	agaatttaaa	aaatatata	420
attttgaga	cagagtctca	ctctgtcacc	caggtagag	ggcagtggtg	tagtctctac	480
tcactgcaac	ttctgcctcc	tgtgttaag	cgattcttct	gtctcagcca	cctgagtagc	540
tgggattaca	ggtcctgccc	accacgccc	gctaattttt	ttgtattttt	agtagaggca	600
gggtttcacc	acgttgcacc	ggctggtgtc	gaactccctga	cctcagatgg	tccacctgcc	660
ttggtctccc	aaaaaaaaaa	aaaaaggcg	gccgc			695

<210> 60
<211> 314
<212> DNA
<213> Homo sapiens

<400> 60

gtcgacccac	gcgtccgcctt	tgaggagcat	tcctctagat	tgcacaaggg	acagtgcctt	60
taaccaagcg	aggagtccaa	agctcaggac	ctgactaccc	tgagggcacg	ctgacgcctc	120
ttcccagggg	gatggggagc	tttctgcacc	cccagtgc	tctcctcatc	acgttctgt	180
ccgtccttgg	gaaaggcctg	cattctgatc	cttccagggc	cttcgagcat	ggaggggcac	240
tgggaaaggt	cccccgaggg	aggagcacgt	tgctgagtaa	agaggtgtt	ctaaaaaaaa	300
aaaaaaaaaa	aagg					314

<210> 61
<211> 734
<212> DNA
<213> Homo sapiens

<400> 61

gactgcttat	atggcatt	gtctttccc	tggcactgcc	actgtcacca	ccatccccct	60
tctggatccc	tacttaccc	cttcatgctg	ctctggggc	agtgcctctg	ctgccatgt	120
gtacttgagc	ctgctgtac	agccatgcct	gaagatggc	cccccttc	tcttcctgtc	180
ccaccaaata	tgaccagctc	taggttccat	tacttctgg	ctttgcctca	aataaaaactt	240
acacaatttt	atccaaacc	caggtcttct	tctgcaacac	ccgagaaaaaa	tattgggctg	300
caggagccag	agaggagaga	gagattact	ggtgagagtt	gtaggtggg	attgaaagcc	360
aagtcatgtc	tttgcacccac	cagaaactca	ctaggatgt	cacaatgcc	ctgtgtatgt	420
kttaaaatat	gtaaactaacc	tgcacgttgc	gcacatgtac	cctaaaaactt	caagtatata	480
taaararaga	aagaactgst	gatacacata	tcatgaaaaa	agaccaaata	aaataaaaaaa	540
ataaaaataa	ataaataaaa	taaaaatatgt	ccacaaatgc	tttgatgttc	ctttgttct	600
tgatctgtat	gctagcaaca	caggttcatt	ccgtttgtga	aaattcattt	agctgtgctc	660
ttatgagctg	tgtacttctc	tacatgtatg	ttaaatgtgg	acaagaactt	cacataaaaa	720
tcattttaaa	aaaa					734

<210> 62
<211> 1410
<212> DNA
<213> Homo sapiens

<400> 62

ccgcctcctt	ggcgcccagc	cggtccaggc	ctctggcgaa	catggcgctt	gtccccctgcc	60
aggtgctgca	gatggcaatc	ctgctgtctt	actgcttat	cctgtgtaaac	tacaaggcca	120
tcgaaatgcc	ctcacaccag	acctacggag	ggagctggaa	attcctgacg	ttcattgtac	180
tggttatcca	ggctgtcttt	tttggcatct	gtgtgctgac	tgatctttcc	agtcttctga	240
ctcgaggaag	tgggaaccag	gagaagaga	ggcagctcaa	gaagctcatc	tctctccggg	300
actggatgtt	agctgtgtt	gcctttctgt	ttggggttt	tgtttagca	gtgttctgga	360
tcatttatgc	ctatgacaga	gagatgata	acccgaagct	gctggataat	tttattccag	420
ggtgtgctgaa	tcacggaatg	cacacgacgg	ttctgcctt	tatattaatc	gagatgagga	480
catcgaccca	tcagtatccc	agcaggagca	gcccacttac	cgcctatgt	accttctctg	540
ttggctatat	attatgggt	tgctgggtgc	atcatgtaa	tggcatgtgg	gtgtacectt	600
tcctggaaaca	cattggccca	ggagccagaa	tcatcttctt	tgggtctaca	accatcttaa	660
tgaacttcct	gtacctgctg	ggagaagttc	tgaacaacta	tatctggat	acacagaaaa	720
gtatgaaaga	agagaaaagaa	aaggctaaat	tggaatgaga	tccaaagtcta	aacgcaagag	780
ctagattgag	ccgcccattga	agactccctc	ccctcggca	ttggcagtgg	gggagaaaaag	840
gcttcaaaagg	aacttggtgg	catcagcacc	cccccccccc	aatgaggaca	ccttttatata	900
ataaaatatgt	ataaacatag	aatacagt	tttccaaaag	aactcaccct	cactgtgt	960
taaagaattc	ttcccaaagt	cattactgat	aataacattt	tttcctttt	tagttttaaa	1020
accagaattg	gaccttggat	ttttatttt	gcaattttaa	ctccatctaa	tcaagaaaaga	1080
ataaaaagttt	attgcacttc	tttttgagaa	mtatgtaaa	gtcaaagggg	catatataga	1140
gtaaggcattt	tgtgtattt	atccctaaagg	tggctgtat	catgaaccta	ggccaccatg	1200
gggacctgag	agggaaagggg	acagatgttt	ctcatttgc	aatgtcacag	ttgcctcaaa	1260
tgagcaccat	ttgttaataat	gatgtcaatt	tcatgaaaag	cctgagtgta	ttgcattct	1320
tgatttaatc	atgtgaaaact	tttccttagat	gcaaatgctg	actaataaaag	acaaagccac	1380
cctgaaaaaaaa	aaaaaaaaaa	ggcgccgc				1410

<210> 63
<211> 1231
<212> DNA
<213> Homo sapiens

<400> 63

ggcacgagtg	aatgtcgagg	agttccagga	tctctggcct	cagttgtcct	tggttattga	60
tggggacaa	attggggatg	gccagagccc	cgagtgtcgc	cttggctcaa	ctgtggttga	120
tttgtctgt	cccgaaaaagt	ttggcatcat	tcgtccaggc	tgtccctgg	aaagtactac	180
agccatcc	caacagaagt	acggactgct	cccctcacat	gcgtcctacc	tgtgaaactc	240
tgggaagcag	gaaggccaa	gacctggtgc	tggatactat	gtgtctgtcc	actgacgact	300
gtcaaggcct	catttgcaga	ggccacccga	gctaggcac	tagctgact	tttaaggcag	360
tgtgtcttc	tgagcaact	agaccaagcc	cttggagctg	ctgttttagc	ttgcacctg	420
ggggaaaggat	gtattttattt	gtattttcat	atatcagcca	aaagctgaat	ggaaaagttt	480
agaacattcc	taggtggcct	tattctataa	agtttcttct	gtctgtttt	tttttcaatt	540
aaaaagtaat	taaataaacag	attagaatct	agtgagagcc	tcctctctgg	tgggtgggtgg	600
catttaaggt	caaaccagcc	agaagtgtct	gtgctttta	aaaagtctca	gttggctg	660
tgtggtggt	catgcctgt	atcccaacat	tctgggaggc	ccagggccgg	gaactgctt	720
agccccagga	gttcagaatc	agcctggca	acatagaat	actccgtctc	ataaaaattt	780
ataaaataaaa	agtctcagg	gacaaaaggc	tcctgaagct	agaaccagg	ttggataaaag	840
attgaagagc	cacaggccac	tttccctct	gagccattgg	gccttagtgg	gtcatgtatt	900
gtaatttgctc	gcagggagag	cagtctttt	ggtgtatag	tggatgtct	gcttagttgg	960
caggggttca	gtccaaatgg	aagaatattt	ggaataaaac	ctccactatc	ctttatagcc	1020

agggactttt ttcctattta ttcataaaaat aaattatagt taattatacc cataacacacct	1080
ttattnaaat ccagtgttct ccgcagcctt ttgtctattt atatgtgtac caagtgttaa	1140
acataattat tattgggcat ttgaactttt ttttcttta aagaatgct gctattaaac	1200
atatttgtaa atggaaaaaaa aaaaaaaaaa a	1231

<210> 64
<211> 612
<212> DNA
<213> Homo sapiens

<400> 64	
ggtcgaccca cgcgtccgag catttgtctg tataattttt gttattgaat taaaatctt	60
tgggacccca acaggatgag atcattggcc agctggcttc ctcccacctg cacctggact	120
aaaattcccc gtggcatttag aggtgtttcg taaggtgtc cctgtgtct gtcctacaga	180
ttgcagtggc tctgctggaa aagaacggaa ttctatgca gttgcgtgtg tcatgaaggt	240
ctctgcacag tgggtgtgtt tcttgcgt ctttctcca ctctgcctt ctgtgaaatg	300
tgccagcagt ggacagaaca gggcagagg tgatcgtga ccattgcaca gaatatcagt	360
aagtgttga aggtatata tagtggccaa caaattgtaa gcaaaatacc aggaacttcc	420
taatcttagta gaaaattttt tattgtttt acaaacatct gatctactg acactgaaag	480
tccttagaag gagaattgct tgaacccgga aggtggcgt tgcagtgagc caagatggcg	540
ctactgcact ccagctggg caataggaat gaaaactccgt caccaaaaaaaaaaaaaaa	600
aaggcggcc gc	612

<210> 65
<211> 2270
<212> DNA
<213> Homo sapiens

<400> 65	
ttttttttttaa acaatccatt ttaatcatct aaattattta caatacaata	60
acatggattc atcctttta agacatggga ttgtaaaaat caacaagtga atgatgcttc	120
aaataataca tttaaataca ttaatcaaattt ttttcagtg cttaaaactt tttctccatg	180
ggacagcagg ctctggacaa aagtgcctag catacaagtt ttcccaattt cttcttatca	240
taccagctgc acataaaaag gttcatcacc tcctgtctcc aaagtgtctc cttactgagt	300
gttcccaggc agacaatagt tcctggata gtgcgtttt gtaacagaaa agcccaagcg	360
tagaggacgg attaaaaggc agggaccaga cggccatgga tacaaatccc aagacagagg	420
atgccccatg cttcccccattt gaagcttattc tgcgtgcctg tgtctccatg attgcaggca	480
tagagctact tgggacccctc aggatgattt acttagcgat atgcatttttta cattctaaga	540
atcaaaatgg tcctgtattt cccaatagag aaaatagagc caattcatttgc ttctcccttc	600
tccctctga agccagttt taaagatgag ctttacccag aaaataagcc ccaaagaact	660
ctcatctaaa tgatcagacc cttcttaaat tacctttggc aacctaggta attctttttt	720
attacacacc tccaacctga ccctttctac agtttcaact ataaaatgttc atgccccctr	780
tcaaataacg ttgcttaggat gaatttgcca caggttttag tacagagaga acaagcaaga	840
aaaatgttagt tttttttttt aaggagatgt gccaggatgt cagtcctcat attggtccc	900
ttctctctct ctatcccca aggttaagtcc ttgttgcact tgataagctt tagtccttct	960
gtacaacttc tagaagatgc acttaatggt gcttcttgc actttccagaa ctcacccct	1020
attctacctg taaggctgtt ggggagcattt ccaatcaaca taaggcctac cccttttagcc	1080
acgaaaatca gccaggcattt atgtttctgc accaccaccc gcttcctga cggacactgg	1140
tgctgtatgc aaaaatgggca cagtaccgca gctggttctt cttttcgag tttgttagata	1200
agaaataaaaa aacattttca ttccctcaca agcttaatctt agtaatataa ctgcctaaaa	1260
aaaatcaaaac cataaaataaa cctatgtgtaa aaacaaaatca catgacttgc tgacttctct	1320
aaaattaatgt tcaagggaaaa aaggaaaaagt tgatcccaag taaaatccct tgaccacagc	1380
tgtctgaaat tagccagggg aatgggagac accaccaaga acctcagctc tttcctgccc	1440

tgtatTTcaa	ggggagtgtt	gtggcTTca	caaATgaaaa	ttatgaatca	caaAGataaa	1500
cgtccTca	ctcaacCTgg	tgaatCCTca	ggaatgtcat	gaggatgaca	acacagggtt	1560
aattcattt	ttctcagtct	ccccCTgac	tccacaaaag	cttgcTTtc	ccaacacaag	1620
gggCTgggag	gtccagtcta	gacagagcat	gctgtgggg	taaacagtaa	ccatgtgatc	1680
ccatgattcc	cagagCTctg	agcacAAAGC	tttcatccc	agtggcaact	ggaatgtggg	1740
taattCTgtA	aactcatggc	cacacTTta	atgcttgggg	acagtggtg	gagtcaGCCa	1800
gagCTCTTT	ccaacttcat	ctagggtctt	ctctCTggaa	aagcttagtG	acgttCTCG	1860
aaggTTTATT	tggtaagga	gtattgctaa	aacactttt	aaaaatCCAC	tttgaacaca	1920
tgtgtAAGCT	gaaaagaaaa	tgacatataat	acctccattG	aagctgggaa	agtgaaaagg	1980
ctgacgaaat	gtctgaaatc	ctgaggcTTt	cctggTTcta	ttttAataca	gcgtacaggt	2040
aacagatgat	ctcatttacc	ttctgaatga	cccAGcACTc	aatttCCCTA	aaactgctca	2100
gctccacttG	gaaatcacca	ggggacttga	aatcttccc	cttagactca	gggagacacc	2160
cagaccagga	agaagggcac	tgtatTTTC	agggacccaa	aagcccactt	ttttttttt	2220
ttttttttt	ggaattcgat	atcaagctta	tcgataccgt	cgacctcgag		2270

<210> 66
<211> 1283
<212> DNA
<213> Homo sapiens

<400> 66						
ggcacgagcg	agggaacaga	ttcccagggt	ggggTgggg	agggctgggc	ctttgctcct	60
ttgtctcTT	tcccaaggca	aagtgaagag	aagagAGtga	ctccTTCTtc	actcaggGaa	120
cccaggcagg	gatgaAGcgc	ctgtggTgtc	tgagctgggt	cccgGGGCTG	caggGGGAGCC	180
cctcagtGtt	gtcctCTgtA	ttcttCTCCG	tgttcaAAcc	acagctgcat	tggacatgca	240
gtcaggGTc	ctctcaCTgg	caccCTCCt	gcctttcat	tctttttct	ggatAGtctt	300
tcatcaAGtt	ttctCTgCCT	tcacCTgtct	cttccTGAAT	cagttcacct	tgaggggggt	360
taacagAGCA	cTTggcCagg	ctctgttct	ccaggTTCCa	ggccAGcccc	cgggACTCAG	420
ggcCTgcTT	cccCTCACCT	tcttgAGCAG	cacAAACTCG	ttctCTGCTG	ctgtCCGCTT	480
gttgattttc	tcctcataACC	tgtggGAATG	gcgaggGCTC	atggGTTAAT	atctcaCTGA	540
aagCCCTTGc	tttcaCAGGG	cAGCgttGAG	caaggAGCAG	cgtgtCCATC	agaAGATAcA	600
ggtgctGGGG	geegcAGAGT	actGGGcAGG	ggtAAGTGGG	ggaaggCTTC	ctggaggagg	660
gaacatGCTA	accAGTTGG	aagaATGAGA	ctgttAAAGA	tccAGCTTGG	caaACGAGGA	720
aggAGCACAT	ggAGCgAAATG	ccCTGTGGGA	ctctcAGGAGG	aaccAGGATG	tgaACTGCC	780
tccccAAATT	tgAGTACAGC	tttacaAAATG	acaAAAGCCT	ccaatCTGCA	tttCCTCAGT	840
tacCCttGAG	AGCAGTCTG	gAGCCAGATG	cacttaACCC	tcctCTTACA	tgggAGAGAA	900
cgtgAGTGT	ttccccAAAC	attCCCTAAA	cccAGAGCCA	gagataACCC	tctgCCCCACT	960
gcccAGCTCA	ctgggCATT	gtcCTTAAGAG	tcaAGGCCAGA	ggctggAGGA	gcAGAGAGCA	1020
agttCCAGAG	ttttgttGGG	gtgACTCTGC	ttgatATGAC	caAGAACAAAT	gccCTCCACT	1080
gacCTCCAAA	gcATTAAAGC	tgggtGACT	gccAGGGGTC	ccttggAGGG	acaAGGGCAG	1140
ttgtCCAGTT	acAGGGGGAC	tcctCCTGCT	cacCTTTCT	tgtAGTCCtC	cactacGTCC	1200
cgcacATTCC	tcaGCTCCGA	gtccAGCCTC	accCTGTCCC	cAGACAGCgt	ctccAGCTGC	1260
ttccgcAGGT	tgctgatGTA	GCC				1283

<210> 67
<211> 1263
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1256)
<223> n equals a,t,g, or c

<400> 67	
gaggagatcg ccacctccat cgaacccatc cgcgacttcc tggccatcg tttcttcgc	60
tccatagggc tccacgtgtt ccccacgtt gtggcgtacg agctcacggt gctgggtttc	120
ctcacctgt cagtggttgt gatgaagttt ctctggcg cgctggctt gtctctcatt	180
ctgccgagga gcagccagta catcaagtgg atcgctctg cggggcttgc ccaggtcagc	240
gagttttctt ttgtcctggg gagccggggc cgaagagcgg gegtcatctc tcggggagg	300
tacccctta tactgagtgt gaccacgc tc acccttgc tcgccccggt gctgtggaga	360
gctgcaatca cgagggtgtt gcccagacgg gagagacggg ccagcctctg atggctcgg	420
gatgatggac cgtggaaaggg aagcgctgtt ggggagtgag cgcttagatg gccagcagct	480
gctccctctg ggaagctcgc accttggcaa cagaacagcc ctctagcaga gcgtcagtgc	540
agtcgtgtta tccccggctt tacagaatat tcttgccta ttttagaatt ttccggagta	600
gtttatttgc agtctgttga ttatgtcgag tagaccggg acactgcgtt ttaccgtatca	660
ccttgaatgt ggtgccttgg tgcctttt ttttttttcc ctgaaaattat tattaatttt	720
ctattgttag ttcatcagtt catagttttt ttagtaaaga agcaaaaatta aaaggcttt	780
aaaaatgtac aacttcagaa ttataatctg ttagtcaaattt atttgttattt aaacatttct	840
gtaatatgaa gttgtaatcc tggccgttag ctggaaagct tacttttgc tcttaaagcc	900
tatgttttctt aaaatgagac aaatacggat gtctatttgc cttttattgt aacttttaaa	960
tgaaaataatt tcatgtcaat ttcttatttgc tatattcattt aaaaatatttgc tttaaattc	1020
acaagaatattt gtattcttta ataaaagataa ttatgtatca tggataattt aattgaaattt	1080
tattaaaatc tggttttattt aaaaaaaaaaaa aaaaaaaaaac tcgagggggg gccccgttacc	1140
caatttgcggc tataatgttagt cgttattacaa ttcaactggcc gtcgttttac aacgtcgtga	1200
ctggggaaaac cctggcggttta cccaaactttaa tcgccttgc agcacatccc ctttgnacgc	1260
tttg	1263

<210> 68
<211> 1617
<212> DNA
<213> *Homo sapiens*

```
<220>
<221> SITE
<222> (1578)
<223> n equals a.t.g. or c
```

```
<220>
<221> SITE
<222> (1586)
<223> n equals a.t.g. or c
```

```
<220>
<221> SITE
<222> (1605)
<223> n equals a.t.g. or c
```

```

<400> 68
tcgacccacg cgtccggaa acctgatact gcaacctgca atgttaggatg tttgtatggc      60
atttaaaggt aatggtgatg ttatttatttc tatactttgc atactgttag agtaattttc     120
actctgtctt aagtgtgagt aaggctcttc taaaaatctt gtcttgcca agaaaatttt     180
aaatcacata cgaagacgtc tgttgctaac agttaacttt atgaggttaac tatatccccc    240
tatttctctg gactcatttt taaaaaaatat gccgaatact gcatactgtt taaggttagta   300
tataagttt atgagagaagt ggagagctt cttcctgaa aagtccgtat ttgttgagat   360
accatttgcc tcacagagag gtgtccccca ctcccatcccc cattgccaga taaaataaata 420
ttttgagaaaa agtgacctaa aacagctgga aatcttaggt gcatctgtct gcagacctcc 480

```

ttaagcaggg tgtatcttac aattccctta ctgcactggg taagtgttaa cttagtttt	540
gttttgcct ttgccttaaa tattctccaa attaccattt atgcaacatg gttagggtta	600
atactgcattg gtatcattt acttgttca tgaacttcc agtactgtac aaggtaaca	660
aagaatgcc tgtgttatcc tcattctca ctttttact ctgtggttt agcacagtaa	720
ggtaactgcaa agacccctt cc当地atgtc tccttgactt tattccttgg gccaatttcg	780
tatcctcaac atcctaagat ttgttgc tatcaactgac ctgtgggttgg cctgttttat	840
tctaaattcc agaaaaagtcc aatcccagta ttgc当地at caaaaccgat	900
gttgtgatcc tacccctt actatttta ctggccaaat gccttatttt tttaattatt	960
attatttta acttttggg cacacaaaaa tcagcaattc tc当地gaagcg ttgttagtg	1020
ttgc当地acttgc tggactcat tc当地ccctt gagccagcca atggggagga	1080
ataggataat gcaaaacacat gttttgtttt ctc当地ttca aataatttac catgttaaaa	1140
taaactttc ttgtttttt atttgttagag tc当地taagt accccatattt aaatgcgc	1200
tttattttt ttgttaggtc ttgtttttt tctgtttttt tttgtttt tttgttaat	1260
aaggtaactg ggcaatccaa caccccccgg ggattctggc ttttagtattt tatcagccat	1320
tttaaaatta aatataaaaa ttctttgtaa gaaaacttgca tc当地at ttttattgc	1380
aattgaaaatg gtaaaaata agacaatgt a agtaagaccc tc当地atgtc taatacaaac	1440
ttggcttcag caagtggcctt atttttttaa gggttttgaa agttgtgtg tttgtgtcg	1500
tgccgtgtgt gtgggttct tt当地aaatg gatagtagag ttgtggctgg ataagggtac	1560
ctgtaatggg ggtttggnc gcaagnctga aatttatact tt当地naataa aaactac	1617

<210> 69

<211> 1389

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (755)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1177)

<223> n equals a,t,g, or c

<400> 69

gcttttttag gcattcattt gacacttgc ttaataagaa tagtttctta gttggcataa	60
tgcttctgaa gtaatggtac tt当地aaataa tt当地tcat gaactttaag cattccttt	120
gaaatcttgc tt当地actcta tctagtcagc ctttataggc aatccaaagg gatgtttgg	180
atgcttagt ccagtggttc tc当地agatgt gtctgtggag tc当地ggaaatg cgctgagacc	240
cttccaggca atttgc当地c tcaaaaactaa tt当地agaatg acaccaggat gttctgtgcc	300
ttt当地gttgc tggttgc当地 tt当地actgtat gatgc当地agaaatggggag gagtaaaatc	360
actgggttctt taccactatt caagacatgt gc当地aaaact gt当地gttctt agtaggcatt	420
gtatcctgca cagctcccc cc当地ggatgt gatggaaagac caaggaaagca gt当地aaatgg	480
aggtaacacgg gaagcacttc ct当地gc当地gg tgaaggatgt tgactgtttt aaggaaaagc	540
acttataatgca tgggttgc当地 cgtgatgtatgca accagctgccc tt当地atgg aacatgactt	600
ttacttgc当地 gagtaactgtat cagaaaaacca atttactgtat cttgtgtttt tagcagacat	660
tttcttgc当地 atgaaagaatg gggctgtat cttcaggaaa atgctgtatca gtatctgttgc当地	720
ccaaaagaaaaa ttgtgatgtat cagccaaaga atagnaatct agaaaaactgt tattcmcttc	780
catgggcttgc atgmccctt agtacttaga ctttctgtat gagataagcg gtggcataa	840
caaattgtatc gtttctgtat cttatctaaat acatggatca acatatrtaa gatctgcaca	900
actccctgga ccagatgtt ccaaatgtat gttgctttt gttacaaaat cagggaaatag	960
atagaagatt cattccaaataa atgaaagata gactgtatgga tt当地atgtat acagaatagg	1020
aaaatgtatc gacatgtttt cagattccac ct当地caacta attttaaga agctaccact	1080

tgtcaggccag	gcacagtgtct	cacgcctata	atccccaaacac	tttggggagtc	caagggtggc	1140
agatcacttg	aggtcaggag	ttcaagcctg	gcccaacntgg	tgaaaagactt	ctctactaaaa	1200
actacaaaaaa	tttagctggc	atgggtgtgg	gtacctgtaa	tcccaagctac	tctggaggt	1260
gaggcgaggag	aattgcctga	gcctgggagg	cagaggttgc	agtggagccaa	gatcgcgcca	1320
ctgcacaccca	gcctggcaa	caagtgcgaa	actctgtctc	aaaaaaaaaa	aaaaaaaaaa	1380
aaactcgtag						1389

<210> 70
<211> 1896
<212> DNA
<213> *Homo sapiens*

<220>
<221> SITE
<222> (1802)
<223> n equals a,t,g, or c

```
<220>
<221> SITE
<222> (1856)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (1886)
<223> n equals a,t,g, or c
```

atgcaaaatt	gtcttgaacc	tgcgataaaaa	ttttgttgga	cttttttttc	attgcagtgr	1620
aaagggccat	gtagcatgcc	tcaaagccag	gttaactcagc	ctagtccttg	tttaaggcagt	1680
tttgatattc	atycaaagttc	aattttcyca	cctgatttwa	kgatttaattt	cctkggaaaa	1740
attttggaaaa	gttttccaaa	gaaagtaaaa	aattttaaata	atcccgtaac	cccgtataat	1800
angaggattt	aaccttccag	gttccaaatg	gttttgggtg	gcaattttcc	cttccnaagg	1860
tccctttttt	ttcccaatgg	gtaatnnaat	aattaa			1896

<210> 71
<211> 308
<212> DNA
<213> *Homo sapiens*

```
<400> 71
ggcacaggc ggcgctgcga ggacccatgc agctgacgct ggggggcgcg gccgtggcg 60
cgggcgccgt gctggccgccc agcctgctct gggcgctgcgc cgtgggcctc tacatgggc 120
agctggagct ggacgtggag ctggtgcccg aggacgacgg gacggcctcc gcggaaaggcc 180
ctgatgagggc gggtcggccg ccacccgagt gagcgacacg gccgtggggc ctggcaggcg 240
ctggacacgcg cccgaggact gggacattaa acctgacctc ccctcctcca aaaaaaaaaa 300
aaaaaaaaa 308
```

<210> 72
<211> 1688
<212> DNA
<213> *Homo sapiens*

<220>
<221> SITE
<222> (912)
<223> n equals a.t.q. or c

<400> 72	
acccacgcgt ccgctcatgt ggacttatgc cagtctagag gcagaatcag aaggctggt	60
tgaacatatac gcttccctt tttcctctcc ctccgccccct cccagtagac tccatcttc	120
aatgttgcag cctggttgag aaggagagaa aaaggtaggc ggaatttcca ggagatcccc	180
aagaatgcgt ccttgtctgt ggacaaaagat ggaccatgtg cccttcggaa tttagggatag	240
aaacaaatat tgtgtctct taacgattaa gctgtttat ggtgggtttt caggtttta	300
cctttttctt ttacccctt actctgcaag aatggggaaa gaatgcatac tgcaaaaatg	360
agtcttttaa attctgtctg cctactagg ttaagtatata ggtatgttg aaaatttcca	420
atgatgagag acagcacaaat aaatgtacact tatctcccta ggctgaaggc cataactaca	480
tagtggagta atttaaagaac tctcttgct tcaccaacccc aaaaggttgc tttttgatag	540
caactggcta atgaattttt aaaaagagaa gaaaaatact agttttcccc tcttttggga	600
aatagatttt aaatggctaa actactagcc taaaactac tagtctataa atcaactacc	660
acttttgcata atctgacagg ccacattttt atatggccct ttacagaatg gagtgtgttg	720
aacaggatac taacgccatg gagttgagct gggcctagcg atggagggac actctaacac	780
aactttccct cagcttattat gcaacagatc agggaaaaag atggatgac agatgggtc	840
agacagaaaa agcttctggg aaacaagctt acatagtctt tttaaaatg cacaaggcct	900
cccagctaa angtcacttg gtttgggctt cattaggact ggagactttg ttggagttct	960
ttctggaaac ttggagatgt gatgatattc aggctctgaa acattcccg cgctccccg	1020
agggtgccccac ttctcaaga tggaaaactgt gactaaaaaa attaataata aatgtttctg	1080
agctgcctgt gttctccctg tgggggtgag agaaggggact agactcctaa gcctgcctca	1140
gatacaagag ggatcattgg ctccaaatttt agagaacttg aaagcaaggc ttggacaaa	1200
attttgagac cctaatactt ttacccctt ccaaattacc caacatacgg taaacaacat	1260
ttgtgcagaa gtatgtatgt atttagttca ggttgacttg tgccttata aactgttact	1320

caaattgattt	gaacttttat	gcgactggga	ttttttttt	ccaaagctac	aagcatggcc	1380
gcctgtggta	tcgagggttt	gcaaaacaata	tctgtttgc	gcttcctgtt	ttaacacctacc	1440
tcgtttgtt	tgttttgtt	tcactgttca	tcacagcagt	gttatctcca	ggagacatata	1500
agagagctca	accggcaatc	tcaggtgcat	ttaacatttt	taaaacgaaa	cagtagttga	1560
ccaaattttt	cttctaaaaa	aatttggaaat	ggggggaaatc	caatgacaaa	aactaatgtg	1620
gcttgtttct	ggagaaaata	attactgtaa	atggaacaac	aacaacaata	aaacacacgt	1680
taaacatc						1688

<210> 73
<211> 1138
<212> DNA
<213> Homo sapiens

<400> 73						
gggcgcctgt	agtcccagct	attcaggagg	ccgaggcagg	agaattgcct	gaactcagga	60
ggcggasttg	cagtgagccg	agatcgcc	attgcactcc	agcctgggtg	acagagtgg	120
actctttctc	ccaaaaaaaaa	aaaaaaaaaa	aaagtcaaat	gcagctggga	atgtggttcg	180
tgcctttttg	tatattaacc	atttggaaact	tgggtgttaag	gtgggggttg	caatgtcagg	240
cctggctgca	gcagctcatg	tcttttaggt	gtgccttttc	cctctctcg	ggggctcgag	300
caagactacc	ttcatacatatg	ggctctccag	ttacatagca	actccagtgt	taaattccat	360
ctttttttcc	tggaaaagcc	gtagaaaagga	cacctggaca	tgcctgctgc	acaggttgc	420
tgccttcccc	atcagccsca	gaaggaggaa	ctttgcttc	ttctctcaca	gctgtgtgt	480
cataagaagt	agttcggatg	atgtgggtcc	caccatgtat	tccttctcg	ttccatgttag	540
agtaaaaataa	atgggagttc	tgtttaatgc	atcacctcg	ttcatatattgc	atttgccaaag	600
aaagtgcata	tttatttgaac	attaggattt	aatttcttac	tgagtaatca	atttcagtag	660
taagttaaaa	tgcctctat	taatggacaa	ctgcaaccgt	taatcagagt	tacagtagat	720
taacagttgt	cagcatttat	gctaataatgc	ctaataaaacc	gtgggctcat	gatttgcact	780
ttataattcc	atatttctca	aaacagttgg	taataactttt	tgcttgaagg	tattgattct	840
tttgtccctt	tgcctgctac	ttggagatgt	agagaaaagct	aaatgacatt	ttcacggta	900
tgacacaata	tcaccccttg	ctttgcaca	cttggcttg	tgtcaaaata	gatggaaagg	960
gttcattttt	tctggctgc	tactgtttaa	tttgatctgg	tgtgtgacta	aagcaagaca	1020
aatagtattt	ttaatgaaac	catttaataa	cctctggtag	cttagagtcg	aaggcatttg	1080
aaaaatgc当地	ttaaaggatg	ccttagatgta	aacaaaaaaaaa	aaaaaaaaagg	gccccgc当地	1138

<210> 74
<211> 777
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (761)
<223> n equals a,t,g, or c

<400> 74						
gtagcacctt	gaaattgggc	agttctgaat	atgctgtga	gtaaaggaa	aatcaactatc	60
tttttaggac	ctttggaaatg	tggctccatg	catttgcata	cgttgttctc	ttcagggctg	120
attttctgg	gctgttctac	tcctctatcc	ttctgtgatt	gtctccaat	tcttttattta	180
tggtttaggt	tccctgtaga	aaccagtggg	gtgtgttagtt	aacaagtgtc	aaaaggagta	240
gaataattac	tttatgtgat	gtacttacga	gaataactact	tagtagaaatc	cagtataacc	300
aaacaaaaatg	tagacgtatt	taactatcca	gtgtgtcagc	tacacatttt	ctcatctta	360
tcacttctgc	tctggatatt	gtgatctact	ttcctatctc	tttgatattt	tkttttcaca	420
tttctttttt	gtgtaaaactg	ctctataactc	ttattgaaac	ttgagcataa	ttttatattt	480

acatagtaaa gtttctgata tgattagaac ataagttgtw tctcctaatt ttccaaataga	540
gccattgatk tttcattta acccctttta atggaacact tactagctt ctaaattata	600
aacttactaa cttaaatat acatgaatta ttctcgca ttctaaaac aagggtactg	660
aacttcgwtt tcttgatgt tcagggaaa agaattctga gtgttggaaa ggactttaga	720
tgtcttccaa ggatttatgg gatcaattta agaaaaaaaaaaaaaaa naaaaaaaaaaaaa	777

<210> 75
<211> 1060
<212> DNA
<213> Homo sapiens

<400> 75	
gatgtatttc cttaatatgt agtttcagaa gtggaaattna ttagagttaa actaaactca	60
ttaaatttag agtttcttat tgcctttcat gagaacattt ttcctttca ttcataaaatg	120
atattgaaac actatattct tactttcata ttccctgttta tattttgtt tttcatgttta	180
aacattttac attctaatag taacctcatc gacctgttaa aaggcaatat aagatttaga	240
ttattaaata gcatgtataa tatgtgatca gtaatctca atgagcttgk tcttcattta	300
attgcaacgt tatgtctgat ttttttgkt gcaaagctt cagaatctt acttgtggta	360
atcttcttt aaaaaagctt ttaacagaat taatargtca tcacgtttagt ataaatgatt	420
aaggaaatga tgccttaat acatkgattt attaaaacta tcattttgaa aaattatatt	480
ggtacaaact agtgtctact gctattactc atacattca gaattcatac atggatatcg	540
tcttaggattt ttttttgcg taatcatgag ttacgggttt aaagttatag ttttaattta	600
attatgttat agtgttaattt tatctgtttt acatctact tttgtatctg aaaccgttcg	660
aaaataatata ttattaaagg ccagttgaca aaatttccac tcctcctccc cagtgtgact	720
ttccttattt gtattatacc tataaagact accttaca tcggccaggc acagtggctc	780
acgtctgtca tcccagcaact ttggggaggac gaggtgggca gattgcctga gctcaggagt	840
tggagaccag cctgggtaat atagtgagat cctgtctta caaaatatac aaaattagct	900
aggcgtgcct gtatgtccag ctacttggga ggctgaggtg gtaggatggc atagagtcca	960
ggaggcagag gttcgactga gctgagatgg tgccactgca ctccagcctc agtgcagag	1020
ccagtccctg tctcaaaaaa aaaaaaaaaa gggcgccccgc	1060

<210> 76
<211> 1503
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (18)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> SITE

<222> (1501)
<223> n equals a,t,g, or c

<400> 76

gtggangccg	ctcctganaa	ctagtggtc	ccccgggctg	ncaggattcg	gcacgagaat	60
gaatggcaaa	gaaatagaag	gggaagaaaat	tgaaatagtc	ttagccaage	caccagacaa	120
gaaaaggaaa	gagcgccaag	ctgctagaca	ggcctccaga	agcaactgcgt	atgaagatta	180
ttactaccac	cctcccttc	gcatgccacc	tccaattaga	ggtccccgtc	gtgggtggggg	240
gagagggtgga	tatggctacc	ctccagatta	ctacggctat	gaagattact	atgatgatta	300
ctatggttat	gattatcacg	actatcgtag	aggctatgaa	gatccctact	acggctatga	360
tgatggctat	gcagtaagag	gaagaggagg	aggaaggggg	gggcgagggtg	ctccaccacc	420
accaaggggg	aggggagcac	cacccctcaag	aggttagagct	ggctattcac	agagggggggc	480
acctttggga	ccaccaagag	gctctagggg	tggcagaggg	ggtcctgctc	aacagcagag	540
aggccgtgg	tcccgtggat	ctcgccggca	tcgtggggc	aatgttaggag	gcaagagaaaa	600
ggcagatggg	tacaaccacg	ctgattccaa	gcgtcgctcg	ccacaacaacca	acagaactgg	660
ggttcccaac	ccatcgctca	gcagccgctt	cagcaagggtg	gtgactattc	tggtaactat	720
ggttacaata	atgacaacca	ggaattttat	caggatactt	atggcaaca	gtggaaagttag	780
acaagtaagg	gcttggaaat	gatactggca	agatacattt	ggctctagat	ctacattctt	840
aaaaaaaaaa	aattggctta	actgtttcat	ctttaagttag	cattttgtcg	ccattttgtat	900
tgggctgaag	aatactcatat	tgtgtatata	ctcaagtctt	tttatttttc	ctcttttcat	960
aaatgctctt	ggacattattt	gggttgcag	agttccctta	ttctgggat	tacaatgctt	1020
ttatcgtttc	aggcttcattt	ttagcttcaa	aacaagctgg	gcacactgtt	aaatcatgat	1080
tttgcagaac	ctttgggttt	ggacagtttc	attttttgg	atttggata	gattacatag	1140
gagttatggag	tatgtgtaa	ataaaaaatac	aagcttagtgc	tttgcatttag	tagtttaag	1200
aaattaaagc	aaacaaattt	aagttttctt	gtattgaaaa	taacctatga	ttgttatgttt	1260
tgcatcccta	gaagtaggtt	aactgtgttt	ttaaattgtt	ataacttcac	accttttga	1320
aatctgcctt	acaaaatttg	tttgcattaa	acgtcaaaaag	ccgtgacaat	ttgttctttg	1380
atgtgattgt	atttccattt	tctgttcat	gtaagatttc	aataaaacta	aaaaatctat	1440
tcaaaaacaww	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1500
naa						1503

<210> 77
<211> 872
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (844)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (858)
<223> n equals a,t,g, or c

<400> 77

ggggaaagttc	ttcactgcct	tgcatttgac	tccagatccc	tccatccctcc	cagaggccttg	60
gcctcaaaaa	tgctgattct	agcatcatgg	aaatgctgtc	ctcaaagtgg	tctaaacggg	120
tttgtcttc	acttgctcac	ttaatctccc	ttttcatagg	gctgttgg	ttacttctgg	180
gaagttctgt	ttaccctgga	acagaaactc	tctccctaa	aaagttgattt	tattgaccca	240
tggaggccag	agacacttag	gcatatttc	cctccagact	agaagcttct	gaggaggacc	300
tcctgagtct	gcaccctgge	tccctgctgt	gctgaggggcc	cccgtgttaa	cctcacgttg	360
tgccctctct	gattcagagg	gcccagtgtg	gttctgtcag	ccaggcagtg	ccccagctc	420

tacagaaaatg agttgtcatt gcatcctagg gccagggtct tcgtgcttgt gtgtgttacg	480
tggaaagtatg tggacaccaa gtgtccctgg atggccacag cctgcgaagg aaactggggc	540
cagcagctgc tctgtgtttt cagccaaacaa tggctccctgc ccactgccgc tgcataacca	600
ccagaggcag gcttccttg acacaggcct gtcgttggag catgtccctg gcgagtccta	660
tttctattcc cctgtgggtt agggacaggc agctgtacct tcagtgtgtt gctggggcag	720
gagaatcgct tgaaccggga ggcggagggt gcagtgagcc aaaattgcac cactgcactg	780
cagtctgcag gacagagaga ggctmtatct caaaaaaaaaaaaaaaa actcgagggg	840
gggnccggga cccaatnngc catataggaa aa	872

<210> 78
<211> 573
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (560)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (563)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (566)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (567)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (571)
<223> n equals a,t,g, or c

<400> 78	
gatcaaggta ctttagtttg acaatcaggt cccaaactct ttttcttgc tcatttattc	60
attcaacaag tattttttgt gcactgaata tgtggccctc actaggcaga tgctgcctat	120
tctttgcct gttaactaat ttaaccttgc tcatacctc ccaaatcacc ttatgctcca	180
gagaaacttg tgtatggta cgtaccacat aatgtatgtt tggtaacta cagatagttg	240
atccagtaag attaccatgg agctgaaaaa ttccaatggc ctagtattta ctgtgtttt	300
aattattatt ttggaatgta ctccctttac ttataagaaa ctttagctgta aaacagccctc	360
agtcatgttc ttcatgaggt atttcagaaa atggcatgac tatcatagga gatgacagat	420
tcatgcattt tattccccct gaagactttc cagtgggaca agatgtggag gtggaaagaca	480
gtgtatattga tgatcctgac cctgcataaa tctagctaa tatgtgtgtt tgtcttagtt	540
gctgacaaaa aaaaaaaaaaaaaaaa naa	573

<210> 79
<211> 1509

<212> DNA
<213> Homo sapiens

<400> 79
ggcacgagga tgtaccta at gagcttcc attca cttt taaaataat ttgtatgtgt
accatctgg tcctctcccc tcccgtttt taaaaatatac aggatagcac tcccaggcca
cttgggtctc agttaagat ccctattaa tacatctgaaag gaaaatagag ccaagacctc
tggctcaaa tatataggaa ttgccttct ttagcttca ggactattgt gtaaaaccaa
gtaggggtct aatccctag aaggtagggg ctatccctt aaagagaata tgccccaga
ttattagcac tttagagga gaagccaagg tatgtagggg tggctggctg gcccattcgt
ggagcacgaa gagagaatgg gataccattg tggaaagaga agaaaagttc ctcaggggcc
tcccactgct aaagttttt gtgagatgtt gatctgtct tcctggattt gactttaaa
gaaattattc tggcagcaca tggtagtattc ttggatgatc ttgctgtct tattttccct
tttgtgtgtg tgggtgtg tggtaggttca tgggtttca ttgttaactc catctgctta
ggagagtggg ctctctataa gggAACCTGC tgtaaacttc attgcagcaa ggatgttagag
agaaaatagga cttaaattcca cttaggggctc tcatacaca ctttaaggag gagatttcta
gaaaaactgg gccagatttt ctttgttctc catcatatc atgtggcagg ctgttcagtt
ttcttactct tacctatgtg atatttctc gtaacgtgtc caaaaagaaa aaagacccaa
tcagtgctc ttgactttgt tcttgatcc ctcatgttct tcttgatcc agcatgtgtc
gggttccaa ttttgggtat gagttgcaaa atttaaccat tgggtttgtg ccctaccag
gggactcccc agtttctgac ttgaagtata ctgagaagaa tccacgggt gctatctggc
cagatataag tagattctat ttccctgggtt ctccctctcc ctgaggaccc ttttttat
tgtccccctc tcttaggttaa ttctccctt atttgacttt gttgagaagg aggttggaca
gttagattagc aaaggccaa gtgcacaaatt acagtgtgtt agagtgtggg gggaaaatta
gtcttatttt tccctacatg ggataacaaca ctgtgaattc aatcttcaac tgaaggccct
gcagttctcc taaaacatag ttgtttgtt ttctttaaca aagtttaagc tagtgttaat
aaattaaaaaa aaattgttttgc tctgtctact tcagcttgc ttatgccca ttcatattg
ttgtctgtgt tgtaattcat aacttttgc accatttctg atgtgtaaaa ttgggtgtct
tgtaaatatac ttataaagag ttcaattgtt aataaactat tggctgtttt aaaaaaaaaaa
aaaaaaaaaa

<210> 80
<211> 1109
<212> DNA
<213> *Homo sapiens*

```

<400> 80
ccacgcgtcc ggccgcagaa cgggctccgc ggacgcacggg ctccagggac gcacaggcag 60
ccccctccc accgcgggtg cggggggcgg gggggctgcc cccatgcggg gcccttcctg 120
gtcgccggct cggccgctgc tgctgctgtt gctgctgctg tcgccttggc ctgtctggc 180
ccaagtgtcg gccaggggct cggccctcggg gtccctggc gccccggact gccccggagg 240
gtgcacgtgc gtgcggggag gcctgcggc tgtcggcaact ctgcgtgccc gccgtgcccc 300
ccccctcgg cctgcgcctg cggcgctgc tgctggacca caaccgcgtc cgtgcgtgc 360
cgccagggtgc ctgcgggaa gcggggcgcg tacagcgcct ggacctgcgc gagaacggc 420
tgcaactcggt gcatgtgcga gccttctgg gcctgggcgc gtcgcagctg ctggacctga 480
gcgcaccaacca gctggaaagca ctggcaccaag ggactttcgc gccgcgtgcgc ggcgtgcgc 540
acctctcatt ggccggcaac cggctggcgc gcctggagcc cggcgctca ggcgcgtcc 600
cgctgctgcg ctcactcagc ctgcaggaca acgagctggc ggcactcgcc cggggctgc 660
tggggccggct gcccgccta gacgcgtgc acctgcgcgg caacccttg ggctgcgggt 720
gcgcgtctgc cccgccttcgc gcctggctgc gcgggcaccc gtcgcggcgc tcagaggccg 780
agacgggtct ctgcgtgtgg cggggacgcc tgacgctcag ccccttgact gcctttccg 840
acggccgcct tagccattgc ggcgcggcgc tcgcctgcg ggacctggcc cgtggttac 900
acgcgtcgggc cggccttcctt ctcgtcagc ctggcttcct gcctggcgct gggctctggg 960
ctcaccggct gccgtgcgcg cggccggccgc ctccgcacccg cccgcctccgg cccggccgaga 1020

```

ccgtccagac ccgaaccccg atcccaccc ccacggctgt gcctcgcccc cgAACCCGGG	1080
gagccccgtc cgctgccgc caaggctga	1109

<210> 81
<211> 807
<212> DNA
<213> Homo sapiens

<400> 81	
cccacgcgtc cggacgtcct gatagatcct ctgctccaat aggcaactcc ggccttcct	60
gccctgacct ggaacctctg ggagggctgc agagtaagtgc cccctctgc gctccgacgg	120
aggcacgagg cctgtggagt aggtccctct gttccgacag gtgcgacact tggcgctcca	180
tgcttgcggg tgccgggagg cctggcctcc cccagggccg ccacctctgc tggttgtct	240
gtgcttcac cttaaagctc tgccaagcag aggctccctgt gcaggaagag aagctgtcag	300
caagcacctc aaatttgcct tgctggctgg tggaaagagtt tgtggtagca gaagagtgt	360
ctccatgtc taatttccgg gctaaaacta cccctgagtg tggcccaca ggatatgtag	420
agaaaaatcac atgcagctca tctaagagaa atgagttcaa aagctgcccgg ttcagctttg	480
aatggaaacaa cgcttatttt ggaagttcga aaggggctgt cgtgtgtgt gccctgatct	540
tcgcttgtct tgcatttcatt cgtcagcgcac aattggacag aaaggctctg gaaaagggtcc	600
ggaagcaaat cgagtcata tagctacatt ccacccttgc atcctgggtc ttagagaccc	660
tatctcagac agtggaaatgt aaatggactg atttgcactc ttggttctt ggagccttgc	720
ggtggaatcc cttttccccc atcttcttct ttcagatcat taatgagcag aataaaaaaga	780
gtaaaatggt aaaaaaaaaaaaaaaa	807

<210> 82
<211> 1043
<212> DNA
<213> Homo sapiens

<400> 82	
ggcacgagtt gggccgggca ccccccagaag ctgaccccttga gacaaggatt tgggtgcaag	60
tggtttattt ggcagggtgcc cagaaagtgc tgacaggagt gggaaagtga gtttagggag	120
agaaggaagc cactacagggc tatgttcatg tgccagggttac tgctgtggg aactggggct	180
tacggatttc taggagatga cgtggaaatac acctcagtgt tgccccacca gaagggcaag	240
gaagcatggg tatttatatg tcagctccca ttcatttattt gctgagggca gctcctagag	300
ggcattgggt ctgcgtttca agcctgctgc acataggctg agaggaatcc ctgagttcga	360
gtcacaggcg cccacagtca tgctcagaca gcacatacag gaacagtgc tgccaggggc	420
atagggtggc cacaatacc accagttata aagagggaaatg atggaaagga aagacaagag	480
gaagggtgtgg agtttagattc ctgggtcaga tgtgaacccc tggctctcaa aacactcctt	540
ctttttttct tttttttttt tttttagaca ggatctcaact ctgttgacaca ggctagagtt	600
cagtgggtgtatcagggtctc gtggcagcct ctacccctta ggctcacatg atcctccac	660
ctcagcctcc tgtagtagctg ggactagagg cacacatcac cacacttgc tagtattaa	720
atttttctgt agaagtccat ggcgcgtgc tcatgcctgt aatcccgca ctggggagg	780
ccgaggcagg tggatcacct gaggtcagga gttcaagacc agcctggcca acatggtaa	840
accccgccctc tactaaaaat aaaaaaaaaat tagcctgggtc tcgtggcagg ctccctgtat	900
cctggctcct tggaggctg aggtaggaga atcacttgcata cccagaatgt ggagctgc	960
gtgagctgag atcatgccat tacactccag cctggcaag aagagtgaaa ctccatcgca	1020
aaacaaaaaaaaaaaaaaa aaa	1043

<210> 83
<211> 1173
<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (548)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (603)

<223> n equals a,t,g, or c

<400> 83

gtgtctcag	aaaaaaagaaa	aaagtttcta	aagtaaaaat	tgaaagtact	tcccctacaa	60
ccacagggtt	cttgacaga	ttaatgtaaa	ttcttcaga	tactcttctg	tggatgtaga	120
aacatgcaga	atgaggcaag	ctttaatttg	cttatgtcac	ttactgtgga	tagccttca	180
tatcttataa	gttaatgtca	gagcagcaat	ctcattttt	tccaattttgt	aaacatttta	240
tttaacctta	tgatggatat	tttggtgat	ttcagtatta	caaaaatgcc	tattaatagt	300
atattttcat	tatatttctg	ttacgaaatt	ataatgtac	aaacattact	atgcctgtgg	360
cagtatacat	ctgcacaagt	tttggaaatgt	ttatgcattc	ataggcaaaa	atgggataac	420
ttttgggcag	tggtcatgt	taatctgttg	atcagaatcc	agagattgcc	cttcccttg	480
ccaaattgtt	taagagtacm	ctagtttttg	gccgggtgca	rtggctcatg	cctgtatccc	540
agcatttnng	aggccaagac	gggcggatca	caaggtcagg	agatcgggac	catcctggct	600
aanttggta	ggccccatc	tactaaaaat	tccaaaaaaaa	cccacmaaaa	ccaaaaaaaaac	660
ccrcgccttgk	tggtggatt	acaggcatgt	gcmacaacac	ccggctaatt	ttttttgtat	720
tttttagtaga	ggtgggtgt	caccatgttg	gccaggctga	tctcaaactc	ctggccttaa	780
gtgatctgcc	caccccgac	tcccaaagtgt	cggaattaca	ggcgtgagcc	accgcgccc	840
gccactgggtt	tttaaacttt	attttgaat	tatccaggc	tggcgcagt	ggttacgccc	900
tgtgatccca	acactttggg	aggccgaggc	ggcggatca	cgaggtcagg	agatcaagac	960
catccctggct	aacccgtct	ctactaaaaat	cagccggca	cggtggcagg		1020
tgcctgttagt	cccagctact	cagtggctgt	aggcaggaga	atgttatgaa	cccgggaggc	1080
ggagcttgca	gtgagctgag	atcacgccac	tgcactccag	cctggagac	agagtgagac	1140
tctgtctcaa	aaaaaaaaaa	aaaaaaaaactc	gag			1173

<210> 84

<211> 1561

<212> DNA

<213> Homo sapiens

<400> 84

ggcacgagt	aggctcatgt	ctgacctgca	gaactgtata	atgataaatt	atgttgtttg	60
aaaccgctac	atttgcgtt	atttgttaca	gcagcaatag	aaaacgaatc	ccctgcccag	120
aatgacttcc	tcctttcctg	tcggacgaag	gctcagccct	tctgtgaaa	gcttgcctcc	180
ctaagtatgc	acacccaatg	ccgaataactc	cccagaagca	gctgctattt	tctgaggaca	240
atgagttgt	tgttaagcctg	agaacaggac	gaaaaccac	tttgcagca	gccctgcgtg	300
tgacggccat	gccctcgag	ggcagggttg	ttttgcatac	tgctttctgt	cctgcctttt	360
tccccccatg	ggtcctgtct	ggctcttttg	cttctcact	ttgtgcagaa	agccatctca	420
actcttctca	caggagaata	gctgtatgga	cgtgcaggg	ggagttacca	catgcctacc	480
tccatggttt	tcgagagggg	cccctgcccc	aatgtctcag	tggccacctt	catcagacca	540
tggagcagtc	agagcgggaa	gggattctag	agttggtcca	gtccaaccat	ctcatcttac	600
atgtgaagga	ggaaaggaag	aaagggagaa	aaataagaaa	gctgaggtca	accctcctac	660
agggatgggc	ctggccaaca	ggatcccaag	ggatgacata	acattgaaat	taagaaacca	720
agggaaagtt	agaactaaag	aaaacagaac	ccagtcaagcc	aagaggcattc	cttgagggcc	780
aaccaagccg	tcaaacctgg	atgcccccg	cgagtcaagaa	agtcgggtgc	ctcaagagcc	840

aaggcagccaa	gaaatgggt	ctggaaactgg	cactttggtc	cgcctctgtg	cactcaccca	900
gaaagggtgg	aagggaccct	gggaccaagt	gccaaaggta	cacaacggat	gaatagactg	960
ctggacttca	aactgaacat	gccatttgc	caaagcagtc	atcaccttcc	gtgaatcata	1020
aatgtttgtt	caaagccaca	aatgtatata	ctctttgtat	gtatacagat	ttttctaaa	1080
ggttaacatc	taaacagatc	aattaaggtc	agcctaatt	tgtctgagct	ttttggtaa	1140
agtttcttga	gtaattgagc	gaattcaagt	ttctggctt	ctccttctc	tttctccatt	1200
taaaaacatga	tctcatgaaa	tttttgtccc	aagaaaggca	ggattacatt	ttcttttaac	1260
agtttgagtt	ggtgttagtgt	attcttggtt	atcagaatac	tcataatagct	ttgggatttt	1320
gaattgttaa	atattcatga	tgtgtgaaaa	atcatgatac	atactgtaca	atctcagtgc	1380
cacaaaattg	gatgttgc	ctacacacgc	acaggaccta	gaagagcatg	tcaaactata	1440
aactgcctgt	gattgtgaat	gactttgttc	tttgcttctt	gcgttttca	gtttcctata	1500
atgcacatct	taactttaa	aaaataaagg	ttatTTaaa	agccaaaaaaaa	aaaaaaaaaa	1560
a						1561

<210> 85

<211> 1433

<212> DNA

<213> Homo sapiens

<400> 85

cccgaggccg	tggacgcct	acagctgaga	aggggaccca	aggggtcgcc	cgcggccaag	60
gcccctagga	ccggccccc	agctcacgt	ggcgacggca	ttatkagaca	ttctgcgtca	120
ggtccggct	cctggacttc	gccttcccc	agccctggag	gtggggagaa	aaggttcacc	180
aatttttaaa	atccaaatat	atctcatggt	acagtgaaag	aactggccag	agagtctgga	240
agtttgggtt	ctggccttgg	ctgtgccact	gactcaactgt	gaccttggga	tcttgctgctg	300
tgaagacatt	tcccaagtgc	ttcatgttag	ccagcaaatac	tgacccacaa	ggcctgaaa	360
gaggtgattt	ttaggttgc	cagaggtggt	cttatccagc	tcagcttccc	ctgggaccca	420
ccgtgggacc	tgagggcagaa	ctggggtgga	cttggctcc	tccatggcac	accggctgca	480
gatacgtact	ctgacgtggg	atgtgaagga	cacgtgctc	aggctccgccc	accctttagg	540
ggaggcctat	gccaccaagg	cccgccccc	tgggtggag	gtggagccct	cagccctgga	600
acaaggcttc	aggcaggcat	acagggctca	gagccacagc	ttcccccaact	acggcctgag	660
ccacggccta	accccccgc	agtgggtgct	ggatgtggc	ctgcagaccc	tccacctggc	720
gggtgtccag	gatgttcagg	ctgtagcccc	catcgctgaa	cagcttata	aagacttcag	780
ccacccctgc	acctggcagg	tgttggatgg	ggctgaggac	accctgaggg	agtgccgcac	840
acggggctg	agactggcag	tgtatctccaa	cttgaccga	cggctagagg	gcatcttgg	900
gggccttggc	ctgcgtgaac	acttcgactt	tgtgtgacc	tccgaggctg	ctggctggcc	960
caagccggac	ccccgcattt	tccaggaggg	cttgcggctt	gctcatatgg	aaccagttagt	1020
ggcagccat	gttgggata	attacctctg	cgattaccag	gggcctcggg	ctgtggcat	1080
gcacagcttc	ctgggtgtt	gcccacagc	actggacccc	gtgtcaggg	attctgtacc	1140
taaagaacac	atcccccct	ctctggccca	tctcctgcct	gccttgact	gcctagaggg	1200
ctcaactcca	gggttttag	gccagtgagg	gaagtggctg	gccttagggcc	atggagaaaa	1260
ccttaaaca	accctggaga	cagggagccc	cttcttctc	cacagctctg	gaccttccc	1320
cctctccctgc	ggccttgc	acctactgtg	ataataaaggc	agtgagtgct	gagctctcac	1380
cttccccca	ctaaaaaaaaaa	actcgagggg	gggcccggta	ccc		1433

<210> 86

<211> 1377

<212> DNA

<213> Homo sapiens

<400> 86

ggcacgagg	ccagtcctga	ttccatcttc	ttacaagtta	gggagctggg	tccaggcctg	60
gatccatgtt	attatgaatc	aggaagttgg	gtccaggcc	ggctccatgt	tcctgcaggt	120

cagggcaggt cttcccccgaa	gtgatggctc ttggactgtg	ctcctctggg gccctctcaa	180
ctctgtgtct gtcatctgtc	acctgcctgg ccattatggt	tttgatggca gtggatggc	240
tccatggac ttcaggcctg	gggtgagact caggaccctg	gggtgggcat ggatgggat	300
atggacccc taaaaagaagg	gaagctgaga gactttttc	ctttaaagac ttttccatgt	360
tatctccact cagagaattc	tttctgcaa agtcacggga	gggaggtgac attgagccct	420
ccaatgtgac agaaaactgt	ctgggaaactt tacatgtgtt	acctaattt ttttaattatc	480
ccagcaactc cacaaagttag	gcatttttat tggtgaggaa	acagaagctt agagactttg	540
tgagacttgc ccgagacccc	aggtcacaca ccagcaagga	tgaggtcaag cttttaatcc	600
aggtctgcct ggcttcaagt	ccacaccctt tcacaacaat	gaactttctt tatgattgca	660
gatattattt ggggaaacttt	acatcaaaca ttgactacat	aaaacttcaa ccatagacta	720
tattcttgtt tttgaaact	gtgaagactc aaattttta	taaactcaga acagtttca	780
gttttctcta gatatcgaa	gatgggctgt gtttttgc	tgttgcctag tgaggctgat	840
tgttagtcag acagggtgat	cagtttgggtt ggagtaggct	attgtggttc tctctcatca	900
ggaaagaggg gatgcactt	gccccctcaac tccaagttgg	tggtgcgtatg atttttccat	960
attctccctt aacaggctgt	gagggagtct gggccaggca	ctaggccatg agcagggcag	1020
actgggttaa acccttagcg	agccctcttc cagccacgag	gaaaccttggaa gtgtgtcg	1080
gcctgtgtgc tgcgtgtgt	tgtgtgtgaa tgcacacgtg	tgtgcatgca ctgtgagctg	1140
gtgtgtcat gtgcactggt	gtgtgcgttt gtgtgtgtgt	gtgtgtgtgc atgtgtgtgc	1200
tgggtgcaca catcatatg	tctctgtta tacatgtgt	tgtgtgccag tgggtgcatg	1260
tgttgtaca gtgtgcgtgt	gtgtgtgtgt ttgtgcacat	gagctgctgc acacatataa	1320
gcctgtgaa tttagggaaag	aagaaaggct ccggcttaca	aaaaaaaaaaaa aaaaaaaaaa	1377

<210> 87

<211> 1715

<212> DNA

<213> Homo sapiens

<400> 87

ggcacgaggg acattggagc	tcccccacacc actcatgtct	gccaccaggc tataacaacta	60
cgtggctgtat cacgccagct	cttaccacat gaagccattt	cgaatggccc ggccaggggg	120
cccagaacac aacgagttat	ccctgggtgtc ggcacatggc	agttctggct cctaccttgg	180
ctctgagggaa cttcgacacc	aggatgactt tgatgtgtct	ctgcttgcgt gtcaactgtgc	240
tgcaccctt gaggagcaag	gagaggctga gccgcacgtt	ctgcggctac agttcttcgt	300
gggtgtcacc agccagcgag	agctttccc caggctcaact	gctgacatgc gccgccttccg	360
gaagccaccc agactgcccc	ctgagccaga ggctctggg	agttcagctg gcagccctgg	420
ggaggcctca gggcttattt	tagcgcctgg accggcttct	ctgttcccac cactggctgc	480
agaggtgggc atggcacgag	cacggcttgc tcagctggt	cggttggctg gagggcactg	540
ccgtcgccgac acccttttgg	agcccttctt cttgtctggag	ccacccggggc ctgatcgact	600
gcggctaggg gggcccttgg	ccctggcaga gctggagggaa	ctcctagaag cagtccatgc	660
caaattccatt ggggacatcg	acccccagct ggactgtttc	ctatccatga cggctcttgc	720
gtaccagagc ctgatcaaag	ttctcctaag ccgttccccc	agagctgtcg ccatttccaa	780
agcccaagact tggaaactca	gtacctgggtt ggcgtgaatc	agaagttcac tgactgtct	840
gcgcctagtt tctggactcc	acttagggaa gacgtctctg	aagtgggtt ccgagaagcc	900
cttccagttac agccccagga	cacgagaagc cccccctggcc	aactggtctc cacctaccac	960
cacctggagt ctgtcatcaa	cacaggctgtt tcacccttc	tggacccggcc tcctctgaag	1020
ggagttggact ggaccactga	atgtcaactgt tccttgaatc	atggggctac cagattgcct	1080
gccagaggca ggactgacca	gcccttctgg gccccagggc	aagccagaca ctgagtgaca	1140
ccaaaggctt tgtaactatg	tcttgagggt ctgtgttttt	agctggcag caggaaccgc	1200
cctccccaaa caccacacgc	cactgaccca tccaggactc	cagagacta ggtcaacccc	1260
gaggaccctt tggcccttc	tgggttactc ctteggcccc	ccctggtaga gtctcgaggag	1320
ttcacacagg gtggcaaaca	cccccttagag ctcctctgcc	tgaatctgc ccccttagct	1380
ttgaccactg tcagccacct	gtgtcccttg agccttgggg	tcttcacttc ccacttggac	1440
atcaactgtcg gacattccca	tcgagatgac acctgggttc	caatcccagc tctgccttgc	1500
aagcaacttgc gcccaccgtc	aagtccctt gctctcgac	cctgggttgc tcatccctta	1560

atgagggtggg ttcagaagct ctcccatctt cacagcaacc ctggcactgg cttctcaatg ggagggaagt cagcagagaa actgaagtgt tagacactat gtgtcccacc accccattac agagacatat gacaatgaaa aaaaaaaaaaaaaa	1620 1680 1715
---	----------------------

<210> 88
<211> 417
<212> DNA
<213> Homo sapiens

<400> 88 ccacgcgtcc gctcctcttag aggctccaca tgaagtcccc gtgctacagt cctagttatt ttgccttctt ctgcctgggt ttctttcaga tcacccagc cagttctcag acacttaggg gacatgttct ctgcaggacc actctgaggg actcttctgc atattgctga cctgagagga tggcctcaga gctgacttgg gcaatcctcc ccaacaggaa ggggagacat tgcctgccac tgaggaaaca ggtcatgaag gtggagataa gctgcaaggg gcbaagcaac tttatgtcag tggaaaacgt gtctcttaa agctgctatg tgaacagctt ttacagtcataaatttacc taaactaagg taaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa	60 120 180 240 300 360 417
--	--

<210> 89
<211> 1167
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (432)
<223> n equals a,t,g, or c

<400> 89 gggggtgggg cagggcgcgg tggggaaat ggcgtaccag agcttgcggc tggagtacct gcagatccca ccggtcagcc ggcctacac cactgcctgc gtcctcacca ccgcgcgcgt gcagttggaa ttgatcacac cttttcagtt gtacttcaat cctgaattaa tctttaaaca ctttcaataa tggagattaa tcaccaactt cttatttttt gggccagttt gattcaattt tttatttaac atgattttc tatatecgta ctgtcgaatg cttagaagaag gctttccg aggtecgaca gcagactttt tatttatgtt ctttttttgtt ggattctta tgaccctttt tggctgtttt gtgagcttag tttttttttt ccagccctt acaataatgc tcgtctatgt gtggaggcga angaaccctt atgtccgcatt gaacttcttc ggccttctca acttccaggc cccccttctg ccctgggtgc tcatggatt ttcccttgggtt ttggggaaact caatcattgt ggacctttt ggtattgcag ttggacacat atattttttcc ttggaaagatg tatttccaa tcaaccttgtt ggaataagaa ttctgaaaac accatctatt ttgaaagcta tttttgatac accagatgag gatccaaatt acaatccact accttgaggaa cggccaggag gcttcgcctg gggtgagggc cagcggcttg gaggttaaag cagcagtgcc aataatgaga cccagctggg aaggactcgg tgataccac tgggatcttt tattttttgt tgcaaaagtg tggacactt tgacagcttgcagattttt actccagaag cactttatga aatggtacac tgactaatcc agaagacatt tccaacagt tgccagttgtt ccctcaactac actggtaactg aaagtgtaat ttcttagagc caraaaactg gagaacaaa tattctgcac cctctaacaa gtacatgatg acttgatttt tatggtataa gcagagcatt ttcttcctct ttttgataga tgaggccatg gtgtaaatgg aagtttcaga gaggacaaaaaaa taaaacggaa ttccatttt ctctactgt aaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1167
---	---

<210> 90
<211> 1892

<212> DNA

<213> Homo sapiens

<400> 90

ccacgcgtcc	gggggaccgg	acggatcttc	tccggccatg	aggaagccag	ccgctggctt	60
cctttcccta	ctcctgaagg	tgctgctcct	gcctctggca	cctgcccgcag	cccaggattc	120
gactcagcc	tccactccag	gcagccctct	ctctccttacc	gaatacgaac	gcttcttcgc	180
actgctgact	ccaaccttgg	aggcagagac	tacctggcg	ctccgtgcaa	cccacggctg	240
ccggaatccc	acactcggt	agctggacca	atataaaaac	cacggcttag	tgccccatgg	300
tgctgtctgc	tccaaacctcc	cttatgcctc	ctggtttag	tcttctgccc	agttcaactca	360
ctaccgttgc	tccaaaccacg	tctactatgc	caagagagtc	ctgtgttccc	agccagtctc	420
tattctctca	ccttaaacactc	tcaaggagat	agaagcttca	gctgaagtct	caccaccac	480
gatgacccctc	cccacatctcac	cccacattcac	agtgcacagaa	cgccagacct	tccagccctg	540
gccttgagagg	ctcagcaaca	acgtggaaa	gctccttacaa	tcctcccttg	ccctggaaag	600
ccaggagcaa	gcccagagc	acaaggagaa	gcaaggagtg	gagcacaggc	aggagccgac	660
acaagaacac	aaggcaggaa	agggggcagaa	acaggaagag	caagaagagg	aacaggaaga	720
ggagggaaag	caggaagaag	gacaggggac	taaggaggg	cgggaggctg	tgtctcagct	780
gcagacagac	tcagagccca	agtttcactc	tgaatctcta	tcttcttaacc	cttccttctt	840
tgctccccgg	gtacgagaag	tagagtctac	tccttatgata	atggagaaca	tccaggagct	900
cattcgatca	gccccaggaaa	tagatgaard	aatgtaaaata	tatgtatgaga	actcctactg	960
gagaaaccaa	aaccctggca	gcctcctgca	gctgccccac	acagagcctt	gctgggtctg	1020
tgctattcga	tcgtggagaa	tacctgcata	ataacccccca	cagccaaggc	ctggaagtac	1080
atggaggagg	agatccttgg	tttcgggaaag	tcggctctgt	acagccttgg	gccccgacac	1140
atgtctaccc	gtgccctctg	tgacttctgc	tccttggaaagc	tggagcagtg	ccactcagag	1200
gccagccctc	agcggcaaca	atgcgcacacc	tcccacaaga	ctccctttgc	agcccccttgc	1260
ttgcctccca	gagcctgtcc	atcggcaacc	aggttagggtc	cccagaatca	ggccgctttt	1320
acgggcttgg	tttgtacgg	gggctccaca	tggacttctg	gtgtgcccgg	cttgcacacg	1380
aaggctgtga	agatgtccga	gtctctgggt	ggctccagac	ttagttccctt	agcttccagg	1440
atggggattc	ccttaccaaga	tttgtgacac	agactatatac	cagtacccaa	actactgttc	1500
cttcaaaaagc	cagcagtgtc	tgtatgagaaa	ccgcaatcgg	aagggtgtccc	gcatgagatg	1560
tctgcagaat	gagacttaca	gtgcgtctgag	ccctggcaaa	agtgaggagc	tttgtcttcg	1620
atggaggccag	gagttcagca	ccttgcactt	aggccagttc	ggatgagctg	gctgtctattc	1680
tgccccacacc	ccagcccaac	ctgcccacgt	tctctattgt	tttgagaccc	cattgtcttc	1740
aggctggccc	ttctgggtct	gttactcggc	ccctactcac	atttccttgg	gttggagacaa	1800
cagtcccaaga	gagggccatg	gtgggagtg	gccctcccta	aaagatgact	ttacataaaa	1860
tgttgatctt	aaaaaaaaaa	aaaaaaaaaa	aa			1892

<210> 91

<211> 523

<212> DNA

<213> Homo sapiens

<400> 91

cacagcaaag	caaggctcaa	gagccaagct	tcagaccaat	cccccacgt	gaagtcccc	60
gtgcgagtgc	cccttgaagg	aggtttcta	acagggtgagt	ggtctgattc	tgtctctgc	120
ctgtggatg	gatgggctgg	cacttgatgg	ctctccctcc	ccctcacccy	ccacggagaa	180
ggcttggaaagg	tgcatttctc	agacttcctt	gcctggaaa	tggaaagtga	tgcagaggat	240
ccaaacgtct	cctccggcagg	cttgggtggtg	gacgtgttgttgg	gccatgttcc	agggggccagc	300
tgctggctcc	gtgggtgtcg	agaggaaggg	ggaaggctgt	ctattttttg	gccaggatga	360
atccagcaga	tgtggtaggt	cctggccgt	tgctgaccgg	tgggtctacc	gggtgtcccg	420
gagctaattgg	tccccagatg	ctccacccgtc	ctgatgtggc	agaggcatgg	cattttggcg	480
ggccagtttgc	gtggcatactt	ggaaaccgtt	ttggaggctc	gag		523

<210> 92
 <211> 1382
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1382)
 <223> n equals a,t,g, or c

<400> 92

gcccggctggc	agcacgactc	gcgttagccgt	gcgccgattt	cctctcgccc	tggcaatgg	60
tcccggtgc	cggtcgacga	ccgccccggcg	tcatgcggct	cctcggtctgg	tggcaagtat	120
tgctgtgggt	gctgggactt	cccgtcccgcg	gcgtggaggt	tgcagaggaa	agtggtcgt	180
tatggtcaga	ggagcagcct	gctcacccctc	tccaggtggg	ggctgtgtac	ctgggtgagg	240
aggagctct	gcatgaccccg	atggggccagg	acagggcage	agaagaggcc	aatgcggtgc	300
tggggcttgg	cacccaaggc	gatcacatgg	tgatgtgtc	tgtgatttct	ggggaaagctg	360
aggacaaga	gagttcagag	cctagccggcg	tcacccgtgg	tgctggagga	gcggaggact	420
caaggtgcaa	cgtccgagag	agccttttct	ctctggatgg	cgctggagca	cacttccctg	480
acagagaaga	ggagtttattac	acagagccag	aagtggcgga	atctgacgca	gccccggacag	540
aggactccaa	taacactgaa	agtctgaaaat	ccccaaagggt	gaactgtgag	gagagaaaaca	600
ttacaggatt	agaaaaatttc	actctgaaaa	ttttaaatat	gtcacaggac	cttatggatt	660
ttctgaaccc	aaacccgttgt	gactgtactc	tagtccctgtt	ttacaccccg	tgggtcccgct	720
tttctgcctt	tttggccccc	cactttaact	ctctggcccg	ggcatttcca	gcttttact	780
ttttggcact	ggatgtcatct	cagcacagca	gccttctac	cagggttggc	accgttagctg	840
ttcctaataat	tttatttattt	caaggagcta	aaccaatggc	cagatttaat	catacagatc	900
gaacactgga	aacactgaaa	atcttcattt	ttaatcagac	aggtatagaa	gcacaagaaga	960
atgtgggtgt	aactcaagcc	gaccataatag	gcccttctcc	cagcactttt	ataaaaatgt	1020
tggactgttt	gcttgttattt	tccttattct	tttttaattag	tttttattatg	tatgtctacca	1080
ttcgaactga	gagtttccgg	tggcttaattc	caggacaaga	gcagggacat	gtggagtagt	1140
gatgggtctga	aaagagttgg	aaagagggaaac	ttcaatcctt	cgtttcagaa	attagtgtcta	1200
cagtttccata	cattttctcc	agtgacgtgt	tgacttggaa	cttcaggcag	attaaaagaa	1260
tcatttttttgc	aacaactgaa	tgtataaaaa	aattataaac	tgggtttta	actagtattt	1320
caataagcaa	atgcaaaaaat	attcaataga	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1380
an						1382

<210> 93
 <211> 1747
 <212> DNA
 <213> Homo sapiens

<400> 93

ccacgcgtcc	ggcttacctgt	gcatcggtct	gctcatgctg	ctgctgctca	tcttctggat	60
cgcgcggccc	catggggccca	ccaacatcat	ggtctacatc	agcatctgt	ccttgcgtgg	120
cagtttccacc	gtgccttcca	ccaagggcat	cgggctggcg	gcccaagaca	tcttgcataaa	180
caacccgtcc	agttagagag	ccctctgtct	gtgcctggta	ctctggcccg	tgctcggt	240
cagcatcatc	gtcccgatca	ggtacatcaa	caaggcgctg	gagtgtttcg	actccctcggt	300
gttcggggcc	atctactacg	tcgtgtttac	cacgctggtc	ctgctggccct	cagccatcct	360
cttccggggag	tggagcaacg	tgggccttgt	ggacttcttg	ggatggccct	gtggattcac	420
gaccgtctcc	gtggggatttgc	tccttataca	ggtgttcaaaa	gagttaattt	tcaaccttgg	480
ggagatgaac	aaatctaata	tggaaacaga	ctagatttgc	ataggagctt	ggatgggtcg	540
aggaataggc	attggggatgt	ttttctggcc	gtgatggat	gtgaagtaga	agagggtcc	600
gatcatggtg	tttagaatttgc	ctggatagta	acaggtggtc	tgggtggatag	cggggagcat	660
ggctcagcac	cagacgagag	gcccagcage	ctctgcagcc	caaacgtccc	aacgggtgcct	720

ggaccatctc ttctgatgag acgaatctca ttttcatatc cattaacctg gaagcttca	780
tgaatatttc ttctttaaaa cattttaca ttatataac agaaaaagat gggctttc	840
tgggttaggtg gtacatgata gcagagatat tttacttag attactttgg gaatgagaga	900
ttgtgtcttg aactctgcac tgtacaggat gtgtctgt tagtgttagt ttgcattaag	960
catgtataca ttcaagtatg tcatccaaat aagaggcata tcattgaatt gtttttaatc	1020
ctctgacaag ttgactcttc gaccccccacc cccacccaag acatttaat agtaaaataga	1080
gagagagaga agagttatg aacatgaggt agtgttccac tggcaggatg acttttcaat	1140
agctcaaatac aatttcagtg ctttatcac ttgaattatt aacttaat gactcttaat	1200
gtgtatatgt tcttagatta gaataatgca acttcgagta tgctttaata tttcaatatt	1260
caagttacaa atgtataagg cagttagaaa taatacagtc acatgtcaat taatgtatagg	1320
gaaacattct gagaaatgca ttgttaagggtg actttattgt gtgaacatca tggagtgcac	1380
ttatacaaac ctatggga cacctatgac ccacccaggc cagatggta agcctgttc	1440
tcctgggcca cacacctgtc cagcatgtc ctgcactgaa taccgcaggc aattgtacca	1500
cagtgttag tatttgtt tacaaacata ggaaaggta agtaaaacta tggtattaca	1560
atgttatggg accaccgtca tgtaagtggg atgtcttga cagaaacatg gttacgtgg	1620
tcatgactgt atattcaactg gaagatagtc aagactaaag acacattaga gcaaattgac	1680
ccctttaaca tggatttatt gtccaaattaa agacagttga tttaagtgc aaaaaaaaaa	1740
aaaaaaaa	1747

<210> 94
<211> 600
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (553)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (560)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (589)
<223> n equals a,t,g, or c

<400> 94	
gaattcggca cgagcggcac gagccgagat cgttctgggg ctgctggat ggacgcttat	60
tgctgaaact gaggacttcc gggccccgc attggctgg gtcattttt tagctgtatt	120
ttactgggtc ctcaccgtst tcttcctcat tatctacata acaatgacct acaccaggat	180
tccccaggtg ccctggacaa cagtgggcct gtgtttaaac ggcagtgcct tcgtcttgc	240
cctctctgcc gctgtgttag atgcatttc cgtctccct gagaaggaca gtcacaactt	300
caacagctgg gcggcctcat cttctttgc cttcctggc accatctgct acgctggaaa	360
tacatatttc agtttawag catggagawc caggaccata cagtgattt ccattttgtat	420
aattaaaaagg aaaaaaaaaaag gaagactctc actgtaaaaa cagctgtagg tataatgtat	480
attcccagag aattgtatatt aactaattaa tgtttttat attcttaat ttgcaccaa	540
attgtggttt gtnacaattn aactgggtta ctttatttgg caagtgtntt aggctttaa	600

<210> 95
<211> 586

<212> DNA

<213> Homo sapiens

<400> 95

ggcacgaggt	ttttccttt	ataacggaag	ttttataatt	catctttat	gtaagtgtaa	60
ttctcattaa	aaatacccta	aagcttaaaag	tttgcaggc	tgcggcgcct	aaccacaaac	120
agtttgatgc	tgccccctag	cgttgcattc	ccttcacctt	ttgctaaaat	aaggtaatgt	180
ttaaattaca	attagattt	cttactgcgt	taaatctggt	ctattttagt	ttcctctggg	240
tagtttgtgt	tgctaataag	atggacgtaa	gtgttttga	actggtgaat	tctgattgct	300
tttagcccccc	agttttccaa	atagggggtga	attttggta	gagatagaac	aatcaccaag	360
ttacctgtct	ccaaaaaaga	aatttacgta	tgggattgtt	ttcaaagcgg	gaagttagct	420
gtgtaaataaa	caacaatttt	atataatttaa	tctgggcttc	tccttatctt	gaatgatata	480
aaaatctact	ttcttagatta	atttagttcc	atataacttt	gtattgcttt	gactgtactg	540
ataataaaagt	ttgaaagtgt	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	586

<210> 96

<211> 802

<212> DNA

<213> Homo sapiens

<400> 96

ggcacgagcc	ctcccccctg	ctcgccccca	gattccccctc	ccctccctgg	tgctttgtc	60
tggagggtgt	tatgggtttg	tgtgtgtatg	agcgtgtgtg	tgtttttgga	tttcagacta	120
attttctgga	gtttctgccc	ctgctctgctg	tcacccctcac	gtcacttcgc	cagcagtagc	180
agaggccgcg	gccccggcgc	ccggaattgg	gttggaggcag	gagcctcgct	ggctgcgttcg	240
ctcgcgtct	acgcgcgtcg	tccccggcgg	tagcaggagc	ctggaccccg	gccccggcgg	300
cgggcgtgag	gccccggagc	ccgggtgagc	agcgcagata	gtgccctcg	tcgcctcg	360
cctcaactgtc	tccccctggg	gccccctcg	ctactcccc	gttgggacgt	gccccggccac	420
ctgcccgcgc	cacccggcacc	cacccggcgt	ggcggattct	gcagcatcat	tcgggggccc	480
cgtcgccgag	ccaaagccgc	cggcagtc	cgcattcccc	ttaaagggt	ccttcgcccc	540
gcctgtacca	tggaaatctg	tcttggggac	cctttcccta	cctccctcc	cttggcctca	600
ggctcgaaaga	gagagtggc	acactggtg	ctccagcggc	gtcagtgc	tcgccccca	660
agttgattcc	tggcactca	tccatccaca	gtctccggc	tggggtcg	gtggggatga	720
cgcgagcaga	gagggagagt	gcccccaatta	gtgggttgg	gggtcctacg	ctcagtc	780
cgcgtgtctg	tttgtcctca	gc				802

<210> 97

<211> 1226

<212> DNA

<213> Homo sapiens

<400> 97

ggcacgagca	tgctttgctt	acaatggagt	ctgcagttag	gggagatgct	gggatagcca	60
tttccatggc	tcttttatgc	aaggcacaat	ttcatctcct	.agatggactt	cctggtttc	120
tcttactgca	gttaacactgg	ccttcccttc	tctaattcct	taccccgact	gccccatccc	180
tgtgttaact	caggatgcca	agtggccctc	agattacact	tctccagata	gctgaatgag	240
tctgcttc	ctgtgactgg	gacctgaatg	acctgcagtc	agggcccaga	gttgggactc	300
tatactaccc	tgggctctgg	tctgttagtt	tgttagtagcc	accggtaata	agccaagggc	360
taggctctt	tttgagttt	tggccacctg	gaattttcag	tcatctcatg	atacaggcgg	420
gaggggcaga	acagatagat	tacgacaggt	ttgggttttta	attttccaa	ccaaatggaa	480
aggcaagttt	gtcttataga	aagcactact	gcacttagta	gctatgtat	tttgagcaaa	540
ccacataatc	tctcttagtgc	cattttccctaa	accacaagat	aaagatgtta	cattgtcaaa	600
gcttgcgtta	gattgggggt	gaatgaaaat	tattccttgc	tttcatcact	acctttatag	660

ctctcatcac tacctttata gctcatca	gtgcctttt ttcttccta	agaaaagacat	720
cacatccctc tccttcctc ctctgtgctc	ctgtccctcc ctccccctag	caaggccag	780
gcaaagctgg agatgaagct gaagatccag	agtttccctag aacgcactt	aaggatggct	840
aaggaaaggg aagcctgact gtcggcag	gagggtgcag tatctcttgc	tggaaacaca	900
gccagttcc acaatgccta gactgttat	gtctatttgc acaagattgg	ctttccat	960
tttggagtgg tcagacattt tattttgtt	caagatttac tggcggttta	gacaaatttg	1020
caaaaactgtg ctttattga ctttttgaat	aaacttttgtt attctggagc	aatgtattt	1080
atttatttgtt atgtcaatg acaaacttgg	tatttttccc atgtttgaca	tttatgttat	1140
gtttgttaga atttttagtgt ttgtctaagt	acacacatat atcaacaaat	taaactgaa	1200
tcgtttcaaa aaaaaaaaaa aaaaaa			1226

<210> 98
<211> 1120
<212> DNA
<213> Homo sapiens

<400> 98			
aggggactct acccctctcc cagcaatgtc	taaagtcaagg catctgaaaa	ccagcagtaa	60
tcctgcctt gaagtttata aggaaaggag	ctaaaaagag aaccaaattc	agcctgtgtt	120
ggaactctca gtcccagagg ggtgtggttt	atagctctcc ggcctgtgt	tggacttagg	180
ctgtgaccca cagaaggacg ccagaaagta	ctcaagacat tcacgggtcc	ccggtcagca	240
ctcgccatga cgaagacttc tacatgcata	taccacttcc ttgttcttag	ctggtataact	300
ttcctcaatt attacatctc acaggaagga	aaagacgagg taaaaacccaa	aatcttgca	360
aatgggtgca ggtggaaata tatgacgctg	cttaatctgc tcttgcagac	cattttctac	420
gggggtcacct gcctggatga tttgtgtgaa	agaaccaaag gggaaaaaga	cattaaggtc	480
ctaaactgcct tcagagaccc gcttttccacc	actctggctt ttccctgtatc	cacgtttgta	540
tttttggcat tctggatccct ctttctctac	aatcgagatc tcatttaccc	caaggtccct	600
gataactgtca tccccgtgtc gctgaatcat	gcaatgcaca ctttcatatt	ccccatcaca	660
ttggctgaag tggcctcactcc tatccatcaa	agaagacagg actcaccc	720	
stggctgtcg ccagcattgc ttacatcagc	cgcacatctt ggctctactt	tgagacgggt	780
acctgggtgt atccctgtgt tgccaaactc	agccttttgg gtctagcagc	tttcttctct	840
ctcagctacg ttttcatcgc cagcatctac	ctacttggag agaagctcaa	ccactggaaa	900
tggggtgaca tgaggcagcc acggaaagaag	aggaagtaat tgcacaccat	tttccaagaa	960
ccaaagaaaga agaaaacaca agagattttt	ctcatctttt ttttttttt	tctggtgag	1020
ggaggtggtg gagaaacata gcaaagttagg	agggacagag agtgatactt	aaatttaata	1080
agaggttcgt gaaggtaaaa aaaaaaaaaa	aaaactcgcg		1120

<210> 99
<211> 2596
<212> DNA
<213> Homo sapiens

<400> 99			
ccacgcgtcc gacttggcaa gcgttccacaa	ccaaaatggc cagctttc	tggaagatata	60
tgtaaaacgt gatggatttc cactatgggt	tggcctctca agtcatgtat	gaagtgaatc	120
aagttttgaa tggctctatgt gtagtacatt	tgactatatc ccatggaaag	gccaaacatc	180
tcctggaaat tggatccaaa aggaacttgg	aaacatgaaa aatgcactc	240	
tgttaaggat ggtgttattt gttataaacc	tacaaaatct aaaaagctgt	cccgcttac	300
atattcatca agatgtccag cagcaaaaga	gaatgggtca cggtggatcc	agtacaaggg	360
tcactgttac aagtctgtatc aggcattgc	cagttttca gaggccaaaa	aattgtgttc	420
aaaacatgtat cactctgcaa ctatcgatc	cataaaaagat gaagatgaga	ataaaatttgc	480
gagcagactg atgagggaaa ataataacat	taccatgaga gtttggcttg	gattatctca	540
acattctgtt gaccagtctt ggagttgggtt	agatggatca gaagtgcacat	ttgtcaaata	600

ggaaaataaa agtaagagtg gtgttggaaag atgttagcatg ttgatagctt caaatgaaac	660
ttggaaaaaaa gttgaatgtg aacatggtt tggaagagtt gtctgcaaag tgcctctggg	720
ccctgattac acagcaatag ctatcatagt tgccacacta agtatcttag ttctcatggg	780
cggactgatt tgggtcctct tccaaaggca cgggtgcac ctggcggtt tctcatcagt	840
tcgatatgca caaggagtga atgaagatga gattatgctt ccttcttcc atgactaaat	900
tcttctaaaaa gtttctaatt tgcaactaat gtgttatgag aaattagtca cttaaaatgt	960
cccagtgca gtatctactc tgctccaaag tagaactctt aaatacttt tcagttgtt	1020
agatcttagg catgtgctgg tatccacagt taattccctg ctaaatgcca tgtttacac	1080
cctaattaaat agaatggagg ggactccaaa gctgaaactg aagtccaaat tgtttgaca	1140
gtaatatgtt taatgttcat ttctctgtt tgaatgtgat tggttaacttag atatgtat	1200
ttaatagaa tttaatacaa aacttcttag aaaattaaaa taggcattt actaggtgac	1260
atgtctactt tttaattttt aagagcatcc ggccaaatgc aaaatttagta cctcaaagta	1320
aaaattgaac tgtaaaactct atcagcatgg ttcaaaaata gtcattttt gcaactggg	1380
aaaataaaaca ataagacatg cttaactttt aatttttatt ttttgagac tgagtcttc	1440
tctgttgcggc aggctggagt acaatggcgt gatctcggt cactgcaaat ctccgcctcc	1500
caggttcaag cgattctcct gcctcagcct cctgagtagc tgggattaca ggcaactgcc	1560
accatgcccc gcttaattttt gtatttttag tagagatggg gtttcaccat gttggccagg	1620
ctggctcga actcgtgacc gcagggtgate ctccccctc ggcctccca agtgctggg	1680
ttacaggcat gaccgaccgc gcctggccctc tgcttactttt ttatatacgaa aatgattcc	1740
tcttggcaag atgtttcttatttca aagttatttc ataccattat tatgtaaata	1800
tgaagagttt ttctctgtttt ataattgtttt ataaaaacaat gactttttaaa gatttagtgc	1860
ttaacattttt cccaaatgttg ggaacattat tttagattt agtaggtacc ttgttagcgt	1920
gtgctttgca ttctctgtatg tattacatga ctgtttcttt tgtaaaagaga atcaactagg	1980
tatthaagac tgataattttt acaattttata tgcttcacat agcatgtcaa cttttacta	2040
agaattttgtt ttactttttt aacatgtgtt aaacagagaa agggtccatg aaggaaagtg	2100
tatgagttgc atttggaaaaaa tgagactttt tcagtgaaac tctaaacattt gtgatgacta	2160
ctaaacaaatg taaaattatg agtgattaag aaaacattgc ttgtgtgtt tcactttaag	2220
ttttgacacc tagattatag tcttagtaat agcatccact ggaaaagggtg aaaatgtttt	2280
attcagcatt taacttacat ttgtactttt gtagttttt gtataaaaatc catagattta	2340
ttttacattt agagtattta cactatgata aagttgtaaa taatttcttta agacagtttt	2400
tatatagtct acagttgtcc tgatttcttta ttgaattttt tagacttagtt ctcttgcctt	2460
gtgatctgtg tacaattttt gtcactaaga ctccctcca agaactaagc caacttgcgt	2520
tgaaaagcac agctgtatataatggtgatg tcataataaaa gttgttttat cttttaagta	2580
aaaaaaaaaaaaaaa aaaaaaa	2596

<210> 100
<211> 1020
<212> DNA
<213> Homo sapiens

<400> 100	
aaacttagggg aaaaatgtgc caacatatac aaagatcttc agaaactctc tcgcctctt	60
aaagaccagc tgggtatcc ttctctggct ttacccgac aagcactgaa cctaccagat	120
gtatgggtt tggcgctt cccattggaa ctgaaactac ggatcttccg acttctggat	180
gttcgttccg tcttgtctt gtctcggtt tgctgtgacc tctttactgc ttcaatgac	240
ccactcctgt ggagggtttt atatctcggt gatttcgag acaatactgt cagagttcaa	300
gacacagatt ggaagactgt acaggaagag gcacatacaa agaaaagaat ccccgaaagg	360
gcgggttggc atgtcctgc catcgtaac tcacaccatt ccattctatc ccaaccctt	420
gcaccctagg ccatttccta gctcccgct tcctccagga attatcggtt gtgaatatga	480
ccaaagacca acactccct atgttgagaa cccaaatcagt tcactcattc ctggctctgg	540
ggagacgccc agccagtttcc tccactgag accacgctt gatccagttt gcccaactcc	600
aggacctaacc cccatcttgc cagggcgagg cggcccaat gacagatttcc cctttagacc	660
cagcagggtt cggccaaactg atggccggct gtcattcatg tgattgattt gtaatttcat	720
ttctggagct ccatttgc ttgtttctaa actacagatg tcaactcctt ggggtgctga	780

tctcgagggt tattttctga ttgtgggttt gagaggttgc ctcggcagaaa ccttttaaga	840
gatacatatta tagcccttagg ggtggtatga cccaaagggtt cctctgtgac aagggttggcc	900
ttggaaatag ttggctgcca atctccctgc tcttggttct cctcttagatt gaagttgtt	960
ttctgatgtt gttcttacca gattaaaaaa aagtgttaat taaaaaaaaaa aaaaaaaaaaa	1020

<210> 101
<211> 1520
<212> DNA
<213> *Homo sapiens*

<220>
<221> SITE
<222> (71)
<223> n equals a,t,g, or c

<220>
<221>. SITE
<222> (473)
<223> n equals a,t,g, or c

<210> 102
<211> 1306
<212> DNA
<213> *Homo sapiens*

<220>
 <221> SITE
 <222> (1300)
 <223> n equals a,t,g, or c

<400> 102
 aattccccggg tcgaccccacg cgtccggaat ttaaggacc cacactacct tcccgaagtt 60
 gaaggcaagc ggtgattgtt tgttagacggc gctttgtcat ggacacctgtg cggttggaa 120
 tattgctttt ccttttttg gccgtgcacg aggctggc tggatgtt aaggaggagg 180
 acgatgacac agaacgctt cccagcaa at gcgaagtgtg taagctgtc agcacagagc 240
 tacaggcggg actgagtcgc accggtcgtat ctgcagaggt gctggagctg gggcaggtgc 300
 tggatacagg caagaggaag agacacgtc cttacacgtt ttcagagaca aggctggaa 360
 aggcctttaga gaatttatgt gagcgatcc tggactatag tggactatag tggactatag 420
 gctcaactgag atatgccaag ggtcagatgc agaccatggc aacactgaaa ggcctagtgc 480
 agaagggggtt gaaggtggat ctgggatcc ctctggagct ttgggatgag cccagegtgg 540
 aggtcacata cctcaagaag cagttgtgaga ccattttggg rgargaggaa gaagaggagg 600
 aagaggaagg gggagacaag atgaccaaga caggaagcca ccccaaactt gaccgagaag 660
 atctttgacc ctgcctttt agccccccagg agggaaaggg atcatggaga gccccttaaa 720
 gcctgcactc tccctgtcc acagcttca gggtgtgttt atgagtgact ccacccaagc 780
 ttgttagctgt tctctccat ctaacacgtt gcaagatcc ggtggaaacag catgacatgg 840
 cttctgggtt ggagggtggg ggtggaggtc ctgcctcttag agatgaactc tatccagccc 900
 cttaaattggc aggtgtatgt gtcgacatgt ctgaaagctt tccttttaa ctgatcccc 960
 ccccaaccaa aagtccacgg tggcaacttca gctgtggct ttgggaaatg cacttagctc 1020
 cttaaaggctt gtttttagac ctttccaagg aagaggccag aacggacatt ctctgcgatc 1080
 tataatacatt gcctgtatcc aggaggctac acaccagcaa accgtgaagg agaatgggac 1140
 actgggtcat ggcctggagt tgctgataat ttaggtggg tagataactt gtcactttaa 1200
 gctcaatgtt acccagagcc caccatatac tttataggt gctcaatttt ctatatcgct 1260
 attaaactttt tttttttt tctaaaaaaaaaaaaaaaactcga 1306

<210> 103
 <211> 785
 <212> DNA
 <213> Homo sapiens

<400> 103
 ctttttagaaag gtacgcctgc aggtaccggc ccggaaattcc cgggtcgacc cacgcgtcc 60
 ggaaatgaac taccattttt aacttctgtt tttttattgtt gaaaatgatt cacgaattcc 120
 aaatcagatt gccaggaaga aataggacgt gacggtaactg gcccctgtga ttctcccaagc 180
 cttgcagtc cgcttaggtga gaggaaaaagc tctttacttc cggccctggc agggacttct 240
 gggttatggg agaaaccaga gatggaaatg agggaaatat gaactacagc agaagccct 300
 gggcagctgt gatggagccc ctgacattac tcttcttgc tctgtccctgc cttttttccc 360
 tctgcgaggc agtgggggtgg gattcagagt gcttagtctg ctcactgggaa gaagaagagt 420
 tcctgcgcattt gcaagccctg ctgtgtggct gtcgtttaca ttgggaggt gtcctgtatg 480
 tctgtacgtt gggactgcc ttttttttttggaa agataaaaa accttagcatc ctgttctcac 540
 cctctaagct gcattgagaa atgactcgatc tctgtattt tattttttttaaactttaa 600
 cttaaagggttca ttcgtgtccaa acatttttttaa gagctgtacc aaaaacaaaaa gcctgtactc 660
 acatcacaat gtcattttttttaa taggagcgtt ttgttatttt tacaaggcag aatgggggtgt 720
 aacagttgaa ttaaacttag caatcacgtt ctcaaaaaaaaaaaaaaaaaggcgcg 780
 gcccgc 785

<210> 104
 <211> 2015
 <212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1981)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1990)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2001)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2002)

<223> n equals a,t,g, or c

<400> 104

ccnngaatnc	cgggtcgacc	cacgcgtccg	gcctgcgctg	ccagcagcca	ggagccagga	60
gccaagagca	gagcgcgcage	atgaacttgg	gggtcagcat	gctgaggatc	ctcttcctcc	120
tggatgttagg	aggagctcaa	gtgctggcaa	caggcaagac	ccctggggct	gaaattgatt	180
tcaagtacgc	cctcatcggg	actgctgtgg	gtgtcgccat	atctgctggc	ttcctggccc	240
tgaagatctg	catgatcagg	aggcacttat	ttgacgacga	ctcttccgac	ctgaaaagca	300
crccctgggg	cctcagtgac	accatccccgc	taaagaagag	agccccaagg	cgaaaaccaca	360
atttctccaa	aagagatgca	caggtgattt	agctgttagt	gagcagtgac	gtgaagaggg	420
tttcttagccc	cgtgaaaac	agcccatgtt	taacatctca	ggatgtcctg	cattcaaaca	480
cccaaggctg	gtaatgaact	ttcacatgga	ctaatattt	gaggcaata	atagaaggaa	540
tagaatatac	agtgcctctg	tcctgaagga	aaatatcatg	ccctttctgg	aagaaacgga	600
ctgcacagag	gaaggattga	gcaatttgc	ctgcagtgga	agaaggtgga	caccaaaagc	660
ttcacccctgt	gttgagactg	tccatgcttc	catgaggcca	tgtgtccat	gtccgtggaa	720
cctaccacag	aaaatggctc	atgaaaaggg	aatccgacc	caacacacag	cttccttacac	780
actgccatct	tatcaacagt	taggcactac	tttgtaaac	gattagcttc	accctcttag	840
ctgcccaggag	atcccttctt	aaagatggac	tatgtgaaga	ttcgggagtc	ctgaaacatg	900
gggactccgg	gatggctct	agccctatcg	atgatgaaca	ctggccttct	ggagggaaaa	960
tggcagtcgt	ggctggcggt	gttaggaaggg	ctttgggtt	catggaatgg	gcctgctgct	1020
ctcagaccc	caaaggatgg	aaccaacgaa	ggaccaaata	agaaaagcaga	tgcttgccct	1080
gcagaggggcc	atgaatgtca	gttatttattt	ttctccctat	acaatttattt	tgtggttatt	1140
attacaatgt	acatggctgt	tgcataagaag	acatgactgg	tggaggctga	ggaaagccat	1200
gacattctac	aattgccatc	aggctaaggc	cccgtgagca	tttctctccc	ttgtaatatt	1260
aaccctgtat	ttctggatc	acatcacgga	atattcttg	ccttccact	ttccaggaaa	1320

tctctcgac tggctaccc tccttgtgt tgatgaaaga tgagctatat ttca	1380
agtgcgtgt tgtcatratt tgcctggact cccaggcgt ctcttaccca acttgataac	1440
gatgcgtttc attagcagcc ttgttaact gataaccaag agcggtaatg tgatactcat	1500
aagcaatttt ctgtgttag gataaaataa accatctgt atggaaaaaaa aaaaaaaaaa	1560
aaaaaaaaaaa aaaaggcg gccgctctag aggatccaag ctacgtacg cgtgcacg	1620
acgtcatagc tcttctatag tgkcacctaa attcaattca ctggccgtcg tttacaacg	1680
tcgtgactgg gaaaaccctg cgcttaccca acttaatcgc ctgcagcac atccccctt	1740
cgcagctgg cgtaatagcg aagaggccc caccgatcgc cttcccaac agttgcgcag	1800
cctgaatgcc gaatgggacg cgccctgtag cggcgcatta agcgcggcgg gtgtgggt	1860
tacgcgcacgt gtgaccgcta cacttgccag cgccctagcg cccgctcctt tcgcttctt	1920
cccttcctt ctcgccacgt tcgcccgggtt tccccgtcaa gctttaatc gggggctcc	1980
nttaaggtn ccaattaagg nnttaccggg acctt	2015

<210> 105

<211> 367

<212> DNA

<213> Homo sapiens

<400> 105

cggcacgagt gtaaatgtca ccaccaaagg tttgcaccct gatcaaaaag agtatgaaaa	60
gaataatacc acaacactta tggcctgtct tggaggcctt ctggggatta ttgggtgtat	120
atgtcttatac agctgcctct ctccagaaat gaactgtat gttggacaca gctatgttag	180
gaattactta cagaaaccaa ctttgcatt aggtgacctt tatecttcctc tgataaatct	240
ctggaaagca gggaaaagaaa aaagtacatc actgaaagta aaagcaactg ttataggttt	300
accaacaaat atgtcctaaa aaccaccaag gaaacctact ccaaaaatga aaaaaaaaaa	360
aaaaaaaaa	367

<210> 106

<211> 1889

<212> DNA

<213> Homo sapiens

<400> 106

ctcatccttc tatcatcata tggagtggca ataatgaaaa tgaggaggcg ctgatgatga	60
attggtatca tattcgtttc actgaccggc caatctacat caaggactat gtgacactct	120
atgtaaaaa catcagagag ctcgtactgg caggagacaa gagtcgtctt ttattacgt	180
ccagtctac aaatggggct gaaactgtt cagaagcctg ggtctctcaa aaccctaata	240
gcaattattt tggtgatgta cattttatg actatatcag tgattgtgg aactggaaag	300
ttttccaaa agctcgatt gcatctgaat atggatatca gtcctggccg tccttcagta	360
cattagaaaa ggtctcgct acagaggact ggtcttcaa tagcaagttt tcacttcatc	420
gacaacatca cgaagggtgg aacaaacaaa tgctttatca ggctggactt catttcaaac	480
tcccccaag cacagatcca ttacgcacat taaaagatac catctacctt actcaggtga	540
tgcaggccc gttgtcaaaa acagaaactg aattctaccg ccgttagtcgc agcgagatag	600
tggatcagca agggcacacg atgggggcac tttattggca gttgaatgac atctggcaag	660
ctccttcctg ggcttctctt gatacggagg aaagtggaaa atgcttcatt actttgctca	720
gaatttctt gctccactgt tgccactgt tttgaaatga aaacatgttc tatatctatg	780
gtgtgtcaga tcttactcg gattattcga tgacactcag tttgagatgc catacatgga	840
gctccctgga gcccgtgtgc ttcgtgtga ctgaacgttt tttgatgaaa ggaggagagg	900
ctgtctgcct ttatgaggag ccagtgtctg aattgtcgat gagatgtgg aattgcacac	960
gggaaagctg ttttacctt cagctgacca tgaactcctg agcccgacca	1020
actaccactt cctgtcctca ccgaaggagg ccgtgggct ctgcaaggcg cagatcactg	1080
ccatcatctc tcagcaaggt gacatattt ttttgacct ggagacctca gctgtcgctc	1140
cctttgtttt gttggatgta ggaagcatcc cagggagatt tagtgcataat ggtttcctca	1200

tgactgagaa gacacgaact atattatTTT accCTTggga gcccaccAGC aagaatgagt	1260
tggagcaATC tttcatgtg acctcctAA cagatATTa ctGAAGGAAT ctAGGTGta	1320
tttTCAGTgg acaatggaa TAAAGCATTt ctaaAGCACC GACTGGAGAG gaaggcaaca	1380
gagacaAGGA gagaAGCCGA gagACATGtC TGCGTGTcC CACGCACTG AGCGATGCT	1440
CTGTGAAGAG TTGTACACTG AACATTTCA GGGGAGGCTG TTTACCCAGG CAATGTCCTC	1500
AAACAAGCCT GTGCCGGGT GTCCTGGAAt CTGTGCCAGG ACTGTGTTT TAGCCCTCA	1560
CCTCTCAGCT TTAGCAGGAC ATGAACCAgT TATAACAAGA TGGCCCTGCA GCTGGTTACA	1620
AGAATGTGAC ATGGCAGGAT CTATGGAACC AAATGGAAGG TTTTGAGGTG ATGTAGGTCT	1680
TTCACAGTTA GCTTGGGAA ATACAGAATA CTCAAATAAA GTGCTTGT ATTATTCAG	1740
AGGGAATGGC GATGAAATG TTACAACAGA GATTCTTGG TGGTAGCTAT TTGGGTAAG	1800
GTATATGGAT ATTtTCTGT ACATGTGAAA TTATATAAAA ATAAAAGTtA TATAAATTAC	1860
ATTGAAAAAA AAAAaaaaAA AAAAaaaaAA	1889

<210> 107

<211> 1201

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1086)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1161)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1176)

<223> n equals a,t,g, or c

<400> 107

cggcacAGC ggctggcAGC acgactcgCG tacCGtgcGC cgattgcCTC tcggccTggg	60
caatggTccc ggctgcccGGT cgacgacCGC cccgCGtCAT gCGGCTCCTC ggctggTggc	120
aagtattGCT gtgggtGCTG ggacttCCCG tccgCGGCGT ggagggacCT tatggatttt	180
ctGAACCCAA acggtagtGA ctgtactcta gtcctgtttt acacCCCGtG gtGCCGCTTT	240
tctGCCAGTT tggccccCTCA ctTTAACTCT ctGCCCCGGG catttCCAGC tCTTCACTTT	300
ttggCACTGG atgcatCTCA gcacAGCAGC CTTTCACTCA ggtttGGCAC CGTAGCTGTT	360
cctaataTTT tattatttCA aggAGCTAA ccaatGGCCA gATTTAATCA tacAGATCGA	420
acactggAAA cactgAAAAT CTTCACTTTT aatcAGACAG gtatAGAAGC caAGAAAGAT	480
gtggTggtaA CTCAGGCCGA ccaaataGGC CCTCTTCCCA GCACtTTGAT AAAAGTGTG	540
gactggTTGC ttgtatTTtC CTTATTCTT ttaattAGTT tattatGTA tgctaccatt	600
cgaactgaga gtattCGGT gctaattCCA ggacaAGAGC aggaACATGT ggAGTAGTGA	660
tggTCTGAAA gaagttggAA agAGGAACtTt caatCCTTCG tttcAGAAAT tagtGCTACA	720
gtttcataCA ttttCTCCAG tgacGTGTG acttGAAACT tcAGGCGAGT taaaAGAAATC	780
atTTGTGAA caactGAATG tataaaaaAA ttataAAACTG GTGTTAAC tagtattGCA	840
ataAGCAAAT gcaAAATAT tcaatAGATG cactATTCTT GTTTTACTG catGMacGTA	900
atCCAGTATT TGGKAAAGTA atCCAKTTG AAATGTGRAG RTGTATTCCG GCAGAAATGT	960
gagtagAAATG acAGCTTACT atACAGAAGG CMAAAATAGG ACTCTCAGGT AATAGTTAA	1020
ggAAACCCtT gattcCTTAT gatGATGTT aAGAAAGGTT AGTTTCTGT ttCTTTGCCA	1080
gttttNCTC taggAGTCCA tagCCAGGGA aAGTATGTGA ACCAGAATTG GTTAGTGTGA	1140
ccccCTCAA gtagCCAGTG ntggAAATA AGGGTnCAAT ACCTTGATGT ttGTGATCTC	1200

t

1201

<210> 108

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 108

Met	Asp	Pro	Leu	Cys	Leu	Pro	Ile	Ile	Leu	Phe	Ser	Ala	Val	Val	Leu
1															15

Arg	Asn	Leu	Phe	His	Leu	Ile	Leu	Thr	Phe	His	Tyr	Leu	Pro	Leu	
															30
		20					25								

Phe	Cys	Asp	Asn	Pro	Leu	Ile	Leu	Glu	Asp	Leu	Ser	Cys	Ile	His	Leu
		35					40					45			

Arg	Val	Asn	Ile	Phe	Lys	Ala	Lys	Gln	Pro	Lys	Phe	Tyr	Gly	Asn	Gln
	50				55					60					

Leu	Gln	Pro	Cys	Val	Met	Lys	Ser	Ser	Ala	Xaa					
					65					75					

<210> 109

<211> 202

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (202)

<223> Xaa equals stop translation

<400> 109

Met	Lys	Leu	Leu	Ile	Leu	Phe	Leu	Ser	His	Leu	Leu	Ser	Leu	Ala	Phe
1															15

Gly	Ile	Leu	Cys	Leu	Ser	Val	Thr	Val	Ile	Leu	Ser	Leu	Leu	Ser	
									20						30

Phe	Ser	Lys	Arg	Gly	Phe	Ser	Val	Arg	Ser	Phe	Gly	Thr	Gly	Thr	His
	35						40				45				

Val	Lys	Leu	Pro	Gly	Pro	Ala	Pro	Asp	Lys	Pro	Asn	Val	Tyr	Asp	Phe
	50						55				60				

Lys	Thr	Thr	Tyr	Asp	Gln	Met	Tyr	Asn	Asp	Leu	Leu	Arg	Lys	Asp	Lys
	65						70			75			80		

Glu Leu Tyr Thr Gln Asn Gly Ile Leu His Met Leu Asp Arg Asn Lys
 85 90 95
 Arg Ile Lys Pro Arg Pro Glu Arg Phe Gln Asn Cys Lys Asp Leu Phe
 100 105 110
 Asp Leu Ile Leu Thr Cys Glu Glu Arg Val Tyr Asp Gln Val Val Glu
 115 120 125
 Asp Leu Asn Ser Arg Glu Gln Glu Thr Cys Gln Pro Val His Val Val
 130 135 140
 Asn Val Asp Ile Gln Asp Asn His Glu Glu Ala Thr Leu Gly Ala Phe
 145 150 155 160
 Leu Ile Cys Glu Leu Cys Gln Cys Ile Gln His Thr Glu Asp Met Glu
 165 170 175
 Asn Glu Ile Asp Glu Leu Leu Gln Glu Phe Glu Glu Lys Ser Gly Arg
 180 185 190
 Thr Phe Leu His Thr Val Cys Phe Tyr Xaa
 195 200

 <210> 110
 <211> 371
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (31)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (193)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 110
 Met Gly Leu Lys Leu Leu Gln Lys Pro Gly Ser Leu Lys Thr Leu Ile
 1 5 10 15
 Ala Ile Ile Leu Val Met Tyr Ile Phe Met Thr Ile Ser Val Xaa Cys
 20 25 30
 Trp Asn Trp Lys Val Phe Pro Lys Ala Arg Phe Ala Ser Glu Tyr Gly
 35 40 45
 Tyr Gln Ser Trp Pro Ser Phe Ser Thr Leu Glu Lys Val Ser Ser Thr
 50 55 60
 Glu Asp Trp Ser Phe Asn Ser Lys Phe Ser Leu His Arg Gln His His

65	70	75	80
Glu	Gly	Gly	Asn
Lys	Gln	Met	Leu
85	90	95	
Tyr	Gln	Ala	Gly
			Leu
		His	Phe
			Lys
Leu	Pro	Gln	Ser
Thr	Asp	Pro	Leu
100	105	110	
Arg	Thr	Phe	Lys
			Asp
		Thr	Ile
			Tyr
Leu	Thr	Gln	Val
Met	Gln	Ala	Gln
115	120	125	
Cys	Val	Lys	Thr
		Glu	Thr
			Glu
Tyr	Arg	Arg	Ser
Arg	Ser	Glu	Ile
130	135	140	
Val	Asp	Gln	Gly
			His
		Thr	Met
Gly	Ala	Leu	Tyr
Trp	Gln	Leu	Asn
145	150	155	160
Asp	Ile	Trp	Gln
			Ala
		Pro	Pro
		Ser	Trp
Ala	Ser	Leu	Glu
Tyr	Gly	Gly	Lys
165	170	175	
Trp	Lys	Met	Leu
		His	Tyr
			Phe
			Ala
Gln	Asn	Phe	Phe
		Ala	Pro
		Leu	Leu
		Pro	Val
		Gly	Phe
			Glu
			Asn
			Glu
180	185	190	
Xaa	Phe	Tyr	Ile
Tyr	Gly	Val	Ser
195	200	205	
Asp	Leu	His	Ser
			Asp
		Tyr	Ser
			Met
Thr	Leu	Ser	Val
Arg	Val	Arg	Val
210	215	220	
His	Thr	Trp	Ser
			Ser
		Leu	Glu
			Pro
		Val	Cys
Ser	Arg	Val	Thr
Glu	Arg	Phe	Val
225	230	235	240
Met	Lys	Gly	Gly
		Glu	Ala
			Val
			Cys
Leu	Tyr	Glu	Glu
Pro	Val	Ser	Glu
245	250	255	
Leu	Leu	Arg	Arg
		Cys	Gly
			Asn
			Cys
Thr	Arg	Glu	Ser
Cys	Val	Val	Ser
260	265	270	
Phe	Tyr	Leu	Ser
			Ala
			Asp
			His
			Glu
Leu	Leu	Ser	Pro
Pro	Thr	Asn	Tyr
275	280	285	
His	Phe	Leu	Ser
			Ser
		Pro	Lys
			Glu
			Ala
Val	Gly	Leu	Cys
Lys	Ala	Gln	Ile
290	295	300	
Thr	Ile	Thr	Ala
Ile	Ile	Ile	Ile
		Ser	Gln
			Gln
			Gly
Asp	Ile	Phe	Val
Phe	Asp	Leu	Glu
305	310	315	320
Thr	Ser	Ala	Val
Ala	Val	Ala	Pro
		Phe	Val
Trp	Leu	Asp	Val
Gly	Ser	Ile	Pro
325	330	335	
Leu	Met	Thr	Glu
Glu	Lys	Arg	Thr
340	345	350	
Thr	Ser	Leu	Thr
Asn	Glu	Glu	Gln
355	360	365	

Asp Ile Tyr
370

<210> 111

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (114)

<223> Xaa equals stop translation

<400> 111

Met Arg Pro Leu Leu Leu Gly Gly Tyr Trp Val Leu Cys Leu Ser Val
1 5 10 15

Leu Gly His Ala Ala Leu Tyr His Phe Trp Leu Arg Glu Glu Gly Lys
20 25 30

Gly Pro Pro Gln Val Xaa Ser Val Leu Ala Leu Ala Leu Pro Ala Gly
35 40 45

Ser Cys Ala Pro Gly Leu Pro Phe Pro Gly Pro Leu Ile Pro Thr Gln
50 55 60

Leu Leu Phe Ala Leu Glu Trp Gly Thr Pro Thr Pro Leu Arg Asp His
65 70 75 80

Pro Pro His Ser Met His Ser Ala Pro Gln Asn Pro Pro Val Phe Leu
85 90 95

Gly Thr His Thr Cys Pro Pro Ser Trp Tyr Phe Arg Leu Ile Pro Gln
100 105 110

Ala Xaa

<210> 112

<211> 152

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (152)

<223> Xaa equals stop translation

<400> 112
Met Arg Arg Leu Leu Leu Val Thr Ser Leu Val Val Val Leu Leu Trp
1 5 10 15

Glu Ala Gly Ala Val Pro Ala Pro Lys Val Pro Ile Lys Met Gln Val
20 25 30

Lys His Trp Pro Ser Glu Gln Asp Pro Glu Lys Ala Trp Gly Ala Arg
35 40 45

Val Val Glu Pro Pro Glu Lys Asp Asp Gln Leu Val Val Leu Phe Pro
50 55 60

Val Gln Lys Pro Lys Leu Leu Thr Thr Glu Glu Lys Pro Arg Gly Gln
65 70 75 80

Gly Arg Gly Pro Ile Leu Pro Gly Thr Lys Ala Trp Met Glu Thr Glu
85 90 95

Asp Thr Leu Gly Arg Val Leu Ser Pro Glu Pro Asp His Asp Ser Leu
100 105 110

Tyr His Pro Pro Pro Glu Glu Asp Gln Gly Glu Arg Pro Arg Leu
115 120 125

Trp Val Met Pro Asn His Gln Val Leu Leu Gly Pro Glu Glu Asp Gln
130 135 140

Asp His Ile Tyr His Pro Gln Xaa
145 150

<210> 113

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (56)

<223> Xaa equals stop translation

<400> 113

Met Pro Cys Gly Lys Phe Leu Phe Pro Val Ser Pro Val Ser Ser Leu
1 5 10 15

Ser Leu His Trp Ser Ala Val Leu Leu Leu Leu Ala Asp Phe Pro
20 25 30

Arg Val His Gly Ser Pro Pro Gly Val Ser Arg Val Ser Ile Leu His
35 40 45

Cys Leu Phe Pro Phe Leu Ser Xaa
50 55

<210> 114
<211> 237
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (237)
<223> Xaa equals stop translation

<400> 114
Met Glu Val Arg Leu Ile Phe Leu Ser Gly Leu Cys Ile Ala Val Ala
1 5 10 15

Val Val Trp Ala Val Phe Arg Asn Glu Asp Arg Trp Ala Trp Ile Leu
20 25 30

Gln Asp Ile Leu Gly Ile Ala Phe Cys Leu Asn Leu Ile Lys Thr Leu
35 40 45

Lys Leu Pro Asn Phe Lys Ser Cys Val Ile Leu Leu Gly Leu Leu Leu
50 55 60

Leu Tyr Asp Val Phe Phe Val Phe Ile Thr Pro Phe Ile Thr Lys Asn
65 70 75 80

Gly Glu Ser Ile Met Val Glu Leu Ala Ala Gly Pro Phe Gly Asn Asn
85 90 95

Glu Lys Leu Pro Val Val Ile Arg Val Pro Lys Leu Ile Tyr Phe Ser
100 105 110

Val Met Ser Val Cys Leu Met Pro Val Ser Ile Leu Gly Phe Gly Asp
115 120 125

Ile Ile Val Pro Gly Leu Leu Ile Ala Tyr Cys Arg Arg Phe Asp Val
130 135 140

Gln Thr Gly Ser Ser Tyr Ile Tyr Tyr Val Ser Ser Thr Val Ala Tyr
145 150 155 160

Ala Ile Gly Met Ile Leu Thr Phe Val Val Leu Val Leu Met Lys Lys
165 170 175

Gly Gln Pro Ala Leu Leu Tyr Leu Val Pro Cys Thr Leu Ile Thr Ala
180 185 190

Ser Val Val Ala Trp Arg Arg Lys Glu Met Lys Lys Phe Trp Lys Gly
195 200 205

Asn Ser Tyr Gln Met Met Asp His Leu Asp Cys Ala Thr Asn Glu Glu
210 215 220

Asn Pro Val Ile Ser Gly Glu Gln Ile Val Gln Gln Xaa
225 230 235

<210> 115
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (44)
<223> Xaa equals stop translation

<400> 115
Met Phe Cys Phe Tyr Leu His Phe Ile Phe His Val Leu Ser Tyr Lys
1 5 10 15

Leu Asn Pro Leu Leu Phe Phe Ser Cys Ser Cys Phe Cys Phe Ile Leu
20 25 30

Val Phe Leu Phe Pro Asp Tyr His Leu Gly Met Xaa
35 40

<210> 116
<211> 65
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 116
Met Val Arg His Ile Arg Glu Arg Arg Arg Gln Pro Leu Ala Phe Gln
1 5 10 15

Arg Val Leu Leu Ser Leu Cys Leu Leu Glu Gly Ile Trp His Ser Pro
20 25 30

Ala Ala Ala Ala Gly Gly Ser His Cys Ser Ser Trp Pro Ser Leu
35 40 45

Tyr Thr Thr Phe Gln Arg Val Ser Leu Leu Glu Leu Asp Leu Gly Leu
50 55 60

Xaa
65

<210> 117
<211> 118
<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (118)

<223> Xaa equals stop translation

<400> 117

Met Ala Arg Ser Ala Leu Arg Leu Glu Ile Leu Gly Gln Leu Leu Val
1 5 10 15

Gly Val Ser Ser Cys Cys Ala Glu Ile Arg Ser Arg Ser Tyr Leu Gly
20 25 30

Phe Cys Trp Lys Asn Ile Gln Asp Glu Arg Lys Lys Ile Ile Leu
35 40 45

Arg Gly Ser Arg Asn Leu Leu Cys Pro Arg Leu Leu Arg Pro Leu Glu
50 55 60

Pro Val Gln Ala Lys Gly Thr Gln Ser Val Asp Pro Arg Glu Val Val
65 70 75 80

Arg Glu Thr Arg Ser Met Ser Thr Leu Pro Ala Asp Phe Cys Leu Leu
85 90 95

Pro Gln Ala Ser Arg Met Ala Gln Lys Gly Ser Pro Ser Arg Ser Ser
100 105 110

Leu Gln Leu Leu Phe Xaa
115

<210> 118

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (65)

<223> Xaa equals stop translation

<400> 118

Met Thr Val Ser Leu Phe Leu Leu Ala Thr Ser Gln Ser Gln Asp
1 5 10 15

Gly Cys Cys Asp Ser Gly Ser Cys Pro Asn Ser Arg Gln Gln Glu Gly
20 25 30

His Gly Ala Ala Pro Ala Ser Arg Cys Pro Cys Arg Pro Ser Leu Gln
35 40 45

Ala Gln Glu Pro Lys Glu Glu Ser Thr Gln Met Trp Cys Ser His Leu
50 55 60

Xaa
65

<210> 119
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 119
Met Leu Lys Trp Thr Gly Phe Leu Val Val Leu Val Ala Phe Lys Lys
1 5 10 15

Ile Ser Ala Ser Phe Gln Val Asn Tyr Asn Leu Lys Phe Glu Ile Ser
20 25 30

Phe Gly Glu Pro Trp Lys Phe Thr Gln Trp Xaa
35 40

<210> 120
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 120
Met Ser Phe Gly Ile Ser Ile His Thr Cys Thr Tyr Leu Ile Phe Ile
1 5 10 15

Ala Phe His Phe Ile Ala Leu Cys Lys Val Thr Phe Phe Thr Asp Ser
20 25 30

Arg Phe Gly Asn Pro Met Ser Ile Ser Leu Ser Ala Pro Phe Phe Xaa
35 40 45

<210> 121
<211> 140
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (140)
<223> Xaa equals stop translation

<400> 121
Met Ala Leu Gly Ile Gln Lys Arg Phe Ser Pro Glu Val Leu Gly Leu
1 5 10 15

Cys Ala Ser Thr Ala Leu Val Trp Val Val Met Glu Val Leu Ala Leu
20 25 30

Leu Leu Gly Leu Tyr Leu Ala Thr Val Arg Ser Asp Leu Ser Thr Phe
35 40 45

His Leu Leu Ala Tyr Ser Gly Tyr Lys Tyr Val Gly Met Ile Leu Ser
50 55 60

Val Leu Thr Gly Leu Leu Phe Gly Ser Asp Gly Tyr Tyr Val Ala Leu
65 70 75 80

Ala Trp Thr Ser Ser Ala Leu Met Tyr Phe Ile Val Arg Ser Leu Arg
85 90 95

Thr Ala Ala Leu Gly Pro Asp Ser Met Gly Gly Pro Val Pro Arg Gln
100 105 110

Arg Leu Gln Leu Tyr Leu Thr Leu Gly Ala Ala Ala Phe Gln Pro Leu
115 120 125

Ile Ile Tyr Trp Leu Thr Phe His Leu Val Arg Xaa
130 135 140

<210> 122
<211> 92
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (92)
<223> Xaa equals stop translation

<400> 122
Met Met Asp Phe Leu Arg Cys Val Thr Ala Ala Leu Ile Tyr Phe Ala
1 5 10 15

Ile Ser Ile Thr Ala Ile Ala Lys Tyr Ser Asp Gly Ala Ser Lys Ala
20 25 30

Ala Gly Gly Ser Val Pro Asp Thr Arg Ala Val Cys Pro Ser Arg Ser
35 40 45

Glu Met Gly Arg Glu Leu Gly Ala Ala Ala Ser Arg Glu Gln Gly Val
50 55 60

Ser Pro Val Met His Pro Ile His Pro Val His Arg Cys Leu Ala Ser
65 70 75 80

Leu Leu Pro Ser Cys Leu Gln Leu Xaa Ser Thr Xaa
85 90

<210> 123

<211> 347

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (242)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (246)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (347)

<223> Xaa equals stop translation

<400> 123

Met Arg Arg Gly Ala Gly Ala Ala Arg Gly Arg Ala Ser Trp Cys Trp
1 5 10 15

Ala Leu Ala Leu Leu Trp Leu Ala Val Val Pro Gly Trp Ser Arg Val
20 25 30

Ser Gly Ile Pro Ser Arg Arg His Trp Pro Val Pro Tyr Lys Arg Phe
35 40 45

Asp Phe Arg Pro Lys Pro Asp Pro Tyr Cys Gln Ala Lys Tyr Thr Phe
50 55 60

Cys Pro Thr Gly Ser Pro Ile Pro Val Met Glu Gly Asp Asp Asp Ile
65 70 75 80

Glu Val Phe Arg Leu Gln Ala Pro Val Trp Glu Phe Lys Tyr Gly Asp
85 90 95

Leu Leu Gly His Leu Lys Ile Met His Asp Ala Ile Gly Phe Arg Ser
100 105 110

Thr Leu Thr Gly Lys Asn Tyr Thr Met Glu Trp Tyr Glu Leu Phe Gln
115 120 125

Leu Gly Asn Cys Thr Phe Pro His Leu Arg Pro Glu Met Asp Ala Pro
130 135 140

Phe Trp Cys Asn Gln Gly Ala Ala Cys Phe Phe Glu Gly Ile Asp Asp
145 150 155 160

Val His Trp Lys Glu Asn Gly Thr Leu Val Gln Val Ala Thr Ile Ser
165 170 175

Gly Asn Met Phe Asn Gln Met Ala Lys Trp Val Lys Gln Asp Asn Glu
180 185 190

Thr Gly Ile Tyr Tyr Glu Thr Trp Asn Val Lys Ala Ser Pro Glu Lys
195 200 205

Gly Ala Glu Thr Trp Phe Asp Ser Tyr Asp Cys Ser Lys Phe Val Leu
210 215 220

Arg Thr Phe Asn Lys Leu Ala Glu Phe Gly Ala Glu Phe Lys Asn Ile
225 230 235 240

Glu Xaa Asn Tyr Thr Xaa Ile Phe Leu Tyr Ser Gly Glu Pro Thr Tyr
245 250 255

Leu Gly Asn Glu Thr Ser Val Phe Gly Pro Thr Gly Asn Lys Thr Leu
260 265 270

Gly Leu Ala Ile Lys Arg Phe Tyr Tyr Pro Phe Lys Pro His Leu Pro
275 280 285

Thr Lys Glu Phe Leu Leu Ser Leu Leu Gln Ile Phe Asp Ala Val Ile
290 295 300

Val His Lys Gln Phe Tyr Leu Phe Tyr Asn Phe Glu Tyr Trp Phe Leu
305 310 315 320

Pro Met Lys Phe Pro Phe Ile Lys Ile Thr Tyr Glu Glu Ile Pro Leu
325 330 335

Pro Ile Arg Asn Lys Thr Leu Ser Gly Leu Xaa
340 345

<210> 124
<211> 234
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (173)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (234)

<223> Xaa equals stop translation

<400> 124

Met His Arg Gly Lys Leu Asp Cys Ala Gly Gly Ala Leu Leu Ser Ser
1 5 10 15

Tyr Leu Ile Val Leu Met Ile Leu Leu Ala Val Val Ile Cys Thr Val
20 25 30

Ser Ala Ile Met Cys Val Ser Met Arg Gly Thr Ile Cys Asn Pro Gly
35 40 45

Pro Arg Lys Ser Met Ser Lys Leu Leu Tyr Ile Arg Leu Ala Leu Phe
50 55 60

Phe Pro Glu Met Val Trp Ala Ser Leu Gly Ala Ala Trp Val Ala Asp
65 70 75 80

Gly Val Gln Cys Asp Arg Thr Val Val Asn Gly Ile Ile Ala Thr Val
85 90 95

Val Val Ser Trp Ile Ile Ala Ala Thr Val Val Ser Ile Ile Ile
100 105 110

Val Phe Asp Pro Leu Gly Gly Lys Met Ala Pro Tyr Ser Ser Ala Gly
115 120 125

Pro Ser His Leu Asp Ser His Asp Ser Ser Gln Leu Leu Asn Gly Leu
130 135 140

Lys Thr Ala Ala Thr Ser Val Trp Glu Thr Arg Ile Lys Leu Leu Cys
145 150 155 160

Cys Cys Ile Gly Lys Asp Asp His Thr Arg Val Ala Xaa Ser Ser Thr
165 170 175

Ala Glu Leu Phe Ser Thr Tyr Phe Ser Asp Thr Asp Leu Val Pro Ser
180 185 190

Asp Ile Ala Ala Gly Leu Ala Leu Leu His Gln Gln Gln Asp Asn Ile
195 200 205

Arg Asn Asn Gln Asp Leu Pro Arg Trp Ser Ala Met Pro Gln Gly Ala
210 215 220

Pro Arg Lys Leu Ile Trp Met Gln Asn Xaa
225 230

<210> 125

<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 125

Met Gln Gly Val Leu Phe Gly Phe Val Trp Leu Phe Ser Phe Leu Trp
1 5 10 15

Gln Glu Asn Lys Ser Ser Ala Ser Pro Ser Thr Leu Ala Lys Ser Gly
20 25 30

Ser Pro Cys Pro Val Ser Ile Pro Trp Met Pro Gly Val Leu Val Arg
35 40 45

Phe Phe Thr Leu Leu Xaa
50

<210> 126
<211> 82
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (82)
<223> Xaa equals stop translation

<400> 126

Met Arg Met Arg Val Ala Val Ala Pro Arg Pro His Gln His Leu Val
1 5 10 15

Val Ser Val Ser Trp Ile Leu Ala Ile Leu Ile Ser Val Ser Gly Tyr
20 25 30

His Cys Phe His Leu Gln Phe Ser Tyr Met Val Xaa Asn Ile Phe Pro
35 40 45

His Val Tyr Leu Ser Ser Ala Tyr Leu Leu Arg Pro Val Ile Cys Ser
50 55 60

Asp Leu Leu Pro Val Phe Val Cys Leu His Val Cys Leu Cys Leu Ile
65 70 75 80

Phe Xaa

<210> 127

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 127

Met Gly Trp Glu Ala Ala Leu Ala Leu Leu Val Ser Ala Val Phe Phe
1 5 10 15

Pro Trp Cys Thr Ile Gln Arg Pro Asp Val Gly Thr Thr Ser Pro Gly
20 25 30

Gly Leu Glu Arg Arg Ser Lys Gly Phe Xaa
35 40

<210> 128

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals stop translation

<400> 128

Met Thr Phe Met Ile Leu Lys Phe Phe Phe Leu Cys Gly Phe Val Leu
1 5 10 15

Asn Arg Leu Ile Ala Arg Gln Leu Ala Lys Ile His Ala Ile His Ala
20 25 30

His Asn Gly Trp Ile Pro Lys Ser Asn Leu Trp Leu Lys Met Gly Lys
35 40 45

Tyr Phe Ser Leu Ile Pro Thr Gly Phe Ala Asp Glu Asp Ile Asn Lys
50 55 60

Arg Xaa

65

<210> 129

<211> 50

<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals stop translation

<400> 129
Met Ile Val Asn His Phe Ser Phe Leu Phe Cys Trp Ile Val Phe Cys
1 5 10 15

Phe Leu Leu Gln His Ser Cys Phe Cys Cys Ala Tyr Phe Trp Ser Phe
20 25 30

Asp Ser Leu Cys His Cys Phe Leu Ser His Thr Pro Leu Arg Phe Thr
35 40 45

Gln Xaa
50

<210> 130
<211> 227
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (227)
<223> Xaa equals stop translation

<400> 130
Met Glu Thr Val Val Ile Val Ala Ile Gly Val Leu Ala Thr Ile Phe
1 5 10 15

Leu Ala Ser Phe Ala Ala Leu Val Leu Val Cys Arg Gln Arg Tyr Cys
20 25 30

Arg Pro Arg Asp Leu Leu Gln Arg Tyr Asp Ser Lys Pro Ile Val Asp
35 40 45

Leu Ile Gly Ala Met Glu Thr Gln Ser Glu Pro Ser Glu Leu Glu Leu
50 55 60

Asp Asp Val Val Ile Thr Asn Pro His Ile Glu Ala Ile Leu Glu Asn
65 70 75 80

Glu Asp Trp Ile Glu Asp Ala Ser Gly Leu Met Ser His Cys Ile Ala
85 90 95

Ile Leu Lys Ile Cys His Thr Leu Thr Glu Lys Leu Val Ala Met Thr
100 105 110

Met Gly Ser Gly Ala Lys Met Lys Thr Ser Ala Ser Val Ser Asp Ile
115 120 125

Ile Val Val Ala Lys Arg Ile Ser Pro Arg Val Asp Asp Val Val Lys
 130 135 140

Ser Met Tyr Pro Pro Leu Asp Pro Lys Leu Leu Asp Ala Arg Thr Thr
 145 150 155 160

Ala Leu Leu Leu Ser Val Ser His Leu Val Leu Val Thr Arg Asn Ala
 165 170 175

Cys His Leu Thr Gly Gly Leu Asp Trp Ile Asp Gln Ser Leu Ser Ala
 180 185 190

Ala Glu Glu His Leu Glu Val Leu Arg Glu Ala Ala Leu Ala Ser Glu
 195 200 205

Pro Asp Lys Gly Leu Pro Gly Pro Glu Gly Phe Leu Gln Glu Gln Ser
 210 215 220

Ala Ile Xaa
 225

<210> 131
<211> 118
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (118)
<223> Xaa equals stop translation

<400> 131
Met Gln Arg Ile Ala Ser Leu Leu Thr Leu Leu Thr Gln Leu Thr Leu
 1 5 10 15

Ala Ala Gly Ser Thr Pro Ala Glu Thr Ile Ser Asp Ser Ala Glu Ala
 20 25 30

Ser Leu Ser Ala Thr Pro Ser Leu Val Thr Trp Thr Gln Val Ser Gly
 35 40 45

Leu Gln Pro Leu Val Glu Pro Cys Leu Arg Gln Thr Leu Lys Leu Leu
 50 55 60

Ser Arg Pro Glu Met Trp Arg Ala Val Gly Pro Val Pro Val Ala Cys
 65 70 75 80

Leu Leu Phe Leu Gly Ala Tyr Tyr Gln Ala Trp Ser Gln Gln Pro Ser
 85 90 95

Ser Cys Pro Glu Asp Trp Leu Gln Asp Met Glu Arg Leu Ser Glu Ser
 100 105 110

Cys Cys Cys His Cys Xaa

115

<210> 132
<211> 306
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (180)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (197)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (306)
<223> Xaa equals stop translation

<400> 132
Met Ser Glu Asp Arg Pro Met Leu Gln Phe Leu Leu His Thr Ser Phe
1 5 10 15

Leu Ser Pro Leu Phe Ile Leu Trp Leu Trp Thr Lys Pro Ile Ala Arg
20 25 30

Asp Phe Leu His Gln Pro Pro Phe Gly Glu Thr Arg Phe Ser Leu Leu
35 40 45

Ser Asp Ser Ala Phe Asp Ser Gly Arg Leu Trp Leu Leu Val Val Leu
50 55 60

Cys Leu Leu Arg Leu Ala Val Thr Arg Pro His Leu Gln Ala Tyr Leu
65 70 75 80

Cys Leu Ala Lys Ala Arg Val Glu Gln Leu Arg Arg Glu Ala Gly Arg
85 90 95

Ile Glu Ala Arg Glu Ile Gln Gln Arg Val Val Arg Val Tyr Cys Tyr
100 105 110

Val Thr Val Val Ser Leu Gln Tyr Leu Thr Pro Leu Ile Leu Thr Leu
115 120 125

Asn Cys Thr Leu Leu Leu Lys Thr Leu Gly Gly Tyr Ser Trp Gly Leu
130 135 140

Gly Pro Ala Pro Leu Leu Ser Pro Arg Pro Ile Leu Ser Gln Arg Cys
145 150 155 160

Pro His Arg Leu Trp Gly Gly Arg Ser Pro Ala Asp Cys Ser Ala Asp

165	170	175
Cys Arg Gly Xaa Gly Trp Pro Ala Tyr Ser Pro Leu Pro Pro Trp Arg		
180	185	190
Pro Gly Leu Pro Xaa Leu Val Asp Gly Cys Leu Pro Ala Ala Arg Gln		
195	200	205
Pro Phe Arg Pro Leu Leu Pro Pro Ala Leu Gly Arg Leu Leu Ala Ala		
210	215	220
Cys Arg Pro Ser Trp Gly Pro Glu Val Cys Ser Trp Gly Ser Gly Thr		
225	230	235
Leu Ala Cys Pro Leu Cys Leu Arg Pro Arg Val Pro Ser Cys Lys Val		
245	250	255
Gly Pro Asp Ser Pro Ala Phe Pro Ser Pro Gln Cys Leu Thr Arg Gly		
260	265	270
Pro Pro Trp Thr Pro Ser Phe Cys Leu Arg Thr Val Ser Pro Gly Pro		
275	280	285
Ser Ser Met Arg Val Pro Arg Pro Leu Ser Pro Lys Arg Met Cys Gln		
290	295	300
Val Xaa		
305		

<210> 133
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 133
Met Ser Tyr Ser Leu Phe Leu Ala Leu Leu Ser Phe Ala Ser Ala Ile
1 5 10 15

Leu Phe Val Ala Gly Thr Ile Ala Gly Thr Gly Gly Leu Ser Phe His
20 25 30

Gly Ile Ala Thr Ile Phe Val Leu Thr Gly Lys Trp Xaa
35 40 45

<210> 134
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (44)
<223> Xaa equals stop translation

<400> 134
Met Gly Arg Leu Gly Xaa Gln Cys Leu Leu Phe Leu Ala Phe Lys Ala
1 5 10 15

Ile Ser Gly Val Phe Phe Leu Phe Trp Arg Pro Ala Asp Ser Thr Glu
20 25 30

Arg Asn Thr Gln Ser Trp Asp Phe Pro Pro Leu Xaa
35 40

<210> 135
<211> 50
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals stop translation

<400> 135
Met Gly Val Gly Val Leu Arg Ile Leu Leu Ser Cys Leu Gly Glu Ala
1 5 10 15

Ala Pro Lys Ser Ala Gly Thr Ser Leu Glu Ser Ala Lys Glu Cys Trp
20 25 30

Ser Ala Ala Thr Leu Leu Val Leu Cys Val Leu Cys Gln Leu Gln His
35 40 45

Gly Xaa
50

<210> 136
<211> 81
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (81)
<223> Xaa equals stop translation

<400> 136

Met Glu Ser Leu Pro Glu Asn Lys Pro Leu Val Trp Ser Leu Ala Val
1 5 10 15

Ser Leu Leu Ala Ile Ile Gly Leu Leu Leu Gly Ser Ser Pro Asp Phe
20 25 30

Asn Ser Gln Phe Gly Leu Val Asp Ile Pro Val Glu Phe Lys Leu Val
35 40 45

Ile Ala Gln Val Leu Leu Leu Asp Phe Cys Leu Ala Leu Leu Ala Asp
50 55 60

Arg Val Leu Gln Phe Phe Leu Gly Thr Pro Lys Leu Lys Val Pro Ser
65 70 75 80

Xaa

<210> 137

<211> 277

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (277)

<223> Xaa equals stop translation

<400> 137

Met Ile His Val Asn Arg Asn Ile Met Asp Phe Lys Leu Phe Leu Val
1 5 10 15

Phe Val Ala Gly Val Phe Leu Phe Phe Tyr Ala Arg Thr Leu Glu Ser
20 25 30

Lys Pro Tyr Phe Leu Leu Leu Gly Asn Cys Ala Arg Cys Ser Asn
35 40 45

Asp Ile Val Phe Val Leu Leu Val Lys Arg Phe Ile Arg Ser Ile
50 55 60

Ala Pro Phe Gly Ala Leu Met Val Gly Cys Trp Phe Ala Ser Val Tyr

65	70	75	80
Ile Val Cys Gln Leu Met Glu Asp Leu Lys Trp Leu Trp Xaa Glu Asn			
85		90	95
Arg Ile Tyr Val Ser Gly Xaa Val Leu Ile Val Gly Phe Phe Ser Phe			
100		105	110
Val Val Cys Tyr Lys His Gly Pro Leu Ala His Asp Arg Ser Arg Ser			
115		120	125
Leu Leu Met Trp Met Leu Arg Leu Leu Ser Leu Val Leu Val Tyr Ala			
130		135	140
Gly Val Ala Val Pro Gln Phe Ala Tyr Ala Ala Ile Ile Leu Leu Met			
145		150	155
Ser Ser Trp Ser Leu His Tyr Pro Leu Arg Ala Cys Ser Tyr Met Arg			
165		170	175
Trp Lys Met Glu Gln Trp Phe Thr Ser Lys Glu Leu Val Val Lys Tyr			
180		185	190
Leu Thr Glu Asp Glu Tyr Arg Glu Gln Ala Asp Ala Glu Thr Asn Ser			
195		200	205
Ala Leu Glu Glu Leu Arg Arg Ala Cys Arg Lys Pro Asp Phe Pro Ser			
210		215	220
Trp Leu Val Val Ser Arg Leu His Thr Pro Ser Lys Phe Ala Asp Phe			
225		230	235
Val Leu Gly Gly Ser His Leu Ser Pro Glu Glu Ile Ser Leu His Glu			
245		250	255
Glu Gln Tyr Gly Leu Gly Gly Ala Phe Leu Glu Glu Gln Leu Phe Asn			
260		265	270
Pro Ser Thr Ala Xaa			
275			

<210> 138

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 138

Met Cys Gln Thr Leu Pro Ala Arg Leu Arg Ala Gln Cys Ile Ser Ser
1 5 10 15

Leu Leu Phe Leu Leu Met Gly Leu Leu Ala Met Thr Gly Glu Arg Asn
20 25 30

Gln Gly Thr His Tyr Tyr Glu Phe Ser Gly Phe Ile Phe Lys Ser Gln
35 40 45

Met Met Trp Ser Ile Lys Pro Asn Xaa
50 55

<210> 139

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals stop translation

<400> 139

Met Tyr Leu Trp Phe Ser Phe Ser Thr Val Gly Leu Cys Gly Cys Cys
1 5 10 15

Leu Leu Tyr Arg Ala Cys Gly Phe Ile Trp Tyr Leu Leu Leu Leu Gly
20 25 30

His Ser Ser Thr Asn Ser Leu Gln Asp Gly Gly Ala Glu Arg Pro Glu
35 40 45

His Pro Trp Ala His Val Arg Tyr Ser Cys Arg Arg Glu Leu Ser Phe
50 55 60

Trp Phe Tyr Val Phe Asn Xaa
65 70

<210> 140

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (63)

<223> Xaa equals stop translation

<400> 140

Met Glu Pro Glu Ser Trp Ala Leu Cys Leu Leu Leu Phe Leu Gly Thr
1 5 10 15

Ala Leu Gly Tyr Pro Pro Leu Pro Arg His Ser Ser Lys Cys Glu Ile
20 25 30

Leu Glu Val Arg Leu His Leu Leu Pro Leu Leu Ile Asn Ile Gly Met
35 40 45

Met Ser Pro Val Ala Ser Pro Phe Val Cys Ser Ile Thr Gly Xaa
50 55 60

<210> 141
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (89)
<223> Xaa equals stop translation

<400> 141
Met Leu Phe Leu Ser Ala Ser Ile Cys Thr Ser Ala Leu Phe Leu Cys
1 5 10 15

Leu Ser Arg Leu Thr Ile Ser Ala Pro His Pro Ala Trp Trp Gly Arg
20 25 30

Met Pro Thr His Thr Ser Pro Gly His Leu Leu Glu Leu Gln Pro Arg
35 40 45

Gly Met Thr Glu Ser Ile Leu Phe Ser Ile Ser Ala Leu Val Ser Asn
50 55 60

Ser Trp Gly Lys Met Thr Gln Leu Thr Ser Gly Ser His Ser Trp Ser
65 70 75 80

Ser Gly Leu Gln Asn Phe Gln Ala Xaa
85

<210> 142
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 142
Met Arg Pro Val Cys Ser Leu Gly Trp Ala Gly Trp Pro Gly Leu Val
1 5 10 15

Cys Gly Leu Arg Ala Leu Leu Gly Pro Ser Leu Phe Pro Val Thr Phe
20 25 30

Gly Ala Thr Glu Ala Val His Ser Leu Asp Val Cys Ser Xaa

35

40

45

<210> 143
<211> 56
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (56)
<223> Xaa equals stop translation

<400> 143

Met Val Asn Glu Lys Glu Ala Arg Thr Gly Ser Pro Lys Ser Trp Leu
1 5 10 15

Leu Cys Leu Ala Leu Leu Leu Ile Lys Tyr Val Thr Phe Cys Lys Pro
20 25 30

Tyr Leu Thr Lys Pro Tyr Phe Leu His Leu Ser Val Leu Asp Gln Leu
35 40 45

Ser Pro Gly Thr Pro Leu Asp Xaa
50 55

<210> 144
<211> 77
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (77)
<223> Xaa equals stop translation

<400> 144

Met Phe Ile Ala Ile Tyr Phe Lys Ala Phe His Gly Ser Phe Gln Leu
1 5 10 15

Cys Thr Trp Leu Val Ile Met Ile Val Ile Leu Gly Gln Ser Phe Ser
20 25 30

Ala Leu Ala Leu Leu Thr Phe Trp Leu Ile Leu Cys Cys Arg Gly Cys
35 40 45

Pro Val His Cys Arg Val Phe Ser Ser Ile Pro Asp Leu Tyr Leu Leu
50 55 60

Asn Ala Arg Ser Asn Thr Val Pro Pro Ala Gln Leu Xaa
65 70 75

<210> 145

<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 145
Met Phe Phe Leu Ser Met Phe Leu His Ile Val Leu Leu His Cys Gly
1 5 10 15

Asn Ser Phe Tyr Lys Ile Cys His Ser Trp Asp Tyr Ala Ala Leu Gln
20 25 30

Glu Ser Thr Arg Phe Tyr Ser Asn Ser Tyr Xaa
35 40

<210> 146
<211> 102
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (102)
<223> Xaa equals stop translation

<400> 146
Met Glu Leu Glu Arg Cys Ser Val Val Leu Cys Ile Leu Ala Asn Leu
1 5 10 15

Ala Val Leu Arg Ala Leu Phe Leu Pro Cys Ile Ile Phe His Cys Val
20 25 30

Ser Asp Ser Arg Ser Val Asn Arg Glu Thr Lys Val Lys Phe Val His
35 40 45

Thr Ser Val His Gly Val Gly His Ser Phe Val Gln Ser Ala Phe Lys
50 55 60

Ala Phe Xaa Leu Val Pro Pro Glu Ala Val Pro Glu Gln Lys Asp Pro
65 70 75 80

Asp Pro Glu Phe Pro Thr Val Lys Tyr Pro Asn Pro Glu Glu Gly Lys
85 90 95

Gly Val Leu Val Thr Xaa

100

<210> 147
<211> 134
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (134)
<223> Xaa equals stop translation

<400> 147
Met Arg Val Pro Leu Val Leu Ser Trp Ala Phe Val Leu Val Gly Phe
1 5 10 15

Ser Gly Val Tyr Leu Ala Ser Glu Ser Phe Trp Phe Pro Pro Ser Leu
20 25 30

Cys Asp Leu Thr Ser Pro Pro Gly Leu His Leu Trp Lys Phe Ile Arg
35 40 45

Asp Leu Val Ser Met Glu Glu Leu Thr Asp Ser Ala Arg Glu Met Gly
50 55 60

Tyr Trp Met Met Val Phe Ser Leu Lys Ala Met Phe Pro Val Ser Ser
65 70 75 80

Gly Cys Phe Gln Glu Arg Gln Glu Thr Asn Lys Ser Leu Thr Leu Leu
85 90 95

Arg Cys Ser Gln Arg Asp Thr Ser Pro Leu Met Asp Gly Gln Thr Trp
100 105 110

Ala Arg Val Arg Val Thr Lys Pro Pro Thr Thr Ala Thr Ala Ala Tyr
115 120 125

Asn Arg His Ile Arg Xaa
130

<210> 148
<211> 50
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals stop translation

<400> 148
Met Lys Ser Leu Phe Cys Ile Tyr Phe Leu Arg Trp Pro Met Gly Leu
1 5 10 15

Ser Trp Gly Glu Thr Phe Ile Leu Leu Arg Asp Ser Leu Ala Ile Asn
20 25 30

Phe Gln Ser Phe Ser Lys Ala Ala Ser Gly Asp Ile Phe Gly Cys His
35 40 45

Asp Xaa
50

<210> 149
<211> 64
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (64)
<223> Xaa equals stop translation

<400> 149
Met Ser Cys Gly Leu Xaa Phe Gly Pro Trp Phe Val Pro Met Leu Leu
1 5 10 15

Met Ser His Ser Leu Leu Pro Ser Trp Ser Gly Leu Trp Val Thr Thr
20 25 30

Trp Asn Gly Ser Ser Gly Glu Arg Thr Pro Ser Pro Trp Arg Arg Lys
35 40 45

Arg Ala Ser Gln Ser Ala Gly Arg Ile Ala Ser Trp Met Ser Phe Xaa
50 55 60

<210> 150
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 150

Met	Leu	Ser	Ser	Pro	Asn	Leu	Ala	Ala	Ser	Leu	Leu	Cys	Leu	Trp	His
1				5					10					15	

Ser	Gly	Ser	Ala	Thr	Asn	Trp	Ala	Pro	Pro	Cys	Ala	Gly	Met	Trp	Ala
								25					30		

Ser	Arg	Cys	Gly	Trp	Lys	Val	Ser	Pro	His	Pro	Glu	Ala	Gly	Pro	Cys
		35					40					45			

Ser	Ser	Ala	Leu	Trp	Val	Ser	Cys	Cys	Val	Xaa	Ala	Glu	Gln	Pro	Gln
							50		55			60			

Pro	Gly	Gly	Arg	Glu	Pro	Arg	His	Arg	Gly	Xaa					
		65			70				75						

<210> 151

<211> 55

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals stop translation

<400> 151

Met	Pro	His	Ile	Ser	Phe	Cys	Leu	Gly	Thr	Pro	Tyr	Val	Val	Ala	Val
1							5			10			15		

Tyr	Leu	Pro	Ala	Trp	Ile	Val	Met	Leu	Leu	Leu	Pro	Gly	Val	Arg	Pro
					20			25				30			

Tyr	Ser	Ser	Leu	Gln	Ala	Leu	Lys	His	Pro	Ser	Cys	Ser	Ser	Ser	Ser
					35		40				45				

Val	Cys	Ala	Pro	Tyr	Met	Xaa									
		50			55										

<210> 152

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (58)

<223> Xaa equals stop translation

<400> 152

Met Gly Leu Asn Ile Ser Pro Trp Cys Phe Leu Ala Ile Leu Thr Cys
1 5 10 15

Ala Ile Ser Ala Ala Phe Ile Ser Val Gly Val Val Cys Trp Leu Leu
20 25 30

Phe Leu Ile Ser His Arg Ser Ser Lys Asn Leu Arg Lys Ser Arg Val
35 40 45

Arg Gly Val Trp Glu Asn Glu Glu Ile Xaa
50 55

<210> 153

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 153

Met Ala Tyr Val Leu Ala Val Leu Cys Phe Lys Ser Leu Trp Ala Leu
1 5 10 15

Phe Lys Pro Asn Lys Gln Leu Ile Glu Phe Leu Leu Met Val Lys Val
20 25 30

Val Lys Ile Pro Leu Cys Tyr Leu Arg Gln Leu Leu Gly Gly Ile Lys
35 40 45

Thr Pro Arg Val Xaa
50

<210> 154

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 154

Met Asp Gly Gly Pro Gly Ala Phe Ser Arg Ala Trp Val Leu Gln Ile
1 5 10 15

Pro Trp Leu Leu Leu Ser Gly Gly Asn Phe Ala Leu Cys Glu Pro Arg
20 25 30

Pro Cys Pro Ser Ala Gly His Pro Trp Gln Glu Ala Gly Leu Pro Ser

35

40

45

Ser Pro Xaa
50

<210> 155

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals stop translation

<400> 155

Met Pro Phe Leu Ser Val Trp Phe Phe Asn Leu Gly Leu Ile Phe Gly
1 5 10 15

Val Glu Ser Phe Val Leu Arg Ala Val Leu Phe Ile Ala Gly Cys Ser
20 25 30

Ala Thr Ser Gln Met Glu Ala Ala Ser Pro Tyr Pro Ala Val Thr Lys
35 40 45

Arg Lys Lys Asn Val Ser Xaa His Cys Gln Ile Ser Ser Gly Gly Ala
50 55 60

Pro Gly Xaa
65

<210> 156

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 156

Met Leu Leu Lys Arg Asn Leu Leu Ile Leu Ile Leu Phe Leu Val Thr
1 5 10 15

Cys Phe Asn Phe Val Ser Phe Phe Phe Pro Trp Lys Leu Leu Gly
20 25 30

Ser Pro Phe Tyr Pro Cys Ser Leu Arg Ser Asp Asn Asp Gly Cys Val
35 40 45

Xaa

<210> 157
<211> 61
<212> PRT
<213> Homo sapiens

<400> 157
Met Gly Ser Phe Leu His Pro Gln Trp His Leu Leu Ile Thr Phe Cys
1 5 10 15

Ala Val Leu Gly Lys Gly Leu His Ser Asp Pro Ser Arg Pro Phe Glu
20 25 30

His Gly Gly Ala Leu Gly Lys Val Pro Arg Gly Arg Ser Thr Leu Leu
35 40 45

Ser Lys Glu Val Leu Leu Lys Lys Lys Lys Lys Arg
50 55 60

<210> 158
<211> 118
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (118)
<223> Xaa equals stop translation

<400> 158
Met Leu Leu Trp Trp Gln Cys Leu Cys Cys His Ala Val Leu Glu Pro
1 5 10 15

Ala Ala Thr Ala Met Pro Glu Asp Ala Ala Pro Ser Ser Leu Pro Val
20 25 30

Pro Pro Asn Met Thr Ser Ser Arg Phe His Tyr Phe Trp Thr Leu Leu
35 40 45

Gln Ile Lys Leu Thr Gln Phe Tyr Ser Lys Pro Arg Ser Leu Ser Ala
50 55 60

Thr Pro Glu Lys Asn Ile Gly Leu Gln Glu Pro Glu Arg Arg Glu Arg

95

65 70 75 80

Phe Thr Gly Glu Ser Cys Arg Trp Glu Leu Lys Ala Lys Ser Cys Leu
85 90 95Cys Pro Thr Arg Asn Ser Leu Gly Cys Thr Gln Cys His Cys Asp Gly
100 105 110Xaa Lys Ile Cys Asn Xaa
115

<210> 159

<211> 151

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (151)

<223> Xaa equals stop translation

<400> 159

Met Leu Ala Val Leu Ala Phe Pro Val Gly Val Phe Val Val Ala Val
1 5 10 15Phe Trp Ile Ile Tyr Ala Tyr Asp Arg Glu Met Ile Tyr Pro Lys Leu
20 25 30Leu Asp Asn Phe Ile Pro Gly Trp Leu Asn His Gly Met His Thr Thr
35 40 45Val Leu Pro Phe Ile Leu Ile Glu Met Arg Thr Ser His His Gln Tyr
50 55 60Pro Ser Arg Ser Ser Gly Leu Thr Ala Ile Cys Thr Phe Ser Val Gly
65 70 75 80Tyr Ile Leu Trp Val Cys Trp Val His His Val Thr Gly Met Trp Val
85 90 95Tyr Pro Phe Leu Glu His Ile Gly Pro Gly Ala Arg Ile Ile Phe Phe
100 105 110Gly Ser Thr Thr Ile Leu Met Asn Phe Leu Tyr Leu Leu Gly Glu Val
115 120 125Leu Asn Asn Tyr Ile Trp Asp Thr Gln Lys Ser Met Glu Glu Lys
130 135 140Glu Lys Pro Lys Leu Glu Xaa
145 150

<210> 160

<211> 92
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (92)
<223> Xaa equals stop translation

<400> 160
Met Gly Asp Lys Leu Gly Met Ala Arg Ala Pro Ser Val Ala Leu Ala
1 5 10 15

Gln Leu Trp Leu Ile Cys Leu Cys Pro Glu Ser Leu Ala Ser Phe Val
20 25 30

Gln Ala Val Pro Trp Lys Val Leu Gln Pro Ser Ser Asn Arg Ser Thr
35 40 45

Asp Cys Ser Pro His Met Arg Pro Thr Cys Glu Thr Leu Gly Ser Arg
50 55 60

Lys Ala Gln Asp Leu Val Leu Asp Thr Met Cys Leu Ser Thr Asp Asp
65 70 75 80

Cys Gln Gly Leu Ile Cys Arg Gly His Arg Ser Xaa
85 90

<210> 161
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 161
Met Gln Val Ala Cys Val Met Lys Val Ser Ala Gln Trp Val Cys Phe
1 5 10 15

Phe Val Val Phe Ser Pro Leu Cys Ser Ser Val Lys Cys Ala Ser Ser
20 25 30

Gly Gln Asn Arg Gly Arg Gly Asp Gln Xaa
35 40

<210> 162
<211> 78
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (78)
<223> Xaa equals stop translation

<400> 162
Met Met Leu Gln Ile Ile His Leu Asn Thr Leu Ile Lys Phe Phe Gln
1 5 10 15

Cys Leu Lys Leu Phe Leu His Gly Thr Ala Gly Ser Gly Gln Lys Cys
20 25 30

Leu Ala Tyr Lys Phe Ser Gln Phe Pro Ser Ile Ile Pro Ala Ala His
35 40 45

Lys Lys Val His His Leu Leu Ser Pro Lys Cys Leu Pro Thr Glu Cys
50 55 60

Ser Gln Ala Asp Asn Ser Ser Trp Asp Ser Ala Val Trp Xaa
65 70 75

<210> 163
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 163
Met Lys Arg Leu Trp Cys Leu Ser Trp Val Pro Gly Leu Gln Gly Ser
1 5 10 15

Pro Ser Val Leu Ser Ser Val Phe Phe Ser Val Phe Lys Pro Gln Leu
20 25 30

His Trp Thr Cys Ser Gln Val Ser Ser His Trp His Pro Pro Cys Leu
35 40 45

Phe Ile Leu Phe Ser Gly Xaa
50 55

<210> 164
<211> 90
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (90)
<223> Xaa equals stop translation

<400> 164
Met Lys Phe Leu Leu Ala Ala Leu Val Leu Ser Leu Ile Leu Pro Arg
1 5 10 15

Ser Ser Gln Tyr Ile Lys Trp Ile Val Ser Ala Gly Leu Ala Gln Val
20 25 30

Ser Glu Phe Ser Phe Val Leu Gly Ser Arg Ala Arg Arg Ala Gly Val
35 40 45

Ile Ser Arg Glu Val Tyr Leu Leu Ile Leu Ser Val Thr Thr Leu Ser
50 55 60

Leu Leu Leu Ala Pro Val Leu Trp Arg Ala Ala Ile Thr Arg Cys Val
65 70 75 80

Pro Arg Pro Glu Arg Arg Ser Ser Leu Xaa
85 90

<210> 165
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 165
Met Phe Val Trp His Leu Lys Val Met Val Met Phe Ile Ile Leu Tyr
1 5 10 15

Phe Ala Tyr Cys Glu Ser Asn Phe His Ser Val Leu Ser Val Ser Lys
20 25 30

Pro Leu Leu Lys Ile Leu Phe Leu Pro Arg Asn Leu Xaa
35 40 45

<210> 166
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 166
Met Thr Pro Gly Cys Ser Val Pro Phe Leu Leu Cys Trp Leu Phe Ala
1 5 10 15

Leu Met Met Gln Glu Lys Trp Gly Gly Val Lys Ser Leu Val Ser Tyr
20 25 30

His Tyr Ser Arg Gln Trp His Gln Thr Val Val Val Xaa
35 40 45

<210> 167

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals stop translation

<400> 167

Met Ser Ile Ala Leu Arg Ile Asn Arg Leu His Phe Trp Val Leu Leu
1 5 10 15

Phe Phe Phe Phe Ala Gln Leu Ser Leu Ser Val Asp Leu His Gly
20 25 30

Thr Ser Tyr Ser Leu Lys Ser Leu Ser Tyr Leu Thr Ile Phe Leu Asp
35 40 45

Leu Glu Lys Leu Asp Val Gly Pro Tyr Glu Lys Ile Ile Arg Asn Gln
50 55 60

Ile Xaa

65

<210> 168

<211> 62

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (62)

<223> Xaa equals stop translation

<400> 168

Met Gln Leu Thr Leu Gly Gly Ala Ala Val Gly Ala Gly Ala Val Leu
1 5 10 15

Ala Ala Ser Leu Leu Trp Ala Cys Ala Val Gly Leu Tyr Met Gly Gln
20 25 30

Leu Glu Leu Asp Val Glu Leu Val Pro Glu Asp Asp Gly Thr Ala Ser
35 40 45

100

Ala Glu Gly Pro Asp Glu Ala Gly Arg Pro Pro Pro Glu Xaa
50 55 60

<210> 169
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 169
Met His Thr Ala Lys Met Ser Leu Leu Asn Ser Val Cys Leu Leu Val
1 5 10 15

Leu Ser Ile Trp Tyr Val Val Lys Phe Pro Met Met Arg Asp Ser Thr
20 25 30

Ile Asn Val Pro Tyr Leu Leu Arg Leu Lys Ala Ile Thr Thr Xaa
35 40 45

<210> 170
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (106)
<223> Xaa equals stop translation

<400> 170
Met Ser Gly Leu Ala Ala Ala Ala His Val Phe Arg Val Cys Leu Phe
1 5 10 15

Pro Leu Ser Trp Gly Ser Ser Lys Thr Thr Phe Ile His Gly Leu Ser
20 25 30

Ser Tyr Ile Ala Thr Pro Val Leu Asn Ser Ile Phe Ser Ser Trp Lys
35 40 45

Ser Arg Arg Lys Asp Thr Trp Thr Cys Leu Leu His Arg Leu Ser Ala
50 55 60

Phe Pro Ile Ser Xaa Arg Arg Asn Phe Ala Leu Phe Ser His Ser
65 70 75 80

Cys Val Cys Ile Arg Ser Ser Asp Asp Val Gly Pro Thr Met Tyr
85 90 95

Ser Phe Ser Val Pro Cys Arg Val Lys Xaa
100 105

<210> 171
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 171
Met His Leu Leu Thr Leu Phe Ser Ser Gly Leu Ile Phe Leu Gly Cys
1 5 10 15

Ser Thr Pro Leu Ser Phe Cys Asp Cys Leu Pro Ile Leu Leu Trp
20 25 30

Leu Glu Phe Pro Val Glu Thr Ser Gly Val Cys Ser Xaa
35 40 45

<210> 172
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 172
Met Ile Leu Lys His Tyr Ile Leu Thr Phe Ile Phe Leu Phe Ile Phe
1 5 10 15

Leu Phe Phe Met Leu Asn Ile Leu His Ser Asn Ser Asn Leu Ile Asp
20 25 30

Leu Leu Lys Gly Asn Ile Arg Phe Arg Leu Leu Asn Ser Met Xaa
35 40 45

<210> 173
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 173
Met Ala Thr Leu Gln Ile Thr Thr Ala Met Lys Ile Thr Met Met Ile
1 5 10 15

Thr Met Val Met Ile Ile Thr Thr Ile Val Glu Ala Met Lys Ile Pro
20 25 30

Thr Thr Ala Met Met Met Ala Met Gln Xaa
35 40

<210> 174
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 174
Met Glu Met Leu Ser Ser Lys Trp Ser Lys Arg Val Ala Ala Ser Leu
1 5 10 15

Ala His Leu Ile Ser Leu Phe Ile Gly Leu Leu Phe Leu Leu Leu Gly
20 25 30

Ser Ser Val Tyr Pro Gly Thr Glu Thr Leu Phe Pro Lys Ser Xaa
35 40 45

<210> 175
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 175
Met Trp Pro Ser Leu Gly Arg Cys Cys Leu Phe Phe Cys Leu Leu Thr
1 5 10 15

Asn Leu Thr Ser Cys His Thr Ser Gln Ile Thr Leu Cys Ser Arg Glu
20 25 30

Thr Cys Val Trp Ser Arg Thr Thr Xaa

35

40

<210> 176
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 176

Met Tyr Leu Met Ser Phe Ser Ile His Phe Val Lys Ile Ile Cys Met
1 5 10 15

Cys Thr Ile Leu Val Leu Ser Pro Pro Val Leu Leu Lys Tyr Gln Asp
20 25 30

Ser Thr Pro Arg Pro Leu Trp Ser Gln Cys Lys Ile Pro Ile Asn Tyr
35 40 45

Leu Lys Gly Lys Xaa
50

<210> 177
<211> 250
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (250)
<223> Xaa equals stop translation

<400> 177

Met Arg Gly Pro Ser Trp Ser Arg Pro Arg Pro Leu Leu Leu Leu
1 5 10 15

Leu Leu Leu Ser Pro Trp Pro Val Trp Ala Gln Val Ser Ala Arg Ala
20 25 30

Ser Pro Ser Gly Ser Leu Gly Ala Pro Asp Cys Pro Glu Val Cys Thr
35 40 45

Cys Val Pro Gly Gly Leu Pro Ala Val Gly Thr Leu Ala Ala Arg Arg
50 55 60

Ala Pro Gly Pro Glu Pro Ala Pro Ala Arg Ala Ala Gly Pro Gln
65 70 75 80

Pro Arg Pro Cys Ala Ala Ala Arg Cys Leu Arg Gly Ser Gly Arg Ala
85 90 95

Thr Ala Pro Gly Pro Ala Arg Glu Arg Ala Ala Leu Gly Ala Cys Ala
100 105 110

Ser Leu Leu Gly Pro Gly Arg Ala Ala Ala Gly Pro Glu Arg Gln
115 120 125

Pro Ala Gly Ser Thr Gly Thr Arg Asp Phe Arg Ala Ala Ala Arg Ala
130 135 140

Ala Gln Pro Leu Ile Gly Arg Gln Pro Ala Gly Ala Pro Gly Ala Arg
145 150 155 160

Gly Ala Arg Arg Ala Pro Ala Ala Ala Leu Thr Gln Pro Ala Gly Gln
165 170 175

Arg Ala Gly Gly Thr Arg Ala Gly Ala Ala Gly Pro Pro Ala Arg Ser
180 185 190

Arg Arg Ala Ala Pro Ala Arg Gln Pro Leu Gly Leu Arg Val Arg Ala
195 200 205

Ala Pro Ala Leu Arg Leu Ala Ala Pro Ala Pro Ala Ala Arg Val Arg
210 215 220

Gly Arg Asp Gly Ala Leu Arg Val Ala Gly Thr Pro Asp Ala Gln Pro
225 230 235 240

Pro Asp Cys Leu Phe Arg Arg Arg Leu Xaa
245 250

<210> 178
<211> 148
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (148)
<223> Xaa equals stop translation

<400> 178
Met Leu Ala Gly Ala Gly Arg Pro Gly Leu Pro Gln Gly Arg His Leu
1 5 10 15

Cys Trp Leu Leu Cys Ala Phe Thr Leu Lys Leu Cys Gln Ala Glu Ala
20 25 30

Pro Val Gln Glu Glu Lys Leu Ser Ala Ser Thr Ser Asn Leu Pro Cys
35 40 45

Trp Leu Val Glu Glu Phe Val Val Ala Glu Glu Cys Ser Pro Cys Ser
50 55 60

105

Asn Phe Arg Ala Lys Thr Thr Pro Glu Cys Gly Pro Thr Gly Tyr Val
65 70 75 80

Glu Lys Ile Thr Cys Ser Ser Ser Lys Arg Asn Glu Phe Lys Ser Cys
85 90 95

Arg Phe Ser Phe Glu Trp Asn Asn Ala Tyr Phe Gly Ser Ser Lys Gly
100 105 110

Ala Val Val Cys Val Ala Leu Ile Phe Ala Cys Leu Val Ile Ile Arg
115 120 125

Gln Arg Gln Leu Asp Arg Lys Ala Leu Glu Lys Val Arg Lys Gln Ile
130 135 140

Glu Ser Ile Xaa
145

<210> 179

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 179

Met Phe Met Cys Arg Leu Leu Leu Trp Ala Thr Gly Ala Tyr Gly Phe
1 5 10 15

Leu Gly Asp Asp Val Glu Tyr Thr Ser Val Leu Pro His Gln Lys Gly
20 25 30

Lys Glu Ala Trp Val Phe Ile Cys Gln Leu Pro Phe Ile Ile Gly Xaa
35 40 45

<210> 180

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (56)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 180

Met Leu Gln Thr Leu Leu Cys Leu Trp Gln Tyr Thr Ser Ala Gln Val
1 5 10 15

Leu Lys Met Leu Cys Ile His Arg Gln Lys Trp Asp Asn Phe Trp Ala
20 25 30

Val Val Met Ile Asn Leu Leu Ile Arg Ile Gln Arg Leu Pro Phe Ser
35 40 45

Leu Pro Ile Ala Leu Arg Val Xaa Xaa
50 55

<210> 181

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 181

Met Pro Ser Glu Gly Arg Leu Val Leu Leu Ser Ala Phe Cys Pro Ala
1 5 10 15

Phe Phe Pro Pro Trp Val Leu Ser Gly Ser Phe Ala Phe Ser Leu Cys
20 25 30

Ala Glu Ser His Leu Asn Ser Ser His Arg Arg Ile Ala Val Trp Thr
35 40 45

Xaa

<210> 182

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals stop translation

<400> 182

Met Val Gln Trp Lys Asn Trp Pro Glu Ser Leu Glu Val Trp Val Leu
1 5 10 15

Val Leu Ala Val Pro Leu Thr His Cys Asp Leu Gly Ile Leu Cys Cys
20 25 30

Glu Asp Ile Ser Gln Val Leu His Val Ser Gln Gln Ile Xaa
35 40 45

<210> 183
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 183
Met Ala Leu Gly Leu Cys Ser Ser Gly Ala Leu Ser Thr Leu Cys Leu
1 5 10 15

Ser Ser Val Thr Cys Leu Ala Ile Met Val Leu Met Ala Val Asp Gly
20 25 30

Leu His Gly Thr Ser Gly Leu Gly Xaa
35 40

<210> 184
<211> 80
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (80)
<223> Xaa equals stop translation

<400> 184
Met Thr Leu Met Cys Leu Cys Leu Ser Val Thr Val Leu His Pro Leu
1 5 10 15

Arg Ser Lys Glu Arg Leu Ser Gly Thr Phe Cys Gly Tyr Ser Ser Ser
20 25 30

Trp Cys Ser Pro Ala Ser Glu Ser Ser Ser Pro Gly Ser Leu Leu Thr
35 40 45

Cys Ala Ala Ser Gly Ser His Pro Asp Cys Pro Leu Ser Gln Arg Leu
50 55 60

Leu Gly Val Gln Leu Ala Ala Leu Gly Arg Pro Gln Gly Leu Phe Xaa
65 70 75 80

<210> 185
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 185
Met Lys Ser Gln Cys Tyr Ser Pro Ser Tyr Phe Ala Phe Phe Cys Leu
1 5 10 15

Val Phe Phe Gln Ile Thr Ser Ala Ser Ser Gln Thr Leu Arg Gly His
20 25 30

Val Leu Cys Arg Thr Thr Leu Arg Asp Ser Ser Ala Tyr Cys Xaa
35 40 45

<210> 186
<211> 141
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (141)
<223> Xaa equals stop translation

<400> 186
Met Phe Leu Phe Gly Gly Phe Leu Met Thr Leu Phe Gly Leu Phe Val
1 5 10 15

Ser Leu Val Phe Leu Gly Gln Ala Phe Thr Ile Met Leu Val Tyr Val
20 25 30

Trp Ser Arg Xaa Asn Pro Tyr Val Arg Met Asn Phe Phe Gly Leu Leu
35 40 45

Asn Phe Gln Ala Pro Phe Leu Pro Trp Val Leu Met Gly Phe Ser Leu
50 55 60

Leu Leu Gly Asn Ser Ile Ile Val Asp Leu Leu Gly Ile Ala Val Gly
65 70 75 80

109

His Ile Tyr Phe Phe Leu Glu Asp Val Phe Pro Asn Gln Pro Gly Gly
85 90 95

Ile Arg Ile Leu Lys Thr Pro Ser Ile Leu Lys Ala Ile Phe Asp Thr
100 105 110

Pro Asp Glu Asp Pro Asn Tyr Asn Pro Leu Pro Glu Glu Arg Pro Gly
115 120 125

Gly Phe Ala Trp Gly Glu Gly Gln Arg Leu Gly Gly Xaa
130 135 140

<210> 187

<211> 339

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (339)

<223> Xaa equals stop translation

<400> 187

Met Arg Lys Pro Ala Ala Gly Phe Leu Pro Ser Leu Leu Lys Val Leu
1 5 10 15

Leu Leu Pro Leu Ala Pro Ala Ala Gln Asp Ser Thr Gln Ala Ser
20 25 30

Thr Pro Gly Ser Pro Leu Ser Pro Thr Glu Tyr Glu Arg Phe Phe Ala
35 40 45

Leu Leu Thr Pro Thr Trp Lys Ala Glu Thr Thr Cys Arg Leu Arg Ala
50 55 60

Thr His Gly Cys Arg Asn Pro Thr Leu Val Gln Leu Asp Gln Tyr Glu
65 70 75 80

Asn His Gly Leu Val Pro Asp Gly Ala Val Cys Ser Asn Leu Pro Tyr
85 90 95

Ala Ser Trp Phe Glu Ser Phe Cys Gln Phe Thr His Tyr Arg Cys Ser
100 105 110

Asn His Val Tyr Tyr Ala Lys Arg Val Leu Cys Ser Gln Pro Val Ser
115 120 125

Ile Leu Ser Pro Asn Thr Leu Lys Glu Ile Glu Ala Ser Ala Glu Val
130 135 140

Ser Pro Thr Thr Met Thr Ser Pro Ile Ser Pro His Phe Thr Val Thr
145 150 155 160

Glu Arg Gln Thr Phe Gln Pro Trp Pro Glu Arg Leu Ser Asn Asn Val

110

165

170

175

Glu Glu Leu Leu Gln Ser Ser Leu Ser Leu Gly Ser Gln Glu Gln Ala
 180 185 190

Pro Glu His Lys Gln Glu Gln Gly Val Glu His Arg Gln Glu Pro Thr
 195 200 205

Gln Glu His Lys Gln Glu Glu Gly Gln Lys Gln Glu Glu Gln Glu Glu
 210 215 220

Glu Gln Glu Glu Glu Gly Lys Gln Glu Glu Gly Gln Gly Thr Lys Glu
 225 230 235 240

Gly Arg Glu Ala Val Ser Gln Leu Gln Thr Asp Ser Glu Pro Lys Phe
 245 250 255

His Ser Glu Ser Leu Ser Ser Asn Pro Ser Ser Phe Ala Pro Arg Val
 260 265 270

Arg Glu Val Glu Ser Thr Pro Met Ile Met Glu Asn Ile Gln Glu Leu
 275 280 285

Ile Arg Ser Ala Gln Glu Ile Asp Glu Met Asn Glu Ile Tyr Asp Glu
 290 295 300

Asn Ser Tyr Trp Arg Asn Gln Asn Pro Gly Ser Leu Leu Gln Leu Pro
 305 310 315 320

His Thr Glu Pro Cys Trp Cys Cys Ala Ile Arg Ser Trp Arg Ile Pro
 325 330 335

Ala Ser Xaa

<210> 188

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals stop translation

<400> 188

Met Gln Arg Ile Pro Thr Ser Pro Arg Gln Ala Trp Trp Trp Thr Cys
 1 5 10 15

Trp Ala Met Phe Gln Gly Pro Ala Ala Gly Ser Val Gly Ala Glu Arg
 20 25 30

Lys Gly Glu Gly Cys Leu Phe Phe Gly Gln Asp Glu Ser Ser Arg Cys
 35 40 45

111

Gly Arg Ser Trp Pro Leu Ala Asp Pro Trp Val Tyr Arg Val Leu Arg
50 55 60

Ser Xaa
65

<210> 189
<211> 360
<212> PRT
<213> Homo sapiens

<400> 189
Met Val Pro Ala Ala Gly Arg Arg Pro Pro Arg Val Met Arg Leu Leu
1 5 10 15

Gly Trp Trp Gln Val Leu Leu Trp Val Leu Gly Leu Pro Val Arg Gly
20 25 30

Val Glu Val Ala Glu Glu Ser Gly Arg Leu Trp Ser Glu Glu Gln Pro
35 40 45

Ala His Pro Leu Gln Val Gly Ala Val Tyr Leu Gly Glu Glu Glu Leu
50 55 60

Leu His Asp Pro Met Gly Gln Asp Arg Ala Ala Glu Glu Ala Asn Ala
65 70 75 80

Val Leu Gly Leu Asp Thr Gln Gly Asp His Met Val Met Leu Ser Val
85 90 95

Ile Pro Gly Glu Ala Glu Asp Lys Val Ser Ser Glu Pro Ser Gly Val
100 105 110

Thr Cys Gly Ala Gly Gly Ala Glu Asp Ser Arg Cys Asn Val Arg Glu
115 120 125

Ser Leu Phe Ser Leu Asp Gly Ala Gly Ala His Phe Pro Asp Arg Glu
130 135 140

Glu Glu Tyr Tyr Thr Glu Pro Glu Val Ala Glu Ser Asp Ala Ala Pro
145 150 155 160

Thr Glu Asp Ser Asn Asn Thr Glu Ser Leu Lys Ser Pro Lys Val Asn
165 170 175

Cys Glu Glu Arg Asn Ile Thr Gly Leu Glu Asn Phe Thr Leu Lys Ile
180 185 190

Leu Asn Met Ser Gln Asp Leu Met Asp Phe Leu Asn Pro Asn Gly Ser
195 200 205

Asp Cys Thr Leu Val Leu Phe Tyr Thr Pro Trp Cys Arg Phe Ser Ala
210 215 220

Ser Leu Ala Pro His Phe Asn Ser Leu Pro Arg Ala Phe Pro Ala Leu
 225 230 235 240

His Phe Leu Ala Leu Asp Ala Ser Gln His Ser Ser Leu Ser Thr Arg
 245 250 255

Phe Gly Thr Val Ala Val Pro Asn Ile Leu Leu Phe Gln Gly Ala Lys
 260 265 270

Pro Met Ala Arg Phe Asn His Thr Asp Arg Thr Leu Glu Thr Leu Lys
 275 280 285

Ile Phe Ile Phe Asn Gln Thr Gly Ile Glu Ala Lys Lys Asn Val Val
 290 295 300

Val Thr Gln Ala Asp Gln Ile Gly Pro Leu Pro Ser Thr Leu Ile Lys
 305 310 315 320

Ser Val Asp Trp Leu Leu Val Phe Ser Leu Phe Phe Leu Ile Ser Phe
 325 330 335

Ile Met Tyr Ala Thr Ile Arg Thr Glu Ser Ile Arg Trp Leu Ile Pro
 340 345 350

Gly Gln Glu Gln Glu His Val Glu
 355 360

<210> 190

<211> 160

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (160)

<223> Xaa equals stop translation

<400> 190

Met Leu Leu Leu Leu Ile Phe Trp Ile Ala Pro Ala His Gly Pro Thr
 1 5 10 15

Asn Ile Met Val Tyr Ile Ser Ile Cys Ser Leu Leu Gly Ser Phe Thr
 20 25 30

Val Pro Ser Thr Lys Gly Ile Gly Leu Ala Ala Gln Asp Ile Leu His
 35 40 45

Asn Asn Pro Ser Ser Gln Arg Ala Leu Cys Leu Cys Leu Val Leu Leu
 50 55 60

Ala Val Leu Gly Cys Ser Ile Ile Val Gln Phe Arg Tyr Ile Asn Lys
 65 70 75 80

Ala Leu Glu Cys Phe Asp Ser Ser Val Phe Gly Ala Ile Tyr Tyr Val
85 90 95

Val Phe Thr Thr Leu Val Leu Leu Ala Ser Ala Ile Leu Phe Arg Glu
100 105 110

Trp Ser Asn Val Gly Leu Val Asp Phe Leu Gly Met Ala Cys Gly Phe
115 120 125

Thr Thr Val Ser Val Gly Ile Val Leu Ile Gln Val Phe Lys Glu Phe
130 135 140

Asn Phe Asn Leu Gly Glu Met Asn Lys Ser Asn Met Lys Thr Asp Xaa
145 150 155 160

<210> 191
<211> 101
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (101)
<223> Xaa equals stop translation

<400> 191
Met Phe Val Ala Val Phe Tyr Trp Val Leu Thr Val Phe Phe Leu Ile
1 5 10 15

Ile Tyr Ile Thr Met Thr Tyr Thr Arg Ile Pro Gln Val Pro Trp Thr
20 25 30

Thr Val Gly Leu Cys Phe Asn Gly Ser Ala Phe Val Leu Tyr Leu Ser
35 40 45

Ala Ala Val Val Asp Ala Ser Ser Val Ser Pro Glu Lys Asp Ser His
50 55 60

Asn Phe Asn Ser Trp Ala Ala Ser Ser Phe Phe Ala Phe Leu Val Thr
65 70 75 80

Ile Cys Tyr Ala Gly Asn Thr Tyr Phe Ser Phe Xaa Ala Trp Arg Xaa
85 90 95

Arg Thr Ile Gln Xaa
100

<210> 192
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 192
Met Phe Lys Leu Gln Leu Asp Leu Leu Thr Ala Val Asn Leu Val Tyr
1 5 10 15

Phe Ser Phe Leu Trp Val Val Ser Val Ala Asn Lys Met Asp Val Ser
20 25 30

Val Phe Glu Leu Val Asn Ser Asp Cys Phe Xaa
35 40

<210> 193
<211> 62
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (62)
<223> Xaa equals stop translation

<400> 193
Met Ser Val Cys Val Phe Leu Asp Phe Arg Leu Ile Phe Trp Ser Phe
1 5 10 15

Cys Pro Cys Ser Ala Ser Pro Ser Arg His Phe Ala Ser Ser Ser Arg
20 25 30

Gly Gly Gly Gly Ser Arg Asn Trp Val Gly Ala Gly Ala Ser Leu
35 40 45

Ala Ala Ser Leu Ala Leu Tyr Ala Leu Ser Pro Arg Arg Xaa
50 55 60

<210> 194
<211> 53
<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 194

Met Gln Ala Gln Ile Ser Ser Pro Arg Trp Thr Ser Trp Phe Ser Leu
1 5 10 15

Thr Ala Val Thr Leu Ala Phe Pro Ser Leu Ile Pro Tyr Pro Ser Cys
20 25 30

Gly Ile Pro Val Leu Thr Gln Asp Ala Lys Trp Pro Ser Asp Tyr Thr
35 40 45

Ser Pro Asp Ser Xaa

50

<210> 195

<211> 186

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (114)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (186)

<223> Xaa equals stop translation

<400> 195

Met Thr Leu Leu Asn Leu Leu Leu Gln Thr Ile Phe Tyr Gly Val Thr
1 5 10 15

Cys Leu Asp Asp Val Leu Lys Arg Thr Lys Gly Gly Lys Asp Ile Lys
20 25 30

Phe Leu Thr Ala Phe Arg Asp Leu Leu Phe Thr Thr Leu Ala Phe Pro
35 40 45

Val Ser Thr Phe Val Phe Leu Ala Phe Trp Ile Leu Phe Leu Tyr Asn
50 55 60

Arg Asp Leu Ile Tyr Pro Lys Val Leu Asp Thr Val Ile Pro Val Trp
65 70 75 80

Leu Asn His Ala Met His Thr Phe Ile Phe Pro Ile Thr Leu Ala Glu
85 90 95

Val Val Leu Arg Pro His Ser Tyr Pro Ser Lys Lys Thr Gly Leu Thr
100 105 110

Leu Xaa Ala Ala Ala Ser Ile Ala Tyr Ile Ser Arg Ile Leu Trp Leu
115 120 125

Tyr Phe Glu Thr Gly Thr Trp Val Tyr Pro Val Phe Ala Lys Leu Ser
130 135 140

Leu Leu Gly Leu Ala Ala Phe Phe Ser Leu Ser Tyr Val Phe Ile Ala
145 150 155 160

Ser Ile Tyr Leu Leu Gly Glu Lys Leu Asn His Trp Lys Trp Gly Asp
165 170 175

Met Arg Gln Pro Arg Lys Lys Arg Lys Xaa
180 185

<210> 196

<211> 77

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (77)

<223> Xaa equals stop translation

<400> 196

Met Lys Asn Ala Thr Leu Leu Arg Met Val Leu Phe Val Ile Asn Leu
1 5 10 15

Gln Asn Leu Lys Ser Cys Pro Val Leu His Ile His Gln Asp Val Gln
20 25 30

Gln Gln Lys Arg Met Gly His Gly Ser Ser Thr Arg Val Thr Val
35 40 45

Thr Ser Leu Ile Arg His Cys Thr Val Phe Gln Arg Pro Lys Asn Cys
50 55 60

Val Gln Asn Met Ile Thr Leu Gln Leu Ser Phe Pro Xaa
65 70 75

<210> 197

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (175)

<223> Xaa equals stop translation

<400> 197

Met	Phe	Val	Pro	Ser	Cys	Leu	Cys	Leu	Arg	Phe	Val	Val	Thr	Ser	Leu
1					5				10						15

Leu Leu Gln Met Thr His Ser Cys Gly Gly Phe Tyr Ile Cys Val Ile

20				25					30					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Phe Glu Thr Ile Leu Ser Glu Phe Lys Thr Gln Ile Gly Arg Leu Tyr

35				40					45					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Arg Lys Arg His Ile Gln Arg Lys Glu Ser Pro Lys Gly Arg Phe Val

50				55					60					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Met Leu Leu Pro Ser Ser Thr His Thr Ile Pro Phe Tyr Pro Asn Pro

65				70					75					80
----	--	--	--	----	--	--	--	--	----	--	--	--	--	----

Leu His Pro Arg Pro Phe Pro Ser Ser Arg Leu Pro Pro Gly Ile Ile

85				90					95					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Gly Gly Glu Tyr Asp Gln Arg Pro Thr Leu Pro Tyr Val Gly Asp Pro

100				105					110					
-----	--	--	--	-----	--	--	--	--	-----	--	--	--	--	--

Ile Ser Ser Leu Ile Pro Gly Pro Gly Glu Thr Pro Ser Gln Phe Pro

115				120					125					
-----	--	--	--	-----	--	--	--	--	-----	--	--	--	--	--

Pro Leu Arg Pro Arg Phe Asp Pro Val Gly Pro Leu Pro Gly Pro Asn

130				135					140					
-----	--	--	--	-----	--	--	--	--	-----	--	--	--	--	--

Pro Ile Leu Pro Gly Arg Gly Pro Asn Asp Arg Phe Pro Phe Arg

145				150					155					160
-----	--	--	--	-----	--	--	--	--	-----	--	--	--	--	-----

Pro Ser Arg Gly Arg Pro Thr Asp Gly Arg Leu Ser Phe Met Xaa

165				170					175					
-----	--	--	--	-----	--	--	--	--	-----	--	--	--	--	--

<210> 198

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 198

Met	Gly	Leu	Lys	Arg	Lys	Gln	Gly	Phe	Val	Phe	Leu	Phe	Leu	Leu
1						5			10					15

Lys Ser Thr Val Ala Ser Trp Leu Leu Ser Gly Val Gly Arg Ile Trp

20				25					30					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Gly Leu Val His Phe Val Lys Val Asn His Val Cys Leu Asn Asn Arg

35				40					45					
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--

Gly Val Xaa
50

<210> 199

<211> 190

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (190)

<223> Xaa equals stop translation

<400> 199

Met Gly Pro Val Arg Leu Gly Ile Leu Leu Phe Leu Phe Leu Ala Val
1 5 10 15

His Glu Ala Trp Ala Gly Met Leu Lys Glu Glu Asp Asp Asp Thr Glu
20 25 30

Arg Leu Pro Ser Lys Cys Glu Val Cys Lys Leu Leu Ser Thr Glu Leu
35 40 45

Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu Val Leu Glu Leu
50 55 60

Gly Gln Val Leu Asp Thr Gly Lys Arg Lys Arg His Val Pro Tyr Ser
65 70 75 80

Val Ser Glu Thr Arg Leu Glu Glu Ala Leu Glu Asn Leu Cys Glu Arg
85 90 95

Ile Leu Asp Tyr Ser Val His Ala Glu Arg Lys Gly Ser Leu Arg Tyr
100 105 110

Ala Lys Gly Gln Ser Gln Thr Met Ala Thr Leu Lys Gly Leu Val Gln
115 120 125

Lys Gly Val Lys Val Asp Leu Gly Ile Pro Leu Glu Leu Trp Asp Glu
130 135 140

Pro Ser Val Glu Val Thr Tyr Leu Lys Lys Gln Cys Glu Thr Met Leu
145 150 155 160

Glu Glu Glu Glu Glu Glu Glu Glu Gly Gly Asp Lys Met Thr
165 170 175

Lys Thr Gly Ser His Pro Lys Leu Asp Arg Glu Asp Leu Xaa
180 185 190

<210> 200

<211> 80

<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (80)
<223> Xaa equals stop translation

<400> 200

Met Asn Tyr Ser Arg Ser Pro Trp Ala Ala Val Met Glu Pro Leu Thr
1 5 10 15

Leu Leu Phe Leu His Leu Ser Cys Leu Leu Ser Leu Cys Glu Ala Val
20 25 30

Gly Trp Asp Ser Glu Cys Leu Val Cys Ser Leu Gly Glu Glu Glu Phe
35 40 45

Leu Arg Met Gln Ala Leu Leu Cys Gly Cys Arg Leu His Leu Gly Gly
50 55 60

Val Leu Tyr Val Cys Thr Leu Gly Thr Ala Cys Ile Trp Lys Ile Xaa
65 70 75 80

<210> 201
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (106)
<223> Xaa equals stop translation

<400> 201

Met Asn Leu Gly Val Ser Met Leu Arg Ile Leu Phe Leu Leu Asp Val
1 5 10 15

Gly Gly Ala Gln Val Leu Ala Thr Gly Lys Thr Pro Gly Ala Glu Ile
20 25 30

Asp Phe Lys Tyr Ala Leu Ile Gly Thr Ala Val Gly Val Ala Ile Ser
35 40 45

Ala Gly Phe Leu Ala Leu Lys Ile Cys Met Ile Arg Arg His Leu Phe
50 55 60

Asp Asp Asp Ser Ser Asp Leu Lys Ser Thr Pro Gly Gly Leu Ser Asp
65 70 75 80

Thr Ile Pro Leu Lys Lys Arg Ala Pro Arg Arg Asn His Asn Phe Ser

120

85

90

95

Lys Arg Asp Ala Gln Val Ile Glu Leu Xaa
100 105

<210> 202
<211> 80
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (80)
<223> Xaa equals stop translation

<400> 202
Met Ala Cys Leu Gly Gly Leu Leu Gly Ile Ile Gly Val Ile Cys Leu
1 5 10 15

Ile Ser Cys Leu Ser Pro Glu Met Asn Cys Asp Gly Gly His Ser Tyr
20 25 30

Val Arg Asn Tyr Leu Gln Lys Pro Thr Phe Ala Leu Gly Glu Leu Tyr
35 40 45

Pro Pro Leu Ile Asn Leu Trp Glu Ala Gly Lys Glu Lys Ser Thr Ser
50 55 60

Leu Lys Val Lys Ala Thr Val Ile Gly Leu Pro Thr Asn Met Ser Xaa
65 70 75 80

<210> 203
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 203
Met Gly Leu Lys Leu Leu Gln Lys Pro Gly Ser Leu Lys Thr Leu Ile
1 5 10 15

Ala Ile Ile Leu Val Met Tyr Ile Phe Met Thr Ile Ser Val Ile Ala
20 25 30

Gly Thr Gly Lys Phe Ser Gln Lys Leu Asp Leu His Leu Asn Met Asp
35 40 45

Ile Ser Pro Gly Arg Pro Ser Val His Xaa
50 55

<210> 204

<211> 161

<212> PRT

<213> Homo sapiens

<400> 204

Met Asp Phe Leu Asn Pro Asn Gly Ser Asp Cys Thr Leu Val Leu Phe
1 5 10 15 .

Tyr Thr Pro Trp Cys Arg Phe Ser Ala Ser Leu Ala Pro His Phe Asn
20 25 30

Ser Leu Pro Arg Ala Phe Pro Ala Leu His Phe Leu Ala Leu Asp Ala
35 40 45

Ser Gln His Ser Ser Leu Ser Thr Arg Phe Gly Thr Val Ala Val Pro
50 55 60

Asn Ile Leu Leu Phe Gln Gly Ala Lys Pro Met Ala Arg Phe Asn His
65 70 75 80

Thr Asp Arg Thr Leu Glu Thr Leu Lys Ile Phe Ile Phe Asn Gln Thr
85 90 95

Gly Ile Glu Ala Lys Lys Asn Val Val Val Thr Gln Ala Asp Gln Ile
100 105 110

Gly Pro Leu Pro Ser Thr Leu Ile Lys Ser Val Asp Trp Leu Leu Val
115 120 125

Phe Ser Leu Phe Phe Leu Ile Ser Phe Ile Met Tyr Ala Thr Ile Arg
130 135 140

Thr Glu Ser Ile Arg Trp Leu Ile Pro Gly Gln Glu Gln Glu His Val
145 150 155 160

Glu

<210> 205

<211> 137

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

122

<400> 205

Ile	Pro	Glu	Asn	Arg	Arg	Pro	Ala	Ser	Xaa	Cys	Thr	Trp	Ser	Met	Trp
1															15
5															

Thr	Ser	Arg	Thr	Thr	Arg	Arg	Pro	Pro	Trp	Gly	Arg	Phe	Ser	Ser
20														

Val	Ser	Ser	Ala	Ser	Val	Ser	Ser	Thr	Arg	Lys	Thr	Trp	Arg	Thr	Arg
35															

Ser	Thr	Ser	Cys	Cys	Arg	Ser	Ser	Arg	Arg	Arg	Val	Ala	Ala	Pro	Phe
50															

Cys	Thr	Pro	Ser	Ala	Ser	Thr	Glu	Pro	Ser	Ala	Arg	Met	Glu	Pro	Pro
65															

Leu	Glu	Leu	Pro	Val	Val	His	Thr	Phe	Ser	Phe	Leu	Thr	Phe	Val	Phe
85															

Thr	Tyr	Arg	Cys	Ser	Ala	Gly	Asp	Gly	Ser	Ile	Thr	Gln	Ile	Asn	Cys
100															

Ala	Tyr	Glu	Met	Gly	Glu	Met	Pro	Lys	Arg	Gln	Met	Lys	Ala	Ile
115														

Lys	Phe	Leu	Leu	Phe	His	Phe	Tyr	Leu
130								

<210> 206

<211>	41
<212>	PRT
<213>	Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids.

<400> 206

Ile	Pro	Glu	Asn	Arg	Arg	Pro	Ala	Ser	Xaa	Cys	Thr	Trp	Ser	Met	Trp
1															15

Thr	Ser	Arg	Thr	Thr	Arg	Arg	Pro	Pro	Trp	Gly	Arg	Phe	Ser	Ser
20														

Val	Ser	Ser	Ala	Ser	Val	Ser	Ser	Thr
35								

<210> 207

<211> 43

<212> PRT

<213> Homo sapiens

<400> 207

Arg Lys Thr Trp Arg Thr Arg Ser Thr Ser Cys Cys Arg Ser Ser Arg
1 5 10 15

Arg Arg Val Ala Ala Pro Phe Cys Thr Pro Ser Ala Ser Thr Glu Pro
20 25 30

Ser Ala Arg Met Glu Pro Pro Leu Glu Leu Pro
35 40

<210> 208

<211> 53

<212> PRT

<213> Homo sapiens

<400> 208

Val Val His Thr Phe Ser Phe Leu Thr Phe Val Phe Thr Tyr Arg Cys
1 5 10 15

Ser Ala Gly Asp Gly Ser Ile Thr Gln Ile Asn Cys Ala Tyr Glu Met
20 25 30

Gly Glu Glu Met Pro Lys Arg Gln Met Lys Ala Ile Lys Phe Leu Leu
35 40 45

Phe His Phe Tyr Leu
50

<210> 209

<211> 223

<212> PRT

<213> Homo sapiens

<400> 209

His Pro Ser Ile Ile Ile Trp Ser Gly Asn Asn Glu Asn Glu Ala
1 5 10 15

Leu Met Met Asn Trp Tyr His Ile Ser Phe Thr Asp Arg Pro Ile Tyr
20 25 30

Ile Lys Asp Tyr Val Thr Leu Tyr Val Lys Asn Ile Arg Glu Leu Val
35 40 45

Leu Ala Gly Asp Lys Ser Arg Pro Phe Ile Thr Ser Ser Pro Thr Asn
50 55 60

Gly Ala Glu Thr Val Ala Glu Ala Trp Val Ser Gln Asn Pro Asn Ser
65 70 75 80

Asn Tyr Phe Gly Asp Val His Phe Tyr Asp Tyr Ile Ser Asp Cys Trp
85 90 95

Asn Trp Lys Val Phe Pro Lys Ala Arg Phe Ala Ser Glu Tyr Gly Tyr

100	105	110
-----	-----	-----

Gln Ser Trp Pro Ser Phe Ser Thr Leu Glu Lys Val Ser Ser Thr Glu
 115 120 125

Asp Trp Ser Phe Asn Ser Lys Phe Ser Leu His Arg Gln His His Glu
 130 135 140

Gly Gly Asn Lys Gln Met Leu Tyr Gln Ala Gly Leu His Phe Lys Leu
 145 150 155 160

Pro Gln Ser Thr Asp Pro Leu Arg Thr Phe Lys Asp Thr Ile Tyr Leu
 165 170 175

Thr Gln Val Met Gln Ala Gln Cys Val Lys Thr Glu Thr Glu Phe Tyr
 180 185 190

Arg Arg Ser Arg Ser Glu Ile Val Asp Gln Gln Gly His Thr Met Gly
 195 200 205

Ala Leu Tyr Trp Gln Leu Asn Asp Ile Trp Gln Ala Pro Ser Trp
 210 215 220

<210> 210

<211> 160

<212> PRT

<213> Homo sapiens

<400> 210

Val Arg Val His Thr Trp Ser Ser Leu Glu Pro Val Cys Ser Arg Val
 1 5 10 15

Thr Glu Arg Phe Val Met Lys Gly Gly Glu Ala Val Cys Leu Tyr Glu
 20 25 30

Glu Pro Val Ser Glu Leu Leu Arg Arg Cys Gly Asn Cys Thr Arg Glu
 35 40 45

Ser Cys Val Val Ser Phe Tyr Leu Ser Ala Asp His Glu Leu Leu Ser
 50 55 60

Pro Thr Asn Tyr His Phe Leu Ser Ser Pro Lys Glu Ala Val Gly Leu
 65 70 75 80

Cys Lys Ala Gln Ile Thr Ala Ile Ile Ser Gln Gln Gly Asp Ile Phe
 85 90 95

Val Phe Asp Leu Glu Thr Ser Ala Val Ala Pro Phe Val Trp Leu Asp
 100 105 110

Val Gly Ser Ile Pro Gly Arg Phe Ser Asp Asn Gly Phe Leu Met Thr
 115 120 125

Glu Lys Thr Arg Thr Ile Leu Phe Tyr Pro Trp Glu Pro Thr Ser Lys

125

130 135 140

Asn Glu Leu Glu Gln Ser Phe His Val Thr Ser Leu Thr Asp Ile Tyr
145 150 155 160

<210> 211
<211> 171
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 211
Pro Arg Leu Thr Pro Arg Met Lys Trp Pro Thr Ala Ala Leu Ala Ser
1 5 10 15

Arg Leu Leu Gly Trp Thr Val Leu Arg Pro Pro Tyr Pro Arg Val Pro
20 25 30

Ser Leu Pro Gln Val Thr Leu His Pro Thr Asp Gly Leu Met Ala Val
35 40 45

Leu Tyr Thr Gly Gly Glu Gly Arg Thr Leu Gly Glu Gln His Phe Phe
50 55 60

His Glu Thr Phe Val Thr Arg Trp Leu Leu Gly Pro Val Pro Val Arg
65 70 75 80

Phe Gly Ala Cys Ser Pro Leu Ser Phe Leu Ala Pro Arg Arg Gly Gln
85 90 95

Gly Ala Pro Ala Gly Xaa Phe Cys Ala Cys Pro Arg Pro Ala Ser Arg
100 105 110

Gln Leu Cys Pro Trp Pro Ala Leu Pro Gly Thr Pro Tyr Ser Asn Ser
115 120 125

Ala Pro Leu Cys Thr Gly Met Gly His Ser Asn Thr Pro Gln Gly Pro
130 135 140

Pro Ser Pro Gln Tyr Ala Leu Ser Pro Thr Glu Pro Thr Ser Leu Ser
145 150 155 160

Gly Asn Ser His Leu Pro Ala Ile Leu Val Leu
165 170

<210> 212

<211> 41
<212> PRT
<213> Homo sapiens

<400> 212
Pro Arg Leu Thr Pro Arg Met Lys Trp Pro Thr Ala Ala Leu Ala Ser
1 5 10 15

Arg Leu Leu Gly Trp Thr Val Leu Arg Pro Pro Tyr Pro Arg Val Pro
20 25 30

Ser Leu Pro Gln Val Thr Leu His Pro
35 40

<210> 213
<211> 41
<212> PRT
<213> Homo sapiens

<400> 213
Thr Asp Gly Leu Met Ala Val Leu Tyr Thr Gly Gly Glu Gly Arg Thr
1 5 10 15

Leu Gly Glu Gln His Phe Phe His Glu Thr Phe Val Thr Arg Trp Leu
20 25 30

Leu Gly Pro Val Pro Val Arg Phe Gly
35 40

<210> 214
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 214
Ala Cys Ser Pro Leu Ser Phe Leu Ala Pro Arg Arg Gly Gln Gly Ala
1 5 10 15

Pro Ala Gly Xaa Phe Cys Ala Cys Pro Arg Pro Ala Ser Arg Gln Leu
20 25 30

Cys Pro Trp Pro Ala Leu Pro Gly Thr Pro
35 40

<210> 215
<211> 47
<212> PRT

<213> Homo sapiens

<400> 215

Tyr Ser Asn Ser Ala Pro Leu Cys Thr Gly Met Gly His Ser Asn Thr
1 5 10 15

Pro Gln Gly Pro Pro Ser Pro Gln Tyr Ala Leu Ser Pro Thr Glu Pro
20 25 30

Thr Ser Leu Ser Gly Asn Ser His Leu Pro Ala Ile Leu Val Leu
35 40 45

<210> 216

<211> 27

<212> PRT

<213> Homo sapiens

<400> 216

His Leu Leu Glu Val Thr Pro Cys Arg Leu Pro Val Pro Glu Phe Pro
1 5 10 15

Gly Arg Thr Pro Arg Gly Ser Arg Thr Pro Asp
20 25

<210> 217

<211> 239

<212> PRT

<213> Homo sapiens

<400> 217

Met Ile Pro Gly Ser Asp Ser Gln Thr Ala Leu Asn Phe Gly Ser Thr
1 5 10 15

Leu Met Lys Lys Lys Ser Asp Pro Glu Gly Pro Ala Leu Leu Phe Pro
20 25 30

Glu Ser Glu Leu Ser Ile Arg Ile Gly Arg Ala Gly Leu Leu Ser Asp
35 40 45

Lys Ser Glu Asn Gly Glu Ala Tyr Gln Arg Lys Lys Ala Ala Ala Thr
50 55 60

Gly Leu Pro Glu Gly Pro Ala Val Pro Val Pro Ser Arg Gly Asn Leu
65 70 75 80

Ala Gln Pro Gly Gly Ser Ser Trp Arg Arg Ile Ala Leu Leu Ile Leu
85 90 95

Ala Ile Thr Ile His Asn Val Pro Glu Gly Leu Ala Val Gly Val Gly
100 105 110

Phe Gly Ala Ile Glu Lys Thr Ala Ser Ala Thr Phe Glu Ser Ala Arg
115 120 125

Asn Leu Ala Ile Gly Ile Gly Ile Gln Asn Phe Pro Glu Gly Leu Ala
130 135 140

Val Ser Leu Pro Leu Arg Gly Ala Gly Phe Ser Thr Trp Arg Ala Phe
145 150 155 160

Trp Tyr Gly Gln Leu Ser Gly Met Val Glu Pro Leu Ala Gly Val Phe
165 170 175

Gly Ala Phe Ala Val Val Leu Ala Glu Pro Ile Leu Pro Tyr Ala Leu
180 185 190

Ala Phe Ala Ala Gly Ala Met Val Tyr Val Val Met Asp Asp Ile Ile
195 200 205

Pro Glu Ala Gln Ile Ser Gly Asn Gly Lys Leu Ala Ser Trp Ala Ser
210 215 220

Ile Leu Gly Phe Val Val Met Met Ser Leu Asp Val Gly Leu Gly
225 230 235

<210> 218

<211> 43

<212> PRT

<213> Homo sapiens

<400> 218

Met Ile Pro Gly Ser Asp Ser Gln Thr Ala Leu Asn Phe Gly Ser Thr
1 5 10 15

Leu Met Lys Lys Lys Ser Asp Pro Glu Gly Pro Ala Leu Leu Phe Pro
20 25 30

Glu Ser Glu Leu Ser Ile Arg Ile Gly Arg Ala
35 40

<210> 219

<211> 41

<212> PRT

<213> Homo sapiens

<400> 219

Gly Leu Leu Ser Asp Lys Ser Glu Asn Gly Glu Ala Tyr Gln Arg Lys
1 5 10 15

Lys Ala Ala Ala Thr Gly Leu Pro Glu Gly Pro Ala Val Pro Val Pro
20 25 30

Ser Arg Gly Asn Leu Ala Gln Pro Gly
35 40

<210> 220
<211> 44
<212> PRT
<213> Homo sapiens

<400> 220
Gly Ser Ser Trp Arg Arg Ile Ala Leu Leu Ile Leu Ala Ile Thr Ile
1 5 10 15

His Asn Val Pro Glu Gly Leu Ala Val Gly Val Gly Phe Gly Ala Ile
20 25 30

Glu Lys Thr Ala Ser Ala Thr Phe Glu Ser Ala Arg
35 40

<210> 221
<211> 43
<212> PRT
<213> Homo sapiens

<400> 221
Asn Leu Ala Ile Gly Ile Gly Ile Gln Asn Phe Pro Glu Gly Leu Ala
1 5 10 15

Val Ser Leu Pro Leu Arg Gly Ala Gly Phe Ser Thr Trp Arg Ala Phe
20 25 30

Trp Tyr Gly Gln Leu Ser Gly Met Val Glu Pro
35 40

<210> 222
<211> 43
<212> PRT
<213> Homo sapiens

<400> 222
Leu Ala Gly Val Phe Gly Ala Phe Ala Val Val Leu Ala Glu Pro Ile
1 5 10 15

Leu Pro Tyr Ala Leu Ala Phe Ala Ala Gly Ala Met Val Tyr Val Val
20 25 30

Met Asp Asp Ile Ile Pro Glu Ala Gln Ile Ser
35 40

<210> 223
<211> 25
<212> PRT
<213> Homo sapiens

<400> 223
Gly Asn Gly Lys Leu Ala Ser Trp Ala Ser Ile Leu Gly Phe Val Val

130

1 5 10 15

Met Met Ser Leu Asp Val Gly Leu Gly
20 25

<210> 224
<211> 11
<212> PRT
<213> Homo sapiens

<400> 224
Thr Arg Pro Ile Thr Tyr Val Leu Leu Ala Gly
1 5 10

<210> 225
<211> 35
<212> PRT
<213> Homo sapiens

<400> 225
Gly Thr Ser Leu Thr Ala Pro Leu Leu Glu Phe Leu Leu Ala Leu Tyr
1 5 10 15

Phe Leu Phe Ala Asp Ala Met Gln Leu Asn Asp Lys Trp Gln Gly Leu
20 25 30

Cys Trp Pro
35

<210> 226
<211> 30
<212> PRT
<213> Homo sapiens

<400> 226
Leu Ala Asn Phe Glx Cys Ser Asp Cys Ala Gln Thr Val Leu Phe Val
1 5 10 15

Leu Glx Phe Glx Ile Leu Val Phe Thr Tyr Glu Ile Pro Phe
20 25 30

<210> 227
<211> 75
<212> PRT
<213> Homo sapiens

<400> 227
Gln Ala Trp His Glu Val Gly Gly Val Arg Arg Cys Trp Phe Val
1 5 10 15

Leu Gly Glu Arg Arg Ala Gly Ser Leu Leu Ser Ala Ser Tyr Gly Thr

20 25 30

Phe Ala Met Pro Gly Met Val Leu Phe Gly Arg Arg Trp Ala Ile Ala
35 40 45

Ser Asp Asp Leu Val Phe Pro Gly Phe Phe Glu Leu Val Val Arg Val
50 55 60

Leu Trp Trp Ile Gly Ile Leu Thr Leu Tyr Leu
65 70 75

<210> 228

<211> 125

<212> PRT

<213> Homo sapiens

<400> 228

Pro Gly Met Val Leu Phe Gly Arg Arg Trp Ala Ile Ala Ser Asp Asp
1 5 10 15

Leu Val Phe Pro Gly Phe Phe Glu Leu Val Val Arg Val Leu Trp Trp
20 25 30

Ile Gly Ile Leu Thr Leu Tyr Leu Met His Arg Gly Lys Leu Asp Cys
35 40 45

Ala Gly Gly Ala Leu Leu Ser Ser Tyr Leu Ile Val Leu Met Ile Leu
50 55 60

Leu Ala Val Val Ile Cys Thr Val Ser Ala Ile Met Cys Val Ser Met
65 70 75 80

Arg Gly Thr Ile Cys Asn Pro Gly Pro Arg Lys Ser Met Ser Lys Leu
85 90 95

Leu Tyr Ile Arg Leu Ala Leu Phe Phe Pro Glu Met Val Trp Ala Ser
100 105 110

Leu Gly Ala Ala Trp Val Ala Asp Gly Val Gln Cys Asp
115 120 125

<210> 229

<211> 18

<212> PRT

<213> Homo sapiens

<400> 229

His Glu Arg Asn Cys Phe Pro Met Trp Leu Asn His Ser Ala Phe Pro
1 5 10 15

Pro Val

<210> 230
<211> 132
<212> PRT
<213> Homo sapiens

<400> 230
Gly Trp Thr Arg Glu Asn Asp His Arg Ala Leu Ser Lys Ala Gly Ile
1 5 10 15

Gly Ser Ala Glu Ile Gln Pro Ser Asn Leu Arg Val Gly Ser Ala Lys
20 25 30

Asp Leu Gly Lys Pro Trp Ala Gly Lys Leu Leu Leu Ser Ser Cys
35 40 45

Leu Leu Phe Phe Ser Leu Gly Val Leu Tyr Arg Gly Gln Met Leu Ala
50 55 60

Pro Pro Leu Gln Glu Asp Trp Lys Gly Gly Val Lys Asp Ser Asp Leu
65 70 75 80

Ile Asp Asp Ser Ser Ala Ser Pro Ile Pro Pro Ser Tyr Leu Glu Tyr
85 90 95

Lys Ala Ala Leu Tyr Pro Phe Ser Glu His Lys Ser Val Arg Asn Ala
100 105 110

Thr Asp Ser Leu Thr Phe Phe Leu Val Thr Asp His Phe Leu Asp Asn
115 120 125

Gln Asp Ser Gln
130

<210> 231
<211> 45
<212> PRT
<213> Homo sapiens

<400> 231
Gly Trp Thr Arg Glu Asn Asp His Arg Ala Leu Ser Lys Ala Gly Ile
1 5 10 15

Gly Ser Ala Glu Ile Gln Pro Ser Asn Leu Arg Val Gly Ser Ala Lys
20 25 30

Asp Leu Gly Lys Pro Trp Ala Gly Lys Leu Leu Leu
35 40 45

<210> 232
<211> 46
<212> PRT
<213> Homo sapiens

<400> 232

Ser Ser Cys Leu Leu Phe Phe Ser Leu Gly Val Leu Tyr Arg Gly Gln
1 5 10 15

Met Leu Ala Pro Pro Leu Gln Glu Asp Trp Lys Gly Gly Val Lys Asp
20 25 30

Ser Asp Leu Ile Asp Asp Ser Ser Ala Ser Pro Ile Pro Pro
35 40 45

<210> 233

<211> 41

<212> PRT

<213> Homo sapiens

<400> 233

Ser Tyr Leu Glu Tyr Lys Ala Ala Leu Tyr Pro Phe Ser Glu His Lys
1 5 10 15

Ser Val Arg Asn Ala Thr Asp Ser Leu Thr Phe Phe Leu Val Thr Asp
20 25 30

His Phe Leu Asp Asn Gln Asp Ser Gln
35 40

<210> 234

<211> 11

<212> PRT

<213> Homo sapiens

<400> 234

Leu Lys Phe His Gln Glu Ser Leu Ser Gly Asp
1 5 10

<210> 235

<211> 25

<212> PRT

<213> Homo sapiens

<400> 235

Glu Ala Lys Ser Arg Pro Val Thr Gln Ala Gly Val Gln Trp His Asp
1 5 10 15

Leu Gly Ser Leu Gln Pro Leu Pro Pro
20 25

<210> 236

<211> 25

<212> PRT

<213> Homo sapiens

<400> 236

Glu	Ala	Lys	Ser	Arg	Pro	Val	Thr	Gln	Ala	Gly	Val	Gln	Trp	His	Asp
1				5				10						15	

Leu	Gly	Ser	Leu	Gln	Pro	Leu	Pro	Pro
			20			25		

<210> 237

<211> 137

<212> PRT

<213> Homo sapiens

<400> 237

Ala	Leu	Val	Leu	Val	Cys	Arg	Gln	Arg	Tyr	Cys	Arg	Pro	Arg	Asp	Leu
1				5			10						15		

Leu	Gln	Arg	Tyr	Asp	Ser	Lys	Pro	Ile	Val	Asp	Leu	Ile	Gly	Ala	Met
			20			25						30			

Glu	Thr	Gln	Ser	Glu	Pro	Ser	Glu	Leu	Glu	Leu	Asp	Asp	Val	Val	Ile
		35				40						45			

Thr	Asn	Pro	His	Ile	Glu	Ala	Ile	Leu	Glu	Asn	Glu	Asp	Trp	Ile	Glu
		50				55					60				

Asp	Ala	Ser	Gly	Leu	Met	Ser	His	Cys	Ile	Ala	Ile	Leu	Lys	Ile	Cys
		65			70				75				80		

His	Thr	Leu	Thr	Glu	Lys	Leu	Val	Ala	Met	Thr	Met	Gly	Ser	Gly	Ala
			85				90					95			

Lys	Met	Lys	Thr	Ser	Ala	Ser	Val	Ser	Asp	Ile	Ile	Val	Val	Ala	Lys
			100			105						110			

Arg	Ile	Ser	Pro	Arg	Val	Asp	Asp	Val	Val	Lys	Ser	Met	Tyr	Pro	Pro
			115			120					125				

Leu	Asp	Pro	Lys	Leu	Leu	Asp	Ala	Arg
			130			135		

<210> 238

<211> 319

<212> PRT

<213> Homo sapiens

<400> 238

Asp	Val	Glu	Ser	Arg	Gly	Pro	Ser	Ala	Arg	Cys	Leu	Pro	Val	Val	Pro
1				5				10					15		

Gly	Ser	Leu	Leu	Pro	Gly	Leu	Glu	Pro	Ala	Thr	Lys	Leu	Met	Pro	Gly
			20			25					30				

Gly Leu Ala Pro Gly His Gly Ala Pro Val Arg Glu Leu Leu Leu Pro
35 40 45

Leu Leu Ser Gln Pro Thr Leu Gly Ser Leu Trp Asp Ser Leu Arg His
50 55 60

Cys Ser Leu Leu Cys Asn Pro Leu Ser Cys Val Pro Ala Leu Glu Ala
65 70 75 80

Pro Pro Ser Leu Val Ser Leu Gly Cys Ser Gly Gly Cys Pro Arg Leu
85 90 95

Ser Leu Ala Gly Ser Ala Ser Pro Phe Pro Phe Leu Thr Ala Leu Leu
100 105 110

Ser Leu Leu Asn Thr Leu Ala Gln Ile His Lys Gly Leu Cys Gly Gln
115 120 125

Leu Ala Ala Ile Leu Ala Ala Pro Gly Leu Gln Asn Tyr Phe Leu Gln
130 135 140

Cys Val Ala Pro Gly Ala Ala Pro His Leu Thr Pro Phe Ser Ala Trp
145 150 155 160

Ala Leu Arg His Glu Tyr His Leu Gln Tyr Leu Ala Leu Ala Leu Ala
165 170 175

Gln Lys Ala Ala Ala Leu Gln Pro Leu Pro Ala Thr His Ala Ala Leu
180 185 190

Tyr His Gly Met Ala Leu Ala Leu Leu Ser Arg Leu Leu Pro Gly Ser
195 200 205

Glu Tyr Leu Thr His Glu Leu Leu Leu Ser Cys Val Phe Arg Leu Glu
210 215 220

Phe Leu Pro Glu Arg Thr Ser Gly Gly Pro Glu Ala Ala Asp Phe Ser
225 230 235 240

Asp Gln Leu Ser Leu Gly Ser Ser Arg Val Pro Arg Cys Gly Gln Gly
245 250 255

Thr Leu Leu Ala Gln Ala Cys Gln Asp Leu Pro Ser Ile Arg Asn Cys
260 265 270

Tyr Leu Thr His Cys Ser Pro Ala Arg Ala Ser Leu Leu Ala Ser Gln
275 280 285

Ala Leu His Arg Gly Glu Leu Gln Arg Val Pro Thr Leu Leu Leu Pro
290 295 300

Met Pro Thr Glu Pro Leu Leu Pro Thr Asp Trp Pro Phe Leu His
305 310 315

<210> 239
<211> 44
<212> PRT
<213> Homo sapiens

<400> 239
Asp Val Glu Ser Arg Gly Pro Ser Ala Arg Cys Leu Pro Val Val Pro
1 5 10 15

Gly Ser Leu Leu Pro Gly Leu Glu Pro Ala Thr Lys Leu Met Pro Gly
20 25 30

Gly Leu Ala Pro Gly His Gly Ala Pro Val Arg Glu
35 40

<210> 240
<211> 45
<212> PRT
<213> Homo sapiens

<400> 240
Leu Leu Leu Pro Leu Leu Ser Gln Pro Thr Leu Gly Ser Leu Trp Asp
1 5 10 15

Ser Leu Arg His Cys Ser Leu Leu Cys Asn Pro Leu Ser Cys Val Pro
20 25 30

Ala Leu Glu Ala Pro Pro Ser Leu Val Ser Leu Gly Cys
35 40 45

<210> 241
<211> 45
<212> PRT
<213> Homo sapiens

<400> 241
Ser Gly Gly Cys Pro Arg Leu Ser Leu Ala Gly Ser Ala Ser Pro Phe
1 5 10 15

Pro Phe Leu Thr Ala Leu Leu Ser Leu Leu Asn Thr Leu Ala Gln Ile
20 25 30

His Lys Gly Leu Cys Gly Gln Leu Ala Ala Ile Leu Ala
35 40 45

<210> 242
<211> 44
<212> PRT
<213> Homo sapiens

<400> 242
Ala Pro Gly Leu Gln Asn Tyr Phe Leu Gln Cys Val Ala Pro Gly Ala

1 5 10 15

Ala Pro His Leu Thr Pro Phe Ser Ala Trp Ala Leu Arg His Glu Tyr
20 25 30

His Leu Gln Tyr Leu Ala Leu Ala Leu Ala Gln Lys
35 40

<210> 243

<211> 44

<212> PRT

<213> Homo sapiens

<400> 243

Ala Ala Ala Leu Gln Pro Leu Pro Ala Thr His Ala Ala Leu Tyr His
1 5 10 15

Gly Met Ala Leu Ala Leu Leu Ser Arg Leu Leu Pro Gly Ser Glu Tyr
20 25 30

Leu Thr His Glu Leu Leu Ser Cys Val Phe Arg
35 40

<210> 244

<211> 44

<212> PRT

<213> Homo sapiens

<400> 244

Leu Glu Phe Leu Pro Glu Arg Thr Ser Gly Gly Pro Glu Ala Ala Asp
1 5 10 15

Phe Ser Asp Gln Leu Ser Leu Gly Ser Ser Arg Val Pro Arg Cys Gly
20 25 30

Gln Gly Thr Leu Leu Ala Gln Ala Cys Gln Asp Leu
35 40

<210> 245

<211> 53

<212> PRT

<213> Homo sapiens

<400> 245

Pro Ser Ile Arg Asn Cys Tyr Leu Thr His Cys Ser Pro Ala Arg Ala
1 5 10 15

Ser Leu Leu Ala Ser Gln Ala Leu His Arg Gly Glu Leu Gln Arg Val
20 25 30

Pro Thr Leu Leu Pro Met Pro Thr Glu Pro Leu Leu Pro Thr Asp
35 40 45

Trp Pro Phe Leu His
50

<210> 246

<211> 25

<212> PRT

<213> Homo sapiens

<400> 246

Val Gly Ser Val Leu Gly Ala Phe Leu Thr Phe Pro Gly Leu Arg Leu
1 5 10 15

Ala Gln Thr His Arg Asp Ala Leu Thr
20 25

<210> 247

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 247

Leu Glu Cys Thr Asp Thr Ile Met Val His Cys Ser Leu Lys Leu Leu
1 5 10 15

Ser Pro Ser Asp Xaa Ser His Ser Ala Ser Gln Val Ala Lys Thr Arg
20 25 30

Gly Val His His Xaa Thr Gln Leu Ile Phe Lys Val Phe Phe Val Xaa
35 40 45

Met Gly Ser His Ser Thr Lys Tyr Xaa Ser Ile Arg Pro Gly Leu Leu
50 55 60

Pro
65

<210> 248
<211> 14
<212> PRT
<213> Homo sapiens

<400> 248
Glu Ser Ser Phe Val Pro Pro Ala Ala His Ser Ser Leu Cys
1 5 10

<210> 249
<211> 172
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 249
Leu Leu Pro Gly Gln Gln Glu Ala Thr Gln Cys Val Glu Ala Gly Ala
1 5 10 15

Gly Glu Gly Ala Leu Thr Pro Met Cys Pro Cys Arg Gln Glu Gln Phe
20 25 30

Val Asp Leu Tyr Lys Glu Phe Glu Pro Ser Leu Val Asn Ser Thr Val
35 40 45

Tyr Ile Met Ala Met Ala Ile Gln Met Ala Pro Phe Ala Ile Asn Tyr
50 55 60

Lys Val Arg Pro Gly Pro Cys Xaa Asn Ile His Cys Leu Pro Thr Gln
65 70 75 80

Pro His Pro Met Lys Pro Ser Val Pro His Pro His Arg Ala Arg Pro
85 90 95

Ser Trp Arg Ala Cys Pro Arg Thr Ser Pro Trp Cys Gly Val Trp Gln
100 105 110

Phe His Ser Trp Pro Ser Leu Ala Cys Ser Ser Ala Pro Arg Pro Thr
115 120 125

Ser Thr Ala Ser Leu Ala Ser Trp Thr Ser Leu Trp Ser Ser Ser Trp
130 135 140

Ser Leu Pro Arg Ser Cys Ser Trp Thr Ser Ala Trp Arg Ser Trp Pro
145 150 155 160

Thr Ala Ser Cys Ser Ser Ser Trp Gly Pro Arg Ser
165 170

<210> 250
<211> 45
<212> PRT
<213> Homo sapiens

<400> 250
Leu Leu Pro Gly Gln Gln Glu Ala Thr Gln Cys Val Glu Ala Gly Ala
1 5 10 15

Gly Glu Gly Ala Leu Thr Pro Met Cys Pro Cys Arg Gln Glu Gln Phe
20 25 30

Val Asp Leu Tyr Lys Glu Phe Glu Pro Ser Leu Val Asn
35 40 45

<210> 251
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 251
Ser Thr Val Tyr Ile Met Ala Met Ala Ile Gln Met Ala Pro Phe Ala
1 5 10 15

Ile Asn Tyr Lys Val Arg Pro Gly Pro Cys Xaa Asn Ile His Cys Leu
20 25 30

Pro Thr Gln Pro His Pro Met Lys Pro Ser Val Pro
35 40

<210> 252
<211> 42
<212> PRT
<213> Homo sapiens

<400> 252
His Pro His Arg Ala Arg Pro Ser Trp Arg Ala Cys Pro Arg Thr Ser
1 5 10 15

Pro Trp Cys Gly Val Trp Gln Phe His Ser Trp Pro Ser Leu Ala Cys
20 25 30

Ser Ser Ala Pro Arg Pro Thr Ser Thr Ala

35

40

<210> 253
<211> 41
<212> PRT
<213> Homo sapiens

<400> 253

Ser Leu Ala Ser Trp Thr Ser Leu Trp Ser Ser Ser Trp Ser Leu Pro
1 5 10 15

Arg Ser Cys Ser Trp Thr Ser Ala Trp Arg Ser Trp Pro Thr Ala Ser
20 25 30

Cys Ser Ser Ser Trp Gly Pro Arg Ser
35 40

<210> 254
<211> 48
<212> PRT
<213> Homo sapiens

<400> 254

Thr Arg Asn Ile Leu Ser Phe Ile Lys Cys Val Ile His Asn Phe Trp
1 5 10 15

Ile Pro Lys Glu Ser Asn Glu Ile Thr Ile Ile Ile Asn Pro Tyr Arg
20 25 30

Glu Thr Val Cys Phe Ser Val Glu Pro Val Lys Lys Ile Phe Asn Tyr
35 40 45

<210> 255
<211> 27
<212> PRT
<213> Homo sapiens

<400> 255

Leu Val Val Leu Phe Ala Ser Ser Asn Ser Arg Tyr Leu Lys Tyr Phe
1 5 10 15

Phe Leu Val Pro Leu Ile Leu Gly Ser Ala Trp
20 25

<210> 256
<211> 20
<212> PRT
<213> Homo sapiens

<400> 256
His Glu Trp Lys Cys Lys Gln Lys Tyr Ser Glu Gly Ser Gly Asn Thr
1 5 10 15
Arg Ile Gly Asn
20

<210> 257
<211> 20
<212> PRT
<213> Homo sapiens

<400> 257
Leu Leu Pro Leu Cys Phe Leu Gly Pro Arg Gln Val Leu Glu Glu Phe
1 5 10 15
Pro Ser Ile Val
20

<210> 258
<211> 12
<212> PRT
<213> Homo sapiens

<400> 258
Pro Thr Arg Pro Ser Lys His Gln Glu Ala Gly Ser
1 5 10

<210> 259
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 259
Gly Gln Gly Pro Ala Gly Arg Trp Val Arg Arg Leu Pro Cys Ser Arg
1 5 10 15

Arg Ala Gly Gly Glu Arg Gly Pro His Trp Gly Val Trp Ala Gly Pro
20 25 30

Gln Met Ser Cys Gly Leu Xaa Phe Gly Pro
35 40

<210> 260
<211> 193

<212> PRT

<213> Homo sapiens

<400> 260

Ala Thr Met Leu Thr Glu Pro Gln Asn Pro His Leu Ile Gly Phe Val
20 25 30

Ala Tyr Ser Gly Pro Ser His Thr Thr Gln Pro His Lys Tyr Trp Leu
35 40 45

Leu Leu Asp Gly Gln Ala Asp Pro Ala Ala Ala Glu Gly Pro Val Lys
50 55 60

Arg Lys Ala Ala Ser Val Val Trp Trp Pro Gln Ala Leu Arg His Leu
65 70 75 80

Ser Leu Leu Val His Cys Trp Glu Glu Ser Tyr Glu Met Asn Ile Gly
85 90 95

Cys Gln Ser Leu Trp Ala Gly Gly Leu Ala Ser Ser Gly Asn Gly Trp
100 105 110

Asp Leu Gly Val Ala Phe Arg Arg Asp Thr Cys Met Ser Ser Ser Ser
115 120 125

Leu His Trp Lys Glu Phe Lys Tyr Ala Pro Gly Ser Leu His Tyr Phe
130 135 140

Ala Leu Ser Phe Val Leu Ile Leu Thr Glu Ile Cys Leu Val Ser Ser
145 150 155 160

Gly Met Gly Phe Pro Gln Glu Gly Lys His Phe Ser Val Leu Gly Ser
165 170 175

Pro Asp Cys Ser Leu Trp Gly Arg Asp Glu His Val Pro Arg Glu Phe
 180 185 190

Ala

<210> 261

<211> 42

<212> PRT

<213> Homo sapiens

<400> 261

Trp Arg Thr Gln Gly Pro Met Val Leu Leu Trp Val Val Thr Cys Pro
1 5 10 15

Ala Thr Met Leu Thr Glu Pro Gln Asn Pro His Leu Ile Gly Phe Val
20 25 30

Ala Tyr Ser Gly Pro Ser His Thr Thr Gln
35 40

<210> 262

<211> 41

<212> PRT

<213> Homo sapiens

<400> 262

Pro His Lys Tyr Trp Leu Leu Leu Asp Gly Gln Ala Asp Pro Ala Ala
1 5 10 15

Ala Glu Gly Pro Val Lys Arg Lys Ala Ala Ser Val Val Trp Trp Pro
20 25 30

Gln Ala Leu Arg His Leu Ser Leu Leu
35 40

<210> 263

<211> 41

<212> PRT

<213> Homo sapiens

<400> 263

Val His Cys Trp Glu Glu Ser Tyr Glu Met Asn Ile Gly Cys Gln Ser
1 5 10 15

Leu Trp Ala Gly Gly Leu Ala Ser Ser Gly Asn Gly Trp Asp Leu Gly
20 25 30

Val Ala Phe Arg Arg Asp Thr Cys Met
35 40

<210> 264

<211> 44

<212> PRT

<213> Homo sapiens

<400> 264

Ser Ser Ser Ser Leu His Trp Lys Glu Phe Lys Tyr Ala Pro Gly Ser
1 5 10 15

Leu His Tyr Phe Ala Leu Ser Phe Val Leu Ile Leu Thr Glu Ile Cys
20 25 30

Leu Val Ser Ser Gly Met Gly Phe Pro Gln Glu Gly
35 40

<210> 265

<211> 25

<212> PRT
<213> Homo sapiens

<400> 265
Lys His Phe Ser Val Leu Gly Ser Pro Asp Cys Ser Leu Trp Gly Arg
1 5 10 15
Asp Glu His Val Pro Arg Glu Phe Ala
20 25

<210> 266
<211> 31
<212> PRT
<213> Homo sapiens

<400> 266
Ile Ala Gln Gly Thr Val Pro Leu Thr Lys Arg Gly Val Gln Ser Ser
1 5 10 15
Gly Pro Asp Tyr Pro Glu Gly Thr Leu Thr Pro Leu Pro Arg Gly
20 25 30

<210> 267
<211> 31
<212> PRT
<213> Homo sapiens

<400> 267
Ile Ala Gln Gly Thr Val Pro Leu Thr Lys Arg Gly Val Gln Ser Ser
1 5 10 15
Gly Pro Asp Tyr Pro Glu Gly Thr Leu Thr Pro Leu Pro Arg Gly
20 25 30

<210> 268
<211> 28
<212> PRT
<213> Homo sapiens

<400> 268
Asp Cys Leu Tyr Leu Ala Leu Ser Phe Pro Trp His Cys His Cys His
1 5 10 15
His His Pro Pro Ser Gly Ser Leu Leu Tyr Pro Phe
20 25

<210> 269
<211> 101
<212> PRT
<213> Homo sapiens

<400> 269

Ala Ser Leu Pro Pro Ser Arg Ser Arg Pro Leu Ala Asn Met Ala Leu
1 5 10 15

Val Pro Cys Gln Val Leu Arg Met Ala Ile Leu Leu Ser Tyr Cys Ser
20 25 30

Ile Leu Cys Asn Tyr Lys Ala Ile Glu Met Pro Ser His Gln Thr Tyr
35 40 45

Gly Gly Ser Trp Lys Phe Leu Thr Phe Ile Asp Leu Val Ile Gln Ala
50 55 60

Val Phe Phe Gly Ile Cys Val Leu Thr Asp Leu Ser Ser Leu Leu Thr
65 70 75 80

Arg Gly Ser Gly Asn Gln Glu Gln Glu Arg Gln Leu Lys Lys Leu Ile
85 90 95

Ser Leu Arg Asp Trp
100

<210> 270

<211> 16

<212> PRT

<213> Homo sapiens

<400> 270

Met Ser Arg Ser Ser Arg Ile Ser Gly Leu Ser Cys Pro Trp Leu Leu
1 5 10 15

<210> 271

<211> 45

<212> PRT

<213> Homo sapiens

<400> 271

Asp His Trp Pro Ala Gly Phe Leu Pro Pro Ala Pro Gly Leu Lys Phe
1 5 10 15

Pro Val Ala Leu Glu Val Phe Arg Lys Val Leu Pro Ala Val Cys Pro
20 25 30

Thr Asp Cys Ser Gly Ser Ala Gly Lys Glu Arg Asn Ser
35 40 45

<210> 272

<211> 47

<212> PRT

<213> Homo sapiens

<400> 272

Glu Glu Ile Ala Thr Ser Ile Glu Pro Ile Arg Asp Phe Leu Ala Ile
1 5 10 15

Val Phe Phe Ala Ser Ile Gly Leu His Val Phe Pro Thr Phe Val Ala
20 25 30

Tyr Glu Leu Thr Val Leu Val Phe Leu Thr Leu Ser Val Val Val
35 40 45

<210> 273

<211> 7

<212> PRT

<213> Homo sapiens

<400> 273

Tyr Cys Asn Leu Gln Cys Arg
1 5

<210> 274

<211> 44

<212> PRT

<213> Homo sapiens

<400> 274

Ser Ala Leu Ile Gly Asn Pro Lys Gly Cys Phe Gly Cys Phe Ser Pro
1 5 10 15

Val Val Leu Arg Glu Trp Ser Val Glu Ser Trp Lys Ser Leu Arg Pro
20 25 30

Phe Gln Ala Ile Cys Lys Leu Lys Thr Asn Phe Arg
35 40

<210> 275

<211> 8

<212> PRT

<213> Homo sapiens

<400> 275

His Glu Ala Ala Leu Arg Gly Pro
1 5

<210> 276

<211> 26

<212> PRT

<213> Homo sapiens

<400> 276

Ser Asn Ala Ala Gly Asn Val Val Arg Ala Phe Leu Tyr Ile Asn His
1 5 10 15

Leu Lys Leu Gly Cys Lys Val Gly Leu Ala
20 25

<210> 277
<211> 25
<212> PRT
<213> Homo sapiens

<400> 277
Asn Trp Ala Val Leu Asn Met Leu Leu Ser Lys Gly Lys Ile Thr Ile
1 5 10 15

Phe Leu Gly Pro Leu Glu Cys Gly Ser
20 25

<210> 278
<211> 49
<212> PRT
<213> Homo sapiens

<400> 278
Pro Ser His Gln Thr Arg Lys Gly Lys Ser Ala Lys Leu Leu Asp Arg
1 5 10 15

Pro Pro Glu Ala Leu Arg Met Lys Ile Ile Thr Thr Thr Leu Leu Leu
20 25 30

Ala Cys His Leu Gln Leu Glu Val Gly Val Val Val Gly Glu Val
35 40 45

Asp

<210> 279
<211> 51
<212> PRT
<213> Homo sapiens

<400> 279
Phe Gln Ala Ser Ser Ala Asn Asn Gln Gln Asn Trp Gly Ser Gln Pro
1 5 10 15

Ile Ala Gln Gln Pro Leu Gln Gln Gly Gly Asp Tyr Ser Gly Asn Tyr
20 25 30

Gly Tyr Asn Asn Asp Asn Gln Glu Phe Tyr Gln Asp Thr Tyr Gly Gln
35 40 45

Gln Trp Lys

50

<210> 280

<211> 264

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 280

Trp Xaa Pro Leu Leu Xaa Thr Ser Gly Ser Pro Gly Leu Xaa Gly Phe
1 5 10 15Gly Thr Arg Met Asn Gly Lys Glu Ile Glu Gly Glu Glu Ile Glu Ile
20 25 30Val Leu Ala Lys Pro Pro Asp Lys Lys Arg Lys Glu Arg Gln Ala Ala
35 40 45Arg Gln Ala Ser Arg Ser Thr Ala Tyr Glu Asp Tyr Tyr Tyr His Pro
50 55 60Pro Pro Arg Met Pro Pro Ile Arg Gly Arg Gly Arg Gly Gly
65 70 75 80Arg Gly Gly Tyr Gly Tyr Pro Pro Asp Tyr Tyr Gly Tyr Glu Asp Tyr
85 90 95Tyr Asp Asp Tyr Tyr Gly Tyr Asp Tyr His Asp Tyr Arg Gly Gly Tyr
100 105 110Glu Asp Pro Tyr Tyr Gly Tyr Asp Asp Gly Tyr Ala Val Arg Gly Arg
115 120 125Gly Gly Gly Arg Gly Gly Arg Gly Ala Pro Pro Pro Arg Gly Arg
130 135 140Gly Ala Pro Pro Pro Arg Gly Arg Ala Gly Tyr Ser Gln Arg Gly Ala
145 150 155 160

Pro Leu Gly Pro Pro Arg Gly Ser Arg Gly Gly Arg Gly Pro Ala

Tyr Ala Val Arg Gly Arg Gly Gly Arg
20 25

<210> 284
<211> 28
<212> PRT
<213> Homo sapiens

<400> 284
Pro Pro Pro Arg Gly Arg Ala Gly Tyr Ser Gln Arg Gly Ala Pro Leu
1 5 10 15

Gly Pro Pro Arg Gly Ser Arg Gly Gly Arg Gly Gly
20 25

<210> 285
<211> 35
<212> PRT
<213> Homo sapiens

<400> 285
Ala Asp Gly Tyr Asn Gln Pro Asp Ser Lys Arg Arg Gln Pro Thr Thr
1 5 10 15

Asn Arg Thr Gly Val Pro Asn Pro Ser Leu Ser Ser Arg Phe Ser Lys
20 25 30

Val Val Thr
35

<210> 286
<211> 19
<212> PRT
<213> Homo sapiens

<400> 286
Leu Gln Ile Pro Pro Ser Ser Gln Ser Leu Gly Leu Lys Asn Ala Asp
1 5 10 15

Ser Ser Ile

<210> 287
<211> 129
<212> PRT
<213> Homo sapiens

<400> 287
Gly Gly Pro Pro Glu Ser Ala Pro Trp Leu Pro Ala Val Leu Arg Ala
1 5 10 15

Pro Val Leu Thr Ser Arg Cys Ala Ser Ser Asp Ser Glu Gly Pro Val
 20 25 30

Trp Phe Cys Gln Pro Gly Ser Gly Pro Ser Ser Thr Glu Met Ser Cys
 35 40 45

His Cys Ile Leu Gly Pro Gly Ser Ser Cys Leu Cys Val Leu Arg Gly
 50 55 60

Ser Met Trp Thr Pro Ser Val Pro Gly Trp Pro Gln Pro Ala Lys Glu
 65 70 75 80

Thr Gly Ala Ser Ser Cys Ser Val Phe Ser Ala Asn Asn Gly Ser Cys
 85 90 95

Pro Leu Pro Leu His Asn His Gln Arg Gln Ala Ser Leu Asp Thr Gly
 100 105 110

Leu Ser Leu Glu His Val Pro Gly Glu Ser Tyr Phe Tyr Ser Pro Val
 115 120 125

Gly

<210> 288
<211> 34
<212> PRT
<213> Homo sapiens

<400> 288
Ser Ser Asp Ser Glu Gly Pro Val Trp Phe Cys Gln Pro Gly Ser Gly
 1 5 10 15

Pro Ser Ser Thr Glu Met Ser Cys His Cys Ile Leu Gly Pro Gly Ser
 20 25 30

Ser Cys

<210> 289
<211> 28
<212> PRT
<213> Homo sapiens

<400> 289
Trp Thr Pro Ser Val Pro Gly Trp Pro Gln Pro Ala Lys Glu Thr Gly
 1 5 10 15

Ala Ser Ser Cys Ser Val Phe Ser Ala Asn Asn Gly
 20 25

<210> 290
<211> 21
<212> PRT
<213> Homo sapiens

<400> 290
Gln Arg Gln Ala Ser Leu Asp Thr Gly Leu Ser Leu Glu His Val Pro
1 5 10 15

Gly Glu Ser Tyr Phe
20

<210> 291
<211> 29
<212> PRT
<213> Homo sapiens

<400> 291
Ser Ser Ser Leu Val Leu Thr Ile Arg Ser Gln Thr Leu Phe Leu Ala
1 5 10 15

Ser Phe Ile His Ser Thr Ser Ile Phe Cys Ala Leu Asn
20 25

<210> 292
<211> 12
<212> PRT
<213> Homo sapiens

<400> 292
Cys Cys Cys Arg Leu Gly Leu Ser Gly Pro Lys Cys
1 5 10

<210> 293
<211> 22
<212> PRT
<213> Homo sapiens

<400> 293
Arg Ala Phe Trp Gly Leu Gly Ala Leu Gln Leu Leu Asp Leu Ser Ala
1 5 10 15

Asn Gln Leu Glu Ala Leu
20

<210> 294
<211> 34
<212> PRT
<213> Homo sapiens

<400> 294

154

His Ala Ser Gly Arg Arg Thr Gly Ser Ala Asp Asp Gly Leu Gln Gly
1 5 10 15

Arg Thr Gly Ser Gly Pro Pro Thr Ala Gly Ala Gly Gly Gly Ala
20 25 30

Ala Pro

<210> 295

<211> 205

<212> PRT

<213> Homo sapiens

<400> 295

Val Ser Ala Ala Ala Gly Ala Arg Leu Ala Pro Arg Ala Pro Gly Ala
1 5 10 15

Pro Ala Gly Cys Arg Pro Met Arg Gly Cys Ala Ala Arg Ala Ala Ala
20 25 30

Arg Lys Ser Leu Val Pro Val Leu Pro Ala Gly Trp Arg Ser Gly Pro
35 40 45

Ala Ala Ala Ala Arg Pro Gly Pro Arg Arg Leu Ala His Ala Pro Ser
50 55 60

Ala Ala Arg Ser Arg Ala Gly Pro Gly Ala Val Ala Arg Pro Leu Pro
65 70 75 80

Arg Arg His Leu Ala Ala Ala His Gly Arg Gly Cys Gly Pro Ala Ala
85 90 95

Ala Arg Ala Gly Ala Gly Ser Gly Pro Gly Ala Arg Arg Ala Ala Arg
100 105 110

Val Pro Thr Ala Gly Arg Pro Pro Gly Thr His Val His Thr Ser Gly
115 120 125

Gln Ser Gly Ala Pro Arg Asp Pro Glu Gly Glu Ala Leu Ala Asp Thr
130 135 140

Trp Ala Gln Thr Gly Gln Gly Asp Ser Ser Ser Asn Ser Ser Ser Ser
145 150 155 160

Gly Arg Gly Arg Asp Gln Glu Gly Pro Arg Met Gly Ala Ala Pro Pro
165 170 175

Pro Pro Ala Pro Ala Val Gly Gly Pro Leu Pro Val Arg Pro Trp Ser
180 185 190

Pro Ser Ser Ala Glu Pro Val Leu Arg Pro Asp Ala Trp
195 200 205

<210> 296

<211> 368

<212> PRT

<213> Homo sapiens

<400> 296

Thr Arg Pro Ala Ala Glu Arg Ala Pro Arg Thr Thr Gly Ser Arg Asp
1 5 10 15

Ala Gln Ala Ala Gly Leu Pro Pro Arg Val Pro Gly Ala Gly Gly Leu
20 25 30

Pro Pro Cys Gly Ala Leu Pro Gly Arg Gly Leu Gly Arg Cys Cys Cys
35 40 45

Cys Cys Cys Cys Cys Arg Leu Gly Leu Ser Gly Pro Lys Cys Arg Pro
50 55 60

Gly Pro Arg Pro Arg Gly Pro Trp Ala Pro Arg Thr Ala Pro Arg Cys
65 70 75 80

Ala Arg Ala Cys Arg Glu Ala Cys Gln Leu Ser Ala Leu Ser Leu Pro
85 90 95

Ala Val Pro Pro Gly Leu Ser Leu Arg Leu Arg Ala Leu Leu Leu Asp
100 105 110

His Asn Arg Val Arg Ala Leu Pro Pro Gly Ala Phe Ala Gly Ala Gly
115 120 125

Ala Leu Gln Arg Leu Asp Leu Arg Glu Asn Gly Leu His Ser Val His
130 135 140

Val Arg Ala Phe Trp Gly Leu Gly Ala Leu Gln Leu Leu Asp Leu Ser
145 150 155 160

Ala Asn Gln Leu Glu Ala Leu Ala Pro Gly Thr Phe Ala Pro Leu Arg
165 170 175

Ala Leu Arg Asn Leu Ser Leu Ala Gly Asn Arg Leu Ala Arg Leu Glu
180 185 190

Pro Ala Ala Leu Gly Ala Leu Pro Leu Leu Arg Ser Leu Ser Leu Gln
195 200 205

Asp Asn Glu Leu Ala Ala Leu Ala Pro Gly Leu Leu Gly Arg Leu Pro
210 215 220

Ala Leu Asp Ala Leu His Leu Arg Gly Asn Pro Trp Gly Cys Gly Cys
225 230 235 240

Ala Leu Arg Pro Leu Cys Ala Trp Leu Arg Arg His Pro Leu Pro Ala
245 250 255

Ser Glu Ala Glu Thr Val Leu Cys Val Trp Pro Gly Arg Leu Thr Leu
260 265 270

Ser Pro Leu Thr Ala Phe Ser Asp Ala Ala Phe Ser His Cys Ala Gln
275 280 285

Pro Leu Ala Leu Arg Asp Leu Ala Arg Gly Leu His Ala Arg Ala Gly
290 295 300

Leu Leu Pro Arg Gln Pro Gly Phe Leu Pro Gly Ala Gly Leu Trp Ala
305 310 315 320

His Arg Leu Pro Cys Ala Pro Pro Pro Pro His Arg Arg Pro Pro
325 330 335

Pro Ala Glu Thr Val Gln Thr Arg Thr Pro Ile Pro Thr Pro Thr Ala
340 345 350

Val Pro Arg Pro Arg Thr Arg Gly Ala Pro Ser Ala Ala Gln Ala
355 360 365

<210> 297
<211> 47
<212> PRT
<213> Homo sapiens

<400> 297
Gly Cys Arg Pro Met Arg Gly Cys Ala Ala Arg Ala Ala Arg Lys
1 5 10 15

Ser Leu Val Pro Val Leu Pro Ala Gly Trp Arg Ser Gly Pro Ala Ala
20 25 30

Ala Ala Arg Pro Gly Pro Arg Arg Leu Ala His Ala Pro Ser Ala
35 40 45

<210> 298
<211> 30
<212> PRT
<213> Homo sapiens

<400> 298
Pro Gly Ala Val Ala Arg Pro Leu Pro Arg Arg His Leu Ala Ala Ala
1 5 10 15

His Gly Arg Gly Cys Gly Pro Ala Ala Ala Arg Ala Gly Ala
20 25 30

<210> 299

<211> 24
<212> PRT
<213> Homo sapiens

<400> 299
Ser Gly Gln Ser Gly Ala Pro Arg Asp Pro Glu Gly Glu Ala Leu Ala
1 5 10 15
Asp Thr Trp Ala Gln Thr Gly Gln
20

<210> 300
<211> 23
<212> PRT
<213> Homo sapiens

<400> 300
Pro Pro Ala Pro Ala Val Gly Gly Pro Leu Pro Val Arg Pro Trp Ser
1 5 10 15
Pro Ser Ser Ala Glu Pro Val
20

<210> 301
<211> 26
<212> PRT
<213> Homo sapiens

<400> 301
Ala Pro Arg Thr Thr Gly Ser Arg Asp Ala Gln Ala Ala Gly Leu Pro
1 5 10 15
Pro Arg Val Pro Gly Ala Gly Gly Leu Pro
20 25

<210> 302
<211> 22
<212> PRT
<213> Homo sapiens

<400> 302
Gly Pro Arg Pro Arg Gly Pro Trp Ala Pro Arg Thr Ala Pro Arg Cys
1 5 10 15
Ala Arg Ala Cys Arg Glu
20

<210> 303
<211> 31
<212> PRT
<213> Homo sapiens

<400> 303

Ala Val Pro Pro Gly Leu Ser Leu Arg Leu Arg Ala Leu Leu Leu Asp
1 5 10 15

His Asn Arg Val Arg Ala Leu Pro Pro Gly Ala Phe Ala Gly Ala
20 25 30

<210> 304

<211> 24

<212> PRT

<213> Homo sapiens

<400> 304

Leu Gly Ala Leu Gln Leu Leu Asp Leu Ser Ala Asn Gln Leu Glu Ala
1 5 10 15

Leu Ala Pro Gly Thr Phe Ala Pro
20

<210> 305

<211> 36

<212> PRT

<213> Homo sapiens

<400> 305

Pro Pro Gly Ala Phe Ala Gly Ala Gly Leu Gln Arg Leu Asp Leu
1 5 10 15

Arg Glu Asn Gly Leu His Ser Val His Val Arg Ala Phe Trp Gly Leu
20 25 30

Gly Ala Leu Gln
35

<210> 306

<211> 28

<212> PRT

<213> Homo sapiens

<400> 306

Arg Asn Leu Ser Leu Ala Gly Asn Arg Leu Ala Arg Leu Glu Pro Ala
1 5 10 15

Ala Leu Gly Ala Leu Pro Leu Leu Arg Ser Leu Ser
20 25

<210> 307

<211> 26

<212> PRT

<213> Homo sapiens

<400> 307

Leu Pro Ala Leu Asp Ala Leu His Leu Arg Gly Asn Pro Trp Gly Cys
1 5 10 15

Gly Cys Ala Leu Arg Pro Leu Cys Ala Trp
20 25

<210> 308

<211> 34

<212> PRT

<213> Homo sapiens

<400> 308

Thr Val Leu Cys Val Trp Pro Gly Arg Leu Thr Leu Ser Pro Leu Thr
1 5 10 15

Ala Phe Ser Asp Ala Ala Phe Ser His Cys Ala Gln Pro Leu Ala Leu
20 25 30

Arg Asp

<210> 309

<211> 24

<212> PRT

<213> Homo sapiens

<400> 309

Leu His Ala Arg Ala Gly Leu Leu Pro Arg Gln Pro Gly Phe Leu Pro
1 5 10 15

Gly Ala Gly Leu Trp Ala His Arg
20

<210> 310

<211> 24

<212> PRT

<213> Homo sapiens

<400> 310

Thr Val Gln Thr Arg Thr Pro Ile Pro Thr Pro Thr Ala Val Pro Arg
1 5 10 15

Pro Arg Thr Arg Gly Ala Pro Ser
20

<210> 311

<211> 59

<212> PRT

<213> Homo sapiens

<400> 311
His Ala Ser Gly Arg Pro Asp Arg Ser Ser Ala Pro Ile Gly Asn Ser
1 5 10 15

Gly Leu Pro Cys Pro Asp Leu Glu Pro Leu Gly Gly Leu Gln Ser Lys
20 25 30

Cys Arg Leu Cys Ala Pro Thr Glu Ala Arg Gly Leu Trp Ser Arg Ser
35 40 45

Leu Cys Ser Asp Arg Cys Asp Thr Trp Arg Ser
50 55

<210> 312
<211> 29
<212> PRT
<213> Homo sapiens

<400> 312
Gly Leu Pro Cys Pro Asp Leu Glu Pro Leu Gly Gly Leu Gln Ser Lys
1 5 10 15

Cys Arg Leu Cys Ala Pro Thr Glu Ala Arg Gly Leu Trp
20 25

<210> 313
<211> 16
<212> PRT
<213> Homo sapiens

<400> 313
Gln Glu Trp Glu Ser Glu Leu Gly Glu Arg Arg Lys Pro Leu Gln Ala
1 5 10 15

<210> 314
<211> 46
<212> PRT
<213> Homo sapiens

<400> 314
Cys Gln Ser Ser Asn Leu Ile Phe Phe Gln Phe Val Asn Ile Leu Phe
1 5 10 15

Asn Leu Met Met Asp Ile Leu Val Asp Phe Ser Ile Thr Lys Met Pro
20 25 30

Ile Asn Ser Ile Phe Ser Leu Tyr Phe Cys Tyr Glu Ile Ile
35 40 45

<210> 315
<211> 134
<212> PRT
<213> Homo sapiens

<400> 315
Gly Pro Val Trp Leu Phe Cys Phe Leu Thr Leu Cys Arg Lys Pro Ser
1 5 10 15

Gln Leu Phe Ser Gln Glu Asn Ser Cys Met Asp Val Ala Gly Gly Val
20 25 30

Thr Thr Cys Leu Pro Pro Trp Phe Ser Arg Gly Ala Pro Ala Gln Met
35 40 45

Ser Gln Trp Pro Pro Ser Ser Asp His Gly Ala Val Arg Ala Gly Arg
50 55 60

Asp Ser Arg Val Gly Pro Val Gln Pro Ser His Leu Thr Cys Glu Gly
65 70 75 80

Gly Lys Glu Glu Arg Glu Lys Asn Lys Lys Ala Glu Val Asn Pro Pro
85 90 95

Thr Gly Met Gly Leu Ala Asn Arg Ile Pro Arg Asp Asp Ile Thr Leu
100 105 110

Lys Leu Arg Asn Gln Gly Lys Leu Arg Thr Lys Glu Asn Arg Thr Gln
115 120 125

Ser Ala Lys Arg His Pro
130

<210> 316
<211> 42
<212> PRT
<213> Homo sapiens

<400> 316
Val Ala Cys Lys Pro Glu Asn Arg Thr Lys Thr His Phe Ala Ser Ser
1 5 10 15

Pro Ala Cys Asp Gly His Ala Leu Gly Gly Gln Val Gly Phe Ala Ile
20 25 30

Cys Phe Leu Ser Cys Leu Phe Pro Pro Met
35 40

<210> 317
<211> 40
<212> PRT

<213> Homo sapiens

<400> 317

Ser His Pro Met Pro Asn Thr Pro Gln Lys Gln Leu Leu Phe Ser Glu
1 5 10 15

Asp Asn Glu Leu Leu Val Ser Leu Arg Thr Gly Arg Lys Pro Thr Leu
20 25 30

Gln Ala Ala Leu Arg Val Thr Gly
35 40

<210> 318

<211> 59

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 318

Glu Gly Asp Pro Arg Gly Arg Pro Arg Pro Arg Pro Leu Gly Pro Pro
1 5 10 15

Pro Gln Leu Thr Leu Pro Thr Ala Leu Xaa Asp Ile Leu Arg Gln Val
20 25 30

Arg Ala Pro Gly Leu Arg Leu Ser Arg Ala Leu Glu Val Gly Arg Lys
35 40 45

Gly Ser Pro Ile Phe Lys Ile Gln Ile Tyr Leu
50 55

<210> 319

<211> 250

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (145)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 319

Ala His Arg Leu Gln Ile Arg Leu Leu Thr Trp Asp Val Lys Asp Thr
1 5 10 15

Leu Leu Arg Leu Arg His Pro Leu Gly Glu Ala Tyr Ala Thr Lys Ala
20 25 30

Arg Ala His Gly Leu Glu Val Glu Pro Ser Ala Leu Glu Gln Gly Phe

35	40	45
Arg Gln Ala Tyr Arg Ala Gln Ser His Ser Phe Pro Asn Tyr Gly Leu		
50	55	60
Ser His Gly Leu Thr Ser Arg Gln Trp Trp Leu Asp Val Val Leu Gln		
65	70	75
80		
Thr Phe His Leu Ala Gly Val Gln Asp Ala Gln Ala Val Ala Pro Ile		
85	90	95
Ala Glu Gln Leu Tyr Lys Asp Phe Ser His Pro Cys Thr Trp Gln Val		
100	105	110
Leu Asp Gly Ala Glu Asp Thr Leu Arg Glu Cys Arg Thr Arg Gly Leu		
115	120	125
Arg Leu Ala Val Ile Ser Asn Phe Asp Arg Arg Leu Glu Gly Ile Leu		
130	135	140
Xaa Gly Leu Gly Leu Arg Glu His Phe Asp Phe Val Leu Thr Ser Glu		
145	150	155
160		
Ala Ala Gly Trp Pro Lys Pro Asp Pro Arg Ile Phe Gln Glu Ala Leu		
165	170	175
Arg Leu Ala His Met Glu Pro Val Val Ala Ala His Val Gly Asp Asn		
180	185	190
Tyr Leu Cys Asp Tyr Gln Gly Pro Arg Ala Val Gly Met His Ser Phe		
195	200	205
Leu Val Val Gly Pro Gln Ala Leu Asp Pro Val Val Arg Asp Ser Val		
210	215	220
Pro Lys Glu His Ile Leu Pro Ser Leu Ala His Leu Leu Pro Ala Leu		
225	230	235
240		
Asp Cys Leu Glu Gly Ser Thr Pro Gly Leu		
245	250	

<210> 320
<211> 27
<212> PRT
<213> Homo sapiens

<400> 320
Ile Arg Leu Leu Thr Trp Asp Val Lys Asp Thr Leu Leu Arg Leu Arg
1 5 10 15
His Pro Leu Gly Glu Ala Tyr Ala Thr Lys Ala
20 25

<210> 321
<211> 24
<212> PRT
<213> Homo sapiens

<400> 321
Leu Glu Gln Gly Phe Arg Gln Ala Tyr Arg Ala Gln Ser His Ser Phe
1 5 10 15

Pro Asn Tyr Gly Leu Ser His Gly
20

<210> 322
<211> 26
<212> PRT
<213> Homo sapiens

<400> 322
His Leu Ala Gly Val Gln Asp Ala Gln Ala Val Ala Pro Ile Ala Glu
1 5 10 15

Gln Leu Tyr Lys Asp Phe Ser His Pro Cys
20 25

<210> 323
<211> 23
<212> PRT
<213> Homo sapiens

<400> 323
Val Leu Asp Gly Ala Glu Asp Thr Leu Arg Glu Cys Arg Thr Arg Gly
1 5 10 15

Leu Arg Leu Ala Val Ile Ser
20

<210> 324
<211> 26
<212> PRT
<213> Homo sapiens

<400> 324
Arg Glu His Phe Asp Phe Val Leu Thr Ser Glu Ala Ala Gly Trp Pro
1 5 10 15

Lys Pro Asp Pro Arg Ile Phe Gln Glu Ala
20 25

<210> 325
<211> 28
<212> PRT

<213> Homo sapiens

<400> 325

Glu Pro Val Val Ala Ala His Val Gly Asp Asn Tyr Leu Cys Asp Tyr
1 5 10 15

Gln Gly Pro Arg Ala Val Gly Met His Ser Phe Leu
20 25

<210> 326

<211> 23

<212> PRT

<213> Homo sapiens

<400> 326

Val Val Arg Asp Ser Val Pro Lys Glu His Ile Leu Pro Ser Leu Ala
1 5 10 15

His Leu Leu Pro Ala Leu Asp
20

<210> 327

<211> 22

<212> PRT

<213> Homo sapiens

<400> 327

Ile Arg Lys Leu Gly Pro Gly Leu Ala Pro Cys Ser Cys Arg Ser Gly
1 5 10 15

Gln Val Phe Pro Arg Val
20

<210> 328

<211> 241

<212> PRT

<213> Homo sapiens

<400> 328

Lys Pro Leu Arg Met Ala Arg Pro Gly Gly Pro Glu His Asn Glu Tyr
1 5 10 15

Ala Leu Val Ser Ala Trp His Ser Ser Gly Ser Tyr Leu Asp Ser Glu
20 25 30

Gly Leu Arg His Gln Asp Asp Phe Asp Val Ser Leu Leu Val Cys His
35 40 45

Cys Ala Ala Pro Phe Glu Glu Gln Gly Glu Ala Glu Arg His Val Leu
50 55 60

Arg Leu Gln Phe Phe Val Val Leu Thr Ser Gln Arg Glu Leu Phe Pro

166

65	70	75	80
Arg Leu Thr Ala Asp Met Arg Arg Phe Arg Lys Pro Pro Arg Leu Pro			
85	90	95	
Pro Glu Pro Glu Ala Pro Gly Ser Ser Ala Gly Ser Pro Gly Glu Ala			
100	105	110	
Ser Gly Leu Ile Leu Ala Pro Gly Pro Ala Pro Leu Phe Pro Pro Leu			
115	120	125	
Ala Ala Glu Val Gly Met Ala Arg Ala Arg Leu Ala Gln Leu Val Arg			
130	135	140	
Leu Ala Gly Gly His Cys Arg Arg Asp Thr Leu Trp Lys Arg Leu Phe			
145	150	155	160
Leu Leu Glu Pro Pro Gly Pro Asp Arg Leu Arg Leu Gly Gly Arg Leu			
165	170	175	
Ala Leu Ala Glu Leu Glu Leu Leu Glu Ala Val His Ala Lys Ser			
180	185	190	
Ile Gly Asp Ile Asp Pro Gln Leu Asp Cys Phe Leu Ser Met Thr Val			
195	200	205	
Ser Trp Tyr Gln Ser Leu Ile Lys Val Leu Leu Ser Arg Phe Pro Arg			
210	215	220	
Ala Val Ala Ile Ser Lys Ala Gln Thr Trp Glu Leu Ser Thr Trp Leu			
225	230	235	240

Arg

<210> 329
<211> 30
<212> PRT
<213> Homo sapiens

<400> 329
Ala Arg Gly Thr Leu Glu Leu Pro Thr Pro Leu Ile Ala Ala His Gln
1 5 10 15

Leu Tyr Asn Tyr Val Ala Asp His Ala Ser Ser Tyr His Met
20 25 30

<210> 330
<211> 37
<212> PRT
<213> Homo sapiens

<400> 330

Ser His Cys Glu Trp Pro Gly Gln Gly Ala Gln Asn Thr Thr Ser Met
1 5 10 15

Pro Trp Cys Arg His Gly Thr Val Leu Ala Pro Thr Trp Thr Leu Arg
20 25 30

Asp Phe Asp Thr Arg
35

<210> 331

<211> 91

<212> PRT

<213> Homo sapiens

<400> 331

Pro Leu Thr Thr Val Ser His Leu Cys Pro Leu Ser Leu Arg Val Phe
1 5 10 15

Thr Ser His Leu Asp Ile Thr Ala Gly His Ser His Arg Asp Asp Thr
20 25 30

Trp Val Pro Ile Pro Ala Leu Pro Leu Lys His Leu Arg Pro Pro Ser
35 40 45

Ser Pro Phe Ala Leu Gly Pro Trp Val Ser His Pro Leu Met Arg Trp
50 55 60

Val Gln Lys Leu Ser His Leu His Ser Asn Pro Gly Thr Gly Phe Ser
65 70 75 80

Met Gly Gly Lys Ser Ala Glu Lys Leu Lys Cys
85 90

<210> 332

<211> 179

<212> PRT

<213> Homo sapiens

<400> 332

Ser Thr Ala Ala Arg Gly Ala Pro Gly Pro Gly Arg Ala Gly Thr
1 5 10 15

Pro Arg Ser Ser Pro Cys Gln Ile His Trp Gly His Arg Pro Pro Ala
20 25 30

Gly Leu Leu Pro Ile His Asp Gly Leu Leu Val Pro Glu Pro Asp Gln
35 40 45

Ser Ser Pro Lys Pro Leu Pro Gln Ser Cys Arg His Phe Gln Ser Pro
50 55 60

Asp Leu Gly Thr Gln Tyr Leu Val Ala Leu Asn Gln Lys Phe Thr Asp
65 70 75 80

Cys Ser Ala Leu Val Phe Trp Thr Pro Leu Arg Lys Asp Val Ser Glu
85 90 95

Val Val Phe Arg Glu Ala Leu Pro Val Gln Pro Gln Asp Thr Arg Ser
100 105 110

Pro Pro Ala Gln Leu Val Ser Thr Tyr His His Leu Glu Ser Val Ile
115 120 125

Asn Thr Ala Cys Phe Thr Leu Leu Asp Pro Pro Pro Leu Lys Gly Val
130 135 140

Asp Trp Thr Thr Glu Cys His Cys Ser Leu Asn His Gly Pro Thr Arg
145 150 155 160

Leu Pro Ala Arg Gly Arg Thr Asp Gln Pro Phe Trp Ala Pro Gly Gln
165 170 175

Ala Arg His

<210> 333

<211> 56

<212> PRT

<213> Homo sapiens

<400> 333

His Gln Arg Leu Cys Asn Tyr Val Leu Arg Val Cys Cys Pro Ser Leu
1 5 10 15

Ala Ala Gly Thr Ala Leu Pro Lys His Pro Gln Pro Leu Thr His Pro
20 25 30

Gly Leu Gln Arg Val Arg Ser Thr Pro Arg Thr Pro Trp Ala Leu Leu
35 40 45

Gly Tyr Ser Phe Arg Pro Pro Trp
50 55

<210> 334

<211> 28

<212> PRT

<213> Homo sapiens

<400> 334

Pro Gly Gly Pro Glu His Asn Glu Tyr Ala Leu Val Ser Ala Trp His
1 5 10 15

Ser Ser Gly Ser Tyr Leu Asp Ser Glu Gly Leu Arg
20 25

<210> 335
<211> 25
<212> PRT
<213> Homo sapiens

<400> 335
Asp Val Ser Leu Leu Val Cys His Cys Ala Ala Pro Phe Glu Glu Gln
1 5 10 15

Gly Glu Ala Glu Arg His Val Leu Arg
20 25

<210> 336
<211> 28
<212> PRT
<213> Homo sapiens

<400> 336
Arg Leu Thr Ala Asp Met Arg Arg Phe Arg Lys Pro Pro Arg Leu Pro
1 5 10 15

Pro Glu Pro Glu Ala Pro Gly Ser Ser Ala Gly Ser
20 25

<210> 337
<211> 25
<212> PRT
<213> Homo sapiens

<400> 337
Gly Glu Ala Ser Gly Leu Ile Leu Ala Pro Gly Pro Ala Pro Leu Phe
1 5 10 15

Pro Pro Leu Ala Ala Glu Val Gly Met
20 25

<210> 338
<211> 23
<212> PRT
<213> Homo sapiens

<400> 338
Thr Leu Trp Lys Arg Leu Phe Leu Leu Glu Pro Pro Gly Pro Asp Arg
1 5 10 15

Leu Arg Leu Gly Gly Arg Leu
20

<210> 339
<211> 28
<212> PRT

<213> Homo sapiens

<400> 339

Leu Ala Glu Leu Glu Glu Leu Leu Glu Ala Val His Ala Lys Ser Ile
1 5 10 15

Gly Asp Ile Asp Pro Gln Leu Asp Cys Phe Leu Ser
20 25

<210> 340

<211> 197

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (97)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 340

Phe Gln Leu Tyr Phe Asn Pro Glu Leu Ile Phe Lys His Phe Gln Ile
1 5 10 15

Trp Arg Leu Ile Thr Asn Phe Leu Phe Phe Gly Pro Val Gly Phe Asn
20 25 30

Phe Leu Phe Asn Met Ile Phe Leu Tyr Arg Tyr Cys Arg Met Leu Glu
35 40 45

Glu Gly Ser Phe Arg Gly Arg Thr Ala Asp Phe Val Phe Met Phe Leu
50 55 60

Phe Gly Gly Phe Leu Met Thr Leu Phe Gly Leu Phe Val Ser Leu Val
65 70 75 80

Phe Leu Gly Gln Ala Phe Thr Ile Met Leu Val Tyr Val Trp Ser Arg
85 90 95

Xaa Asn Pro Tyr Val Arg Met Asn Phe Phe Gly Leu Leu Asn Phe Gln
100 105 110

Ala Pro Phe Leu Pro Trp Val Leu Met Gly Phe Ser Leu Leu Leu Gly
115 120 125

Asn Ser Ile Ile Val Asp Leu Leu Gly Ile Ala Val Gly His Ile Tyr
130 135 140

Phe Phe Leu Glu Asp Val Phe Pro Asn Gln Pro Gly Gly Ile Arg Ile
145 150 155 160

Leu Lys Thr Pro Ser Ile Leu Lys Ala Ile Phe Asp Thr Pro Asp Glu
165 170 175

Asp Pro Asn Tyr Asn Pro Leu Pro Glu Glu Arg Pro Gly Gly Phe Ala

180 185 190

Trp Gly Glu Gly Gln
195

<210> 341
<211> 108
<212> PRT
<213> Homo sapiens

<400> 341
Gly Val Gly Gln Ala Thr Val Gly Lys Met Ala Tyr Gln Ser Leu Arg
1 5 10 15

Leu Glu Tyr Leu Gln Ile Pro Pro Val Ser Arg Ala Tyr Thr Thr Ala
20 25 30

Cys Val Leu Thr Thr Ala Ala Val Gln Leu Glu Leu Ile Thr Pro Phe
35 40 45

Gln Leu Tyr Phe Asn Pro Glu Leu Ile Phe Lys His Phe Gln Ile Trp
50 55 60

Arg Leu Ile Thr Asn Phe Leu Phe Phe Gly Pro Val Gly Phe Asn Phe
65 70 75 80

Leu Phe Asn Met Ile Phe Leu Tyr Arg Tyr Cys Arg Met Leu Glu Glu
85 90 95

Gly Ser Phe Arg Gly Arg Thr Ala Asp Phe Val Phe
100 105

<210> 342
<211> 23
<212> PRT
<213> Homo sapiens

<400> 342
Leu Ile Phe Lys His Phe Gln Ile Trp Arg Leu Ile Thr Asn Phe Leu
1 5 10 15

Phe Phe Gly Pro Val Gly Phe
20

<210> 343
<211> 25
<212> PRT
<213> Homo sapiens

<400> 343
Phe Leu Tyr Arg Tyr Cys Arg Met Leu Glu Glu Gly Ser Phe Arg Gly
1 5 10 15

Arg Thr Ala Asp Phe Val Phe Met Phe
20 25

<210> 344
<211> 23
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 344
Leu Val Phe Leu Gly Gln Ala Phe Thr Ile Met Leu Val Tyr Val Trp
1 5 10 15

Ser Arg Xaa Asn Pro Tyr Val
20

<210> 345
<211> 21
<212> PRT
<213> Homo sapiens

<400> 345
Val Leu Met Gly Phe Ser Leu Leu Leu Gly Asn Ser Ile Ile Val Asp
1 5 10 15

Leu Leu Gly Ile Ala
20

<210> 346
<211> 25
<212> PRT
<213> Homo sapiens

<400> 346
Asn Gln Pro Gly Gly Ile Arg Ile Leu Lys Thr Pro Ser Ile Leu Lys
1 5 10 15

Ala Ile Phe Asp Thr Pro Asp Glu Asp
20 25

<210> 347
<211> 28
<212> PRT
<213> Homo sapiens

<400> 347

Arg Leu Glu Tyr Leu Gln Ile Pro Pro Val Ser Arg Ala Tyr Thr Thr
1 5 10 15

Ala Cys Val Leu Thr Thr Ala Ala Val Gln Leu Glu
20 25

<210> 348

<211> 31

<212> PRT

<213> Homo sapiens

<400> 348

Arg Leu Ile Thr Asn Phe Leu Phe Phe Gly Pro Val Gly Phe Asn Phe
1 5 10 15

Leu Phe Asn Met Ile Phe Leu Tyr Arg Tyr Cys Arg Met Leu Glu
20 25 30

<210> 349

<211> 12

<212> PRT

<213> Homo sapiens

<400> 349

His Ala Ser Ala Gly Pro Asp Gly Ser Ser Pro Ala
1 5 10

<210> 350

<211> 115

<212> PRT

<213> Homo sapiens

<400> 350

Glu Leu Leu Leu Glu Lys Pro Lys Pro Trp Gln Pro Pro Ala Ala Ala
1 5 10 15

Pro His Arg Ala Leu Leu Val Leu Cys Tyr Ser Ile Val Glu Asn Thr
20 25 30

Cys Ile Ile Thr Pro Thr Ala Lys Ala Trp Lys Tyr Met Glu Glu Glu
35 40 45

Ile Leu Gly Phe Gly Lys Ser Val Cys Asp Ser Leu Gly Arg Arg His
50 55 60

Met Ser Thr Cys Ala Leu Cys Asp Phe Cys Ser Leu Lys Leu Glu Gln
65 70 75 80

Cys His Ser Glu Ala Ser Leu Gln Arg Gln Gln Cys Asp Thr Ser His
85 90 95

Lys Thr Pro Phe Ala Ala Pro Cys Leu Pro Pro Arg Ala Cys Pro Ser

100 105 110

Ala Thr Arg
115

<210> 351
<211> 77
<212> PRT
<213> Homo sapiens

<400> 351
Leu Pro Gly Trp Gly Phe Pro Thr Lys Ile Cys Asp Thr Asp Tyr Ile
1 5 10 15

Gln Tyr Pro Asn Tyr Cys Ser Phe Lys Ser Gln Gln Cys Leu Met Arg
20 25 30

Asn Arg Asn Arg Lys Val Ser Arg Met Arg Cys Leu Gln Asn Glu Thr
35 40 45

Tyr Ser Ala Leu Ser Pro Gly Lys Ser Glu Asp Val Val Leu Arg Trp
50 55 60

Ser Gln Glu Phe Ser Thr Leu Thr Leu Gly Gln Phe Gly
65 70 75

<210> 352
<211> 65
<212> PRT
<213> Homo sapiens

<400> 352
Ser Pro Val Leu Leu Pro Ala Phe Pro Pro Leu Pro Val Pro Leu Leu
1 5 10 15

Ala Leu Pro Val Ser Ala Pro Leu Pro Ala Cys Val Leu Val Ser Ala
20 25 30

Pro Ala Cys Ala Pro Leu Leu Ala Pro Ala Cys Ala Leu Ala Leu Ala
35 40 45

Pro Gly Phe Pro Gly Thr Arg Arg Ile Val Gly Ala Leu Pro Arg Cys
50 55 60

Cys
65

<210> 353
<211> 35
<212> PRT
<213> Homo sapiens

<400> 353
Leu Leu Val Leu Cys Tyr Ser Ile Val Glu Asn Thr Cys Ile Ile Thr
1 5 10 15

Pro Thr Ala Lys Ala Trp Lys Tyr Met Glu Glu Glu Ile Leu Gly Phe
20 25 30

Gly Lys Ser
35

<210> 354

<211> 26

<212> PRT

<213> Homo sapiens

<400> 354

Leu Lys Leu Glu Gln Cys His Ser Glu Ala Ser Leu Gln Arg Gln Gln
1 5 10 15

Cys Asp Thr Ser His Lys Thr Pro Phe Ala
20 25

<210> 355

<211> 40

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 355

Gln Val Ser Gly Leu Ile Leu Ser Leu Ser Cys Gly Met Asp Gly Leu
1 5 10 15

Ala Leu Asp Gly Ser Pro Ser Pro Ser Pro Xaa Thr Glu Lys Ala Gly
20 25 30

Arg Cys Ile Ser Gln Thr Ser Leu
35 40

<210> 356

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 356

Gln Val Ser Gly Leu Ile Leu Ser Leu Ser Cys Gly Met Asp Gly Leu
1 5 10 15

Ala Leu Asp Gly Ser Pro Ser Pro Ser Pro Xaa Thr Glu Lys Ala Gly
20 25 30

Arg Cys Ile Ser Gln Thr Ser Leu Pro Gly Lys Trp Glu Val
35 40 45

<210> 357

<211> 173

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (118)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 357

Arg Ala Ser Lys Thr Val Pro Arg Met Pro Pro Asn Trp Pro Ala Lys
1 5 10 15

Met Pro Cys Leu Cys His Ile Arg Thr Val Glu His Leu Gly Thr Ile
20 25 30

Ser Ser Gly Ala Pro Gly Arg Pro Thr Gly Gln Gln Ala Ala Arg Thr
35 40 45

Tyr His Ile Cys Trp Ile His Pro Gly Gln Lys Ile Asp Ser Leu Pro
50 55 60

Pro Ser Ser Gln His Pro Arg Ser Gln Gln Leu Ala Pro Gly Thr Trp
65 70 75 80

Pro Ser Thr Ser Thr Lys Pro Ala Glu Glu Thr Leu Gly Ser Ser
85 90 95

Ala Ser Leu Pro Ile Ser Gln Ala Arg Lys Ser Glu Lys Cys Thr Phe
100 105 110

Gln Pro Ser Pro Trp Xaa Val Arg Gly Lys Glu Ser His Gln Val Pro
115 120 125

Ala His Pro Ser His Arg Thr Glu Thr Glu Ser Asp His Ser Pro Val
130 135 140

Arg Lys Pro Pro Ser Arg Gly Thr Arg Thr Gly Asp Phe Thr Val Gly
145 150 155 160

Asp Trp Ser Glu Ala Trp Leu Leu Glu Leu Ala Leu Leu
165 170

<210> 358
<211> 23
<212> PRT
<213> Homo sapiens

<400> 358
Arg Met Pro Pro Asn Trp Pro Ala Lys Met Pro Cys Leu Cys His Ile
1 5 10 15
Arg Thr Val Glu His Leu Gly
20

<210> 359
<211> 25
<212> PRT
<213> Homo sapiens

<400> 359
Gly Arg Pro Thr Gly Gln Gln Ala Ala Arg Thr Tyr His Ile Cys Trp
1 5 10 15
Ile His Pro Gly Gln Lys Ile Asp Ser
20 25

<210> 360
<211> 25
<212> PRT
<213> Homo sapiens

<400> 360
Trp Pro Ser Thr Ser Thr Thr Lys Pro Ala Glu Glu Thr Leu Gly Ser
1 5 10 15
Ser Ala Ser Leu Pro Ile Ser Gln Ala
20 .25

<210> 361
<211> 23
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 361
Lys Ser Glu Lys Cys Thr Phe Gln Pro Ser Pro Trp Xaa Val Arg Gly
1 5 10 15
Lys Glu Ser His Gln Val Pro

20

<210> 362
<211> 24
<212> PRT
<213> Homo sapiens

<400> 362
Lys Pro Pro Ser Arg Gly Thr Arg Thr Gly Asp Phe Thr Val Gly Asp
1 5 10 15

Trp Ser Glu Ala Trp Leu Leu Glu
20

<210> 363
<211> 10
<212> PRT
<213> Homo sapiens

<400> 363
Pro Cys Ala Asp Cys Leu Ser Ala Trp Ala.
1 5 10

<210> 364
<211> 11
<212> PRT
<213> Homo sapiens

<400> 364
His Ala Ser Gly Tyr Leu Cys Ile Val Leu Leu
1 5 10

<210> 365
<211> 34
<212> PRT
<213> Homo sapiens

<400> 365
Asn Ser Ala Arg Ala Ala Arg Ala Glu Ile Val Leu Gly Leu Leu Val
1 5 10 15

Trp Thr Leu Ile Ala Gly Thr Glu Tyr Phe Arg Val Pro Ala Phe Gly
20 25 30

Trp Val

<210> 366
<211> 22
<212> PRT

<213> Homo sapiens

<400> 366

Pro Cys Ser Pro Pro Asp Ser Pro Pro Leu Pro Gly Ala Phe Val Trp
1 5 10 15
Arg Val Leu Trp Val Cys
20

<210> 367

<211> 25

<212> PRT

<213> Homo sapiens

<400> 367

Ala Arg Ala Cys Phe Ala Tyr Asn Gly Val Cys Ser Glu Gly Arg Cys
1 5 10 15
Trp Asp Ser His Phe His Gly Ser Val
20 25

<210> 368

<211> 100

<212> PRT

<213> Homo sapiens

<400> 368

Met Ser Asn Met Gly Lys Ile Pro Ser Leu Ser Leu His Ile Pro Ile
1 5 10 15

Asn Lys Tyr Ile Cys Ser Arg Ile Pro Lys Phe Ile Gln Lys Val Asn
20 25 30

Lys Ser Thr Val Leu Gln Ile Cys Leu Lys Arg Gln Ile Ile Leu Asn
35 40 45

Lys Asn Lys Met Ser Asp His Ser Lys Ile Gly Lys Ala Asn Leu Val
50 55 60

Gln Ile Asp Ile His Ser Leu Gly Ile Val Glu Thr Gly Cys Val Pro
65 70 75 80

Ser Lys Arg Tyr Cys Thr Leu Leu Thr Glu Gln Ser Gly Phe Pro Phe
85 90 95

Leu Ser His Pro
100

<210> 369

<211> 84

<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 369
Met Ala Gly Cys Cys Leu Lys Leu Phe Gly Val Leu Ser Leu Cys Phe
1 5 10 15

Leu Cys Gly Leu Ile Ser Ile Glu Arg Val Ile Cys Asn Pro Val Ser
20 25 30

Ala Asp Phe Gln Val Ser Thr Phe Cys Gln Arg His Cys Leu Leu Arg
35 40 45

Ser Lys Val Met Phe Xaa Ile Lys Gly Xaa Thr Ala Thr Ile Glu Val
50 55 60

Ile Asn Glu Asn Cys Thr Leu Val Ala Ala Pro Pro Ile Gly Phe Pro
65 70 75 80

Ile Xaa Phe Leu

<210> 370
<211> 49
<212> PRT
<213> Homo sapiens

<400> 370
Met Ser Asp His Ser Lys Ile Gly Lys Ala Asn Leu Val Gln Ile Asp
1 5 10 15

Ile His Ser Leu Gly Ile Val Glu Thr Gly Cys Val Pro Ser Lys Arg
20 25 30

Tyr Cys Thr Leu Leu Thr Glu Gln Ser Gly Phe Pro Phe Leu Ser His
35 40 45

Pro

<210> 371
<211> 50
<212> PRT
<213> Homo sapiens

<400> 371
Met Ala Gly Cys Cys Leu Lys Leu Phe Gly Val Leu Ser Leu Cys Phe
1 5 10 15

Leu Cys Gly Leu Ile Ser Ile Glu Arg Val Ile Cys Asn Pro Val Ser
20 25 30

Ala Asp Phe Gln Val Ser Thr Phe Cys Gln Arg His Cys Leu Leu Arg
35 40 45

Ser Lys
50

<210> 372
<211> 34
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 372
Val Met Phe Xaa Ile Lys Gly Xaa Thr Ala Thr Ile Glu Val Ile Asn
1 5 10 15

Glu Asn Cys Thr Leu Val Ala Ala Pro Pro Ile Gly Phe Pro Ile Xaa
20 25 30

Phe Leu

<210> 373
<211> 65
<212> PRT
<213> Homo sapiens

<400> 373

Pro Thr Glu Gly Arg Gln Lys Val Leu Lys Thr Phe Thr Val Pro Arg
1 5 10 15

Ser Ala Leu Ala Met Thr Lys Thr Ser Thr Cys Ile Tyr His Phe Leu
20 25 30

Val Leu Ser Trp Tyr Thr Phe Leu Asn Tyr Tyr Ile Ser Gln Glu Gly
35 40 45

Lys Asp Glu Val Lys Pro Lys Ile Leu Ala Asn Gly Ala Arg Trp Lys
50 55 60

Tyr

65

<210> 374

<211> 35

<212> PRT

<213> Homo sapiens

<400> 374

Pro Arg Ser Ala Leu Ala Met Thr Lys Thr Ser Thr Cys Ile Tyr His
1 5 10 15

Phe Leu Val Leu Ser Trp Tyr Thr Phe Leu Asn Tyr Tyr Ile Ser Gln
20 25 30

Glu Gly Lys

35

<210> 375

<211> 24

<212> PRT

<213> Homo sapiens

<400> 375

Pro Thr Glu Gly Arg Gln Lys Val Leu Lys Thr Phe Thr Val Pro Arg
1 5 10 15

Ser Ala Leu Ala Met Thr Lys Thr
20

<210> 376

<211> 27

<212> PRT

<213> Homo sapiens

<400> 376

Phe Leu Asn Tyr Tyr Ile Ser Gln Glu Gly Lys Asp Glu Val Lys Pro
1 5 10 15

Lys Ile Leu Ala Asn Gly Ala Arg Trp Lys Tyr
20 25

<210> 377
<211> 13
<212> PRT
<213> Homo sapiens

<400> 377
Phe Lys Asp Gln Leu Val Tyr Pro Leu Leu Ala Phe Thr
1 5 10

<210> 378
<211> 13
<212> PRT
<213> Homo sapiens

<400> 378
Arg Gln Ala Leu Asn Leu Pro Asp Val Phe Gly Leu Val
1 5 10

<210> 379
<211> 10
<212> PRT
<213> Homo sapiens

<400> 379
Ala Thr Ala Ser His Asp Leu Leu Leu Phe
1 5 10

<210> 380
<211> 97
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 380
Met Ser Ile Asn Ile Cys Leu Met Gln Ser Lys Thr Gln Gly Ser Cys
1 5 10 15

Gln Tyr Leu Leu Leu Pro His Pro Val Pro Ile Ile Leu Lys Val Ser
20 25 30

Thr Val Phe Ser Leu Leu Ser Leu Phe Arg Leu Leu Phe Leu Ser Phe
35 40 45

Cys Pro His Pro Lys Lys Cys Ser Tyr Leu Leu Lys Tyr Tyr Gly Pro

50 55 60

Leu Glu Gly His Lys Thr Leu Xaa Tyr Leu Arg Thr Asn Leu Gly Val
65 70 75 80

Ile Gln Pro Pro Leu Arg Met Tyr Ala Ala Glu Asp Cys Asn Gly Ile
85 90 95

Gly

<210> 381

<211> 46

<212> PRT

<213> Homo sapiens

<400> 381

Met Ser Ile Asn Ile Cys Leu Met Gln Ser Lys Thr Gln Gly Ser Cys
1 5 10 15

Gln Tyr Leu Leu Leu Pro His Pro Val Pro Ile Ile Leu Lys Val Ser
20 25 30

Thr Val Phe Ser Leu Leu Ser Leu Phe Arg Leu Leu Phe Leu
35 40 45

<210> 382

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 382

Ser Phe Cys Pro His Pro Lys Lys Cys Ser Tyr Leu Leu Lys Tyr Tyr
1 5 10 15

Gly Pro Leu Glu Gly His Lys Thr Leu Xaa Tyr Leu Arg Thr Asn Leu
20 25 30

Gly Val Ile Gln Pro Pro Leu Arg Met Tyr Ala Ala Glu Asp Cys Asn
35 40 45

Gly Ile Gly

50

<210> 383

<211> 23

<212> PRT

<213> Homo sapiens

<400> 383

Lys Glu Glu Asp Asp Asp Thr Glu Arg Leu Pro Ser Lys Cys Glu Val
1 5 10 15

Cys Lys Leu Leu Ser Thr Glu
20

<210> 384

<211> 23

<212> PRT

<213> Homo sapiens

<400> 384

Lys Glu Glu Asp Asp Asp Thr Glu Arg Leu Pro Ser Lys Cys Glu Val
1 5 10 15

Cys Lys Leu Leu Ser Thr Glu
20

<210> 385

<211> 19

<212> PRT

<213> Homo sapiens

<400> 385

Leu Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu Val Leu Glu
1 5 10 15

Leu Gly Gln

<210> 386

<211> 19

<212> PRT

<213> Homo sapiens

<400> 386

Leu Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu Val Leu Glu
1 5 10 15

Leu Gly Gln

<210> 387

<211> 12

<212> PRT

<213> Homo sapiens

<400> 387

Arg Gln Ala Val Ile Val Cys Arg Arg Arg Phe Val
1 5 10

<210> 388
<211> 148
<212> PRT
<213> Homo sapiens

<400> 388
Pro Pro Arg Trp Ala His Pro Lys Ala Pro Glu Gly Ser Pro Asp Pro
1 5 10 15

Pro Ser Pro Pro Ser Ala Leu Gly Leu Ser Val Leu Pro Trp Ser Asp
20 25 30

Ser Asp Pro Trp His Ile Ser Val Ser Pro Cys Ala Gln Arg Glu His
35 40 45

Tyr Ser Pro Gly Ser Ala His Ile Asn Ser Leu Arg Pro Leu Pro Ala
50 55 60

Leu Ser Leu Lys Arg Cys Lys Ala Arg Val Ser Ser Ser Cys Leu Tyr
65 70 75 80

Pro Ala Pro Ala Pro Ala Pro Leu Glu Ile Asp Arg Cys Asp
85 90 95

Ser Val Pro Pro Val Ala Leu Cys Ser Ala Ala Tyr Thr Leu Arg Ile
100 105 110

Cys Trp Ala Ser Val Leu Cys His Arg Pro Pro Pro Ser Thr Ser Gln
115 120 125

Pro Lys Pro Arg Ala Arg Pro Lys Lys Gly Lys Ala Ile Phe Pro Thr
130 135 140

Ala Gln Val Pro
145

<210> 389
<211> 71
<212> PRT
<213> Homo sapiens

<400> 389
Pro Pro Arg Trp Ala His Pro Lys Ala Pro Glu Gly Ser Pro Asp Pro
1 5 10 15

Pro Ser Pro Pro Ser Ala Leu Gly Leu Ser Val Leu Pro Trp Ser Asp
20 25 30

Ser Asp Pro Trp His Ile Ser Val Ser Pro Cys Ala Gln Arg Glu His
35 40 45

Tyr Ser Pro Gly Ser Ala His Ile Asn Ser Leu Arg Pro Leu Pro Ala
50 55 60

Leu Ser Leu Lys Arg Cys Lys
65 70

<210> 390

<211> 77

<212> PRT

<213> Homo sapiens

<400> 390

Ala Arg Val Ser Ser Ser Cys Leu Tyr Pro Ala Pro Ala Pro
1 5 10 15

Ala Pro Leu Glu Ile Asp Arg Cys Asp Ser Val Pro Pro Val Ala Leu
20 25 30

Cys Ser Ala Ala Tyr Thr Leu Arg Ile Cys Trp Ala Ser Val Leu Cys
35 40 45

His Arg Pro Pro Pro Ser Thr Ser Gln Pro Lys Pro Arg Ala Arg Pro
50 55 60

Lys Lys Gly Lys Ala Ile Phe Pro Thr Ala Gln Val Pro
65 70 75

<210> 391

<211> 26

<212> PRT

<213> Homo sapiens

<400> 391

Glu Glu Lys Leu Phe Thr Ser Ala Pro Gly Arg Asp Phe Trp Val Met
1 5 10 15

Gly Glu Thr Arg Asp Gly Asn Glu Glu Asn
20 25

<210> 392

<211> 42

<212> PRT

<213> Homo sapiens

<400> 392

Gln Lys Pro Thr Phe Ala Leu Gly Glu Leu Tyr Pro Pro Leu Ile Asn
1 5 10 15

Leu Trp Glu Ala Gly Lys Glu Lys Ser Thr Ser Leu Lys Val Lys Ala
20 25 30

Thr Val Ile Gly Leu Pro Thr Asn Met Ser
35 40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/05804

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 435/320.1, 252.3, 69.1, 6, 7.1; 530/300, 388.22; 514/2; 436/501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EST: Accession No.:AA331279. ADAMS et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 377 (6547 Suppl), 3-174 (1995). Nucleotides 1-314.	1-12, 14-21
A	SCHWARTING, R. et al. Biochemical characterization and purification of human B Cell Stimulatory Factor (BSF). Eur. J. Immunol. 1985, Vol. 15, pages 632-637, see entire document.	1-21

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
07 JUNE 1999	07 JUL 1999

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>D. Lawrence Tor</i> EILEEN O'HARA Telephone No. (703) 308-0196
---	---

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/05804

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-21

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US99/05804**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

C07H 21/04; C07K 1/00, 16/00; C12N 15/00, 1/20; C12P 21/06; A61K 38/00; C12Q 1/68; G01N 33/53, 33/566

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

536/23.5; 435/320.1, 252.3, 69.1, 6, 7.1; 530/300, 388.22; 514/2; 436/501

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

SEQUENCE DATA BASE MPSRCH: EST, GenEmbl, N_Geneseq_34, Issued_Patents_NA, SPTREMBL_8, SwissProt_36, PIR_58, Issued_Patents_AA, (SEQ ID NOS: 11 and 108 only). One nucleotide sequence and one amino acid sequence have been searched. It is not clear which sequences are embraced by the claims because the claims refer to sequences X and Y. The table at pages 180-188 contains many sequences X and Y, yet the claims refer to X and Y in the singular only. Accordingly, the first X nucleotide sequence disclosed and the first Y amino acid sequence disclosed were searched.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-21, drawn to nucleic acid molecules, vectors, host cells containing recombinant nucleic acid molecules, polypeptides, antibodies, a method of producing a polypeptide, a method for treating a medical condition comprising administering a polypeptide, a method of diagnosing a pathological condition by genetic analysis or protein assay, and a method for identifying a binding partner to a polypeptide, for gene 1, the nucleic acid molecule identified by SEQ ID NO:11, and the polypeptide identified by SEQ ID NO: 108, as listed in the table on pages 180-188 of the description. Groups II through XCV, claims 1-21 for each group, drawn to nucleic acid molecules, vectors, host cells containing recombinant nucleic acid molecules, polypeptides, antibodies, a method of producing a polypeptide, a method for treating a medical condition comprising administering a polypeptide, a method of diagnosing a pathological condition by genetic analysis or protein assay, and a method for identifying a binding partner to a polypeptide for, genes 2 through 95, the nucleic acid molecules identified by SEQ ID NOS:12 through 105, and the polypeptides identified by SEQ ID NOS:109 through 202 respectively, as listed in the table on pages 180-188 of the description.

The inventions listed as Groups I through XCV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Pursuant to 37 C.F.R. § 1.475(b-d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto.

Pursuant to 37 C.F.R. § 1.475(b-d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first recited product, a polynucleotide comprising gene No. 1, identified by SEQ ID NO:11, the polypeptide it encodes, identified by SEQ ID NO:108, methods of producing the polypeptide, and methods of using the polynucleotide and polypeptide. Further pursuant to 37 C.F.R. § 1.475(b-d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.